|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2017/7/26 ¤U¤È 02:22:07
|
2022.01-¤@´Á¼Æ¾Ú¤§Àu¤Æ²³ø(Y¥h¦~¤E¤ë®³³oª©À³¸Ó·|¦n¤@ÂI):ir.aslanpharma.com/static-files/2a7f1481-a0b3-47d1-87ef-e6ed30321475 2022.01-KOL²³ø:ir.aslanpharma.com/static-files/379e7107-c421-4401-b035-e43c4b682d19 2022.05.12- ir.aslanpharma.com/static-files/20941066-3bc3-418b-a970-9951565de0f2 2022.06²³ø-ir.aslanpharma.com/static-files/1c525489-d209-42c4-af7e-992f23c4251c 2022.09.15²³ø-ir.aslanpharma.com/static-files/1511fefc-ba34-4ee4-aac0-32f8bc4754a8 |
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/12 ¤U¤È 10:29:17²Ä 2416 ½g¦^À³
|
¥xÁÞ¤j¡A ¦n°ÝÃD¡I ¥i°Ý¤½¥q¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/4/12 ¤U¤È 09:30:17²Ä 2415 ½g¦^À³
|
¤Ñ©R¤j ©Ò¥H 5¤ë15¤é«e¤½§Gªº²Ä¤@©u°]³ø¦pªG²bȬ°t¼Æ ¨È·à±d¨S¦³¤U¥«ªº°ÝÃD ? (6¤ë1¤é«e ) 2020¦~6¤ë1¤é¥H«á , 8¤ë14¤é«e¤½§Gªº²Ä¤G©u°]³ø¦pªG²bȬ°t¼Æ ¨È·à±dÁÙ¨S¦³§¹¦¨¬ü°ê¦s°U¾ÌÃÒ(ADS)¤§µo¦æ´N¦³¤U¥«ªº °ÝÃD ? ¨È·à±dÁÙ¦³4Ó¤ë®É¶¡¨Ó§¹¦¨¬ü°ê¦s°U¾ÌÃÒ(ADS)¤§µo¦æ, ¦¨¥\µo¦æ´N¨S¦³¤U¥«ªº°ÝÃD ³o¼Ë¹ï¤£¹ï? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/12 ¤U¤È 08:30:44²Ä 2414 ½g¦^À³
|
¥xÁÞ¤j¡A ³oÓªk¥O¬O¼Wq±ø¤å¡C°w¹ï²bȤj©ó0¡A¤p©ó3¤¸ªº¤½¥q©Ò³]p¡C ¦ý ¤½¥q²bȤp©ó¹s¡A©Î¤½¥q¸õ²¼¡A´N·|¹F¤U¥«±ø¥ó¡C ©ú¤Ñ¥xÁÞ¤j¡A¥i¥H¦A°ÝÃÒ¥æ©Ò¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X- ÃÒ¥æ©Ò¥h¦~¹{¥¬¡u¤U¥«¾÷¨î¡v¡A¹wp4¤ë1¤é±Ò°Ê¡A¨ä¤¤¡A³]¤U¨â¤j±ø¥ó¥]¬A¤@¡B¥ø·~³QñÃÒ·|p®v¥X¨ãÄ~Äò¸gÀç¯à¤O¦s¦b«¤j¤£½T©w©Ê¬d®Ö³ø§i¡A¤G¡B¨CªÑ²bȧC©ó3¤¸¡A¥unº¡¨¬¨ä¤@¥B¦b¤T¦~¤ºµLªk§ïµ½¡A±N¤©¥H¼È°±¥æ©ö¡A¨Ã©ó°±µP«á¥b¦~±j¨î¤U¥«¡C ¦¹¦¸¬Ì±¡½ÄÀ»¡A¥Dn¼vÅT¥ø·~°]³øÃø²£¡A¥]¬A·|p®v¥i¯à¥X¨ã¦³«¤j¤£½T©w©Ê³ø§i¡A¦Ó¹ï¦¹ÃÒ¥æ©Ò¤w¦³¨Ò¦æ¼f¾\¨î«×¡AÁÙ¦³¤U¥«¾÷¨î¡A±Ò°Ê®ÉÂI²[»\¥h¦~¦~³ø¤Î¤µ¦~²Ä1©u°]³ø¡C ÃÒ¥æ©Ò¸³¨Æªø³\¼ýº½¥ý«e±j½Õ¡A¹L¥hÃÒ¥æ©Ò¥u¦b¥ø·~²bȬ°t¼Æ¡A©Î¾D¨ì°h²¼¦Ó©Úµ´©¹¨Ó¡A¤~±j¨î¤U¥«¡A¦ý¼Wq·sªº¼Ð·Ç«á¡A°]³ø³Q·|p®v»{¥i¦³ºÃ¼{©Î²bȹL§C¡A¤]¯Ç¤J½d³ò¡CÃÒ¥æ©Ò¨Ã¦b¦¹³¡¤À´£¨Ñ½w½Ä¡A¥Dn¦Ò¶q¨S¦³³B²z¹LíL«ÍªÑªº¸gÅç¡AÀH¾÷¨îÂX¥R¡A¤]§Æ±æ¥«³õ§ó°·¥þ¡C money.udn.com/money/story/5607/4447027 |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/4/12 ¤U¤È 06:20:42²Ä 2413 ½g¦^À³
|
¨È·à±d2020¦~3¤ë18¤é«¤j°T®§¤½§i : ¥»¤½¥q¥N·s¥[©Y¤l¤½¥qASLAN Pharmaceuticals Pte. Ltd.¤½§i¨Ì°ê»Ú·|p·Ç«h²Ä36¸¹»{¦CµL§Î¸ê²£´î·l 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¥»¦¸¶È´N±b¦CµL§Î¸ê²£¨Ì¾Ú·|pì«h»{¦C«D²{ª÷´îÈ·l¥¢¡A¸Ó¶µ·l¥¢»{¦C¤£¼vÅT ²{ª÷¬y¶q¡A¥B¹ï¥»¤½¥q¥DnÀç¹B¶µ¥Ø¨ÃµL«¤j¼vÅT¡C ºI¦Ü108¦~12¤ë31¤é¡A¥»¤½¥q±b¤W²{ª÷¤Î¬ù·í²{ª÷¾lÃB¬°¬üª÷22,000 ¥a¤¸¡]·s¥x¹ô665,050¥a¤¸¡^¡C (2)¥»¤½¥q°_ªì«Y¨Ì°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß¡]¥H¤U²ºÙÂd¶R¤¤¤ß¡^ ¥~°ê¦³»ùÃÒ¨éÂdÂi¶R½æ¼f¬d·Ç«h²Ä4±ø²Ä4¶µ¥Ó½ÐªÑ²¼¬°ÂdÂi¶R½æ¤§²Ä¤@¤WÂd¤½¥q¡A ¨Ã©ó106¦~6¤ë1¤é±¾µP¤WÂd¡C¨Ì¾Ú¥»¤½¥q108¦~«×°]°È³ø§iÅã¥Ü¡A ºI¦Ü108¦~12¤ë31¤é¥»¤½¥q²bÈÁö¬°t¼Æ·s¥x¹ô18,070¥a¤¸¡AµM¨ÌÂd¶R¤¤¤ß ÃÒ¨é°ÓÀç·~³B©Ò¶R½æ¦³»ùÃÒ¨é·~°È³W«h²Ä3±ø¤§1²Ä¤@¤WÂd¤½¥q·Ç¥Î¥»°ê¤WÂd¤½¥q ³W©w¡A¤Î²Ä12±ø¤§2²Ä1¶µ²Ä4´Ú¦ý®Ñ³W©w¡A´£¥Ü¥»¤½¥q©ó¤WÂdº¡¤T¦~¥H¤º¡A±o¤£¨ü ¸Ó´Ú©Ò³W©w³Ìªñ´Á°]°È³ø§iÅã¥Ü²bȬ°t¼ÆÀ³²×¤î¨ä¦³»ùÃÒ¨éÂdÂi¶R½æ¤§¨î¡C Ó¤H¬Ýªk¤À¨É: 1 ¨È·à±d2020¦~6¤ë1¤é¥H«eªº°]³ø¦pªG²bȬ°t¼Æ¨Ã¤£²Å¦X¤U¥«n¥ó ( ¤£·|³Qn¨D¤U¥« ) 2 2020¦~6¤ë1¤é¥H«áªº°]³ø ¨Ò¦p2020¦~²Ä2©u°]³ø¨CªÑ²bÈȧC©ó3¤¸´N²Å¦X¤U¥«±ø¥ó( 2020¦~8¤ë14¤é«e¤½§i) ¦ý¬OÁÙ¬On¨Ì¾ÚÃÒ¥æ©Ò¥h¦~¹{§G¤U¥«¾÷¨î¡A¹wp2020¦~4¤ë1¤é±Ò°Ê¡A¨ä¤¤¡A³]¤U¨â¤j±ø¥ó¥]¬A ¤@¡B¥ø·~³QñÃÒ·|p®v¥X¨ãÄ~Äò¸gÀç¯à¤O¦s¦b«¤j¤£½T©w©Ê¬d®Ö³ø§i¡A ¤G¡B¨CªÑ²bȧC©ó3¤¸¡A¥unº¡¨¬¨ä¤@ ¥B¦b¤T¦~¤ºµLªk§ïµ½¡A±N¤©¥H¼È°±¥æ©ö¡A¨Ã©ó°±µP«á¥b¦~±j¨î¤U¥«¡C ±Ò°Ê®ÉÂI: ²[»\¥h¦~¦~³ø¤Î¤µ¦~²Ä1©u°]³ø¡C money.udn.com/money/story/5607/4447027 3 ¨È·à±d¦³¨¬°÷®É¶¡§V¤O¬ãµo²£«~§ïµ½°]°Èµ²ºc , ¤j®a¤£»Ý§Ñ¤Fªk³W¦Û¤vÀ~¦Û¤v 4 ¦³¨Ç¤W¥«Âd¤½¥q¦¨¥ß¤w¶W¹L3¦~¨CªÑ²bȬ°t¼Æ³Qn¨D¤U¥« , ¨È·à±d¹B®ð¦n 2020¦~6¤ë1¤é¤~º¡¤T¦~¦Ó·sªk ±Ò°Ê®ÉÂI: ²[»\¥h¦~¦~³ø¤Î¤µ¦~²Ä1©u°]³ø( ³£¦b3¦~«OÅ@½d³ò) , 2020¦~4¤ë1¤é·sªk¤W¸ô ¯u¬Oµ´³B³{¥Í ! ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò ¦p¦³¿ù»~½Ð§ó¥¿ |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/4/11 ¤U¤È 02:20:36²Ä 2412 ½g¦^À³
|
§Ú¤]ı±o1100±i¨S¦³«Ü¦h~ ¹³§Ú³o¤p¤p©@~ ´N50¦h±i¤F~ ¥u¯à§Æ±æ¨È·à±d¤£nÂ\Äê¤F ¦pªG004¦³³o»ò¦n¡AÀ³¸Ó¶Ò¸êªº¨ì~ |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/4/10 ¤U¤È 06:50:28²Ä 2411 ½g¦^À³
|
¸s¥ú¤~1100±i¨S¤°»òÁ¿¸Ü¤O¶q§a §Ú³oºØ¤p©@³£¦³100±i¤F ¦Ó¥B¤~¤p¿ú¡A¸s¥úþ¥i¯à¥X¨Ó·d¨Æ ÁÙ¬O¾a·à¤l¦Û¤v¦Û±Ï¤~¬O |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/4/10 ¤U¤È 04:01:40²Ä 2410 ½g¦^À³
|
¥¼¨ÓYn¦¨¥ß¦Û±Ï²Õ´,¸s¥ú«ùªÑ¬O§_¦³¾÷·|¦¨¬°§ÚÌ«nªº¤ä«ù ? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/10 ¤W¤È 08:41:25²Ä 2409 ½g¦^À³
|
¼Ú¬w«ÊÂê¥O¤À°ÏÃP¸j ¸q¥Ø¼Ð4¤ë©³ 2020-04-10 05:30:00 ¸qÂê°ê¤@Ó¤ëÁͽw ¤j·N¤£±o ¡e½sĶ¶À¹tØÅ¡þºî¦X³ø¾É¡fªZº~ªÍª¢¬Ì±¡¦b¼Ú¬w©µ¿N¤F¨âÓ¦h¤ë¡A³¡¤À¬Ì±¡¸û¦Ãzµoªº°ê®a¤wµÛ¤â·Ç³ÆÃP¸j«ÊÂê¥O¡A¦ý¤]¦³¤£¤Ö°ê®a¬Ì±¡¥¿¦bÃk¤É¡C¸q¤j§Q¦Û¤T¤ë¤Q¤éÂê°ê§Ü¬Ì¡A¬Ì±¡²×©ó¦b¥þ°ê°±Â\¤@Ó¤ë«áÁͽw¡A¤K¤é·s¼W¦º¤`¯f¨Ò¼Æ»P«¯g±wªÌ¤H¼Æ¬Ò¸û«e¤@¤é§C¡A²Öpªñ¤Q¥|¸U°_½T¶E¯f¨Ò¡C¸q¤j§QÁ`²z¤Õ¸¦¤E¤é³zÅS¡A°²¦p¬ì¾Ç®a»{¥i¡A¸q¤j§Q¥i±æ©ó¥|¤ë©³¶}©l³v¨BÃP¸j¸T¥O¡A¦ý¤Õ¸¦¤]±j½Õ¡A¸q¤j§Q¤´¤£¯à¹ï¬Ì±¡°§C§Ù¤ß¡C ¥ß³³©{¬F©²¤K¤éÁöµM«Å¥¬«ÊÂê¥O¦A©µ¨â¶g¦Ü¤Ü¤C¤é¡A¦ý³W½dµy·LÃP¸j¡A¤¹³\¥Á²³¦b¯S©w³õ©Ò³c°â´Óª«¡BºØ¤l¡BªÎ®Æ¡A¨Ã¶}©ñ¥~Äy¤H¤h¤J¹Ò¨Ì¿Ë¡C¥ß³³©{²Öp¤E¦Ê¦h°_½T¶E¯f¨Ò¡A¤K¤é·s¼W¯f¨Ò¼Æ¶È¦³¤T¤Q¦h°_¡C±¶§J³¡¤À°Ó®a¦Û¤E¤é°_±o¥H«·s¶}±i¡A¬F©²¤]ÃP¸jÅé¨|¬¡°Êªº¨î¡A¤¹³\¥Á²³±q¨ÆÃM³æ¨®¡B¶]¨Bµ¥«D¦h¤H¸s»E¹B°Ê¡F¦Ü©ó¤U¶gªº´_¬¡¸`°²´Á¡A±¶§J¬F©²¬Û«H¥Á²³·|²z©Ê¦a¤£»P¥L¤H¨£±¡A¥H§K®{¼W·P¬V·ÀI¡A¤£¦Ò¼{¦¬ºò¨¾¬Ì¬Fµ¦¡CºI¦Ü¤E¤é¡A±¶§J²Öp¤¤T¤T¤°_½T¶E¯f¨Ò¡C ±¶§J©ñ¼e¹B°Ê ¶ø¤p°Ó®a±N´_¤u ¶ø¦a§Qpµe©ó´_¬¡¸`°²´Á«á¡A¦Û¤Q¥|¤é°_¤¹³\¤p«¬°Ó®a´_¤u¡A¹wp¤¤ë¤@¤éÅý¥þ³¡°Ó®a«·s¶}·~¡F¤¦³Á¤Q¤¤é±N«·s¶}±Ò¾Ç®Õ»PÅ@²z¤¤¤ß¡AÅý®aªøªð¦^¤u§@±^¦ì¡A¦ý¤´¸T¤î¤Q¤H¥H¤W¸s»E¡F«ÊÂê¥O±N©ó¤Q¤T¤é´Áº¡ªº®¿«Â¡Apµe©ó¥|¤ë¤Ü¤é¦Ü¤Ü¤C¤é«·s¶}©ñ¥®¸X¶é¡A¤p¾Ç¤@¦~¯Å¦Ü¥|¦~¯Åªº¾Ç¥Í«h©ó¤Ü¤C¤é«ªð®Õ¶é¡C¶ø¦a§Q¡B¤¦³Á¬Ò²Öp¬ù¤»¤d°_½T¶E¯f¨Ò¡C ¼w°êÁ`²z±ö§Jº¸¤»¤éªí¥Ü¡A¼w°êªº«ÊÂê¥O¦Ü¤Ö·|«ùÄò¦Ü¥|¤ë¤Q¤E¤é¡A½Í½×ÃP¸j¨¾¬Ì¸T¥O¬°®É¹L¦¡A¦ý¦P¤é¥ç¶Ç¥X¼w°ê¤º¬F³¡¥¿¬ãÀÀ¦Û¤Q¤E¤é°_©ñ¼e¸T¥O¡A¨Ã³W¹º©ñ¼e«áªº¨¾¬Ì¹ïµ¦¡C¼w°ê²Öp¤Q¤@¡D¤T¸U°_½T¶E¯f¨Ò¡B¤G¤T¥|¤E°_¦º¤`¯f¨Ò¡C ¼w¦Ü¤Ö«Ê¦Ü19¤é ªk¥¼¨£½w©M ²Öp¹O¤Q¤@¸U°_½T¶E¯f¨Òªºªk°ê¡A¥Ñ©ó¬Ì±¡©|¥¼½w©M¡A¤K¤é«Å¥¬©µªø«ÊÂê¥O¦Ü¥|¤ë¤Q¤¤é¡Aªk°ê½Ã¥Í³¡«ü¥X¡Aªk°êºI¦Ü¤K¤é¤w¦³¤C¤»¤T¤G¦W½T¶E¯f±w©óÂå°|¤º³u¥@¡A°²¦pp¤JÀø¾i°|¤¤ªº¦º¤`¯f¨Ò¡A¦º¤`¯f¨Ò¼Æ±o¦A¥[¤T¦¨¨ì¬ð¯}¸U¤H¡AÁöµM¥[Å@¯f©Ðªº·s¼W¯f±w¤ñ²v¤w¸g³sÄò¤E¤Ñ¤U°¡A¦ýÂå°|ªºÀ£¤O¤´µM«Ü¤j¡C ¼Ú·ù°õ©e·|¤K¤é«Øij¼Ú·ù¦¨û°ê»P¦B®q¡B®¿«Â¡B·ç¤hµ¥¼Ú¬w°ê®a¡A±N¼Ú¬w®È¦æ¸T¥O²Î¤@©µªø¦Ü¤¤ë¤Q¤¤é¡C¥@¬É½Ã¥Í²Õ´¼Ú¬w°Ï¥D¥ô§J¾|®æ¡]Hans Kluge¡^¤]ªí¥Ü¡A¡u²{¦bÁÙ¤£¬OÃP¸j¸T¥Oªº®ÉÔ¡v¡A©IÆ~©Ò¦³°ê®a¦b«OÅ@ÂåÅ@¤Hû¡B³z¹L¤½¦@±¹¬I°±¤î»P´î½wªZº~ªÍª¢ªº¶Ç¼½¡A¥H¤ÎÄ~ÄòÂǥѷ¾³qÅý¥Á²³¿í¦u¨¾¬Ì±¹¬I³o¤TӤ豥[±j§V¤O¡A¨Ã¥I¥X¨â¡B¤T¿ªº§V¤O¨¾¬Ì¡C ¸q¤j§Q°ê®a½Ã¥Í°|º®u¬y¦æ¯f¾Ç®a¹pÂÄ¡]iovanni Rezza¡^ĵ§i¡A§Y¨Ï·s¼W¯f¨Ò¤j´î¡A¯f¬r¤´¦b¤H¸s¤¤¬y«¡A¥Ø«e¥u¬Oº¾Ô¨ú±o¤@¨Ç¦¨¥\¡A¥¼¨Ó»Ýnªø´Á§Ü¾Ô¡C news.ltn.com.tw/news/world/paper/1364945 |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/4/9 ¤U¤È 09:38:21²Ä 2408 ½g¦^À³
|
ADR¤jº¦~ §Æ±æ¯à«ùÄò¤U¥h! |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/4/9 ¤U¤È 08:08:29²Ä 2407 ½g¦^À³
|
To ¦V¤Ñ ¸s¥ú¥h¦~¦~³ø¦³´¦ÅS¡A1100±i¨È·à±d«ùªÑ¤@±i³£¨S½æ¼Ú¡A©Ò¥HÁ«¶W¤jªº¡A¥i¥H¥h¸s¥ú¬ì§Þ©xºô§ë¸ê¤H±M°Ï¸Ì±¦³¡C ÁÂÁ |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/4/9 ¤U¤È 05:55:46²Ä 2406 ½g¦^À³
|
TO¥d¯S¤j¤j: §A»¡ªº¸s¥ú¡A¤§«e§Ú¦³¬Ý¨ì¡A©Ò¥H§Ú¤~«ù¦³¤£¤Ö±i¨È·à±d¡A ¥Ø«e¬Ý°_¨Ó¦³ÂI¨«²´¡C ¸É¤W¬ÛÃöªº³sµ²:www.peterjan.tw/2019/08/22/peterjan21/ ¦ý¥Ø«e±q¸s¥úªºÂà§ë¸ê¤w¬Ý¤£¨ì¨È·à±dªº«ùªÑ¡A¤£¾å±o¬O§_¤w°±·l? |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2020/4/9 ¤U¤È 04:48:03²Ä 2405 ½g¦^À³
|
¨S«H¤ßªº®£·W ¨S¦³½T»{ªº®£·W £¸±iªº½æ³æ¤U¶^5w §ë¸êªÑ²¼30¦~«ç»ò¤]¨S·Q¨ì¬Ý¦ü³z©úªº¤½¥q £¸¬Nªº¤£¤z¹wªÑ»ù«o¬O¦p¦¹ªººG¤£§Ô½ä ¤â¤¤¦³ªÑ²¼¤ß¤¤µLªÑ»ùªº³Ì°ª¹Ò¬É ªáY²±¶}½¹½º¦Û¨Ó §ë¸êªÌ¤ß¤¤£¸ª½¦b°Ý6/1·|¤£·|¤U¥«¡]½Ö¯à§i¶D§Ú¡^ 1¤ë¥÷ªºªÑÁ{·|³q¹Lªº©Ò¦³¼W¸ê¿ìªk¥þ¹L¤F ¡]¥i¥HÄw¸ê¥þ³¡ªº¿ìªk³£³q¹L¤F¡^ ¨S¦³£¸¼Ë¬O½T»{ªº Å¥»¡°Õ4¤ë¥÷n¶}¸³¨Æ·|¬Ý«ç»ò¼W¸ê ¦Aµ¥µ¥§a⋯⋯ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/4/9 ¤U¤È 04:09:39²Ä 2404 ½g¦^À³
|
To ¦V¤Ñ, ¦³¿³½ì¥i¥H¥h¬Ý¸s¥ú¬ì§Þ¥h¦~ªº¦~³ø¡A¥LÁÙ«ù¦³¨È·à±d1100±i»¡¡A¥¦ªº¦¨¥»§Ú·QÀ³¸Ó«Ü°ª¡A¦L¶H¤¤¥i¯à40-50¬Æ¦Ü§ó°ª¡A¨ì®ÉÔ³o¨Ç³£n´£¦CÁ«·l¤F¡A¤£¹Ln¥l¶}Á{®ÉªÑªF·|n3%ªº«ùªÑ¡A¥i¯àÁÙ¬On§ä¨ì¨ä¥¦¤j¤á¡A½Ð¥LÌn¨D¤½¥q¥X±»¡©ú²bȳ¡¤Àn«ç¼Ë³B²z¡A¥Ø«e¶i«×¬°¦ó? §Ú·Q§ë¸ê¤H¤~¯à¦w¤ß§a¡C¦Ó¤£¬OÀqÀqÅý®É¶¡¹L¥hÔ£³£¤£°µ³o¼Ë! Thanks, |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/4/9 ¤U¤È 03:59:24²Ä 2403 ½g¦^À³
|
ÁÂÁÂ¥d¯S¤j¤jªº¦^µª 6/1¸¹¶V¨Ó¶V¹Gªñ¡A»¡¯uªº¦pªG¨È·à±d¤UÂd¡A ¬üªÑADR¯àÄ~Äò¬y³q¡A¥xÆWªº§ë¸ê¤HÀ³¸Ó·|«Ü®ð§a! ¤½¥q¥Ø«e¤]¨S¥ô¦óªº»¡ªk¡A»¡¯uªº¡A§Ú¤@ÂI³£¤£´Á«Ý¥L¥Ö½§Àù¯à¦¨¥\¡C ¦]¬°´N¦p¦P§A»¡ªº¡A¤½¥q³s°ò¥»ªº§@¬°³£¨S¦³¡An¦p¦ó´Á«Ý©O! |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/4/9 ¤U¤È 03:12:36²Ä 2402 ½g¦^À³
|
To ¦V¤Ñ, ¤½¥q·|¦^Âв{ª÷¬O¥Î¨Ó¬ãµoªº¡A¤£¥i¯àÅ@½L©Î¬O´î¸ê¡AªÑ²¼´N¬O¦Û¥Ñªº¥«³õ¡A¤½¥q°ª¼h¤£¦b¥xÆW¡A¸ò¥xÆW³oÃä¤ÏÀ³¤]¨S¦³Ô£¥Î¡A¥u·|¦^Âл¡¦^¥h·|¸ò·s¥[©Y°ª¼h¤ÏÀ³¡A¤§«á¤]¨S¤U¤å¤F¡A¤½¥q°ª¼h¤@©w¦³³d¥ôªº¡A¸Ñ¦£¥¢±Ñ¨â¦¸¨S¦³¥ô¦ó¤H¤U¥x¡AªÑ²¼²bȶ^¯}5¤¸®É¡A¤]¨S¦³¥ô¦ó§@¬°¡A§Ú·Q¤½¥qÀ³¸Ó´N¬O§â¥xÆW¥«³õ·í§@µo¦æADRªº¸õªO§a¡A§_«h¤£·|¥xÆW³oÃä¨S¦³¥ô¦ó°ª¼h¦b¡Aµo¨¥Åé¨t¤]¥~¥]µ¹¤½Ãö¤½¥q¤F¡A·Pı´N¬O¤@°Æ·Ç³ÆÂ÷¶}¥xÆW¥«³õªº¼Ë¤l¤F¡AªÑªF·|¿ï¦b6/29¶}¡A·d¤£¦nÁÙ¤£¥Î¶}©O? ¤@ÂI·Qn¸Ñ¨M°ÝÃD¸Û·N³£¨S¦³¡AµL§Î¸ê²£´î·lª½±µ§â¤½¥q²bÈÂàt¡A¤]¨S¬Ý¨ì¦³¥ô¦ó¨ä¥L¤èªk¨Ó¸Ñ¨M²bÈ°ÝÃD¡AµL½×¬O½æ¥X003©Î¬O001¡AÁÙ¬O»°§Ö§ä¸³ºÊ©Î¬O¤jªÑªF¨p¶Ò¡A³£¨S°¨¤W°µ¡A³oÓ´î·l¤½¥q°ª¼h¬O¦´Nª¾¹Dªº¡A¦ý¬O¦]¬°¤£¼vÅT¬üªÑ¥æ©ö¡A©Ò¥H´N¤£°¨¤W³B²z§a¡A¤Ï¥¿¥LÌ´N¥MµÛ¸U¤@¥xÆW³oÃäºMÂd¤F¡A¬üªÑADRÁÙ¥i¥HÄò¦s³oÓ·Qªk§a¡A©Ò¥H¤~·|§¹¥þ¤£care¥xÆW³oÃ䪺¥æ©ö¨î«×¡A¬ÝµÛ¥xªÑ¸òADR²æ¹_¤]¨S¦³¥ô¦ó§@¬°¡A¤½¥q°ª¼hÁÙ¬O²n»â°ªÁ~¡A¨Ó¥xÆW¶}·|¤]¬O¤@¤U´N°{¤H¤F¡A¥uÄ@·N¥ÎÉ´Úªº¤è¦¡µ¹¤½¥q¦Ó¤£¬O¥Î¨p¶Ò¤è¬Oª`¸ê¡A¥i¯à¤]»¡©ú¸³ºÊ³£¤£¬Ý¦n¤§«áªºµo®i§a¡A§Ú·Q¥xÆW³oÃä¯uªº«ÜÃø±Ï¤F¡AªÑªF·|¤é´Á¤Ó«á±¤F¡A·Qn¥l¶}Á{®ÉªÑªF·|¤]¬O¦³Ãø«×ªº¡A¦Ó¥B©_©Çªº¨Æ±¡¬O¡A¥h¦~12¤ëªì¥i¥H¥ý¤½¥¬²Ä¤@¾¯¶q3Ó¯f±wªº¼Æ¾Ú¡A¦Ó²{¦b«o»¡n°µ§¹¤TÓ¾¯¶q¤~¯à¤½¥¬´Á¤¤¼Æ¾Ú¡A³oÂI¤]¬O«Ü©_©Ç¡A¥¿±`¤½¥qÀ³¸Ón»°§Öµo¥¬§Q¦h®ø®§§a¡A¦Ó¤£¬OÔ£³£¤£°µ¡AÁÙ¬O¤@¼Ë67¤ë¤~n¤½¥¬´Á¤¤¼Æ¾Ú¡A§Ú·Q¥xÆW³oÃ䪺§ë¸ê¤H¥i¯à³£µ¥¤£¨ì¤F§a! Thanks, |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/4/9 ¤U¤È 01:56:40²Ä 2401 ½g¦^À³
|
·Q°Ý¦U¦ì¤j¤j~ ¬°¤°»ò¨È·à±d³£¤£Á«·l´î¸ê©O? ²¦³º¤â¤W¥Ø«e²{ª÷°÷¡A¦ý²bȤwÂàt¡C ³y¦¨¥xªÑªº¬y°Ê©Ê¤£¨Î¡A¦pªG´î¸ê¥i¥HÅý²bÈÂॿ ¥B¤é«á¶Ò¸ê¦³±æ¥i²æÂ÷¥þÃB¥æ³Î¡A³o¿ìªk¤£¬O«Ü¦n¶Ü? §Ú¯uªº«ÜÃhºÃ¨È·à±dªº¸gÀç¹Î¶¤¬O¤£¬O¦³°ÝÃD..... |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/4/9 ¤U¤È 01:02:21²Ä 2400 ½g¦^À³
|
¨È·à±d ADRº¦10% ¥xÆWªº¶^5%.... §Ú¤]¾K¤F |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/8 ¤W¤È 08:37:33²Ä 2399 ½g¦^À³
|
¤¦³Áº¬Û«Å¥¬¡u´_¤u½Æ½Ò¡vªì¨Bp¹º 2020-04-07 ¥Ñ ¥ú©úºô µoªí¤_Àô²y ·sµØªÀô¥»«¢®Ú4¤ë6¤é¹q¡]°OªÌªL´¹¡^¤¦³Áº¬Û¥±¹p¿A¨½§J´Ë6¤éªí¥Ü¡A¤¦³Áªñ´ÁÀ³¹ï·s«a¬Ì±¡±¹¬I±o·í¡A¬F©²±N±q15¤é°_¡u³v¨B¡B¦³±±¨î¦a¡v¸Ñ¸TºÞ¨î±¹¬I¡C ¥±¹p¿A¨½§J´Ë·í¤Ñ¦bº¬Û©²¥l¶}·s»Dµo¥¬·|»¡¡A¤¦³Áªñ´ÁÀ³¹ï¬Ì±¡±¹¬I±o·í¡A¬Ì±¡¦U¶µ¼Æ¾Ú¥Ã¥i±±¡C¦pªG¥Á²³Ä~Äò¿í¦u¨¾¬Ì³W©w¡A¬F©²±N±q15¤é°_¸Ñ¸T³¡¤À¾÷ºc¡A¨ä¤¤¥]¬A¤é¦«¤¤¤ß©M¤p¾Ç1¦Ü5¦~¯Å¡C¦o±j½Õ¡A¤Wz¾÷ºc«·s¶}©ñ«e¥²¶·±Ä¨ú±¹¬I¡A«OÃҨൣ¤§¶¡ªº¦X²z¶ZÂ÷¡C6¦Ü10¦~¯Å¾Ç¥Í±NÄ~Äò©~®a¾Ç²ßª½¦Ü5¤ë10¤é¡C¦P®É¨ú®ø·í¦~°ª¤¤¤J¾Ç¦Ò¸Õ¡A¥H«e¤@¦~¦¨ÁZ§@¬°¤J¾Ç°Ñ¦Ò¡C ¥±¹p¿A¨½§J´Ë¦P®É«Å¥¬¡AÄ~Äò¸T¤î10¤H¥H¤W¶°·|¡AÃö³¬Ãä¹Ò¡B°Ó³õ¡B¹Ï®ÑÀ]¡B¹q¼v°|©MÀ\À]µ¥¦Ü5¤ë10¤é¡C¦P®É¼È°±¨¬²yÁÉ¡Bµ¼Ö·|µ¥¤j«¬¬¡°Ê¦Ü8¤ë¡C¦o¦P®É«ü¥X¡A¦pªG±µ¤U¨Ó¤@©P¬Ì±¡¼Æ¾Ú´c¤Æ¡A±N¨ú®ø¡u´_¤u½Æ½Ò¡vªì¨Bp¹º¡C ¤¦³Á°ê®a¦å²M¬ã¨s©Ò°õ¦æ°Æ©ÒªøÀqº¸¤Ú§J»{¬°¡A¥un¥Á²³Ä~Äò¿í¦u¬F©²³W©w¡A¡u´_¤u½Æ½Ò¡vªì¨Bp¹º±N¬O¡u¦X²zªº¡v¡C ®Ú¾Ú¤¦³Á°ê®a¦å²M¬ã¨s©Ò6¤é¤½¥¬ªº¼Æ¾Ú¡A¤¦³Á¥Ø«e¹ï47340¤H¶i¦æ¤F·s«a¯f¬rÀË´ú¡A²Öp½T¶E¯f¨Ò4681¨Ò¡A¦º¤`187¨Ò¡Aªv¡1378¨Ò¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/6 ¤U¤È 05:17:12²Ä 2398 ½g¦^À³
|
«¤j¬ð¯}¡I ¬ü¬ì¾Çµo²{ªZº~ªÍª¢¯f¬r¡u¸nªù¡v news.ltn.com.tw/news/world/breakingnews/3124622 2020-04-06 17:06:03 ¡e½sĶ³¯¦¨¨}¡þºî¦X³ø¾É¡f¬ü°ê´µ§J¨½´¶´µ¬ã¨s¤¤¤ß¡]Scripps Research Institute¡^ªº¬ã¨s¤Hû«ÅºÙ¤w§ä¨ì¤FªZº~ªÍª¢¯f¬rªº¡uªü°ò´µ¨½¸x¡v¡]¸nªù¡^¡C¥ĻQ¥Î2006¦~±q¤@¦WSARS²¬Â¡ªÌÅ餺¤ÀÂ÷¥X¨Óªº¤@ºØ§ÜÅé¡A´¦¥Ü¤FªZªÍ¯f¬r¼ç¦b®zÂI¡A±N¦³§U©óªvÀø»P¬Ì]¶}µo¡A¤]¥i¯à¹w¥ý¨¾½d¥¼¨Ó¥X²{ªº·s«¬«aª¬¯f¬r¡I ¾Ú^°ê¡m¨C¤é¶l³ø¡nµ¥¦h®a°ê»Ú´CÅé³ø¾É¡Aµoªí¦b¡m¬ì¾Ç¡n¡]Science¡^´Á¥Z¤Wªº³o¶µ¬ã¨s¡Aº¦¸¥H±µªñì¤l¤Ø«×ªº¸ÑªR«×´yø¤F¤HÃþ§ÜÅé»PªZªÍ¯f¬rªº¬Û¤¬§@¥Î¡C³oºØ§ÜÅé¬O¦bSARS·P¬V®É²£¥Íªº¡A¾¨ºÞSARS¬O¥ÑSARS-CoV¡]ÄY«¶Ç¬V©Ê¯gÔ¸s«aª¬¯f¬r¡^¤Þ°_ªº¡A¦ý¥¦»P¾ÉPªZº~ªÍª¢ªº«aª¬¯f¬rSARS-CoV-2¡]ÄY«¶Ç¬V©Ê¯gÔ¸s«aª¬¯f¬r2«¬¡^¡Aµo¥Í¥æ¤e¤ÏÀ³¡C ³o¶µ·sªº¬ã¨s¶°¤¤¦b¤@ºØ¦W¬°CR3022ªº§ÜÅé¤W¡A¬ã¨s¤Hû«ü¥X¡ASARS²¬Â¡ªÌªºCR3022§ÜÅéµ²¦X¨âºØ«aª¬¯f¬r¤W´X¥G¬Û¦Pªº¦ìÂI¡A³oÅã¥Ü¸Ó®a±Úªº«aª¬¯f¬r¨ã¦³«n¥\¯à©M¡u¸nªù¡v¡C¸Ó¬ã¨sªº¸ê²`§@ªÌ«Âº¸»¹¡]Ian Wilson¡^»{¬°¡A¡u³o¥i¥HÀ°§U¹ïSARS-CoV-2¬Ì]©MÀøªkªºµ²ºc³]p¡A¦Ó³o¨Ç¤]±N¨¾½d¨ä¥L¥i¯à¥X²{¦b¥¼¨Óªº«aª¬¯f¬r¡C¡v Wilsonªº¹Î¶¤§Q¥Î¥L̪ºµ²ºc¬M®g§Þ³N¨Ó½T©wCR3022§ÜÅé¬O¦p¦ó»PSARS-CoV-2µ²¦Xªº¡C¤@ÓÃöÁ䪺µo²{¬O¡A³o¨âºØ«aª¬¯f¬rªº§ÜÅéµ²¦X¦ìÂI«D±`¬Û¦ü¡A¥u¬O¦³¥|Ó®ò°ò»Äªº¦ìÂI¤£¦P¡C ¬ã¨sµ²ªGªí©ú¡A³oºØ§ÜÅé¦bªZªÍ¯f¬r¡]SARS-CoV-2¡^¤Wªºµ²¦X¦ìÂI¬O¨ä¡u¸nªù¡v¡A§óºò±K¦aµ²¦X¥¦ªº§ÜÅé¥i¯à·|¦¨¥\¦a¤¤©M¯f¬r¡C³oºØ¤¤©M§ÜÅé¦pªGµo®i¦¨ªvÀø¤èªk¡A¥i¥Î©óªvÀøªZªÍ±wªÌ¡A¨Ã¬°¥¼¨ü·P¬VªºÓ¤H´£¨Ñ¼È®Éªº«OÅ@¡A¨Ò¦p½Ã¥Í«O°·¤u§@ªÌ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/6 ¤W¤È 08:27:25²Ä 2397 ½g¦^À³
|
www.worldometers.info/coronavirus/#countries 4¤ë5¤é: ½T¶E¨Ì¤H¤f¤ñ ¥xÆW¦³15¤H/¦Ê¸U¤H ,¥þ²y±Æ¦W«e60¤Ö´X¦W. ,¦@363¤H½T¶E ·s¥[©Y¦³224¤H/¦Ê¸U¤H ,¦@1,309¤H½T¶E »´ä¦³119¤H/¦Ê¸U¤H ,¦@890¤H½T¶E ¡X¡X¡X¡X¡X¡X¡X- ¬ü°ê1,017¤H/¦Ê¸U¤H ,¦@336,327¤H½T¶E ¦è¯Z¤ú2,816¤H/ ¦Ê¸U¤H ,¦@131,646¤H½T¶E ¸q¤j§Q2,133¤H/¦Ê¸U¤H ,¦@128,948¤H½T¶E ¼w°ê 1,195¤H/¦Ê¸U¤H ,¦@100,123¤H½T¶E ªk°ê 1,422¤H/¦Ê¸U¤H ,¦@92,839¤H½T¶E ¤¤°ê 57¤H/¦Ê¸U¤H ,¦@81,669¤H½T¶E ¥ì®Ô 693¤H/¦Ê¸U¤H ,¦@58,226¤H½T¶E ^°ê704¤H/¦Ê¸U¤H ,¦@47,806¤H½T¶E ¤g¦Õ¨ä321¤H/¦Ê¸U¤H ,¦@27,069¤H½T¶E ·ç¤h2,438¤H/¦Ê¸U¤H , ¦@21,100¤H½T¶E |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/6 ¤W¤È 07:51:50²Ä 2396 ½g¦^À³
|
Ãþ¬Ì](¤f¸n) , ¥xÆWY¦u¦íªÀ°Ï¤j´T·P¬V¡C ¦b¬Ì]¦¨¥\°Ý¥@¤§«e¡A±a°_¤f¸n¥i±Ï¥þ²y¸gÀÙ¡A§Ö³t¦^ÂÐ¥¿±`¥Í¬¡¡C 1. ¥xÆW¨¾¬Ì¸gÅç¨ü¬üÃöª` ¸âªøÅv¡GÀ¹¤f¸nÃþ¦ü¬Ì]§@¥Î 2020-04-04 17:46:47 ¡e°OªÌªL¾å¶³¡þ¥x¥_³ø¾É¡f¬ü°ê¬F©²«Øij¤H¥Á¥X¤J¤½¦@³õ©ÒÀ¹¤f¸n¡A¥x¤j¤½½Ã¾Ç°|°|ªø¸âªøÅv¦bÁy®Ñ¤À¨É¡A¥L¤é«e±µ¨ü¬ü°êµØ²±¹y¬ü°ê¤§µ¡qVoice of America, VOC¡rªº²{³õ³s½u¡A³Q°Ý¤Î¸Ó¤£¸ÓÀ¹¤f¸nªº°ÝÃD¡A¥Lªí¥Ü¡A¥xÆW¤Hı±o¦b¾ÖÀ½Àô¹Ò¤¤À¹¤f¸n¦³§U¨¾¬Ì¡A¦Ó¥L±q±q±Ú¸s¨¾¬Ì¾Ç²z¤W¤ÀªR¡A¤@¥¹¤H¸s¼sªx°tÀ¹¤§«á¡A¦³¥i¯à²£¥Í¡uÃþ¦ü¬Ì]¡vªº¸sÅé§K¬Ì§@¥Î¡A¥t¥~±q¥xÆW´XÓ¤ë¨Óªº¹ê»Úª¬ªpÆ[¹î¥þ¥ÁÀ¹¤f¸nªº²{¶H¡AÀ¹¤f¸n¦³ºû«ù¥Á²³¹ïªZº~ªÍª¢Covid-19¬Ì±¡ÄµÄ±©Êªº½Ã¥Í±Ð¨|¥\®Ä¡C³o¨Ç¥xÆW¤HÀ¹¤f¸nªº¸sÅé¸gÅç¡A³£¬O¹ï¨¾¬Ì¦³¥¿±®Ä¯qªº¿n·¥§@¬°¡C ¸âªøÅvªí¥Ü¡A¬ü°ê¤w¶}©lÂà¦V¡uÀ¹¤f¸n¦³¥Î½×¡v¡A¦ý¬O¤f¸n¡]surgical masks¡^¤£°÷¡B¥u¦n¥Î¥¬±¸n¡]cloth face covers¡^¡I³o¤@¶µ«ü¥O«Øij¬ü°ê¤H¦bÃø¥Hºû«ù¦w¥þªÀ¥æ¶ZÂ÷¡]³æÃä2¤½¤Ø¼e¡B±¿n16¥¤è¤½¤Ø¡^ªº¤½¦@ªÅ¶¡nÀ¹¡u¥¬±¸n¡v¡A²z¥Ñ¤§¤@¬O¤H¸s¤¤¬V¦³¯f¬rªº¤H¦³¤£¤Ö¬O¡uµL¯gª¬¡v¡B¡u¯gª¬«e¡vªº¯f¬r±aìªÌ¡A·|¦bªZº~ªÍª¢¯gª¬µo¥Í«e§â¯f¬r¶Çµ¹§O¤H¡A¤]´N¬O»¡¦b¨S¯gª¬ªº¤H»P¤H±K¤Á±µÄ²¤¬°Ê®É¡]»¡¸Ü¡B«y¹Â©Î¥´¼QÀ¡¡^¤]¥i¯à¦b¤H¸s¤¤¶Ç¶}¨Ó¡C ¦Ó¸âªøÅv¤]´£¨Ñ¤@Ó¥xÆW¸gÅç¡A§@¬°¥@¬É¦@¨Éªº¨¾¬Ì§@ªk¡A¥L¦b¥x¥_®É¶¡3¤ë21¤é¨üÁÜ°Ñ¥[¦ì¦b¬ü°êµØ²±¹y¬ü°ê¤§µªº²{³õ³s½u¡A©MTom Frieden¡]¬ü°ê«e¥ô¯eºÞ¸p¸pªø¡^,¡ACanbiar Ally¡]¯Ã¬ù Albany Institue of International Health Educationªº¥D®u¡^¡AIngrid Katz¡]«¢¦ò¤j¾ÇÂå¾Ç°|§U²z±Ð±Â¡^¡AJason Farkey ¡]¬ù¿«ÀN´¶ª÷´µdivision of infectious diseases aids service ±Ð±Â¡^¤@°_°Ñ¥[¤@³õ¬°ªZº~ªÍª¢Covid-19¯S§OÁ|¿ìªºµêÀÀ¥«¬FÆU·|ij¡A¦b³o¤@³õ¦³¼vµªº²{³õ¸`¥Ø¡A°£¤F´£¨ÑÆ[²³¥¿½Tªº¬Ì±¡¸ê°T©Mª¾ÃѤ§¥~¡A¤]±µ¨ü¨Ó¦Û¥@¬É¦U¦aªºÆ[²³¥Î¤å¦r©M¼vµ´£°Ý¡C ¦b¸`¥Ø²Ä19¤ÀÄÁ¦³¤@¦ì¨Ó¦Û¯Q§JÄõªºDimitriy ¸ß°Ý¸Ó¤£¸ÓÀ¹¤f¸nªº°ÝÃD¡A¥D«ù¤H«ü©w¸âªøÅv¦^µª¡A¸âªøÅv´£¥X¡uÀ¹¤f¸n¦³¥Î½×¡v¡A³o©M·í®É°ê»Ú¶¡¨¾¬Ìªº¥D¬y«äºû¡G»{¬°¤f¸n¥u¦³¥Í¯fªÌ¤~»ÝnÀ¹ªº½×ÂI«Ü¤£¤@¼Ë¡A¤]¤Þ°_Tom Frieden´£¥XWHO©M¬ü°êCDC¡uÀ¹¤f¸nµL¥Î½×¡vªº¥D¬yÆ[ÂI¨Ó°Q½×¡A¦ý³ÌªñÀHµÛ¼Ú¬ü¬Ì±¡¤éº¥ÄY«¡B¼Ú¬ü¤f¸nÄY«¯Ê³fªºÀI®m±¡¶Õ¡A¥þ¥Á¸Ó¤£¸ÓÀ¹¤f¸n¤S¦¨¬°°ê»Ú¨¾¬Ì¸ÜÃD©M¦U°ê¬F©²n±¹ïªºÃøÃD¡A¥B¸ñ¶HÅã¥Ün¤£¬O¥þ²y¤f¸n¯Ê³f¡A¥þ¥ÁÀ¹¤f¸n¦³¥i¯à¦¨¬°¤@¶µ¥þ²y¨¾¬Ìªº·s«ü¤Þ¡I ¸âªøÅv¤]³zÅS¡A¬ü°ê¤§µ¤µ¤Ñ¦A§ä¥L°Ñ¥[¤U¤@¦¸¡]4¤ë21¤é¡^ªºTown Hall Meeting¨Ó¦n¦n°Q½×¤f¸n°ÝÃD¡A±q³oÓÁܽСA¥L¥i¥H·P¨ü¨ì¥@¬É¦U¦a«Ü·Q¤F¸Ñ¡A¥xÆW¨ì¤µ¤ÑÁٺ⤣¿ùªº¨¾¬Ì¦¨ªG¬O«ç»ò¹F¦¨ªº¡H 2. www.chinatimes.com/newspapers/20200405000342-260102?chdtv WHO §ï¤fÀ¹¤f¸n ¼Ú¬ü·s«aªÍª¢¬Ì±¡ÄY«¡A¬Û¹ï¤W¥xÆWµ¥¨È¬w°ê®a«h¨¾¬Ì¦³¦¨¡A¨ä¤¤¥þ¥ÁÀ¹¤f¸n¬O«n¤@Àô¡C¦p¤µ¡A¥ý«e°íºÙ¦³¯f¤~¶·À¹¤f¸nªº¥@½Ã²Õ´¡]WHO¡^¤w§ï¤fºÙ¡A«ö»´ä¸gÅç¡AÀ¹¤f¸n¦ü¥G¦³¥Î¡C¬ü°ê¯e±±¤¤¤ß¡]CDC¡^¤]Âà¦Ó«Øij¥Á²³¥~¥X®ÉÀ¹¡u¥¬¤f¸n¡v¡C¦ý¤é¥»n¨C¤áµo©ñ2°Æ¥¬¤f¸n¡A«o¾D±M®a¥´Áy¡u¨Ã¤£¾A·í¡v¡C ¾Ú^´C³ø¾É¡AWHO¤w¦¬¨ì¨Ó¦Û»´ä¡A¦³Ãö¤f¸n¨Ï¥Îªº¸ê®Æ¡CWHO±M®a¤p²Õ¥D®u¡B^°ê¶Ç¬V¯f±M®a®ü°Ò¡]David Heymann¡^ºÙ¡A¡u»´ä´£¥X¤@¨ÇÃÒ¾ÚÅã¥Ü¡A¤f¸n¥i¯à¦³§U©ó¡]may be useful¡^¨¾¤îÓ¤H¨ü·P¬V¡v¡CWHOºò«æ¶µ¥Øt³d¤H·ç¦w3¤é¥çªí¥Ü¡A¦b«ÜÃø«O«ù¨¬°÷¶ZÂ÷¤ÎªÀ°Ï¶Ç¼½·Uºt·U¯Pµ¥±¡ªp¤U¡A¹ªÀy¤½²³°tÀ¹¤f¸n¥H°§C·P¬V²v¡C ¬ü°êCDC¤]¦b3¤éµoªíÁn©ú»¡¡AŲ©ó³Ì·s¬ã¨sµo²{¤j¶qªºµL¯gª¬¶Ç¼½ªÌ¡A«Øij¥Á²³¦bÃø¥H«O«ùªÀ¥æ¶ZÂ÷ªº¤½¦@³õ©ÒÀ¹¡u¥¬¤f¸n¡v¡A¤×¨ä¬O¨º¨ÇªÀ°Ï¶Ç¼½ÄY«ªº¦a°Ï¡C¦Ü©óÂå¥Î¤f¸n¤ÎN95¤f¸n¡A³o¨ÇÃööb¨¾¬Ìª«¸êÀ³¯dµ¹ÂåÅ@¤Hû¡C¤t´¶Á`²Î«hºÙ¡A¦³Ãö«Øij¯Âºé¬OÅý¥Á²³¦ÛÄ@¨ØÀ¹¡AÁÙ»¡¦Û¤v¥¼¥²·|¿í±q¡C 3. ªZº~ªÍª¢¡nÅK¾¦¡u¤f¸nµL¥Î¬£¡vÂàÅs¡I·s¥[©Y¤Àµo¤f¸n 2020-04-05 19:36:56 ¡e½sĶ³¯¦¨¨}¡þ³ø¾É¡f¾¨ºÞªZº~ªÍª¢¬Ì±¡ÄY«¡A¼Ú¬ü¦U°ê¤½½Ã«ü¾Éì«h¨ÌµM°í«H¡u°·±dªº¤H¤£»ÝnÀ¹¤f¸n¡v¡A¬Ý¦b¥xÆW¤H²´¸Ì¡A¹ê¦b¤£¥i«äij¡C·s¥[©Y§@¬°¨È¬w°ß¤@¡u¤f¸nµL¥Î¬£¡v¡A쥻¤@¼ËÅK¾¦¡A¦ý¦³Å²©ó¬Ì±¡¤É°ª¡A¥[¤WµL¯gª¬·P¬VªÌ¨¾¤£³Ó¨¾¡A·s¥[©Y¬F©²¤w±q5¤é°_¤Àµo¥i«½Æ¨Ï¥Îªº¤f¸nµ¹©Ò¦³®a®x¡Aì¥ý¡u¤£¹ªÀy°·±d°ê¥ÁÀ¹¤f¸n¡v¤]¤£¦A´£¡C ·s¥[©Y¦b2¤ë4¤é¤@¤Ñ·s¼W6ӮרҡA¨Ã¥X²{²Ä¤@¨Ò¤H¶Ç¤HӮסA¤§«á¬Æ¦Ü¥X²{ºÃ¦ü¥X²{ªÀ°Ï·P¬V¡C¦ý·s¥[©YÁ`²z§õÅãÀs¦Ñ¯«¦b¦b¡A¤@¦A©IÆ~¥Á²³¡A¡u°·±dªº¤H¤£»ÝnÀ¹¤f¸n¡v¡C ¤£¹L§õÅãÀs3¤é¸ÑÄÀ¡A¤§«eªº«Øij¬O°ò©ó¥@½Ã²Õ´¡]WHO¡^ªº¬ì¾Ç«Øij»P³W©w¡C¥L¸É¥R¡A¡u·s¥[©Y·í®É¨S¦³¥X²{ªÀ°Ï¶Ç¬V¯f¨Ò¡A©Ò¥H¤£¤Ó¥i¯à¦bµó¤W¹J¨ì«a¯f·P¬VªÌ¡A§ó¤£¥i¯à³Q·P¬V¡C¡v ¥L¸ÑÄÀ¡A¥Ø«e¡u¤w¦³ÃÒ¾ÚÅã¥Ü·P¬VªÌ¨S¦³¥X²{¯gª¬¡A¤]¯à±N¯f¬r¶Ç¬Vµ¹§O¤H¡K¡K¦]¦¹¬F©²¤£¦A¤£¹ªÀy°ê¥ÁÀ¹¤f¸n¡C¡v¦¹¥~¡A¨ØÀ¹¤f¸n¤]¯à«OÅ@¥L¤H¡AÁקK¦³¤H¤£ª¾¹D¦Û¤v·P¬V¯f¬r¡A±q¦Ó¶Ç¬Vµ¹§O¤H¡C ·s¥[©Y¬F©²±q5¤é°_¦Ü4¤ë12¤é¤]¬°©Ò¦³·s¥[©Y®a®x¤Àµo¥i«½Æ¨Ï¥Îªº¤f¸n¡A±N¤â³N¤f¸n¯dµ¹§ó»ÝnªºÂåÅ@¤Hû¨Ï¥Î¡C§õÅãÀs´£¿ô¡AµL½×À¹¤£À¹¤f¸n¡A§ó«nªº¬O¬~¤â¤Î»P¨ä¥L¤H«O«ù¦w¥þ¶ZÂ÷¡C ·s¥[©Y¶T¤u³¡ªø³¯®¶Án3¤é«Øij¡A·s¥[©Y¤H¨ì¤á¥~¤H¦hªº¦a¤è®É¤@©wnÀ¹¤f¸n¡A¦^¨ì®a«á¥i¥H²M¬~©M´½°®¤f¸n¡A¹j¤Ñ«½Æ¨Ï¥Î¡C 4. ªZº~ªÍª¢¬Ì±¡¤É·Å ¦L¥§n¨D¥Á²³¥~¥X¶·À¹¤f¸n ³Ì·s§ó·s¡G2020/04/05 22:16 ¤¤¥¡ªÀ°OªÌ¥Û¨q®S¶®¥[¹F5¤é±M¹q¡^¦L¥§¤µ¤Ñ³q³ø³æ¤é·s¼W181¨ÒªZº~ªÍª¢½T¶E¯f¨Ò¡A²Öp¹F2273¨Ò¡A¦º¤`¤H¼Æ·s¼W7¤H¡AÁ`¼Æ198¤H¡C©xûn¨D¥Á²³¤µ¤Ñ°_¥Xªù³£nÀ¹¤f¸n¡C¶®¥[¹F¤j²³¹B¿é¦Û12¤é°_±N±j¨îÀ¹¤f¸n¡C ¦L¥§2019«aª¬¯f¬r¯e¯f¡]COVID-19¡AªZº~ªÍª¢¡^±wªÌ«æ³t¼W¥[¡A3¤é³q³ø·s¼W196¨Ò¡A¬O³æ¤é³Ì°ª¼W´T¡A¤µ¤Ñ«h¬O²Ä¤G°ª¡A¦º¤`Á`¤H¼Æ¤w¹Gªñ200¤H¡C ¦L¥§½Ã¥Í³¡¯e¯fºÞ¨î¤Î¹w¨¾§½§½ªø¦ãº¿¼w¡]Achmad Yurianto¡^¦b¬Ì±¡§ó·sªº°OªÌ·|¤W«ü¥X¡A¨Ì·Ó¥@¬É½Ã¥Í²Õ´¡]WHO¡^ªº«Øij¡A¤µ¤Ñ°_¥Á²³¥~¥X¥²¶·À¹¤f¸n¡A¦]¬°¦b¤á¥~¥i¯à¹J¨ìµL¯gª¬ªºªZº~ªÍª¢·P¬VªÌ¡C ¦ãº¿¼w©IÆ~¥Á²³¥Î¥i¥H²M¬~«½Æ¨Ï¥Îªº¥¬¤f¸n¡A¨Ï¥Î«á¥HªÎ¨m²M¬~¡A§â¥~¬ì¤f¸n©MN-95¯dµ¹ÂåÅ@¤Hû¨Ï¥Î¡A¤]©IÆ~¥Á²³«O«ùªÀ¥æ¶ZÂ÷¡C ªZº~ªÍª¢¬Ì±¡¤É·Å«á¡A¦L¥§¤wÃø¶R¨ì¥~¬ì¤f¸n¡C¥Á²³«ü¥X¡A¶®¥[¹F¤@²°50Ó¥~¬ì¤f¸nn»ù40¸U¦L¥§¬Þ¦Ü65¸U¦L¥§¬Þ¡]¬ù·s¥x¹ô738¤¸¦Ü1200¤¸¡^¡A¦bªF¤ö«zªr¤ô¡]Surabaya¡^ªº°â»ù¬°50¸U¦L¥§¬Þ¡]·s¥x¹ô923¤¸¡^¡C¥H¤@Ó¤f¸n¦L¥§¬Þ8000¤¸¨Óºâ¡A2Ó¤f¸n´N¤ñ¦L¥§¸ôÃäÅuªºª£¶ºÁÙ¶Q¡C ¶®¥[¹F¬Ùªøªü¥§´µ¡]Anies Baswedan¡^¤µ¤Ñ«h¬On¨D¶®¥[¹Fªº¤j²³¹B¿é¨t²Î¡A¥]¬A±¶¹B¡B»´y¥H¤Î§Ö±¶¤Ú¤h¡]BRT¡^µ¥q©w±j¨în¨D¼«ÈÀ¹¤f¸nªº¿ìªk¡A©ú¤Ñ°_¶}©l«Å¾É¡A¦Û4¤ë12¤é°_±N±j¨î¹ê¬I¡C ¦¹¥~¡A¤µ¦~¥ì´µÄõ±ÐªºÂN§Ù¤ë¹wp4¤ë23¤é¥ª¥k¶}©l¡A¿p´µªL·|¦bÂN§Ù¤ë«á¨â¶g¥ª¥k¶}©lªð¶m¡]mudik¡^»P®a¤H¹Î»E¡A¦@«×ÂN§Ù¤ë«áªº¶}ÂN¸`¡C ¥h¦~¦L¥§¦³1950¸U¥Á²³ªð¶m¹L¶}ÂN¸`¡A¥~¬É¾á¼~¤j§å¤H¼é²¾°Ê±N¨Ï¬Ì±¡ÂX´²¡C¦L¥§Á`²Î¦õ¬ì«Â¡]Joko Widodo¡^¤é«e©çªO¡A¤£·|¨î¥Á²³ªð¶m¡A¦ý¦Ò¼{´£¨Ñ¬z¶Kµ¥¸gÀÙ»¤¦]¡A¹ªÀy¥Á²³§ï¨ì¤é«á¦Aªð¶m¡C ¦L¥§¥æ³q³¡¤w´£¥X¦h¶µ±¹¬I¡A¬ß¥Á²³¥´®øªð¶mpµe¡A¥]¬A¤½¦@¹B¿é©Î¨p¤H¥æ³q¤u¨ãªº¸ü«È¶q³£¶·´î¥b¡A¤½¦@¹B¿éªº²¼»ù´£°ª¡Aªð¶m«á¥H¤Îµ²§ôªð¶m«á¡A³£¥²¶·¦Û§Ú¹jÂ÷14¤Ñ¡A³o¨Ç³W©w±N¹ê¬I¨âÓ¤ë¦Aµø¬Ì±¡ÀË°Q¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/2 ¤U¤È 03:16:25²Ä 2395 ½g¦^À³
|
Aslan001 ¨Ì109¦~预ºâ¤´±N§ë¤J1»õ3¤d800¸U¤¸¤§¬ã¨s费¥Î¡C¬GY¤é«áFDA¦P·N¤p¤T´ÁªºÁx¹DÀùÁ{§É¡A³Q·|p®v½Õ¾ã¬°费¥ÎªºµL§Î¸ê²£¡AÁÙ¦³¤Ï¦^·í¦¬¯qªº¾÷·|¡A¦U¦ì¤j¤j¡A¥i°Ý¤½¥q ¤p¤T´ÁªºFDA¥Ó½Ð¶i«×¬°¦ó¡H ¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ¨È·à±d-KY ¡@¤½¥q´£¨Ñ §Ç¸¹ 2 µo¨¥¤é´Á 109/03/26 µo¨¥®É¶¡ 16:06:25 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ °õ¦æªø µo¨¥¤H¹q¸Ü +65 6222 4235 ¥D¦® ¥»¤½¥q¸³¨Æ·|¨Mij108¦~²{ª÷¼W¸ê°Ñ»Pµo¦æ®ü¥~¦s°U¾ÌÃÒ, ¸êª÷¥Î³~Åܧó¬ÛÃö¨Æ©y ²Å¦X±ø´Ú ¡@²Ä 16 ´Ú ¨Æ¹êµo¥Í¤é 109/03/26 »¡©ú 1.¸³¨Æ·|¨MijÅܧó¤é´Á:109/03/18~109/03/26 2.ìpµe¥Ó³ø¥Í®Ä¤§¤é´Á:108/11/05 3.ÅÜ°Êì¦]: ½t¦]¥»¤½¥q©ó108¦~11¤ë¤½¥¬Áx¹DÀù¤§¥þ²y©Ê¼Ï¯Ã¸ÕÅçTreeToppªºÁ{§É¸ÕÅçµ²ªG¡A¸Óµ² ªG¥¼ÅãµÛ¹F¨ì¹w¥ýÀÀ©wªº¤ô·Ç¡A¥B108¦~²{ª÷¼W¸êµo¦æ·sªÑ°Ñ»P®ü¥~¦s°U¾ÌÃÒ¹ê»Úµo¦æ Á`ª÷ÃB°ò©ó·í®É¸ê¥»¥«³õª¬ªp»Pì¶Ò¸êp¹º¹wpª÷ÃB¦³²§¡C¦]¦¹¡A¥»¤½¥q¦Ò¶q¸êª÷³Ì ¤j¨Ï¥Î®Ä²v¨Ã«·sµû¦ôìp¹º¡AÀÀ±N«e¦¸¶Ò¸êª÷ÃB½Õ¾ã¹B¥Î¡A´£Ä³Åܧópµe¨Ã¥Ñ¸³¨Æ ·|¨Mij³q¹L¡C 4.¾ú¦¸Åܧó«e«á¶Ò¶°¸êª÷pµe: ¥»¤½¥q2019¦~²{ª÷¼W¸êÅÜ°Ê«e«á¤§pµe¤º®e¦C¥Ü¦p¤U¡G ³æ¦ì¡G¥a¤¸ pµe¶µ¥Ø Åܧóp¹º«e Åܰʪ÷ÃB Åܧóp¹º«á Varlitinib (ASLAN001) NT$ 840,000 NT$ (702,000) NT$ 138,000 US$ 28,000 US$ (23,400) US$ 4,600 ASLAN003 NT$ 36,000 NT$ (36,000) NT$ 0 US$ 1,200 US$ (1,200) US$ 0 ASLAN004 NT$ 225,000 NT$ 0 NT$ 225,000 US$ 7,500 US$ 0 US$ 7,500 ¥R¹êÀç¹B¸êª÷ NT$ 99,000 NT$ (20,010) NT$ 78,990 US$ 3,300 US$ (667) US$ 2,633 ¦Xp NT$ 1,200,000 NT$ (758,010) NT$ 441,990 US$ 40,000 US$ (25,267) US$ 14,733 5.¹wp°õ¦æ¶i«×:¹wp109¦~²Ä4©u§¹¦¨ 6.¹wp§¹¦¨¤é´Á:¹wp109¦~²Ä4©u§¹¦¨ 7.¹wp¥i¯à²£¥Í®Ä¯q: ¥»¦¸pµeÅܧó¥Ñ©óÁx¹DÀù¤§¥þ²y©Ê¼Ï¯Ã¸ÕÅçTreeToppªºÁ{§É¸ÕÅçµ²ªG¥¼ÅãµÛ¹F¨ì¹w¥ý ÀÀ©wªº¤ô·Ç¡A¬Gì¥ý¹wpvarlitinib (ASLAN001)¹w³Æ¦b¤¤°ê¤j³°°Ó«~¤Æ¤§«e¸m§@·~¤Î ·sÃĬdÅçµ¥¹wp¥Ó½Ð¤§«áÄò¬ã¨sµo®i¬¡°Ê¬ÛÀ³´î¤Ö¡A¶i¦ÓÀÀ½Õ¾ã¬ÛÃö¸êª÷¹B¥Î¡C ³q¹L¦¹¶µ×¥¿®×¡A¥i¥[±j±±ºÞ¶Ò±o¸êª÷¡A±N¹ê»Ú¶Ò±o¸ê·½»EµJ©ó¥Ø«e¥DnÀç¹B¶µ¥Ø¡A ¥H¼W¥[ªø´Á¸êª÷éw©Ê¡B±j¤Æ¸êª÷ÆF¬¡½Õ«×¯à¤O¡B°·¥þ°]°Èµ²ºc¥~¡A¥ç´£°ª¤½¥qÀç¹B ¯à¤O¡C 8.»Pì¹wp®Ä¯q²£¥Í¤§®t²§: ìp¹º¤¤¡uvarlitinib (ASLAN001)¡v¡B¡uASLAN003¡v¤Î¡u ¥R¹êÀç¹B¸êª÷¡v¤§¦U¶µ³W µe¡A¸g¼f·Vµû¦ô«á¡A½Õ¾ã¦U¶µ©Ò»Ý¸êª÷¡A¥H´Á¹F¨ì±j¤Æ¸êª÷ÆF¬¡½Õ«×¯à¤O¡B°·¥þ°]°È µ²ºc¡A´£°ª¤½¥qÀç¹B¯à¤O¡CÅܧó®t²§¸Ô¾ú¦¸Åܧó«e«á¹ï·Óªí¡C 9.¥»¦¸Åܧó¹ïªÑªFÅv¯q¤§¼vÅT: ¥»¦¸¸êª÷¹B¥Î½Õ¾ã¡A«Y¬°¦]À³¦U¶µpµe¹ê°È¹B§@©Ò»Ý¨Ã¦Ò¶q¹ê»Ú¶Ò±oª÷ÃB¡A¥H¼W¥[ªø ´Á¸êª÷éw©Ê¡B±j¤Æ¸êª÷ÆF¬¡½Õ«×¯à¤O¡B°·¥þ°]°Èµ²ºc¡A´N¤½¥qªø´Áµo®i¦Ó¨¥¡A¹ïªÑ ªFÅv¯q¤§¼vÅT©|Äݦ³¡C 10.ì¥D¿ì©Ó¾P°Óµû¦ô·N¨£ºKn: ¸Ó¤½¥q¥»¦¸pµeÅܧó¥Dn«Y¦]¸Ó¤½¥q©ó108¦~11¤ë¤½¥¬Varlitinib¥þ²y©Ê¼Ï¯ÃÁ{§É¸Õ ÅçTREETOPP¤G½uÁx¹DÀùÁ{§É¸ÕÅçµ²ªG¡A¥¼ÅãµÛ¹F¨ì¹w¥ýÀÀ©wªº¤ô·Ç¥B³Ì²×¹ê»Ú¶Ò±oª÷ ÃB»Pìpµe¦³©Ò®t²§¡A¦Ò¶q¸Ó¤½¥q©óASLAN004²§¦ì©Ê¥Ö½§ª¢·§©À©ÊÅçÃÒ¸ÕÅ礤¨ú±oªì ¨B¥¿¦V¼Æ¾Ú¤Î¸êª÷¨Ï¥Î®Ä²v¤§±¡ªp¤U¡A¨M©w¶i¦æpµeÅܧó¡A´î¤Öì¥ý¹wp¥Î©ó Varlitinib (ASLAN001)¹w³Æ¦b¤¤°ê¤j³°°Ó«~¤Æ¤§«e¸m§@·~¤Î·sÃĬdÅçµ¥pµe¥Ó½Ð¤§ «áÄò¬ã¨sµo®i¬¡°Ê¡AASLAN003¤Î¥R¹êÀç¹B¸êª÷¶µ¥Ø¥ç¦]¹ê»Ú¶Ò±oª÷ÃB¦³¬Û¹ïÀ³´î¤Ö ¡A±N¶Ò±o¸êª÷¹B¥Î©ó¸Ó¤½¥q¥Ø«e¥Dn«ü¼Ð¶µ¥ØASLAN004¤§¬ãµo¡A¥H¹F¸êª÷³Ì°ª¨Ï¥Î®Ä ²v¡AÀÀ±N¶Ò¸êpµe¤¤¶i¦æpµeÅܧó©|ÄݦX²z¡C 11.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ¥»¤½¥q¸³¨Æ·|«Y©ó109/03/18¥l¶}¡A±©¦U¶µÅܧó¶Ò¸êpµe¤å¥óñ®Ö®É¶¡¨ü¥~¦b¦]¯À¼v ÅT©µ¿ð¦Ü109/03/26»¼¥ó¬ÛÃö¥DºÞ¾÷Ãö¨Ã¤©¥H¤½§i¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/1 ¤U¤È 12:52:39²Ä 2394 ½g¦^À³
|
¸¤H¤j, ¤W¦¸ADR¼W¸ê«e,11¤ë20¤é¥ª¥k¬O0.35~0,4¬ü¤¸/ªÑ¡A¤ñ²{¦b§C ´X¤Ñ´N©Ô¨ì³Ì°ª8¬ü¤¸¡C ¨È·àYµLADR¡A«h¦M¤w¡C©Ò¥H¯¸¦b¤½¥qªº¥ß³õºû«ù¥xÆW6497¤W¥«¡AÅýADR§ó¦³¾á«O»ùÈ¡AÀu©ó¤U¥«¡C ¸q¤j§Q¡B¼w°ê¬Ì±¡¦ü¥G¨ì°ª峯¡A¬ü°ê¥i¯à»Ý¦b1~2¶g¡C¤½¥q5¤ë©³«e¼W¸êADR¬O®É¾÷¤ñ¥Ø«e¦n¡C ******¥B¬Ý¦P¯Å³ÌÀuªºASLN004 . |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/1 ¤U¤È 12:38:57²Ä 2393 ½g¦^À³
|
¤@¡AADR¼W¸ê®× 5¤ë©³¥i¤½¥¬ªº¥¼¸Ñª¼¼Æ¾Ú¤ñ¥h¦~12¤ë3¤é¤½¥¬ªº3¦ì¼Æ¾ÚÁÙ¦h¡A ¼W¸ê»ù®æ²zÀ³°ª©ó2.5¬ü¤¸/ªÑ ¤G¡BY¨p¶Ò®×¡A¤£¥Î°eª÷ºÞ·|. ¸³¨Æ·|¦P·N§Y¥i°õ¦æ¡C 1.Y¨p¶Ò¼W¸ê 5»õ¤¸¡AQ4°]³ø ¥i¼µ¨ì ¨ì2021¦~3¤ë©³ ¤½¥¬, 2.·s¥[©Y°]¬F³¡¥H¶Å¤JªÑ¬ù1700¸U¬ü¤¸¡A¥ç¥i¼µ¨ì2021¦~3¤ë. ¦¹´Á¶¡¤µ¦~Q3,µ¥ASLAN004 ´Á¤¤³ø§i¡A´N¥i¶ÒADR §ó¦nªº»ù®æ¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/4/1 ¤U¤È 12:34:39²Ä 2392 ½g¦^À³
|
To ¤Ñ©R¤j, ³o¨Ç§Ú³£ª¾¹D¡A¤£¹L²{¦b¤½¥q¨Ã¨S¦³¥ô¦ó¼Æ¾Ú¸ê®Æ¥i¥H¦V¥«³õ¶i¦æ¶Ò¸ê¡Aªp¥B²{¦bªÑ»ù¨º»ò§C¡A¦pªGn¶i¦æ¶i¦æ¶Ò¸ê¡A¨º»ù®æ¤@©w«Ü§C¡A·d¤£¦n·|Åý²{¦bADR¦A¶^¤@¦¸¡A¥[¤W¨º´µ¹F§Jªº°h³õ¾÷¨î¡AªÑ»ù¦pªG³sÄò30¤Ñ§C©ó1¤¸¬O¥i¥H±j¨în¨D¤U¥«ªº¡A²{¦b¥h¥«³õ¤W¶Ò¸ê®Ú¥»¬O¦×¥]¤l¥´ª¯¡A¦Ó¥B·|ÅýªÑ¥»¤j´T¿±µÈ¡A¨È·à±d·|§óÃø¦³Â½¨ªº¤@¤Ñ¡A¨ä¹ê³Ì²³æ´N¬O¨p¶Ò¡An¨D¤jªÑªF®³¿ú¥X¨Ó«×¹LÃøÃö¡A¤£¹L§Ú·QÀ³¸Ó«Ü§xÃø§a¡A§_«h¤§«e´N·|¥Î¨p¶Òªº¤è¦¡¨Ó¼W¥[²bȤΤ½¥q¥i¥H¹B¥Îªº¸êª÷¡A¦Ó¤£¬O¥Î10%§Q®§¤è¦¡¨Ó§l§ë¸êªº¤H¦å¡AÁ¿ÃøÅ¥ÂI¥i¯à¬O¤jªÑªF¤£Ä@·N¾á«O¡A©Ò¥H¥i¯à¨S¿ìªk¸ò»È¦æÉ¿ú¡A¤~·|¥ÎɶU¦W¸qɵ¹¤½¥q¦ÓÁȨú10%§Q®§¡A¨º®ÉÔÁÙ¦³ªþ¥[±ø¥ó¡AY¥»¤½¥q³Ì²×©ó»OÆWÂdÂi¶R½æ¤¤¤ß°±¤î¤½¶}µo¦æ¡A¸ÓÉ´Ú¤H±N¦³Åv¦æ¨Ï¤U¦C¨â¶µÅv§Q¤§¤@¡G(1)¦b¿Ä¸ê¶U´Ú¨ì´Á®É±N¥»ª÷¨Ã¥[p§Q®§ª÷ÃBÂà´«¬°¬ü°ê¦s°U¾ÌÃÒ¤§Åv§Q (2)±o¥Hɴڰʤä®É»ù®æ»{ÁÊ·sµo¦æ¬ü°ê¦s°U¾ÌÃÒ¤§»{ÁÊÅv§Q¡C¥Nªí¤½¥q¨º®É´N¦³¹w´ú¤½¥q¦³¥i¯à·|ºMÂd¤F¡A©Ò¥H¤~·|¥[µù³o¨â¶µ±ø¥ó¡A¸U¤@ºMÂdÀu¥ý¥i¥HÂà´«¦¨ADRªº¡A¤]¬O³o¨ÇÉ´Úªº¤jªÑªF§a¡A§Ú·Q¥xÆW³oÃ䪺§ë¸ê¤H³£¬O¤ñ¸û«á±ªº¶¶§Ç¡AY¬O¤£¯àÂà´«¡A¤½¥q²Mºâ¥[p10%§Q®§¡A³o¨Ç¤jªÑªF¤]¬O¥i¥H®³¦^¤£¤Ö²{ª÷¡A®Ú¥»¥i¥H»¡¬O¦³ÁȵL½ß¡A§ó¤£¥Î»¡¨È·à±d±q¤WÂd¥H¨Ó¡A¥ÓÁÊ»ù68¤¸¤§«á¥æ©ö¤é¨S¦³¤@¤Ñ¤ñ³oÓ°ª¡AµM«á¤@Ó§«ô¶^´T«Ü¤jn¥X¨Ó¶}»¡©ú·|¡A¹ê¦b¤£¥O¤Hı±o¤½¥q¨Ó¤WÂd¬O¬°¤F¥ÎªÑ²¼´«²{ª÷ªº¡AµM«á¨â¦¸001¸Ñª¼¥¢±Ñ¡A¤]¤£¨£¦³¥ô¦ó°ª¼h¬°¦¹t³d¤U¥x¡A°ª¶¥¥DºÞªºÁ~¤ô¤ä¥X¤]¬O«Ü°ª¡A¤~·|Åý¤½¥qªº²bȤ£¨ì¤@¦~ªº®É¶¡´N¶^¯}5¤¸¡A¶i¦ÓÅܦ¨¥þÃB¥æ³ÎªÑ¡A³s쥻¥H¬°¤W¦¸¼W¸ê¥i¥H²æÂ÷¤À½L¡A¤]¦bµL§Î¸ê²£´î·l¤Ï¦ÓÂàt¶i¦Óµo¥Í¦³ºMÂd¦M¾÷¡A¹ê¦b«ÜÃø¦A¬Û«H¤½¥q»¡ªº¶Ò¸ê®Éµ{¡A¯u¤ßı±o³o¦¸¤UÂdªº¾÷²v«Ü¤j¡A¤j®a¯uªºn¦³¤ß²z·Ç³Æ¡A°£«D¯à¥l¶}Á{®ÉªÑªF·|¡An¤½¥qµ¹Ó»¡ªk¡A§_«h¯uªºn¤p¤ß¨ì®ÉÔ¬O¤@³õªÅ¤F¡C Thanks, |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/1 ¤U¤È 12:19:47²Ä 2391 ½g¦^À³
|
¥h¦~ 11¤ë5¤é¨ú±o¥xÆWª÷ºÞ·|®Öã¼W¸ê 12¤ë6¤é§¹¦¨ADR¼W¸ê ¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ¨È·à±d-KY ¡@¤½¥q´£¨Ñ §Ç¸¹ 1 µo¨¥¤é´Á 108/11/05 µo¨¥®É¶¡ 15:41:16 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ °õ¦æªø µo¨¥¤H¹q¸Ü +65 6222 4235 ¥D¦® ¤½§i¥»¤½¥q¨ú±oª÷ºÞ·|®Öã¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo ¦æ¬ü°ê¦s°U¾ÌÃÒ ²Å¦X±ø´Ú ¡@²Ä 53 ´Ú ¨Æ¹êµo¥Í¤é 108/11/05 »¡©ú 1.¨Æ¹êµo¥Í¤é:108/11/05 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ:¨ú±oª÷¿ÄºÊ·þºÞ²z©eû·|ª÷ºÞÃÒµo¦r²Ä1080334435¸¹®Öã¿ì²z ²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¡C 6.¦]À³±¹¬I:¨Ìª÷¿ÄºÊ·þºÞ²z©eû·|ª÷ºÞÃÒµo¦r²Ä1080334435¸¹®Öã¿ì²z ²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL ¡X¡X¡X¡X¡X¡X¡X¡X¡X- ¥»¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ¨È·à±d-KY ¡@¤½¥q´£¨Ñ §Ç¸¹ 1 µo¨¥¤é´Á 108/12/06 µo¨¥®É¶¡ 06:37:12 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ °õ¦æªø µo¨¥¤H¹q¸Ü +65 6222 4235 ¥D¦® ¤½§i¥»¤½¥q¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ ¬ü°ê¦s°U¾ÌÃÒ¤§¬ÛÃöµo¦æ¸ê°T ²Å¦X±ø´Ú ¡@²Ä 53 ´Ú ¨Æ¹êµo¥Í¤é 108/12/06 »¡©ú 1.¨Æ¹êµo¥Í¤é:108/12/06 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¨Ì³W©óµo¦æ¤é´Á¤½§i¥»¤½¥q¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ ¤§¬ÛÃö¸ê°T¡C 6.¦]À³±¹¬I:µL¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ¥»¤½¥q¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¤§µo¦æ±ø¥ó¦p¤U¡G (1) µo¦æ¤½¥q¡G¨È·à±dªÑ¥÷¦³¤½¥q (2) µo¦æºØÃþ¡G²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ (3) µo¦æÁ`ª÷ÃB¡G¬üª÷14,733,015¤¸ (4) µo¦æÁ`¼Æ¡G¹ê»Úµo¦æ³æ¦ì¼Æ¬°5,893,206³æ¦ì¡A¨C³æ¦ì¬ü°ê¦s°U¾ÌÃÒªí¹ü¥»¤½¥q ´¶³qªÑ5ªÑ¡AÁ`¹ê»Úµo¦æ´¶³qªÑªÑ¼Æ¬°29,466,030ªÑ¡C (5) ¨C³æ¦ìµo¦æ»ù®æ¡G¬üª÷2.5¤¸ (6) ¨CªÑ»ù®æ¡G§é¦X¬°·s»O¹ô¬ù15.24¤¸(«ö¬üª÷§I·s»O¹ô¶×²v=30.48)¡C (7) µo¦æ¤é´Á¡G108/12/06 (8) ¥æ©ö¦aÂI¡G¨º´µ¹F§JÃÒ¨é¥æ©ö©Ò (9) µo¦æ¦aÂI¡G¬ü°ê (10)¦s°U»È¦æ¡G¼¯®Ú¤j³q»È¦æ (11)q»ù¤é¡G108/12/03 (12)¥»¦¸²{ª÷¼W¸ê°ò·Ç¤é¡G¥»¦¸²{ª÷¼W¸êµo¦æ·sªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ©ó 108¦~12¤ë06¤é¦¬¨¬ªÑ´Ú¡A¨Ãq108¦~12¤ë06¤é¬°²{ª÷¼W¸ê°ò·Ç¤é¡C (13)¸êª÷¹B¥Îpµe¤Î¹wp¥i¯à²£¥Í®Ä¯q¡G ¤@¯ë¥ø·~¥Î³~- ¥Î©óASLAN004²§¦ì©Ê¥Ö½§ª¢ªºMADÁ{§É¸ÕÅ秹¦¨¤Î ¤äÀ³ASLAN003§ë¤JAML BEAT«æ©Ê°©Åè©Ê¥Õ¦å¯f¤§Á{§É¶}µo¤Î±´¯Á¡A Àò¨ú§ó¦h¼Æ¾Ú¡A¦³§U»P°ê»Ú¤j¼tÂà¥X±ÂÅv®Ä¯q¡F¨Ã¥R¹êÀç¹B¸êª÷ éwªø´Á¸êª÷¨Ó·½¡A´£¤É¸êª÷½Õ«×¤§¼u©Ê¡C (14)¹ïªÑªFÅv¯q¤§¼vÅT¡G¹wp±N´£¤ÉªÑªF§Q¯q¡Aµo¦æ·sªÑ29,466,030ªÑ¡A ¥[p¥Ø«e¹ê¦¬ªÑ¥»160,488,940ªÑ¡A¨ä¨CªÑµ|«e¬Õ¾lµ}ÄÀµ{«× 15.51 %¡C |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/4/1 ¤U¤È 12:13:17²Ä 2390 ½g¦^À³
|
ÁÂÁ¤ѩR¤j&¸¤H¥d¯S¤j ¨â¦ìªº¦^ÂÐ!ÁÂÁ±z! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/4/1 ¤U¤È 12:10:32²Ä 2389 ½g¦^À³
|
¸¤H¤j¡A ¤½¥q¥¿¿n·¥·Ç³Æ4¤ëªì °eÃÒ´Á·|ADR¥Ó½Ð¼W¸ê®×¡A12/20¤ÑµL·N¨£´N¥i®Ö凖¡C¡]¸g¬dµý) |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/4/1 ¤W¤È 11:17:16²Ä 2388 ½g¦^À³
|
To ¦V¤Ñ, §Ú·QY¬O¤µ¦~6¤ë¨È·à±d«Å¥¬ºMÂdªº¸Ü¡A´N¥Nªí¤½¥q¯uªº©ñ±ó¥xÆW¥«³õ¤F¡A§Ú·Q¤]¤£·|¦³¤§«á«·s¤WÂdªºÄ³ÃD¡A¤@¶¡¤½¥q³s°ò¥»ªº²bȳ£¨S¿ìªkºû«ù¦í¡A§A·QÁÙ·|¦³§ë¸ê¤HÄ@·N¶R³æ¶Ü? ¨ì¤»¤ëªì³Ñ¨âӤ륪¥k®É¶¡¡A²{¦b°e¼W¸ê®×¡A§Ú·Q¦Ê¤À¦Ê¨Ó¤£¤Î¡A¦pªG¨S¦³¨p¶Ò®×µo¥Í¡A¤UÂd¾÷²vÀ³¸Ó¬O¦Ê¤À¦Ê¡A¦Ü©ó¤½¥q¤§«e»¡ªº¨ó§UªÑªFÂà´«ADR¡A¦b¤½¥q¨S¦³´£¨Ñ¥Õ¯È¶Â¦r±¡ªp¤U¡A§Úı±oÁÙ¬On«ù«O¯dºA«×¡A¤j®aÁÙ¬On¦³°µ³ÌÃa±¡ªpªº¥´ºâ¡A¶¶±a¤@´£ADRªºªÑ»ù¦pªG³sÄò30¤Ñ§C©ó1¤¸¡A¤]¬O·|³Qn¨D¤U¥«ªº¡A§Ú·Q²{¦bn¯àÅý¤½¥q¥¿µø³oÓ°ÝÃD¡A¥u¯àÁp²°¤pªÑªF¡A´ê¨ì3%ªºªÑÅv¡A¦V¤½¥qn¨D¥l¶}Á{®ÉªÑªF·|¡An¤½¥qµ¹Ó»¡ªk¡A¥Õ¯È¶Â¦rªºÂà´«¤è¦¡¼g¥X¨Ó¡A§_«h¨ì®É³£ºMÂd¤F¡A¤j®aı±o¤½¥qÁÙ·|¸Ì¥xÆW³oÃ䪺§ë¸ê¤H¶Ü? ©Ò¥H³Ì¦n¥i¥H¦êÁp3%ªÑÅvªº§ë¸ê¤H¡A¤j¬ù¬O5700±iªº¶q¡A¦V¤½¥qn¨D¥l¶}Á{®ÉªÑªF·|¡A§Úı±o¤~·|¤ñ¸û¦³«O»Ù¤F¡C ¤@ÂIÂIÓ¤H¬Ýªk! Thanks! |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/3/31 ¤U¤È 11:22:06²Ä 2387 ½g¦^À³
|
½Ð°Ý¤@¤U¦U¦ì~ ¦pªG¨È·à±d6/1¸¹¶Ò¸ê¤£¶¶¹Eªº¸Ü ¦³¥i¯à¥ý¤UÂd~µ¥¨ì¤U¥b¦~¤½¥¬¼Æ¾Ú¶Ò¸ê¬üªÑADR¦¨¥\ ¦A¤WÂdªº¥i¯à©Ê°ª¶Ü? |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/31 ¤U¤È 06:22:04²Ä 2386 ½g¦^À³
|
´Á«Ý¦^¥»ªº¤@¤Ñ (100±i ¦¨¥»24) ¦ý¤]¦³Ãz±¼ªº¤ß²z·Ç³Æ |
|
|
·|û¡G¦N¦Ì10148522 µoªí®É¶¡:2020/3/31 ¤U¤È 06:00:33²Ä 2385 ½g¦^À³
|
½Ð°Ý¤j®aÁÙ¦³´Á«Ý¶Ü¡H |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/3/30 ¤U¤È 10:19:06²Ä 2384 ½g¦^À³
|
¬üªÑ¤îáA¨È·à±dADR«®À ¦³ÂIµL¨¥....!!! |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/3/27 ¤U¤È 09:45:12²Ä 2383 ½g¦^À³
|
¤U±³o½g³ø¾É~¨È·à±d¦Ñ¬O³QZacksµû¤ñ±j¯P¶R¶i....¦ýªÑ»ùÁÙ¬O«Ü®z¡A«ÜµL¨¥! ---------------------------------------------------------------------------------------------- ASLAN Pharmaceuticals Ltd.¡]ASLN¡^¦ü¥G¬O¤@Ó§l¤Þ¤Hªº¿ï¾Ü¡A¦]¬°¥¦³Ìªñ¤w¤É¯Å¨ìZacks±Æ¦W²Ä¤G¡]ÁʶR¡^¡C¦¬¯q¦ôºâȪº¤W¤ÉÁͶլO¼vÅTªÑ²¼»ù®æªº³Ì±j¤j¦]¯À¡A¥¦¬O¼vÅTªÑ»ùªº³Ì±j¤j¤O¶q¤§¤@¡C Zacksµû¯Åªº°ß¤@¨M©w¦]¯À¬O¤½¥q¤£Â_Åܤƪº¦¬¯qª¬ªp¡C¨t²Î·|¸ò踪Zacks¦@ÃѦôºâ-½æ¤è¤ÀªR¸ÓªÑ²¼ªºEPS¦ôºâªº¦@ÃÑ-¹ï¸Ó¦~«×¶i¦æ¸ò踪¡C ¬Õ§Qª¬ªpÅܤƹï½T©wªñ´ÁªÑ»ù¨«¶Õªº¼vÅT¨ÏZacksµû¯Å¨t²Î¹ïÓ¤H§ë¸êªÌ«D±`¦³¥Î¡A¦]¬°µØº¸µó¤ÀªR®v¥i¯àÃø¥H®Ú¾Úµû¯Å¤W½Õ°µ¥X¨Mµ¦¡C³o¨Ç¥Dn¬O¥ÑÃø¥H¹ê®É¬d¬Ý©M¿Å¶qªº¥DÆ[¦]¯ÀÅX°Êªº¡C ¦]¦¹¡AASLAN Pharmaceuticals Ltd.ªºZacksµû¯Å¤W½Õ°ò¥»¤W¤Ï¬M¤F¨ä¬Õ§Q«e´ºªº¿n·¥©Ê¡A³o¥i¯à·|Âà¤Æ¬°ÁʶRÀ£¤O©MªÑ»ù¤Wº¦¡C ¼vÅTªÑ²¼»ù®æªº³Ì±j¤j¤O¶q ×¥¿«áªº¦¬¯q¦ôºâȤϬM¤F¤½¥q¥¼¨Ó¦¬¯q¼ç¤OªºÅܤơA»P¨äªÑ²¼ªºªñ´Á»ù®æ¨«¶Õ±K¤Á¬ÛÃö¡C³¡¤Àì¦]¬O¾÷ºc§ë¸êªÌªº¼vÅT¡A¥L̨ϥΦ¬¯q©M¦¬¯q¦ôp¨Ópºâ¤½¥qªÑ²¼ªº¤½¤¹»ùÈ¡C¥L̪º¦ôȼҫ¬¤¤¦¬¯q¦ôpªº¼W¥[©Î´î¤Ö¥u·|¾ÉPªÑ²¼¤½¤¹»ùȪº¤W¤É©Î¤U°¡A¦Ó¾÷ºc§ë¸êªÌ³q±`·|¶R½æ¸ÓªÑ²¼¡C¥L̤j¶qªÑ²¼ªº¥æ©öµM«á¾ÉPªÑ²¼ªº»ù®æÅÜ°Ê¡C ¹ï©óASLAN Pharmaceuticals Ltd.¦Ó¨¥¡A¬Õ§Q¹w´úªº´£°ª©MÀH¤§¦Ó¨Óªºµû¯Å¤W½Õ±q®Ú¥»¤W·N¨ýµÛ¸Ó¤½¥q°ò¦·~°Èªº§ïµ½¡C§ë¸êªÌ¹ï³oºØ¤£Â_§ïµ½ªº°Ó·~ÁͶժºÆg½à±N±À°Ê¸ÓªÑ¨«°ª¡C §Q¥Î¦¬¯q¦ôºâ×qªº¤O¶q ¥Ñ©ó¸gÅç¬ã¨sªí©ú¡A¦¬¯q¦ôp×qÁͶջPªñ´ÁªÑ²¼¨«¶Õ¤§¶¡¦s¦b«Ü±jªº¬ÛÃö©Ê¡A¦]¦¹¸ò踪¦¹Ãþ×q¥H°µ¥X§ë¸ê¨Mµ¦¥i¯à¬O¯u¥¿¦³¯qªº¡C¦b³o¸Ì¡A¤[¸g¦ÒÅ窺Zacks RankªÑ²¼µû¯Å¨t²Îµo´§¤F«n§@¥Î¡A¦]¬°¥¦¦³®Ä¦a§Q¥Î¤F¦¬¯q¦ôºâ×qªº¥\¯à¡C Zacks±Æ¦WªÑ²¼µû¯Å¨t²Î¨Ï¥Î»P¦¬¯q¦ôºâ¬ÛÃöªº¥|Ó¦]¯À±NªÑ²¼¤À¬°¤Ãþ¡A±qZacks±Æ¦W²Ä¤@¡]±j¶R¤J¡^¨ìZacks±Æ¦W²Ä¤¡]±j½æ¡^¡A¨ä¥~³¡¼fpy¸ñ¥O¤H¦L¶H²`¨è¦Û1988¦~¥H¨Ó¡AZacks±Æ¦W²Ä¤@ªºªÑ²¼¥§¡¦~¦¬¯q²v¬°25¢H¡C¦b³o¸Ì¡A±z¥i¥H¬d¬Ý·í¤µZacks±Æ¦W²Ä¤@¡]±j¶R¡^ªºªÑ²¼ªº§¹¾ã¦Cªí>>>>¡C ASLAN Pharmaceuticals Ltd.ªº¦¬¤J¦ôp×q ¹wp¸Ó¤½¥q¦bºI¦Ü2019¦~12¤ëªº°]¦~¨CªÑ¦¬¯q-0.65¬ü¤¸¡A¦P¤ñ¼Wªø53.6¢H¡C ¤ÀªR®v¤@ª½¦bèB´£°ª¹ïASLAN Pharmaceuticals Ltdªº¦ôp¡C¦b¹L¥h¤TӤ뤤¡A¹ï¸Ó¤½¥qªºZacks¦@ÃѦôp¤w¼W¥[¤F17.6¢H¡C ©³½u »P¹L©ó¼ÖÆ[ªºµØº¸µó¤ÀªR®vªºµû¯Å¨t²Î¶É¦V©ó°¾«±ÀÂ˪º«Øij¤£¦P¡AZacksµû¯Å¨t²Î¦b¥ô¦ó®É¶¡ÂI³£¹ï¾ãÓ4000¾l°¦ªÑ²¼ºû«ù¡§¶R¤J¡¨©M¡§½æ¥X¡¨µû¯Åªº¬Ûµ¥¤ñ¨Ò¡CµL½×¥«³õ±¡ªp¦p¦ó¡A¥u¦³ZacksÂл\ªº«e5¢HªºªÑ²¼Àò±o¡§±j¤O¶R¤J¡¨µû¯Å¡A±µ¤U¨Óªº15¢HªºªÑ²¼Àò±o¡§¶R¤J¡¨µû¯Å¡C¦]¦¹¡A¦bZacks©ÒÂл\ªºªÑ²¼¤¤±Æ¦W«e20¢HªºªÑ²¼ªº¦ì¸mªí©ú¨ä¥X¦âªº¬Õ§Q¹w´ú×¥¿¥\¯à¡A¨Ï¨ä¦¨¬°µu´Á¤º²£¥Í¶W¥G¥«³õ¹w´Á¦^³øªº¥i¾aÔ¿ï¤H¡C ±z¥i¥H¦b¦¹³B¤F¸Ñ¦³ÃöZacks Rankªº§ó¦h«H®§>>> ±NASLAN Pharmaceuticals Ltd.¤É¯Å¨ìZacks±Æ¦W²Ä¤Gªº¦ì¸m¡A®Ú¾Ú¦ôp×q¡A¥¦¦ì©óZacksÂл\ªºªÑ²¼ªº«e20¢H¡A³o·N¨ýµÛ¸ÓªÑ²¼¦bµu´Á¤º¥i¯à·|¤Wº¦¡C ·QnZacks Investment Researchªº³Ì·s«Øij¶Ü¡H¤µ¤Ñ¡A±z¥i¥H¤U¸ü¥¼¨Ó30¤Ñªº7ºØ³Ì¨ÎªÑ²¼¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/26 ¤W¤È 08:50:18²Ä 2382 ½g¦^À³
|
To «Ó°¶¤j ¤§«e¸ß°Ý¤½¥q¯à§_¥X¨Ó»¡©ú¤§«á¶Ò¸êªº³W¹º¥]¬A¸U¤@¶Ò¸ê¤£¤În¨ó§U§ë¸ê¤HÂàADRµ¥¨Æ©y¡A¦ý¬O¤½¥q¦^ÂФ£¯àÀH«Kµo«°T¡A©Ò¥H¥Ø«e´N¨S¦³¥X¨Ó´N²bÈÂàt¥i¯à¤UÂd³o¥ó¨Æ±¡°µ¥X»¡©ú¸ÑÄÀ¡A¤£¹LY¬OªÑ»ùªi°Ê«Ü¤j¡AÄ´¦p¶^«Ü¦h©Î¬Oº¦«Ü¦h®É¡A¤½¥q´N¥i¥HÂǾ÷¥X¨Ó»¡©ú¤F¡C Thanks, |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/26 ¤W¤È 08:38:53²Ä 2381 ½g¦^À³
|
¥x·à³oÃä³Ì¤jªº°ÝÃD¬O³Q¤½¥q·d¦¨³o¼Ë¨S¤H´±¶R ¨ä¹ê¥unºÃ¼{¸Ñ°£¡A¤@©w·|¤j¤Ï¼u ¤½¥q¯u¸Ó¥[¥[ªo ÃĦ¨¥\»P§_¬O¨ä¦¸¡A¦ýÀ°§ë¸ê¤H¸Ñ°£ºÃ¼{³o¬O¥i¥H°µªº§a |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/26 ¤W¤È 08:31:57²Ä 2380 ½g¦^À³
|
¥xÆW¨î«×¤£¦p¤H. |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/26 ¤W¤È 08:22:12²Ä 2379 ½g¦^À³
|
¸r¼}¬ü°ê§ë¸ê¤H¤£¥Î¾á¤ß²bȬ°tªº°ÝÃD¡A¤]¤£¥Î¹³¥xÆWn¥þÃB¥æ³Î¤S¤À½L¥æ©ö¡A§ó¤£¥Î¾á¤ß¥i¯à·|ºMÂdªº¦M¾÷¡A©Ò¥HASLN¤~¯à¶^²`¤Ï¼u¡A¥xÆW³oÃä§Ú·Q¦³ÂI§xÃø¡A¤£´±Ä~Äò©ê¤U¥hªº§ë¸ê¤HÁÙ¦³¦h¤Ö¡A³o¨Ç¤HÁÙ¨S½æ¥ú¡A§Ú·QªÑ»ù´N¤£·|¤î¶^¡A¤£¹L¤]¤£¯à©Ç³o¨Ç§ë¸ê¤H¡A²¦³º³oÁM¤l¬O¤½¥qѶ¥X¨Óªº¡A¥i¯à¤½¥q¤]¤£¦b·N¥xÆWªºªÑ²¼§a¡A°£«D¥L̪ºÁ~¤ô¬O¥Î¥xÆW³oÃ䪺ªÑ²¼¤ä¥I¡A¥L̤~·|¾á¤ß¸U¤@ªÑ»ù¶^§Ú´Nn³Q´îÁ~¡A§Ú·Q³o¼Ë¥i¯à¨È·à±dªºªÑ»ù´N·|º¦¤F§a¡C §Ú²q¤µ¤ÑÀ³¸Ó¦³¾÷·|¤î¶^¡AÀ³¸Ó·|¦¬3.2-3.3¤§¶¡§a! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/26 ¤W¤È 06:12:22²Ä 2378 ½g¦^À³
|
www.marketwatch.com/investing/stock/asln ADR ¤jº¦¨ì½L«á1.27¬ü¤¸¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/25 ¤U¤È 06:42:49²Ä 2377 ½g¦^À³
|
¥xÁÞ¤j¡A 5¤ë©³ASLAN004 ²Ä¤@¾¯¶q ¥¼¸Ñª¼ªº8Ó¤H¼Æ¾Ú¥i³Q¤½¥¬¡A¦p¥h¦~12¤ë3¤é¤½¥¬ªº¼Æ¾Ú¡A¦Ü©ó²Ä¤G¾¯¶q´N¤£ª¾¹D¤F¡A ¨ä¥L¬O§_¦³±ÂÅv¡A¤£ª¾¡H |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/3/25 ¤U¤È 06:17:38²Ä 2376 ½g¦^À³
|
¤Ñ©R¤j ¤¤ë¥ý§âADR¦¨¥\µo¦æÅý²bÈÂॿ¤~¬O³Ì«nªº¨Æ±¡, ¦Ü©ó¤U¦¸¶Ò¸ê¥H«á¦A»¡ , §¹¦¨·§©À©ÊÅçÃҼƾÚÀu²§¤]¥i¥H±ÂÅv , ¤£¤@©w·|¦³¤U¦¸¶Ò¸ê, ¦´Á±ÂÅv»ù½X¨S¦³¤ñ¸û®t, ¤Ï¦Ó¬O¶V«á´Á±ÂÅv»ù½X·|¦³ÅÜ®t¥i¯à©Ê ( ¦nªF¦è¦³Q·m¨«) ²Ä¤T©u6-9¤ë¤½§iASLAN004´Á¤¤¼Æ¾Ú¤½¥q¤½§iªº½T©w°T®§, 2021¦~ª½±µ¶i¤J¤GB´ÁÁ{§É¤ñ§Ú·Q¹³ªºÁÙ§Ö ì¥»¹w©w²Ä¤G©u¤½§iASLAN004´Á¤¤¼Æ¾Ú (¥i¯à¦]¼Ú¬ü¬Ì±¡ªºÃö«Y ·|¤£·|¬O6-9¤ë¤Ñ®ðº¥¼ö ±ß¤@©u¤½§i¹ï¤½¥q¤ñ¸û¦³§Q? ¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/25 ¤U¤È 05:43:09²Ä 2375 ½g¦^À³
|
¨È·à¦³¤@ªø´ÁÉ´Ú17,065,305¬ü¤¸,¶Å¥D¬O·s¥[©Y°]¤Ñ³¡. ¦pªG¥H¶Å¤JªÑ°¨¤W¸Ñ¨M²bȪº°ÝÃD,¥u¬Ý¤½¥q¬O§_n¥h¨ó½Õ. ¤½¥q¦³«Ü¦h¤l¼u! ASLAN004 ¼Ú¬w°Ï±ÂÅv ¦³5»õ¬ü¤¸ªº¥«»ù¤ô·Ç,(°µ¤T´ÁÁ{§É¥Î) ¦p 2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q. Out-License and Other Agreements Almirall Agreement 2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¨½µ{ª÷?+¾P°â¤À¼í? ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/25 ¤U¤È 05:24:23²Ä 2374 ½g¦^À³
|
Dupixent AD ,Proof-of-Concept °µ§¹ª½±µ°µ Phase 2b . Lerikizumab (¥Ø«e¶i¤J¤T´Á) AD Á{§É¥ç¬O¦p¦¹Proof-of-Concept °µ§¹ª½±µ°µ Phase 2b . Mar 4, 2013 Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis Jul 9, 2014 Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab for Atopic Dermatitis Development History and FDA Approval Process for Dupixent Date Article Jun 26, 2019 Approval FDA Approves Dupixent (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis Mar 11, 2019 Approval FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents Oct 19, 2018 Approval FDA Approves Dupixent (dupilumab) for Moderate-to-Severe Asthma Mar 28, 2017 Approval FDA Approves Dupixent (dupilumab) for Eczema Mar 4, 2017 Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent (dupilumab) in Moderate-to-Severe Atopic Dermatitis Oct 1, 2016 Sanofi and Regeneron Announce Positive Dupixent (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England Journal of Medicine Sep 26, 2016 Sanofi and Regeneron Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA Jun 6, 2016 Sanofi and Regeneron Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients Apr 1, 2016 Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Two Phase 3 Trials in Inadequately Controlled Moderate-To-Severe Atopic Dermatitis Patients Feb 2, 2016 Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data May 18, 2015 Regeneron and Sanofi Announce Positive Pivotal Phase 2b Dupilumab Data in Asthma Nov 20, 2014 Sanofi And Regeneron Announce That Dupilumab Has Received FDA Breakthrough Therapy Designation In Atopic Dermatitis Nov 11, 2014 Sanofi And Regeneron Announce Positive Results From Phase 2b Study of Dupilumab Oct 20, 2014 Sanofi And Regeneron Announce Start Of Phase 3 Study Of Dupilumab in Patients With Atopic Dermatitis Sep 30, 2014 Sanofi and Regeneron Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps Jul 9, 2014 Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab for Atopic Dermatitis May 21, 2013 Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma Mar 4, 2013 Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/25 ¤U¤È 05:17:33²Ä 2373 ½g¦^À³
|
¥xÁÞ¤j, ¤½¥q5¤ë©³¥H«e¶·¼W¸ê¤@¦¸,¨Ó§ïµ½°]°Èµ²ºc¨Ï²bȤj©ó¹s. ¥t¥~¤½¥q3¤ë18¤é¤½§iªºp¹º,©ú¦~¤W¥b¦~n°µªº¬OASLAN004 2bÁ{§É. ¦ôp¥i¥ÎASLAN004 ¤½¥¬´Á¤¤³ø§i¨Ó¶Ò¸ê,¦Ó¬O§_¦~©³? ®Ú¾Úµý´Á§½ªk¥O,Y5¤ë30¤é¼W¸ê,¤U¤@¦¸¥Ó½Ð¬O9¤ëªì +12/20 ¤Ñ+¬ü°ê§@·~®É¶¡¬ù30¤Ñ,¦ôp11¤ëªì. aslan004 ´Á¤¤³Ì¨Î¤½¥¬®É¾÷¦b11¤ë.(¥H¤WÓ¤H¦ôp) |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/3/25 ¤U¤È 05:06:12²Ä 2372 ½g¦^À³
|
¤Ñ©R¤j ¨Ì¾Ú¨È·à±d¤T¤ë¤Q¤Kµo§G°T®§ASLAN004¥Ø«e¥l¶Ò¯f±w¨Ã¨S¦³¨ü¨ì¬Ì±¡¼vÅT¡A²Ä¤T©u¤½§i´Á¤¤¤ÀªR¡]7-9¤ë¡^¡A¤£¬O§A»¡ªº¦~©³¡C2021¦~®i¶}¤Gb´ÁÁ{§É¸ÕÅç¡A¬°¤°»ò¨S¦³ ¤Ga´Á¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/25 ¤U¤È 04:42:50²Ä 2371 ½g¦^À³
|
¥h¦~12¤ë ¬ü°êADR 2.5¬ü¤¸¶Ò¸ê¡A¶^¨ì¥Ø«e¤]¬O¶^60%.©M¥xÆW6497¨È·à¶^´T¬Û·í¡C ¨S¿ìªk¹J¨ì¦Ê¦~¬Ì±¡¡C ASLAN004 ¥Ø«eÁ{§É ¥u¶·8¶gªºªvÀø¡A¤H¼Æ¤]¤Ö ¡A¦ôp¼vÅT¤£¤j¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/25 ¤U¤È 04:32:38²Ä 2370 ½g¦^À³
|
¥xÆW6497 ¨È·à±dªÑ²¼¡AµLªk¹³ADR ªÑ»ù,3~5¤Ñ´N¥i«ì´_¨äÀ³¦³»ùÈ. ©Ò¥H¼ÈµLªk¦¨¬°¤½¥qªº¶Ò¸ê¤u¨ã¡A³o¬O¨Æ¹ê¡AÁÙ¦n¯d¦³ADR §_«h¤U¥«·ÀI¯uªº¤£¤p. ¤£¹³§OªºªÑ²¼¦³¤jªÑªFÅ@½L¡C©Ò¥H¥u¯à´Á«Ý ¦~©³´Á¤¤³ø§i¤½¥¬«áªº¶Ò¸ê °µ©ú¦~2bÁ{§É¡A§Æ±æ²bȯà¦^10¤¸¡AADR»ù®æ¥i¯àn¤W10¬ü¤¸¡C ¥xÆWªº¿ì¤½«Ç¥u¦³7¤H¡A¥þ¬O°]°È¤Hû¡C(¬Q¤Ñ°Ý) ASLAN001 ¼Ð¹vªvÀø µL¿z§Ü·½°ò¦] ªºÁx¹DÀù ·ÀI§ó¤j¡C ¦ý¥»¦³¤p¤T´Áªº¾÷·|¡A©MFDA¦³µL¨ó°Ó°µ¤p¤T´Á¡A¤½¥q¨S¥æ¥N¡H¡]¥i°Ý¤½¥q¦³µL©MFDA¶}·|¡Hµ²ªG¡H¡^ 诒Àø¤@缐GÀù¡A´NÁ׶}¶PÀù¥HER2,IHC¡Ï3 .. ASLAN001¤£¬O¨S®Ä¡A¥u¬O¥L¥i»¡¬O¶PÀù¦~ªº¬Û¦üÃÄ¡C «Øij¤½¥q ASLAN001 ¥þ²y±ÂÅv¡A¥ý±ÂÅv¥X¥hµ¹Áú°êªº¤½¥q¡A¥h°µ¤p¤T´Á(Y¦³¾÷·|) ¥H¤W¬OÓ¤HÆ[¹î |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/25 ¤U¤È 04:18:34²Ä 2369 ½g¦^À³
|
§Úªº·Qªk¸ò¸¤H¤j±µªñ §Ú¤]¬Û«H·à¤l¬O·|Ä~Äò¸gÀç¤U¥h ¦ý¦]¬°¤½¥q°ª¼h³£¬O¥~°ê¤H ©Ò¥H·Pı¤£¬O«Ü«µø¥xÆWªÑªFÅv¯q §Ú·Q³o¤]¬O³y´N¥x·àªÑ»ù¤ñADR§C«Ü¦hªºì¦] ²{¦b·Pı¥´¤°»ò¹q¸Ü¨ä¹ê³£¨S¦³¥Î ®Ú¥»µLªkÁpô¨ì¤½¥q°ª¼h¡A°Ý¤£¨ì¤°»òªF¦è ¤§«e§Ú§ë¸ê¹LÁp¥ÍÃÄ Áp¥ÍÃĤU¿³Âd®É¡A¹q¸Ü«D±`ºZ³q ¬Æ¦Ü¯d¸Ü¡Aµo¨¥¤H©M°]°ÈªøÁÙ·|¿Ë¦Û¦^¹q ¨È·à±d¸ò§ë¸ê¤H·¾³q³o¶ô¯uªº°µ±o«ÜÄê Åý¤H«ÜÃø¦³«H¤ß ¸Ó¤£·|¯uªºn¾x¨ì¦Û±Ï·|¥xÆWªÑªFªºÁnµ¤~¦³¤HÅ¥ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/25 ¤U¤È 03:42:50²Ä 2368 ½g¦^À³
|
¦U¦ì·à¤Í¦n: Á¿¤@¤U³Ìªñªº·P·Q§a¡Aè観·à¤Í°Ý¨ì¬üªL¶R¤F1200±i¡AÃø¹D¥L̤£µh¶Ü? §Ú·Q2018¦~¶R¶W«e´X¤jªº¨é°Ó³£«Üµh§a¡Aªk»È¤Ú¾¤¡B°ê®õºî¦X¡B¤¸¤jµ¥µ¥¨é°Ó¤@°ï¦¨¥»³£¦b30-40¥H¤W¬Æ¦Ü50¦hªº¡A¦ý¬O¥L̤§«á¤@±i¤]¨S½æ¡A¬°Ô£©O? §Ú·QÀ³¸Ó¤]¬O¸}³Â¤F§a¡A쥻·Qµ¥2019ªº¨â¦¸¸Ñª¼¸ÕÅç¡A¤@½uGÀù¸ò¤G½uÁx¹DÀù¡A¨S·Q¨ì³oÓ¨âÓ¾AÀ³¯g¡A³£¬O¤@´Á¼Æ¾Ú¤£¿ù¡A¦ý¬O¤G´Á¸Ñª¼³£¥¢±Ñ¡A¤£À´¬°Ô£¤@½uGÀù¥¢±Ñ¤§«á¡A¤½¥q¨S¦³¹ï¤G½uÁx¹DÀù¸ÕÅç°µ½Õ¾ã¶Ü? ªá¤F1»õ7¤d¦h¸U¬üª÷±ÂÅv¶i¨Óªº001¡Aì¥ý³Qµø§@ÁÈ¿úªºª÷Âû¥À¡A¨S·Q¨ì²{¦b«o¬O©ì«±¨È·à±d°]°Èªº¤@Ó²ÖÂØ¡A©Ò¥H²{¦b004ªº¤@´Á¼Æ¾Ú¡A±q¤@¶}©lªº3Ó¯f¨Ò¬Ý°_¨Ó¼Æ¾Ú«D±`¦n¡A¦ý¬O¦pªG¤§«á¶i¨ì¤G´Á§Ú¤S·|·P¨ì©È©È¤F¡A¨C¦¸³£¬Oªì´Á¼Æ¾Ú«D±`º}«G¡A¦ý¬OÃöÁä®É¨èn¸Ñª¼«o³£¥¢±Ñ¡A ¥t¥~¤½¥q³ºµMÁÙ·Qn¦b4/1¤§«á¡A´N¤£¦b´£¨Ñ¹ï¥~ªº¹q¸ÜÁpô¤è¦¡¤F¡A¤§«á¦^µªªÑªFªº°ÝÃD¡A¥u·|³z¹LIR¡A¤@¶¡¥~¥]ªº¤½¥q¨Ó¸òªÑªF¹ïÀ³¡A¤£ª¾¹D¬O¤£¬O³Ìªñ¹q¸Ü±µ¤Ó¦h¤F¡AÅý¥xÆW³oÃ䪺û¤u®`©È¤F¡A©Ò¥H¸ò·s¥[©Y¨ºÃ䴣ijn§ï¦¨¥þ³£¥Ñ¤½Ãö¤½¥q¨Ó¦^À³ªÑªFªº°ÝÃD¡A§Úı±o³o¬O«D±`¸Ø±iªº¤@¥ó¨Æ±¡¡A¤@¶¡¤½¥q³ºµM¤§«á¤£ÅýªÑªF¥i¥Hª½±µ©M¤½¥q¹ï¸Ü¡A¤Ï¦Ó¬O¥Ñ¤@¶¡¤½Ãö¤½¥q¨Ó¹ïÀ³§ë¸ê¤Hªº´£°Ý¡AµM«á°ÝÃD¤ÏõX¥i¯à¤Snµ¥¤Q¤À¤[¡Aı±o³o¼Ë§ïÅÜ«ÜÄê! ¦Ó¦b§Ú»P¦h¦¸©M¥xÆW¨È·à±d³oÃ䪺û¤u³q¸Ü°Q½×¡A·Pı«D±`¦hªº°ÝÃD¡A³£¬On½Ð¥Ü·s¥[©Y°ª¼h¡A¦Ó¨S¿ìªkª½±µµ¹¤©¬Û¹ïÀ³ªº¦^ÂСA³q±`¦³¨Ç°ÝÃD¥i¯à¤[¤F´N¤£·|¦A¦^À³¤F¡A²¦³º¬O¨Ó¥xÆW³oÃä¤WÂdµo¦æªº¡AÁÙ¬O§Æ±æ¥xÆW³oÃ䦳¤@¦ì¥i¥H¥Nªí¾ãÓ¤½¥qªºµo¨¥Åé¨t¨Ó¦^µª§ë¸ê¤Hªº°ÝÃD¡A¦Ó¤£¬O¥u¯àÂàz§ë¸ê¤Hªº°ÝÃDµ¹·s¥[©Y°ª¼h¡AµM«á¥i¯à¦^ÂФSnµ¥«Ü¤[¤F! ¥Ø«e¨È·à±dµ¹§Úªº·Pı´N¬O¡A¤½¥qÁÙ¬O¦³¤ß·QnÄ~Äò¸gÀç¤U¥h¡A¤£¹L·Pı¥L̤£¬O«Ü²z·|¥xÆW³oÃäªÑªFªºÅv¯q¡A§_«h´N¤£·|Åý¥xÆW¨È·à±d°±¯d¦b¥þÃB¥æ³ÎªÑ¤Î¤À½L¥æ©ö¨º»ò¤[¤F¡A¥[¤W001¥h¦~¸Ñª¼¥¢±Ñ«á¡A¤½¥qÀ³¸Ó¨º®É´N¥i¥H¸ò§ë¸ê¤H»¡¥¼¨Ó¥i¯à·|¦³µL§Î¸ê²£´î·l±¡ªpµo¥Í¡AÅý§ë¸ê¤H¦³¤ß²z·Ç³Æ¡A¦Ó¤£¬O¹³²{¦b¡A¬ðµM¥á¤@Ó¤½§i¥X¨Ó»¡¤½¥q²bÈÂàtªº¡AµM«á»¡¦]¤WÂd¥¼º¡¤T¦~¥[¤W²{ª÷¬yÁÙ¨¬°÷¡A·Q¯»¹¢¤Ó¥¸Ë°µ¨SÔ£¨Æ±¡µo¥Í¡A¥i¥H¬Ý¬ÝªÑ»ù±q¦~ªìªº8¶ô¦h¤@¸ô±Y¶^¨ì²{¦b¸t3¶ô¥XÀY¡A¯u¤ßı±o¤½¥q¯uªº¨S§â¥xÆWªº§ë¸ê¤H©ñ¦b¤ß¤W¡C ¥H¤W¤@ÂIÂI¤ß±o¡A§Æ±æ¦U¦ì·à¤Í¥i¥H¦h¦h¥æ¬y Thanks, |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/25 ¤U¤È 12:55:15²Ä 2367 ½g¦^À³
|
«Øij ¤½¥q ASLAN004°l¥[¤@Á{§É 12¦ì , ¨C¤ë¥´¤@°w¡A¦@¥´¤G°w,(2Ó¤ë)©Î¥´4°w/4Ó¤ë¡A ¥t¹ï·Ó²Õ3¦ì¡A°µ¬°¦~©³ADRÄw¸ê¥Î¡C ¦pªG¤½¥q³W¹º³Ì«á¬O¤@Ó¤ë¤@°w¡A¦@¥|°w¡A³o¬O¥i¦æªº¤è®×¡A¦¤@ÂI°µ§¹¡A¥i増¥[¶Ò¸êªº»ùÈ¡A¦Ó¤£¬Oµ¥¨ì2bÁ{§É°µ§¹¡C ¦³¨ä¥L¤½¥q¡A¬O¦p¦¹°µADÁ{§É(¥u¥´¤@°w)¨Ó¼W¥[¤½¥q»ùÈ¡C www.anaptysbio.com/pipeline/etokimab/ Etokimab, ¤@°w ²Ä57¤Ñ ,·§©À©ÊÁ{§É12¤H(2017¦~¤½¥¬) EASI-50 , 75% (9/12) EASI-75 , 42% (5/12) ªÑ»ù¥«È¤Wº¦24»õ¬ü¤¸(8»õ¬ü¤¸º¦¨ì42»õ¬ü¤¸,2017/10~2018/03) Etokimab, 2´Á300¤HÁ{§É¸Ñª¼¥¢±Ñ.(¤w°±¤î¬ã¨s) |
|
|
·|û¡G¦N¦Ì10148522 µoªí®É¶¡:2020/3/25 ¤U¤È 12:32:56²Ä 2366 ½g¦^À³
|
§Ú¦n©_ªº°Ý¤@¤U¡A¹³¬üªL¤§«e¶Rªº1200¦h±i¡AÃø¹D¥L̤£µh¶Ü¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/25 ¤U¤È 12:09:53²Ä 2365 ½g¦^À³
|
ªø§ëªº·à¤Í ©Ò¦³¶Ò¸ê¤è®×¬Ò¦³¨ä¬yµ{! ·s¥[©Y¬F©²¬Ì±¡±±¨î¤]¬O¤@¬y. 2Ó¤ë´N¯à§¹¦¨¤@¾¯¶qÁ{§É. ²{¦b¯à¥Î¨ì¦~©³. 5¤ë©³«Ü¦³¥i¯à¦p¥h¦~12¤ë¦Aª±¤@¦¸. ³¯«Ø¤¯ °ÆÁ`²Î»¡:2Ó¤ë¥þ²y¬Ì±¡¦³¾÷·|±±¨î. |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/3/25 ¤W¤È 11:13:21²Ä 2364 ½g¦^À³
|
èè§Ú¥´¥h¨È·à±d¸ß°Ý·|¤£·|¤UÂdªº¥i¯à.... ¹q¸Ü: +886 2 3725 7770 ±µ¹q¸Üªº¬O¤@¦ì¨k¥Í¡AÁ¿¸Ü¤ä¤ä§^§^¦³ÂI¤p¤pµ²¤Ú ªí¥Ü»¡¡A¦pªG³Ì«á¨Ó¤£¤Î¤µ¦~6/1¶Ò¸ê§¹¦¨¡A½T¹ê¯uªº¦³¥i¯à´N·|¤UÂd¡A «áÄò¦³´£¥X¤@¨Ç¬Ýªk¡A¦ý§ÚÓ¤H»{¬°³£¬O´x´¤¦b§O¤Hªº¤â¤W(¥DºÞ¾÷Ãö©M¸³¨Æ·|) ³o¤]´N¬O¬°¤°»ò¬üªÑ¤jº¦&¥xªÑ¤jº¦¡A¨È·à±d¤Ï¼u¤£°_¨Óªºì¦]¤F¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/24 ¤W¤È 10:40:50²Ä 2363 ½g¦^À³
|
è襴¹q¸Ü¨ì ¤@.¨È·à±d: ¥x¥_¿ì¤½«Ç 110¥x¥_¥««H¸q°ÏªQ¤¯¸ô100¸¹37¼Ó3711-15«Ç ¹q¸Ü: +886 2 3725 7770 ¶Ç¯u: +886 2 3725 7999 IR: +886 2 2766 1500 Ápô: contact@aslanpharma.com ¥L̦b¥x¥Dn¬O°]°È³¡ªù,¦³¦ì©Ó¿ë¤p©j¦^µª¶¡ÃD¦p¤U: 1.¤½¥q¦]ªk¥OÃö«Y«e¦¹¼W¸ê¤é«á3Ó¤ë¤è¯à°e§@¥Ó½Ð¼W¸ê. 2.°e§@ÃÒ´Á§½¥Ó½Ð¼W¸ê®×12¤Ñ¤ºµL·N¨£´Nºâ®Öã. ¤G.¨DµýÃÒ´Á§½µª 1.KY¤½¥q : ÃÒ´Á§½¥Ó½Ð¼W¸ê®×12¤Ñ/20¤Ñ¤º,µL·N¨£´Nºâ®Öã. 2.Y¨p¶Ò®×¤£¥Î°eÃÒ´Á§½ §ë¸ê¤HªA°È±M½u ª÷¿ÄºÊ·þºÞ²z©eû·|ÃÒ¨é´Á³f§½ ¢·¢¶¢¶¢²¡Ð¢´¢°¢¯¢¯ ---------------------------------------------------- ¥Ø«eÆ[¹î¤½¥q°¾¦n¶¶§Ç 1.ADR (4¤ëªì°e¥ó,³Ì§Ö+12¤Ñ,4¤ë¤U¦¯®Öã) +¬ü°ê§@·~®É¶¡-----³Ì±ß6¤ë1 ¤é§¹¦¨. 2.¨p¶Ò : ©M¨p¶Ò¨â¤j¸³¨Æ½Í¦n»ù¡B¶q+¸³¨Æ·|¦P·N§Y¥i°õ¦æ. |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/24 ¤W¤È 10:14:11²Ä 2362 ½g¦^À³
|
To ¦U¦ì·à¤Í, ±ß¤W·Q¤F¤S·Q¡A¦]¬°°]°ÈÁ`ºÊ¦o¤£¬O¤½¥qµo¨¥¤H¡A¦o»¡ªº¸Ü¤£¥Nªí¤½¥q¡A©Ò¥H©È¤½¥q¥i¯à¤£»{±b¡A·PıÀ³¸ÓÁÙ¬On½Ð¤½¥q¥X¥Ü¥i¥H¥Ñ¶}°Ò¤½¥q¥Ó½ÐÂà´«¬ü°êADRªº¤å¥ó¤ñ¸û¦n¡A¥Õ¯È¶Â¦r¹ï§ë¸ê¤H¤]¤ñ¸û¦³«O»Ù¡A¤j®aY¦³ªÅ¤]¯à¤@°_¥´¹q¸Ü¥h¤½¥q½Ð¤½¥q´£¨Ñ¡A§Ú¤µ¤Ñ¤]·|¦A¥´¹q¸Ü¹L¥hn¨D¡A¤£¹L§Ú·Q¤H¦h¤O¶q¤j¡A¦³¯à¤OªºªÑªFÁÙ¬OÀ°¦£¤@°_¥´¹q¸Ü§a! Thanks! |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/3/24 ¤W¤È 09:08:06²Ä 2361 ½g¦^À³
|
ÁÂÁ¸¤H¤jªº«n®ø®§~~~ §Æ±æ¦Ñ·à°ª¼h¦³¤ß¯d¦b¥xÆW,¨Ã¦b¥xÆWÄ~Äò§¹¦¨004ªºÁ{§É¶}µo,´Á«Ý¥¼¨Ó¦³¥O¤H®¶¾Äªº®ø®§~~~ |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/24 ¤W¤È 12:13:02²Ä 2360 ½g¦^À³
|
ÁÂÁ¸¤H¤j Å¥¨ì±z¸ß°Ýªº®ø®§¡A¥O¤H®¶¾Ä ´Nºâ³Ì«áµ²ªG¤£¦p¤j®aªº·N ÁÙ¬On¸ò±z»¡Án ¦³±z¯u¦n ·PÁ±zªº¥I¥X |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/23 ¤U¤È 11:05:55²Ä 2359 ½g¦^À³
|
To ¦Ñ¯V ¬O쥻¨º°¦ ADR.ªÑ²¼¥N½X¤@¼Ë¬OASLN,¥u¬O±N¥xÆW³oÃ䪺ªÑ²¼Âà´«¹L¥h¡A©Ò¥HÁÙ¬O¦P¤@ÀɪѲ¼¡A¨Ã¨S¦³«·sµo¦æ¼Ú¡I Thanks |
|
|
·|û¡G¦Ñ¯V10146717 µoªí®É¶¡:2020/3/23 ¤U¤È 10:44:23²Ä 2358 ½g¦^À³
|
TO ¸¤H¥d¯S¤j¤j ÁÂÁ±zªºµªÂÐ ´N±z¤µ¤Ñ¸ß°Ýªº :Y¬O¥xÆW³oÃäºMÂd¡A¥¦¥i¥H¥Î¶}°Ò¸s®q³]¸mªº¤½¥qªÑ²¼¥h«H°U¨ÓÂà´««°ADR¡A¹³¥xÆW¨È·à±d´N¬O¥¦ªº¤l¤½¥q¡A©Ò¥H§Ú̪º¥xªÑ´N¥i¥H´«¦¨¶}°Ò¤½¥qªºªÑ²¼¡A¤§«á¦A³z¹L«H°U¶}°Ò¤½¥qªÑ²¼¨Óµo¦æADR¡A¦Ó¤£¬O²{¼Wµo¦æ©Ò¥HªÑ¥»¤£ÅÜ¡AÁÙ¬O¤@¼Ë19¸U±i ¦A³z¹L«H°U¶}°Ò¤½¥qªÑ²¼¨Óµo¦æADR ªº·N«ä¬O¥t¥~µo¦æ¤@¤ä¥Ñ¥xªÑÂà´«Åܨ¦Ó¦¨ªºADR¶Ü?ÁÙ¬OÂন²{¦b§Ú̩Ҭݨ£ªº¬üªÑ¨º¤äADRªÑ²¼?ÁÂÁ |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/23 ¤U¤È 10:03:05²Ä 2357 ½g¦^À³
|
¦U¦ì·à¤Í¦n §Ú¤À¨É¤@¤U¤µ¤Ñ¤½¥q¦^ÂЪº°T®§¡A´N¬O§Ú´£°Ý¸U¤@¨È·à±d¤£©¯¦A¥xÆWºMÂd¤F¡A¨Ì·Ó¤§«eªk»¡·|¤W°õ¦æªø»¡n¨ó§UªÑªFÂà´«¦¨ADR¡A¥i¥H½Ð¤½¥q»¡©ún¦p¦óÂà´«©O¡H ¤½¥q¦^ÂÐ °²³]¥xÆW³oÃäºMÂd ¤½¥qÄ~ÄòÀç¹B §Ṳ́⤤ªº«ù¦³ªÑ²¼³£ÁÙ¦b¥u¬O¤£¯à¦b¥«³õ¥æ©ö¡A§ÚÌÁÙ¬O¨È·à±dªºªÑªF¡AªÑªFÅv¯q¸ò¬üªÑªºªÑªF¬O¤@¼Ëªº¡A¦ý¬On¦p¦óÂà´«©O¡H ¦]¬°¨È·à±d¬OKY¤½¥q¡A©Ò¥H¥¦Ì¬O¦b¶}°Ò¸s®qµù¥Uªº¡AY¬O¥xÆW³oÃäºMÂd¡A¥¦¥i¥H¥Î¶}°Ò¸s®q³]¸mªº¤½¥qªÑ²¼¥h«H°U¨ÓÂà´««°ADR¡A¹³¥xÆW¨È·à±d´N¬O¥¦ªº¤l¤½¥q¡A©Ò¥H§Ú̪º¥xªÑ´N¥i¥H´«¦¨¶}°Ò¤½¥qªºªÑ²¼¡A¤§«á¦A³z¹L«H°U¶}°Ò¤½¥qªÑ²¼¨Óµo¦æADR¡A¦Ó¤£¬O²{¼Wµo¦æ©Ò¥HªÑ¥»¤£ÅÜ¡AÁÙ¬O¤@¼Ë19¸U±i¡A¥u¬O¨ãÅé¤@¦¸¯àÂà´«¦h¤Ö¼Æ¶qÁÙ¦³Âà´«¤èªk³o¨Ç³£nµ¥½T©wºMÂd¤~·|¤½§i¡A¤£¹L¤½¥q½T»{¬O¥i¥H³o¼Ë¾Þ§@ªº¡A¤j®aY¦³ºÃ°Ý¥i¥H¦A¥´¥h¤½¥q¿Ô¸ß¡A¤½¥q¥Ø«e´N«ì´_Âà´«¬O¦Ê¤À¦Ê¥i¥H¾Þ§@ªº¡A¦ý¬OÁÙ¨S¨«¨ì³o¤@¨B©Ò¥H¤]¤£¥i¯à¯S§O´£¥X¨Ó»¡©ú¡C ¥H¤W¬O¤µ¤Ñ§Ú¥´¥h¤½¥q¸ß°Ý°]°ÈÁ`ºÊ¡A¦o¦^ÂЪº¡AY¤j®a¦³¤£²M·¡¥i¥H©ú¤Ñ¦A¥´¥h¤½¥q¿Ô¸ß¡C Thanks |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/23 ¤U¤È 09:51:47²Ä 2356 ½g¦^À³
|
To ¦Ñ¯V¤j ¨È·à±dªºADR¬O¤@ªÑªí¹ü¤ªÑ¥xªÑ¡A©Ò¥H§A°²³]¦³100±i¨È·à±d¥xªÑ¡A°²³]¥þ³¡³£Âà´«¦¨¬üªÑADR¡Apºâ¦p¤U 100±i¥xªÑÁ`¦@¦³100*1000=100000ªÑ ¦ÓADR¤@ªÑ¥i¥H´«¤ªÑ¥xªÑ ©Ò¥H100±i¥xªÑÁ`¦@¥i¥H´«¦¨20000ªÑ¬üªÑ¡A¥H²{»ù¤@¶ô¨Ópºâ¡A´N¬O¦³¨â¸U¬üª÷ªº»ùÈ¡An´«¦¨¥x¹ô»ù®æ´N¦A¼¤W¬üª÷¶×²v§Y¥i¡C Thanks¡I |
|
|
·|û¡G¦Ñ¯V10146717 µoªí®É¶¡:2020/3/23 ¤U¤È 08:28:07²Ä 2355 ½g¦^À³
|
¸¤H¥d¯S¤j¤j §A¯uªºÈ±oÅý¤j®a¨ØªA´L·q¡A§Ú¤]¤@ª½¬O§Aªº¯»µ·C! §Ú·Q½Ð±Ð±z¤@Ó°ÝÃD.°²³]²{¦b´N¥iÂà´«ADR¡A²{¦³100±iªº¥xªÑ¨È·à±d.¥i¥HÂà´«²{¦bADR³ø»ù1.00ªº¨È·à±d´X±i?¡A´«ºâ¥x¹ô100±i¥xªÑ´«ªÑ«áÈ¥x¹ô¦h¤Ö?¥H¥x¹ô:¬ü¤¸40:1pê¿.¤j¬ù¦h¤Ö?ÁÙ¬OÂà´«ADR«á¤@¼Ë¦X¥x¹ô100±i*3300+330000¤¸¶Ü? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/3/23 ¤U¤È 06:27:36²Ä 2354 ½g¦^À³
|
¸¤H¥d¯S,·PÁ±z¦a¥I¥X»PµL¨p¤À¨É! |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/23 ¤U¤È 03:09:09²Ä 2353 ½g¦^À³
|
to ¥d¯S¤j §A¯uªº¶W»{¯u ! ¦ý¬O¨È·à±d¤½¥q¥Nªí³£¤£µ¹ªÑªF¤@Ó»¡ªk ~ ¹ê¦b¬O«Ü¤£t³d¥ô ... |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/23 ¤U¤È 02:19:01²Ä 2352 ½g¦^À³
|
To timchan516¤j, ³o¦U§A¤£¥Î¾á¤ß¡A¨È¸Ö±d¥xªÑÂà´«ADR¡A³Ì¤p³æ¦ì¬O50±i¡A´N¬O50000ªÑ¡A¥un¤j©ó³oӼƦr´N¥i¥H¥Ó½ÐÂà´«¡A³oÓ¬O§Ú¤§«e¦³¥´¥hJP Morgan¨ºÃä¸ß°Ýªº¡A¨Ã¤£»Ýn¨ì3800±i¨º»ò¦h¡A³o¦UÀ³¸Ó¥hJP Morgan ADRªººô¯¸¥i¥H¬d¨ì¡C ºô§}¬O¤U±³oÓ: www.adr.com/drprofile/04522R101 ¥i¥H°Ñ¦Ò¥k¤U¨¤ªº¨ºÓ¥Ó½ÐÂà´«®ÑªºPDFÀÉ¡A¸Ì±¦³»¡©ú³Ì¤p¥Ó½ÐÂà´«¶q¬O¥xªÑ5¥xªÑ5¸UªÑ¡A´N¬O50±i¡C Thanks! |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/23 ¤U¤È 02:01:50²Ä 2351 ½g¦^À³
|
´Nºâ¥i¥H±N¨È·à±dÂà´«ADR ! ¤]¤£¬O¤p´²¤á¥i¥H¥h¶R½æªº !! ¤j®a¥i¥H¦º³o¤@±ø¤ß !! ·í¦~¥x¿n¹q¥Ó½ÐÂà´«ADR¨ä¤¤¦³¤@Ó±ø¥ó´N¬O¤â¤¤«ùªÑ©T¦ì¤£§C©ó¦b¥~¬y³qªÑ¼Æ0.02 ! ¤~¯à¶i¦æ¥Ó½ÐÂà´« ! ¤w¨È·à±d¨Ó´«ºâ ! 19¸U±i¦b¥~¬y³q * 0.02 = ±Nªñ3800±i ! ½Ð°Ý³oÓª©¦³½Ö¦³ 3800±i ? ¥D¦®¡G ¤½§i¥»¤½¥q´¶³qªÑªÑªF°Ñ»P¡u´¶³qªÑÂà´«¬ü°ê¦s°U¾ÌÃÒ¾P°âp¹º¡v¬ÛÃö¨Æ©y¡C »¡©ú¡G ¤@¡B ¥»¤½¥q´¶³qªÑªÑªF²Å¦X¤U¦C±ø¥ó®É¡A±o¨Ì¡u¥xÆW¿nÅé¹q¸ô»s³yªÑ¥÷¦³¤½¥q´¶³qªÑÂà´«¬ü°ê¦s°U¾ÌÃÒ¾P°â¿ìªk¡v°Ñ»P¡u´¶³qªÑÂà´«¬ü°ê¦s°U¾ÌÃÒ¾P°âp¹º¡v¥H¾P°â¨äªÑ¥÷¡G (¤@)³Ì§C«ùªÑ¡G´¶³qªÑªÑªF¤§«ùªÑ¤£§C©ó¥»¤½¥qºI¦Ü¤E¤Q¦~¤@¤ë¤Q¤¤é¤î¤wµo¦æªÑ¥÷Á`¼Æ¤§0.02%¡A§Y2,337,873ªÑ¡C (¤G)³Ìµu«ùªÑ´Á¶¡¡GºI¦Ü¥Á°ê¤E¤Q¦~¤@¤ë¤Q¥|¤é¤î¡A´¶³qªÑªÑªF¥²¶·«ù¦³¨äÀÀ¥X°â¤§´¶³qªÑ¦Ü¤Ö¤@¦~(§Y¦Û¥Á°ê¤K¤Q¤E¦~¤@¤ë¤Q¤¤é¦Ü¤E¤Q¦~¤@¤ë¤Q¥|¤é)¡C (¤T)ªÑªF¤§¨¥÷¡G«DÄݬü°êÃÒ¨éªk¥O©Ò©w¸q¤§¥» ¤½¥q¤§Ãö«Y¤H¡C ¤G¡B ¬°²Å¦X¬ü°êÃÒ¨éªk¥O¤§³W©w¡AªÑªF¥»¦¸ÀÀ´£¼·°Ñ»Pµo¦æ¤§ªÑ¥÷¶·¬°«D¦]¥»¤½¥q¦X¨Ö¥@¤j¿nÅé¹q¸ôªÑ¥÷¦³¤½¥q©Î¼wùÖ¥b¾ÉÅéªÑ¥÷¦³¤½¥q(¤UºÙ¡u¦X¨ÖªÑ¥÷¡v)©Ò´«µo¨ú±o¡CªÑªF¦p«Y³z¹L¶°«O±b¤á»â¨ú¦X¨ÖªÑ¥÷¡A¸Ó¶°«O±b¤á¤º¤§¥»¤½¥qªÑ¥÷±N¤£p¤J³Ì§C«ùªÑ¤§ªÑ¥÷¼ÆÃB¤º¡FªÑªFY¦³¦Û»â¨ú¦X¨ÖªÑ¥÷¤§¶°«O±b¤áÂ༷¥»¤½¥qªÑ¥÷¦Ü¨ä¥L¶°«O±b¤á¡A¸Óµ¥¶°«O±b¤á¤º¤§¥»¤½¥qªÑ¥÷¥ç¤£p¤J³Ì§C«ùªÑ¤§ªÑ¥÷¼ÆÃB¤º¡C ¤T¡B ¥»¤½¥q¥»¦¸¥H¤wµo¦æ´¶³qªÑ°Ñ»Pµo¦æ¬ü°ê¦s°U¾ÌÃÒ¤§ªÑ¥÷Á`¼Æ±N¤£¶W¹L¥»¤½¥q¤wµo¦æ´¶³qªÑÁ`¼Æ¤§0.5%¡C ¥|¡B ¦³·NÄ@¨Ã²Å¦X¤W¦C¸ê®æ¤§¥»¤½¥q´¶³qªÑªÑªF±o©ó¥Á°ê¤E¤Q¦~¤@¤ë¤Q¤¤é°_¦V¥Ó½Ð¥N²z¾÷ºc¿§Qºî¦XÃÒ¨éªÑ¥÷¦³¤½¥q(¦a§}¡G¥x¥_¥«Ã¹´µºÖ¸ô¤G¬q100¸¹10¼Ó¡A¹q¸Ü¡G(02)2366-8739¡A2366-8774)¬¢¸ß¨Ã¯Á¨ú¬ÛÃö¥Ó½Ð®Ñ¥ó¡A¨ÃÀ³©ó¥Á°ê¤E¤Q¦~¤G¤ë¤K¤é¤U¤È¤®É«e¦V¿§Qºî¦XÃÒ¨éªÑ¥÷¦³¤½¥q»¼¥ó¥Ó½Ð°Ñ»P´¶³qªÑÂà´«¬ü°ê¦s°U¾ÌÃÒ¾P°âp¹º¡C¬ÛÃö¸ê°T¥ç¥i¬d¾\¥»¤½¥qºô¯¸¡Gwww.tsmc.com.tw¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/23 ¤W¤È 11:43:16²Ä 2350 ½g¦^À³
|
§Úı±o¤j®a¥i¯àn¦³³ÌÃa¥´ºâ¡A´N¬O¤½¥qºMÂd¤F¦ý¬O¤£¯àÂà´«¦¨ADRªº¤ß²z·Ç³Æ¡A²{¦b¥i¥H°µªº´N¬O¡A½Ð¤½¥q´£¨Ñ¸ê®ÆÃÒ©ú°õ¦æªø¦bªk»¡·|¤W±»¡ªº¬O¥i¦æªº¡A¸U¤@¤½¥q¤£´£¨Ñ¡A´N¥´¹q¸Üµ¹Âd¶R¤¤¤ß½Ð¥LÌ¥h¯Á¨ú¡A¦]¬°°²³]¸U¤@ºMÂd¤F¡A¥u¦³¥xÆW³oÃ䪺§ë¸ê¤H¤£¯à¥æ©ö¡A¦ý¬O¬ü°ê¨ºÃ䪺§ë¸ê¤H¥i¥H¥æ©ö½æ²n²n¬O«Ü¤£¦X²zªº¡A¨Ã¥B¥i¯àn¤w²Õ¦Û±Ï·|ªº¥´ºâ¡A¬Ý¯à¤£¯à¦êÁp¦h¤@ÂI«ùªÑªº§ë¸ê¤H¡A¤@°_n¨D¤½¥q¥X±»¡©ú¡A§_«hªÑªF·|©w¤@Ó6/29¡A·Pı´N¬O·Qn°kÁ׳d¥ô¡A¥¿±`¨Ó»¡¯à¤£¯àÂà´«¡A²{¦b´NÀ³¸Ón¦³µª®×¤F¡A¦Ó¤£¬O¥H©ì«ÝÅÜ¡A´Û¿f§ë¸ê¤H¡A©Ò¥H°²¨Ï¤½¥q¤U¤È¨S¦³µ¹§Ú©ú½Tªº¦^ÂСA§Ú´N·|n¨DÂd¶R¤¤¤ß¥LÌ¥h¦V¤½¥q¯Á¨ú¡AµM«á¥i¯àn¦P®É¦b³oÃäÁÙ¦³§Oªº°Q½×°Ï¦êÁp¡A¤@°_n¨D¤½¥q¥X±»¡©ú¤§«áªº°µªk¡A¦Ó¤£¬O³o¼ËÅý®É¶¡¬y¥¢Ô£³£¤£°µ¡A¤j®a¬°¤F¦Û¤vªºÅv¯q¡A³o®ÉÔ¤@©wn¯¸¥X¨Ó¤F¡A¤£¯à¦A³o¼Ë¤½¥q»¡ªº³£¬Û«H¡AÀqÀq¦a§]¤U¥h¤F¡C |
|
|
·|û¡G¦Ñ¯V10146717 µoªí®É¶¡:2020/3/23 ¤W¤È 11:23:56²Ä 2349 ½g¦^À³
|
¨ä¹ê§ÚÓ¤H¹ï¤½¥q«áÄòÀ³Åܤ£¬O«Üº¡·N¡A·Pı¤£°÷¿n·¥¡A²z½×¤WÀ³¸Ón¦³¨F½L±Àºtªº¦UºØª©¥»¡A¤~¬O¹ï§Ṳ́pªÑªFt³d¡A§Ú̾á¤ßªº´N¬O¤£½T©wªº¤@¨Ç¦]¯À¡AÓ¤Hı±o¤½¥qÀ³¸Ó¥D°Ê¯¸¥X¨Ó¦w¼¾¤pªÑªF¥L̤w¸g¦³¦]À³¹ïµ¦¤~¬O¡A¥i¬O§Ú¦¤W¥´¹q¸Ü¥h¤½¥q¡A·Pı´N¬Oµ¥¹J¨ì°ÝÃD¦A¬ã¨s¡A¤]¤£½T©w¸U¤@ºMÂd¬O§_¯à¯uªºÂରADR¡A´N²Ä¤@Ó±Á{ªº°ÝÃD¶Ò¸ê¦n¹³¨S¥ý§ä¦n¹ï¶H¡A6/1·|¹F¦¨ªº¾÷²v.......¸U¤@¨S¹L¥DºÞ¾÷ºÞ¯à§_®i©µ«áÄò......¸U¤@³£¥¢±Ñ¡AÂàADR¤£¬O¦´N¸Ó¸ò«ß®v¹Î°Q½×¤F¡A«ç»ò¤W¦¸ªk»¡»¡n¨ó§U¥xªÑÂàADRªº¬ÛÃö¨Æ©y¡A³£¨S¥ý·Ç³Æ¡A§Ú¬O¦³ªí©ú§Æ±æ¤½¥q¥ý·Q¦n«áÄò·|±Á{ªº°ÝÃD¥X¨Óµoªí·s»D½Z¡A§i¶D¤pªÑªF§A̳£¤w¸g¦³¦]À³ªº¤è®×¤F¡A.Åý§Ú̯à¤ß¦w¡A«áÄò¸Ô²Ó´N¥æµ¹¨ä¥L¤j¤j¤F¸Ñ¤F¡C§Ú§Ñ¤F°Ý¸U¤@ºMÂd¤]¨S¯àÂàADR¨º¤§«á¦pªG¦³³Q¦¬ÁʬO§_¸Ó¦³ªÑ¥÷¤£ÅÜ¡A§Ú·QÀ³¸Ó¬O¤£Åܧa!³oÀ³¸Ó¬O³ÌÃaªº¥´ºâ¤F¡A¦b¤½¥qÁÙ¨S¯à¥X¨Ó¤½¶}¥Ó©ú«e¡A©¹³o¤è±·QÀ³¸Ó·|¤ñ¸û¯àÄÀÃh |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/23 ¤W¤È 11:15:22²Ä 2348 ½g¦^À³
|
½T¹ê¡A¤j®a¤@°_§V¤O¦V¤½¥q¤ÏÀ³ ©ú½T»¡©ú¤§«á¥xªÑÂà´«ADRªº±¹¬I ³o¬O¤@¾¯±j¤ß°w §Ú¬Û«H¥un¤½¥q¦³»¡©ú¡A¥x·àªÑ»ù¤]·|®i¶}¤Ï¼u ¥Ø«e¥x·à³oÃä¤j®a©ÈªºÀ³¸Ó³£¬O¤UÂd°ÝÃD§a ºÃ¼{¸Ñ°£¡A¤£º¦¤]Ãø ¬Ý¦Ñ¯V¤j¤À¨É¤½¥qªº¦^À³ §Úı±o¦ü¥G¤w«ÜÃø»°¤W6¤ë2¤é«eÄw¸ê§¹¦¨(¤½¥q¦^À³«Ü¨S«H¤ß) ©Ò¥H¥Ø«e³Ì«nªº¤w¤£¬O¶Ò¸ê ¦Ó¬OÂàADRªº¨ãÅ黡©ú ¤j®a¤]¤£¥Î©ÈÂàADR«Ü³Â·Ð ¥un¥i¥HÂà¡A¶}Ó¬üªÑ±b¤á©Î½Æ©e°U«Ü²³æ §ÚÓ¤H¬O«Ü·QÂনADR°Õ¡A¤jº¦¤j¶^¤@¦¸¸Ñ¨M |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/23 ¤W¤È 11:07:59²Ä 2347 ½g¦^À³
|
To «Ó°¶, §Ú¨Ó¸ÑÄÀ¤@¤U¬°Ô£¥xÆW¨È·à±dºMÂdªº¸ÜADRÁÙ¦b¡A¸U¤@¨È·à±d³QÂd¶R¤¤¤ßn¨D¦b¥xÆW¥«³õºMÂdªº¸Ü¡AÁöµMºMÂd¤F¦ý¬O«ù¦³¨È·à±dªºªÑ²¼ÁÙ¬O¤@¼Ë¬O¨È·à±dªºªÑªF¡AÁÙ¬O¸òADRªºªÑªF¤@¼Ë¬O¤½¥qªºªÑªF¡A¥u¬O¥xÆW³oÃ䪺ªÑ²¼¨S¿ìªk¦b¥«³õ¤W¥æ©ö¡A¦ý¬OªÑ²¼ÁÙ¬O¦s¦bªº¡A©Ò¥HADR¤@¼Ë¥i¥HÄ~Äò¦sÄòµÛ¡A°£«D¤½¥q²Mºâ¸Ñ´²µ²§ôÀç·~¡AADR¤~·|®ø¥¢¡A¦ý¬O¦pªG¥xªÑ¦bºMÂd«á¨S¿ìªkÂà´«ADRªº¸Ü¡A¨º´N¥u¯àµ¥¤½¥q¥¼¨Ó«·s¤WÂd¤~¯à¥æ©ö¤F¡A©Ò¥H¹ï¥xÆWªºªÑªF«Ü¤£¤½¥¡AADRÁÙ¬O¯àÄ~Äò¦bNASDAQ¥æ©ö¡A¦ý¬O¥xÆW³oÃä¥u¯à°®Àü²´µ¥«·s¤WÂd¤~¯à¥X²æ¤F¡A©Ò¥H¤j®a¤@©wn¨D¤½¥q´£¥X¥i¥HÂà´«ªº¤èªk¡A½T«O¸U¤@ºMÂd¤§«á¡AÁٯഫ¦^¿ú¡A§_«h´N¥u¯à¬ÝµÛ¸U¤@¤§«á004¦¨¥\¤§«á¡A¬ü°ê§ë¸ê¤H¶}¤ß¼Æ¿ú¡A¦ý¬O¥xÆW§ë¸ê¤HÔ£³£¨S¦³¤F¡A§Ú¤w¸gn¨D¤½¥q¥X¨Ó»¡©ún¦p¦óÂà´«¡A¬O§_¦³¤å¥ó©Î¬O«ß®vÁn©ú½Z¤§Ãþªº¤å¥ó¡An½T«O¸U¤@ºMÂd«á¡A¥xªÑ¬O¦Ê¤À¦Ê¥i¥HÂà´«¦¨ADRªº¡A§_«h´Nsªº¬Æ»ò³£¨S¦³¤F¡A¥u¯à²Õ¦Û±Ï·|¤F¡C Thanks! |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/23 ¤W¤È 10:36:06²Ä 2346 ½g¦^À³
|
©Ò¥H¤½¥qªº·N«ä¬O·à¤l¦b¥xªÑ¸U¤@¤UÂd¡AADRÁÙ¦b? |
|
|
·|û¡G¦Ñ¯V10146717 µoªí®É¶¡:2020/3/23 ¤W¤È 09:47:13²Ä 2345 ½g¦^À³
|
¤½¥qªí¥Ü4¤ëªì·|¶Ò¸ê·|°e¥ó.§Æ±æ¯à»°¦b6¤ë2¤é«e¶Ò¸ê§¹¦¨.´Nµ¥ª÷ºÞ·|..µ¥¥DºÞ¾÷Ãö®Öã¡A¦pªG¨Ó¤£«æ6¤ë1¤é«e´N¬Ýª÷ºÞ·|Ä@¤£Ä@·N®i©µ¶Ò¸ê¡A¦pªG¶Ò¸ê¥¢±Ñ±µ¤U¨Ó´N¸ò«ß®v°Q½×ÂàADRªº¥i¦æ©Ê¡A·|ºÉ¶q¬°¥xªÑ¤pªÑªF§ä¥X¦n¤è®×¡A²³æ´N³o¼Ë |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/3/23 ¤W¤È 12:14:34²Ä 2344 ½g¦^À³
|
·PÁ¤j®a³Ìªñ´£¨Ñªº¸ê°T¤À¨É¡A³o·í¤¤³Ì«nªº¬O¤½¥q¤T¤ë¤Q¤K¤é¤½§iªº«°T¡A¥i°Ñ¦Ò2330½g¤Ñ©R¤jªº¤À¨É ¥t¥~¥h¦~²Ä¥|©u»{¦C Varlitinib µL§Î¸ê²£´îȪº¤@¦¸©Ê´î·l ÅÞ¿è¤W¥i¥H»{¦C´îÈ¡A¬O¤£¬O¤]»¡©ú¨ä¥L²£«~¤]¥i¥H»{¦CµL§Î¸ê²£¼WÈ¡H |
|
|
·|û¡G¦Ñ¯V10146717 µoªí®É¶¡:2020/3/22 ¤U¤È 11:24:45²Ä 2343 ½g¦^À³
|
jones¤j¥i¬O·Ó±z3/19ªº»¡ªk:·|û¡Gjones10146258 µoªí®É¶¡:2020/3/19 ¤U¤È 08:36:0 ¦pªGºMÂdÀ³¸Ó¬O¤£¯àª½±µÂà´«³á¡AADR¥s®ü¥~¦s°U¾ÌÃÒ¡A¤±iÂd¶R¤¤¤ß±¾µPªº¥xªÑªí¹ü¤@±i¬üªÑ¡A¦pªGºMÂd¡A´N¨S¦³±¾µPªº¥xªÑ¡A¦ÛµM¤]´N¤£·|¦³¬üªÑ¤F¡A©Ò¥H¦pªG¤U¥«À³¬O¨âÃä¦P¨B¤U¥«¡C ¨º»ò¬°¦ó¬P´Á¤¬üªÑ¤S¤j¶^¥B¦¬³Ì§C¡A¦Ó¨È·à±dadk¤Ï¦Ó¨S°k©R¤j¶^¡A¤Ï¦Óº¦7.53%¡A¥i¥H¸Ñ´b¤@¤U¶Ü? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/22 ¤W¤È 07:47:19²Ä 2342 ½g¦^À³
|
³oÓ¬ü°ê³Õ¤h¤ÀªR®vµ¹¤©ASLN ADR 5¬ü¤¸ªº¥Ø¼Ð»ù. ³¯³Õ¤h¬OH.C.ªÑ²¼¬ã¨sªº±`°È¸³¨Æ¡C·Å¿à¯S¡]Wainwright¡^¦b¥Íª«§Þ³N©M»sÃÄ»â°ì§¡¨ã¦³±M·~ª¾ÃÑ¡C³¯³Õ¤hªº¬ã¨s²[»\¤F¬ü°êÂåÀø«O°·¦æ·~ªº§ë¸ê¾÷·|¡C ¥[¤JH.C.¤§«e³®¦¿à¯S¡]Wainwright¡^¡A³¯³Õ¤h´¿¦bAegis Capital Corp.¾á¥ôªÑ²¼¬ã¨s°ÆÁ`ºÊ¡A¨Ã¦bMorgan Morgan TriArtisan¡ALLC¾á¥ô¬ã¨sû¡C Chen³Õ¤hÁÙ´¿¦b¯Ã¬ùªº¶R¤è°òª÷Zhang Capital Management¾á¥ô¥æ©ö§U²z¡C¦b¦¹¤§«e¡A³¯³Õ¤h¬O¯Ã¬ù«°¥«¤j¾Çªº¬ã¨s§U²z¡A¥Lªº¬ã¨s¥Dn¶°¤¤¦b§Q¥ÎRNA¤zÂZ¤èªkªº³J¥Õ½è«H¸¹¶Ç¾É°ì¤W¡C³¯³Õ¤h¦b»â¥ýªº¦P¦æµû¼f´Á¥Z¤Wµoªí¤F´X½g¤å³¹¡A¦b¦UºØ¬ì¾Ç·|ij¤W¤¶²Ð¤F¬ã¨s¦¨ªG¡A¨Ã¦b¯Ã¬ù¥«¦ë¯S¾Ç°|±Ð±Â¥Íª«¾Ç½Òµ{¡C ³¯³Õ¤hªº±Ð¨|I´º¥]¬A³Õ¤h¾Ç¦ì¡CÀò±o¯Ã¬ù«°¥«¤j¾Ç¥Íª«¤Æ¾Ç±M·~ªº¾Ç¤h¾Ç¦ì´_¥¹¤j¾Ç¥Íª«ª«²z¾Ç³Õ¤h¾Ç¦ì¡C³¯³Õ¤hÁÙ¬O¯S³\ª÷¿Ä¤ÀªR®v¡]CFA¡^ªº¯S³\«ù¦³¤H¡C Dr. Chen is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biotechnology and the pharmaceutical sectors. Dr. Chen¡¦s research covers investment opportunities in the U.S. healthcare industry. Prior to joining H.C. Wainwright, Dr. Chen worked as an Associate Director of Equity Research at Aegis Capital Corp. and as a Research Associate at Morgan Joseph TriArtisan, LLC. Dr. Chen also worked as a Trading Associate at Zhang Capital Management, a New York-based buy-side fund. Prior to that, Dr. Chen was a Research Associate at the City University of New York where his research focused primarily on protein signaling domains utilizing an RNA interference approach. Dr. Chen published several articles in leading peer-reviewed journals, presented research at various scientific conferences, and taught biology courses at Hunter College in New York City. Dr. Chen¡¦s educational background includes a Ph.D. in biochemistry from the City University of New York and a B.S. in Biophysics from Fudan University. Dr. Chen is also a Chartered Financial Analyst (CFA) charterholder. ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/19 ¤U¤È 09:24:44²Ä 2299 ½g¦^À³ ¬ü°ê¨é°Ó¤µ¤Ñªº¨È·à¥Ø¼Ð»ù5¬ü¤¸/ªÑ Pharmaceuticals (ASLN) Christine Brown- March 19, 2020, 8:06 AM EDT SHARE ON: In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals (ASLN), with a price target of $5.00. The company¡¦s shares closed last Monday at $0.94, close to its 52-week low of $0.35. According to TipRanks.com, Chen is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -19.0% and a 31.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics. Currently, the analyst consensus on Aslan Pharmaceuticals is a Moderate Buy with an average price target of $5.00. |
|
|
·|û¡Gjones10146258 µoªí®É¶¡:2020/3/22 ¤W¤È 01:48:25²Ä 2341 ½g¦^À³
|
1. ´î·l2300¸U¤£¬O¤½¥q¡u´±¤£´±¡v¡A¬O·|p®v¡u·Ç¤£·Ç¡v¡Ct±§Î¶H¡HµØ¬Mºñ¯à«Ü³ßÅwt±§Î¶H¶Ü¡H´N¬OÀrÆj§Þ½a¤F¡A¸gÀ礣µ½¡A¨S©Û¤F°Ú¡A³Ì«á¥u¯à»¡©êºp 2. 004¬O¤£¥i¯àÂনµL§Î¸ê²£ªº¡A¦U¦ì¤j¤j³£¶K¤FIFRSªº³W©w¡A½Ð°Ý²Å¦Xþ¤@¶µ¥iÂàµL§Î¸ê²£¡H¥iÂ઺¸Ü¦bÅÜ¥þÃB¥æ³Î®É´NÂà¤F¡AÁÙ·|µ¥¨ì²{¦b¡C 3. ¤p§ÌÓ¤H¬O«D±`¤£¬Ý¦n¡A¦ýÄ@·N©ê¨ì©³ªº¤p§Ì¤]¤©¥H´L«¡A¤À¨É¤£¦P¨¤«×µ¹¦U¦ì¦Ó¤w¡C |
|
|
·|û¡G¦Ñ¯V10146717 µoªí®É¶¡:2020/3/21 ¤U¤È 10:37:18²Ä 2340 ½g¦^À³
|
¤½¥q´±¦b¥h¦~²Ä¥|©u»{¦C Varlitinib µL§Î¸ê²£´îÈ 2,300 ¸U¬ü¤¸ ªº¤@¦¸©Ê´î·l®É¡A·Q¥²¤w¸g°µ¦n¸U¥þ·Ç³Æ¤~¹ï¡A§_«h¦p¦¹¤@¦¸»{¦C³y¦¨²bÈÂàt¡A¦pªG´N¦¹¤UÂd<³o¼Ë¹ï¤½¥q§Î¶Hµ´¹ït±¤]·|µ¹¥¼¨ÓÄw¸ê±a¨Ó§xÃø¡A§Ú¬O¤£¤Ó»{¬°¤½¥q·|¦³³o¼Ëªº«äºû¡F¸Ô²Óªºµª®×´N³Â·Ðª©¤W¤f½Õ¦nªº¤j¤j¡A¬P´Á¤@¸ß°Ý¤½¥qÅo¡A´Á«Ý¨Îµ¡A |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/21 ¤U¤È 08:23:24²Ä 2339 ½g¦^À³
|
¦pªG¦³ªø´ÁÆ[¹î·à¤lÄw½Xªº À³¸Ó·|µo²{·à¤l¦Û±q¤G½uÁx¹DÀù¥¢±Ñ«á Äw½X¬O¶V¨Ó¶V¶°¤¤ ÁöµMªÑ»ù¤@ª½¤U¶^¡A¦ý¤j¤á¤£¦ý¨S¶]¤Ï¦Ó¼W¥[«ùªÑ ¦pªG¤µ¤Ñ¤½¥q·Q©ñ¥ô¥L¤UÂdÀ³¸Ó¤£·|¬O³o¼Ë ¦´N˳f˪ºµ}ù¼M°Õ ¦Ó¥B¦³ªO¤Í»¡¥xªÑ¤UÂdADR¤]·|¸òµÛ¤U¥« ¨ä¹ê³o¼Ë¤Ï¦Ó¦n §ÚË·Q¬Ý¬Ý¦pªG¯uªº¤UÂd ¤½¥q«ç»ò¸ò¶RADRªº¨º¨Ç¤jªÑªF¥æ¥N ì«h¤W§ÚÓ¤H¬O¸û¤£¾á¤ß·à¤l¤UÂdªº°ÝÃD ¦b·NªºÁÙ¬O004¼Æ¾Úªº¦nÃa ¤j®a¥[ªo¤F |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/21 ¤U¤È 05:19:30²Ä 2338 ½g¦^À³
|
ASLAN004ªº¥þ²yµo®i¡B»s³y¡B°Ó«~¤ÆÅv¬O¨È·àªº«n¸ê²£,Ó¤H¦ôp¦b¬Û¹ï¤ñ¸û¦P¾÷Â઺ Lilly µo®ilebrikizumab ,¼çÈ12»õ¬ü¤¸. ¬O§_¦³¥i¯à,³z¹L¤½ÃÒ¦ô»ù¡A¥»°ê·|p®v¡BÃÒ´Á·|¦P·N¤U¯Ç¤J¸ê²£? Ó¤H¤F¸Ñ: ¤wµo®i¦¨¥»vs¼ç¦b¥«È¼ô§Cªk ,·|p«O¦uì«h·|¥Hµo®i¦¨¥»¬°¼ç¦b»ùÈ. |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/21 ¤U¤È 05:19:13²Ä 2337 ½g¦^À³
|
¤j®a¥i¥H°Ñ¦Ò¤@¤U ! ¤@¯ë¥Í§Þ·~±`見¤§µL§Î¸ê²£¨ú±o來·½¦³¤T¡G ³æ¿W¨ú±o¤§µL§Î¸ê²£ **************³æ¿W¨ú±o¤§µL§Î¸ê²£(¤@) ³æ¿W¨ú±o¤§µL§Î¸ê²£³q±`²Å¦XµL§Î¸ê²£»{列±ø¥ó¡C ¥¼來¸gÀÙ®Ä益«Ü¦³¥i¯à流¤J¥ø·~ ¦¨¥»¯à¥i¾a¿Å量 ¦p¡G³æ¿W¨ú±o±M利Åv¡B¯S³\Åv©M°Ó¼ÐÅvµ¥¡C **************³æ¿W¨ú±o¤§µL§Î¸ê²£(¤G) ³æ¿W¨ú±oµL§Î¸ê²£ªº¦¨¥»¦p¤U¡G ÁʶR»ù®æ¡A¥]¬A¦U¶µµ|®½(¦pÃöµ|¡B不¥i°h¤§ÁʶRµ|) ¨Ï¸Ó¸ê²£¹F¥i¨Ñ¨Ï¥Î狀ºA«e¤§¥iª½±µÂkÄݦ¨¥» ·íµL§Î¸ê²£¤w¹F¥i¨Ñ¨Ï¥Î狀ºA«á¡A©Òµo¥Íªº¦¨¥»不À³¦A ¤J±b¡C **************³æ¿W¨ú±o¤§µL§Î¸ê²£(¤T) ¥iª½±µÂkÄݦ¨¥»¡AÁ|例¦p¤U ¥iª½±µÂkÄݦ¨¥»¡AÁ|例¦p¤U¡G ª½±µ¨Ï¸ê²£¹F¥i¨Ñ¨Ï¥Î狀ºA©Ò¤ä¥Iû¤u¤§勞°È¦¨¥»¡C ª½±µ¨Ï¸ê²£¹F¥i¨Ñ¨Ï¥Î狀ºA¤§±M·~ªA°È¶O¡C(¦pŲ»ù¤½¶O¡B律®vÅU °Ý¶O) ´ú¸Õ¸Ó¸ê²£¬O§_¤w¹F¥i¨Ñ¨Ï¥Î狀ºA¤§¦¨¥»¡C 不ÄÝ©óµL§Î¸ê²£¦¨¥»¤§¤ä¥X¡AÁ|例¦p¤U 不ÄÝ©óµL§Î¸ê²£¦¨¥»¤§¤ä¥X¡AÁ|例¦p¤U¡G ±À¥X·s²£«~©ÎªA°È¤§¦¨¥»(¥]¬A¼s§i¤Î±À¾P¬¡°Ê¦¨¥»µ¥)¡C ·sÀç·~³B©Ò©Î·s«È¤á¤§·~°È¶}µo¦¨¥»(¥]¬Aû¤u°V練¦¨¥»)¡C ºÞ理¦¨¥»¤Î¨ä¥L¶¡±µ¦¨¥»¡C ¥H©µ¿ð¥I´Ú(Payment is deferred beyond normal credit terms)ªº ¤è¦¡¨ú±oµL§Î¸ê²£¡A¨ä利®§¤ä¥X³q±`À³列¬°¶O¥Î¦Ó«D¸ê²£¦¨¥»¡C (IFRS) |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/21 ¤U¤È 05:01:07²Ä 2336 ½g¦^À³
|
¨È·à±d108¦~«×Q4°]³øµL§Î¸ê²£¤w¸gÁͪñ©ó0 ~ ªí¥Ü ASLAN004©|¥¼¯Ç¤JµL§Î¸ê²£ ! ©Ò¥HÁÙ¬O¦³¨âÓ´ù¯íªº¾÷·| ²Ä¤@ ¬Ý·|p®v¬O§_¦P·NALANA004¯Ç¤J2020Q1ªº°]³ø¬°µL§Î¸ê²£(4¤ë¤¤¤U¦¯°]³ø´¦ÅS) ²Ä¤G ¨p¶Ò |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/21 ¤U¤È 03:29:43²Ä 2335 ½g¦^À³
|
¥¼¨ÓASLAN004 ¶i¤J¤T´ÁÁ{§É¡]¦ôp2022¦~)¶·¥I¤W´åCSL ¤@»õ¬üª÷¡]30»õ¥x¹ô)ªº¦X¬ùª÷¡C ¬Û¹ï©ó¤é«e¨Ï²bȤj©ó¹s¡A7»õ¥x¹ô¬ù¥|¿¦h¡C ¨º¤@Ó®e©ö¡H |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/3/21 ¤U¤È 02:56:51²Ä 2334 ½g¦^À³
|
¤µ¦~¤¤ë©³¯à¤£¯à¶Ò¨ì¿ú~«Ü«n!!¦Ü¤ÖÅý²bÈÂॿ ¥H¨È·à±dªº¸³ºÊ«ùªÑ¨Ó¬Ý~ À³¸Ó¤£·|Åý¥L¤UÂd¤~¬O ¤×¨ä¦b004Á٬ݦnªºª¬ªp¤U! |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/3/21 ¤U¤È 02:52:31²Ä 2333 ½g¦^À³
|
TO«Ó°¶ §Ú¦³54±i¦¨¥»6.X ¤]¤£¥i¯à²{¦b½æ~! ¤£®t¨º¤@ÂI¿ú ¤@°_¥[ªo |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/21 ¤U¤È 02:00:44²Ä 2332 ½g¦^À³
|
¶Ì¤F¤~²{¦b½æ §Ú¦³100±i¡A¸ò§A©é¨ì©³ |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/3/21 ¤U¤È 01:49:33²Ä 2331 ½g¦^À³
|
¤Ñ©R¤j ¤½¥q©ÈªÑªF¾á¤ß©Ò¥H¯S§Oµo«°T»¡©ú¡A²{¦b¤j®a³£²M·¡¤F¡A¦]¬°¤Ó«n¤F¤j®an°O¤U¨Ó ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/21 ¤W¤È 11:22:59²Ä 2330 ½g¦^À³
|
¥xÁÞ¤j, ½Ð¸ÔŪ¦¹«°T 7. ¡]2¡^¥»¤½¥q°_ªì«Y¨Ì°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß¡]¥H¤U²ºÙÂd¶R¤¤¤ß¡^ ¥~°ê¦³»ùÃÒ¨éÂdÂi¶R½æ¼f¬d·Ç«h²Ä4±ø²Ä4¶µ¥Ó½ÐªÑ²¼¬°ÂdÂi¶R½æ¤§²Ä¤@¤WÂd¤½¥q¡A ¨Ã©ó106¦~6¤ë1¤é±¾µP¤WÂd¡C¨Ì¾Ú¥»¤½¥q108¦~«×°]°È³ø§iÅã¥Ü¡A ºI¦Ü108¦~12¤ë31¤é¥»¤½¥q²bÈÁö¬°t¼Æ·s¥x¹ô18,070¥a¤¸¡AµM¨ÌÂd¶R¤¤¤ß ÃÒ¨é°ÓÀç·~³B©Ò¶R½æ¦³»ùÃÒ¨é·~°È³W«h²Ä3±ø¤§1²Ä¤@¤WÂd¤½¥q·Ç¥Î¥»°ê¤WÂd¤½¥q ³W©w¡A¤Î²Ä12±ø¤§2²Ä1¶µ²Ä4´Ú¦ý®Ñ³W©w¡A´£¥Ü¥»¤½¥q©ó¤WÂdº¡¤T¦~¥H¤º¡A±o¤£¨ü ¸Ó´Ú©Ò³W©w³Ìªñ´Á°]°È³ø§iÅã¥Ü²bȬ°t¼ÆÀ³²×¤î¨ä¦³»ùÃÒ¨éÂdÂi¶R½æ¤§¨î¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/18 ¤U¤È 07:32:48²Ä 2283 ½g¦^À³ ¡X¡X¡X¡X¡X¡X¡X¡X¡X ¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ¨È·à±d-KY ¡@¤½¥q´£¨Ñ §Ç¸¹ 4 µo¨¥¤é´Á 109/03/18 µo¨¥®É¶¡ 15:32:09 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ °õ¦æªø µo¨¥¤H¹q¸Ü +65 6222 4235 ¥D¦® ¥»¤½¥q¥N·s¥[©Y¤l¤½¥qASLAN Pharmaceuticals Pte. Ltd. ¤½§i¨Ì°ê»Ú·|p·Ç«h²Ä36¸¹»{¦CµL§Î¸ê²£´î·l ²Å¦X±ø´Ú ¡@²Ä 53 ´Ú ¨Æ¹êµo¥Í¤é 109/03/18 »¡©ú 1.¨Æ¹êµo¥Í¤é:109/03/18 2.¤½¥q¦WºÙ: ASLAN Pharmaceuticals Pte. Ltd. 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¤l¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:100% 5.µo¥Í½t¥Ñ: (1)¥»¤½¥q®Ú¾Ú°ê»Ú·|p·Ç«h²Ä36 ¸¹¤½³ø³W©w¡A©ó¸ê²£t¶Åªí¤é°õ¦æ¸ê²£´î·lµû¦ô ´ú¸Õ¨Ã¸g·|p®v¬d®Ö§¹µ¤¡C©ó108¦~²Ä¥|©u°w¹ïVarlitinib§Þ³N±ÂÅv»{¦CµL§Î ¸ê²£´î·l·l¥¢ª÷ÃB¦@p¬üª÷23,000 ¥a¤¸¡]·s¥x¹ô709,499¥a¤¸¡^¡A¬ÛÃö¼Æ¦r±N ¤Ï¬M©ó108¦~«×°]°È³øªí¡C (2)¥»¤½¥q©ó108¦~11¤ë11¤é«Å¥¬Varlitinib°w¹ïÁx¹DÀù¤§¥þ²y©Ê¼Ï¯Ã¸ÕÅçTreeTopp ªºÁ{§É¸ÕÅçµ²ªG¡A¸Ó¬ã¨s¨Ã¥¼¹F¨ì¦@¦P¥Dnµû¦ô«ü¼Ð¡C°ò©ó¸Ó¹êÅ礧µ²ªG¤Î ¸ê·½°t¸m¡A¥»¤½¥q¨M©w¼È°±¹ïVarlitinib¶i¤@¨B¶}µo»P§ë¸ê¡A¨Ã¹w´ÁVarlitinib ©Ò²£¥Í¤§¥¼¨Ó²{ª÷¬y¶qª÷ÃB±N·|´î¤Ö¡C¬G©ó¸ê²£t¶Åªí¤é°w¹ïVarlitinib¶i¦æ¡@ ¥i¦^¦¬ª÷ÃB¤§µû¦ô¡A¥i¦^¦¬ª÷ÃB¬°¤½¤¹»ùÈ´î¥X°â¦¨¥»»P¨ä¨Ï¥Î»ùȤ§¸û°ªªÌ¡A ¨Ï¥Î»ùÈ«h¬O®Ú¾Ú¥¼¨Ó²{ª÷¬y¶q§é²{¦Ó±o¡C¸g¥Ñ¤WzµL§Î¸ê²£´î·l´ú¸Õ¡A½T©w ¨ä±b±»ùȤw¶W¹L¥i¦^¦¬ª÷ÃB¡A¬G¤©¥H¥þ¼Æ»{¦C´î·l·l¥¢p¬üª÷23,000¥a¤¸ ¡]·s¥x¹ô709,499¥a¤¸¡^¡C Áö¥»¤½¥q¥i¯à¦b±N¨Ó¨M©w¹ïVarlitinib¶i¦æ±´¯Á©Ê¬ã¨s¡A¦ýºI¦Ü¥Ø«e¨Ã¤£¹wp¹ï Varlitinib«ùÄò§ë¤J¸êª÷¡A¨ÃµLªk«OÃÒ¥¼¨Ó¦³¨ä¸ê·½©µÄò¶}µo¡A¬G¨Ì¾Ú¬ÛÃö·|p ·Ç«h³W©w¤©¥H»{¦C«ez´î·l·l¥¢¡C (3)¥»¤½¥q¸³¨Æ·|·~¤w³q¹L¤Wzµû¦ô¨Ã¨Mij³q¹L©ó108¦~«×»{¦C¸Ó¶µ«¤jµL§Î¸ê²£´î·l ·l¥¢¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¥»¦¸¶È´N±b¦CµL§Î¸ê²£¨Ì¾Ú·|pì«h»{¦C«D²{ª÷´îÈ·l¥¢¡A¸Ó¶µ·l¥¢»{¦C¤£¼vÅT ²{ª÷¬y¶q¡A¥B¹ï¥»¤½¥q¥DnÀç¹B¶µ¥Ø¨ÃµL«¤j¼vÅT¡C ºI¦Ü108¦~12¤ë31¤é¡A¥»¤½¥q±b¤W²{ª÷¤Î¬ù·í²{ª÷¾lÃB¬°¬üª÷22,000 ¥a¤¸ ¡]·s¥x¹ô665,050¥a¤¸¡^¡C (2)¥»¤½¥q°_ªì«Y¨Ì°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß¡]¥H¤U²ºÙÂd¶R¤¤¤ß¡^ ¥~°ê¦³»ùÃÒ¨éÂdÂi¶R½æ¼f¬d·Ç«h²Ä4±ø²Ä4¶µ¥Ó½ÐªÑ²¼¬°ÂdÂi¶R½æ¤§²Ä¤@¤WÂd¤½¥q¡A ¨Ã©ó106¦~6¤ë1¤é±¾µP¤WÂd¡C¨Ì¾Ú¥»¤½¥q108¦~«×°]°È³ø§iÅã¥Ü¡A ºI¦Ü108¦~12¤ë31¤é¥»¤½¥q²bÈÁö¬°t¼Æ·s¥x¹ô18,070¥a¤¸¡AµM¨ÌÂd¶R¤¤¤ß ÃÒ¨é°ÓÀç·~³B©Ò¶R½æ¦³»ùÃÒ¨é·~°È³W«h²Ä3±ø¤§1²Ä¤@¤WÂd¤½¥q·Ç¥Î¥»°ê¤WÂd¤½¥q ³W©w¡A¤Î²Ä12±ø¤§2²Ä1¶µ²Ä4´Ú¦ý®Ñ³W©w¡A´£¥Ü¥»¤½¥q©ó¤WÂdº¡¤T¦~¥H¤º¡A±o¤£¨ü ¸Ó´Ú©Ò³W©w³Ìªñ´Á°]°È³ø§iÅã¥Ü²bȬ°t¼ÆÀ³²×¤î¨ä¦³»ùÃÒ¨éÂdÂi¶R½æ¤§¨î¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/21 ¤W¤È 11:16:19²Ä 2329 ½g¦^À³
|
2¤ë26¤é¶}§¹¼W¸ê®×ªºªÑªF·|¡A3¤ë26¤éÀ³¨ú±oÃÒ´Á·|µL·N¨£«á°õ¦æ¡C ¤µ¦~5¤ë31¤é«e¡AY¨p¶Ò¨Ï¦b¤µ¦~©³²bȤj©ó¹s¡A¶È¬ù7»õ¥x¹ô¡C 谮¦b»ùÈ360»õ¡A§A¬O¤jªÑªF¡A§A¤£·|°Ñ»P¨p¶Ò¶Ü¡H 12¥ü¥x¹ô¨â¤jªÑªF ݸ³¨Æ¡G·s¥[©Y°]¬F³¡¤QÀq§JÃļt¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/3/21 ¤W¤È 11:04:38²Ä 2328 ½g¦^À³
|
aslanpharma.com/zh/2020/03/18/aslan-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-corporate-update/ ¨ì12¤ë©³²{ª÷ÁÙ¦³2220¸U¬ü¤¸¡A¦ó¨Ó²bÈÂàt¼Æ¡A¦pªG§C©ó¤T¤¸¨Ì¾Úªk³W¤]¬O¤T¦~¥¼§ïµ½¤~·|¤U¥«¡A¦óªpÁÙ¦³ADR¥iµo¦æ «Øij¦A¬d²M·¡¦A¤À¨É¡C |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/3/21 ¤W¤È 10:54:36²Ä 2327 ½g¦^À³
|
To:¸¤H¤j/T¤j ¨ä¹êÁÙ¦³¤@ӸѤè...¬JµM001³£¯à¦CµL§Î¸ê²£´î·l¦Ó°§C²bÈ,¨º004¤]À³¸Ó¥i¥H¥Î¥¼¾ã²zªº¼Æ¾ÚÁͦV¨Ó¦CµL§Î¸ê²£¼W¥[¦Ó¦b2020-Q1°]³ø®É¥Î©ó´£¤É²bȧa~~~¤j®aı±o¦³µL¾÷·| ???? |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/21 ¤W¤È 10:51:41²Ä 2326 ½g¦^À³
|
ı±o¤j®a²{¦b¯à°µªº¨Æ´N¬O½Ð¤½¥q¥X¨Ó»¡©ú¤@¤U¡A¸U¤@ºMÂd¤Fn¦p¦óÂà´«¨ì¬üªÑ¥h¡A¥Î¦óºØ¤èªk¥Õ¯È¶Â¦r»¡²M·¡Á¿©ú¥Õ¡A¥h¦~ªk»¡·|³Å«i°õ¦æªø¦b°OªÌ¤jªÑªFÁÙ¦³¤@°ï§ë¸ê¤H±«e»¡¥i¥HÂà´«¡A¨º¤½¥q´N¦³¸q°Èn¹ï§ë¸ê¤HÄÀºÃ¡A»¡©ú«ç¼Ë¾Þ§@¨Ã«OÃÒ¥i¦æ¡A§_«h¤j®a´N¥i¥H¥h±±§i¤½¥qI«H§a¡A¿ýµÀɧڳ£ÁÙ¦³¯dµÛ¡A©Î¬O¥´µ¹Âd¶R¤¤¤ß§ë¸ê¤H«OÅ@±M½u½Ð¥LÌn¨D¤½¥q¥X¨Ó»¡©ún«ç¼Ë³B²zÂà´«ªº¨Æ±¡¡A³o®ÉԹε²´N¬O¤O¶q¡A¤j®a¦³ªÅ¥i¥H¦h¥´¹q¸Ü¥h¤½¥q¸òÂd¶R¤¤¤ß¡A§Ú·Q¦h´XÓ§ë¸ê¤Hn¨D¥X±»¡©ú¡A¤½¥qÀ³¸Ó´N¤£´±¸Ë¶Ì§a¡A¤j®a¤@°_§V¤O¥´¹q¸Ü§a¡I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/21 ¤W¤È 10:41:33²Ä 2325 ½g¦^À³
|
¨È·à³æASLAN004谮¦b³Q¨ÖÁÊ»ùÈÁÙ¦³12»õ¬ü¤¸¡C Ó¤H¦ôºâ ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/1/14 ¤U¤È 05:36:42²Ä 2192 ½g¦^À³ ¨È·à¼ç¦b»ùȦôºâ: ¨È·à±d¤½¥qY²{¦b³Q¨ÖÁʪº»ùÈ°_½X16»õ¬ü¤¸°_¸õ¡C ¤@¡A Lilly µo®ilebrikizumab ¦¨¥»¹w¦ô¡]¬ü°ê°ÏAD)¡G Lebrikizumab 8»õ¬ü¤¸¡ÏRoch À³¥I´Ú 2.1»õ¬ü¤¸¨½µ{ª÷¡Ï10.25 »õ¬ü¤¸¾P°â¨½µ{ª÷¡Ï<= 10%¾P°â¤À¼í¡Ï3´ÁÁ{§É¦¨¥»- 3000¸U¬ü¤¸¡]¼Ú¬w¦¬¤J¡^ ¤G¡A 1.Lilly °²³]¦¬ÁÊ Lebrikizumab È8»õ¬ü¤¸.¡A¨ä¥L3»õ¬ü¤¸ 2.2017/08/08 (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. 2.1 , 2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q. Out-License and Other Agreements Almirall Agreement 2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¨½µ{ª÷?+¾P°â¤À¼í? ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O 2.2019/05/31 , CSL ±ÂÅv ASLAN004 µ¹ ¨È·à±d, «eª÷+¨½µ{ª÷ 1.25»õ¬üª÷ +§t³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷=7.8»õ¬üª÷+ ¥[¾P°â¤À¼í<= 10%. ¤T¡Aµo®i ASLAN004 ¦¨¥»¹w¦ô 7.8»õ¬ü¤¸¡]¨½µ{ª÷)¡Ï<= 10%¾P°â¤À¼í¡Ï3´ÁÁ{§É¦¨¥»¡Ï2´ÁÁ{§É¦¨¥»¡]¦ô600¸U¬ü¤¸)¡Ð1.1»õ¬ü¤¸¡]¼Ú¬w±ÂÅv) ¥|¡B¥Ñ ¤@Lebrikizumal ¦¨¥» VS ¡B¤TASLAN004 pºâ¦¨¥» ¤§®t²§ ¤@¡A Lebrikizumab ¦¨¥»8¡Ï2.1¡Ï10.25-0.3=20.05 »õ¬ü¤¸ ¡Ï <=10%¾P°â¤À¼í¡Ï3´ÁÁ{§É¦¨¥» ¤T¡AASLAN004¦¨¥»7.8¡Ï0.06¡Ð1.1=7.76 »õ¬ü¤¸¡Ï <=10%¾P°â¤À¼í¡Ï3´ÁÁ{§É¦¨¥» ¤Wz®t²§ = 20.05-7.76=12.29»õ¬ü¤¸ ***°²³]Àø®Ä¨âÃĬ۷í¡C ¤¡A ¥Ñ¥|¨âÃĵo®i¦¨¥»®t²§¡Aª¾µo®iASLAN004 AD¦¨¥»¤ñLebrikiumab «K©y12.29»õ¬ü¤¸. ¥t¥~¥[¤WASLAN001 ¼ç¦b²b²{ª÷È°²³]4»õ¬ü¤¸. ¬G¨È·àY²{¦b³Q¨ÖÁʪº»ùÈ°_½X16»õ¬ü¤¸°_¸õ¡C ¡X¡X-©|¥¼¦ôASLAN004 ¨ä¥L¾AÀ³¯gªº»ùÈ¡C¡X¡X |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/21 ¤W¤È 10:14:13²Ä 2324 ½g¦^À³
|
µo¦æ¬ü°ê¨È·àADRªº¨é°Ó¦b¬Ý¹L¨È狮¦~³ø«á¡A3¤ë19¤é给ªº³Ì·s¥Ø¼Ð»ù5¬ü¤¸/ªÑ¡C ¥«È¦ô57»õ¥x¹ô¡A ¦b¥xÆW³ºn³Q¤U¥«·ÀI¡A¯uªºxxx ¥xÆWªk¥O¯uªº¸¨«á¬ü°ê¬Æ¦h¡A¥H²bȧí¨î创·s¤½¥qªº¶Ò资¡A¸Ó³QÀË°Q¡C |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/21 ¤W¤È 08:31:21²Ä 2323 ½g¦^À³
|
ºñ¯à3/20¤½§i²bÈÂàt¤§«á¤@¸ô¶^°±¨ì¤U¥« ! µØ¬M3/27¤½§i²bÈÂàt¤§«á¤@¸ô¶^°±¨ì¤U¥« ! ¨È·à±d3/18¤½§i²bÈÂàt¤§«á¨S¶^°± ? ÁÙ¬O¤w¸g¶^¨ì¤j®a³£³Â·ô¤F ½æ¤]¨S¦h¤Ö¿ú ... À°¤j®a§ä¤F«Ü¦h¸ê®ÆÁÙ¬On«Å¥¬ ¨È·à±d§Y±N¤UÂdªº©R¹B .. °ò¥»¤WASLN ADR¬O¨È·à±dªº®ü¥~«H°U¾ÌÃÒ¦pªG¨È·à±d¤UÂd¤F ASLN¦ÛµMµLªk¥æ©ö ¤]¤£n»¡¥i¥HÂà´«¨ì¬üªÑADR¤F ! Á`¤§¤j®an©ê«ù³ÌÃaªº¥´ºâ¨È·à±d§Y±Nn¤UÂdªº¨Æ¹ê¤F,¤â¤W¦pªGÁÙ¦³¦Ê±iªº§ë¸êªÌ,¤U©P¦pªG¦³¾÷·|ºCºC½æÁÙ¥i¥H®³¦^´X¤Q¸U... Â÷¤UÂd³Ñ¤U¤£¨ì2.5Ó¤ë³{·s«aªÍª¢¸êª÷°kÂ÷,±Ï©R¨p¶Ò¸êª÷n§Y®É±Ï´©¾÷·|´ù¯í ! ¯¬¤j®a¶¶¤ß¦p·N ! ¦Û¤v§V¤O¤u§@¦A§â³o¿úÁȦ^¨Ó§a !!! ¥[ªo !!!! ±ªO¼t¤¤µØ¬MºÞ3/27¤µ¤Ñ±ß¶¡¦bÃÒ¥æ©Òµo¥¬«°Tªí¥Ü¡A¥h¦~¤jÁ«·s¥x¹ô252.83»õ¤¸¡A¾ÉP¨CªÑ²bÈÂରt0.7¤¸¡F¥xÆWÃÒ¨é¥æ©ö©Òªí¥Ü¡AYµØ¬M©ú¤Ñ¥Ó³ø°]³ø¡A³Ì§Ö5¤ë8¤é¤U¥«¡C ¤Ó¶§¯à¼tºñ¯à (3519-TW) ¤µ (3/20) ¤é¸³¨Æ·|³q¹L¥h¦~°]³ø¡A¥h¦~²Ä 4 ©u»{¦C¸ê²£´î·l¡B¥´®ø®Æ·½¦X¬ù·l¥¢¡A¥H§ïµ½¤½¥q°]°Èµ²ºc¡AÀvÁÙ§Q®§¡A¨Ï¤½¥q²bÈÂରt¼Æ¡A¨CªÑ²bȤj´T·Æ¸¨¦Ü - 5.53 ¤¸¡A±N©ó·|p®v¥X¨ã¬d®Ö³ø§i«á¡A«Ý¦¬¨ì¥DºÞ¾÷Ãö³qª¾¡A©ó¥DºÞ¾÷Ãö¤½§i«á 40 ¤Ñ¤U¥«¡C ºñ¯àªí¥Ü¡A¥Ñ©ó¤Ó¶§¯à²£·~¼@¯Pªi°Ê¡A¤½¥qÁö¥[³tÂ૬¡A¤´¤£¤Î²£·~§Ö³tÅܤơAÀç¹BµLªk¤Î®ÉÀò§Q¡A¥[¤W»{¦C¸ê²£´î·l»P·l¥¢µ¥¡A¨Ï¥h¦~°]³ø²bÈÂରt¼Æ¡A¶dtªÑªF»P¦U¬É¹ïºñ¯àªº´Á«Ý¡A¹ï¦¹¦VªÑªF»PªÀ·|¤j²³P¤W¸Û¼°ºp·N¡C |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/3/20 ¤U¤È 10:49:12²Ä 2322 ½g¦^À³
|
«D±`ÁÂÁ³oÃ䪺·à¤Í¤@¤@ªº¦^ÂЩM°lÂÜ~·P¿E¤£ºÉ ¤]¸Û¤ß¯¬¥¼¨Óªº¤@¤Ñ§Ú̳£¯àÁÈ¿ú!! |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/20 ¤U¤È 10:10:03²Ä 2321 ½g¦^À³
|
To T¤j §Ú·Q¥i¯à¤½¶}¸ê°T¯¸¤W±ÁÙ¨S¦³¤½§i¡A©Î¬Oµ¥¤§«áÂd¶R¦³µo¤½§i»¡¤½¥q²bÈÂàtªºn§ë¸ê¤Hª`·N¡A©Î³\¤~·|¤ñ¸û¦h¤Hª`·N¨ì§a¡A²¦³º¥¦¤W©u²bÈÁÙ¦³¨â¶ô¦h¡AÁöµM¦]¬°001ªº¸Ñª¼¥¢±Ñ³Q¦©°£µL§Î¸ê²£¡A¦ý¬O¥i¯à«Ü¦h§ë¸êªÌ·Q¬Ý004ªº´Á¤¤¼Æ¾Ú©Ò¥H¿ï¾Ü¨S½æªÑ²¼§a¡A¤£ºÞ¦p¦ó¤½¥q³£µo¤½§i6/29n¶}ªÑªF·|¡A¥NªíÀ³¸Ó¬O¦³´£¤É²bȪº¤èªk§a¡A§_«h¤£·|¤@°_¤½§i¥X¨Ó§a¡I ÃD¥~¸Ü¤µ¤Ñ¨È·à±dªºADRªí²{ÁÙ¤£¿ù¡I Thanks¡I |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/20 ¤U¤È 09:40:16²Ä 2320 ½g¦^À³
|
¦n§a §Ú§ä¨ì¤F ¬O¦b²Ä¤Q¤G±ø¤§¤G²Ä4ÂI ¤£¹L¬°¦ó¨È·à±d¨S¦³¹³¥h¦~ªººñ¯à..µ¥·Ç³Æ¤U¥«ªº¤½¥q³sÄò¶^°± ? ¯u¬O¥O¤Hª±¨ý ... ²Ä¤Q¤G±ø¤§¤G µo¦æ¤H¦³¤U¦C±¡¨Æ¤§¤@ªÌ¡A¥»¤¤¤ß±o²×¤î¨ä¦³»ùÃÒ¨éÂdÂi¶R½æ¡A¨Ã³ø½Ð¥D ºÞ¾÷Ãö³Æ¬d¡G ¤@¡B¸ÓªÑ²¼¤w¦b»OÆWÃÒ¨é¥æ©ö©ÒªÑ¥÷¦³¤½¥q¤W¥«ªÌ¡C ¤G¡B¸gªk°|µô©w«Å§i¯}²£¤w½T©wªÌ¡C ¤T¡B¸gªk°|µô©w㤩«¾ã½T©wªÌ©Î¨Ì¤½¥qªk²Ä¤G¦Ê¤K¤Q¤±ø¤§¤@²Ä¤T¶µ²Ä ¤G´Ú³W©w»é¦^«¾ã¤§Án½Ð½T©wªÌ¡C ¥|¡B¨ä¨ÌÃÒ¨é¥æ©öªk²Ä¤T¤Q¤»±ø³W©w¤½§i¨Ã¥Ó³ø¤§³Ìªñ´Á°]°È³ø§iÅã¥Ü²b Ȭ°t¼ÆªÌ¡F¸É¦æ¤½§i¨Ã¥Ó³ø¤§°]°È³ø§iÅã¥Ü²bȬ°t¼ÆªÌ¥ç¦P¡C¦ý ¨Ì¥»¤¤¤ß¼f¬d·Ç«h²Ä¤T±ø²Ä¥|¶µ¥Ó½ÐªÑ²¼¬°ÂdÂi¶R½æªÌ¡A©ó¤WÂdº¡¤T ¦~¥H¤º¡A±o¤£¨ü¥»´Ú¨î¡C |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/20 ¤U¤È 09:15:12²Ä 2319 ½g¦^À³
|
to ¸¤H¤j¤j ³o¬OÂd¶R¤¤¤ß§ä¥X¨Óªº¤½§i ! www.tpex.org.tw/web/bulletin/announcement_law/ann_detail.php?l=zh-tw&content_file=MTA4MDA1MzgzMTEuaHRtbA%3D%3D&content_number=MTA4MDA1MzgzMTE%3D ¤@¼Ë¦³ªþ¥óÀÉ®× ! |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/20 ¤U¤È 08:23:26²Ä 2318 ½g¦^À³
|
¥xª©¡uíL«ÍªÑ¡v¡Aª÷ºÞ·|²×©ón°Ê¤â³B²z¡A±j¨î¤U¥«¾÷¨î109¦~4¤ë1¤é±N¥¿¦¡¤W¸ô¡A®Ú¾Ú²Îp¡A¤W¥«Âd¥Ø«e¦@¦³24®a²Å¦X°h³õ¾÷¨î¡A¦ýn³sÄò12©u¡]¦@3¦~¡^°]³ø¹F¨ì²bȧC©ó3¤¸¡A¥B·|p®v¥X¨ãÄ~Äò¸gÀ禳ºÃ¼{ªº«Øij®Ñ¡A¤~·|¤U¥«Âd¡C ¡@¤W¥«12®a¦W³æ¤¤¡A¥]¬AªFµØ¡B¥»·ù¡B·ç§Q¡B¤d¿³¡BªF°T¡BÛ¸¡B¬ì·¡B¤O¯S¡B¸Û¬ü§÷¡B±y§J¡B¤ÑÃv¤ÎµØ¤W¡F¤WÂd12®a¦W³æ¤¤¡A«h¦³®¦±o§Q¡B®õ°¶¡B·s¹s°â¡BµØ¸q¡B¤Î¦¨¡B¤¸³Ó¡B¤¤Z¡B¦X¨¹¡B±d§e¡B¦ÊÀ²¡B¤¸¶©¤Î¥xìÃĵ¥¡C ¡@ª÷ºÞ·|¥D©eÅU¥ß¶¯ªí¥Ü¡A´î¸ê¤]¬O§ïµ½Åé½èªº¤@ºØ¤è¦¡¡AY´î¸ê«áÅé½èÁÙ¬OµLªk§ïµ½¡AÁÙ¬O·|±Ò°Ê¤U¥«¡A´î¸ê¤£¥²µM¬O¨ú¥©ªº¤èªk¡AY¬O¦³¾á¤ß°µ°²ªº¸Ü¡A¥«³õºÊµø³æ¦ì¦³ÃÒ¥æ©Ò¡BÂd¶R¤¤¤ß¡A·|¬d®Ö¬ÛÃöªº°]³ø¡C ¡@¬°´£¤É¤W¥«Âd¤½¥q«~½è¡BÁקK§ë¸ê¤H½ò¨ì¡u¦a¹pªÑ¡v¡AÃÒ¥æ©Ò¡u°h³õ¾÷¨î¡v±N±q109¦~4¤ë1¤é¹ê¬I¡A¦ý©Ò¿×ªº¹ê¬I¡AÃÒ¥æ©Ò«ü¥X¡A¬O«ü¨Ì108¦~«×°]³ø¤½§i²Å¦X¤U¥«¦W³æ¡A±µ¤U¨Ó·|¥ýµ¹¤©3¦~Æ[¹î´Á¡A¤§«á¦A¸g¹L¥b¦~¼È°±¥æ©ö¤´¥¼§ïµ½¤~·|¥¿¦¡¤U¥«¡A¦]¦¹¡A³Ì§Ön112¦~10¤ë1¤é¤~·|¦³¤½¥q¤U¥«Âd¡C ¡@ÃÒ¥æ©ÒÀÀqªº°h³õ¾÷¨î¡A¬O¥H¡u²Å¦XñÃÒ·|p®v¥X¨ãÄ~Äò¸gÀç¯à¤O¦s¦b«¤j¤£½T©w©Êªº¬d®Ö³ø§i¡A©Î¨CªÑ²bȧC©ó3¤¸ªº¥þÃB¥æ³ÎªÑ¡v±N¤U¥«¡A¨ÌÃÒ¥æ©Òºô¯¸¤½§i¡A¥H¤µ¦~¦Ü²Ä¤T©u¬°¤î¡A¦@¦³12®a¤W¥«¤½¥q²Å¦X¡A¦Ó¤WÂd¨ÌÂd¶R¤¤¤ßºô¯¸¤½§i¡A«h¦³12®a²Å¦X¡CÂd¶R«ü¥X¡A¥Ø«e²Ä¤T©u°]³ø²Å¦XíL«ÍªÑ¡A¶È¦³4®a¤WÂd¤½¥q¡C ¡@ÃÒ¥æ©Ò±j½Õ¡A©ú¦~3¤ë©³«e·|¥H108¦~«×¤½§i°]³ø¬°·Ç¡A¨Ã¥¿¦¡¹ï¥~¤½§i¦W³æ¡A¦ý·|¦Aµ¹¤©¤W¥«¤½¥q3¦~ªº½Õ¾ã¡AY©¡®É¥¼½Õ¾ã¡A±N¥¿¦¡¼È°±¥æ©ö¥b¦~¡AY³o¥b¦~¤º¥i§ïµ½¡A¤´¦³¾÷·|§K©ó¤U¥«¡AY³o¥b¦~¤º¥¼§ïµ½¡A´N½T©wn¤U¥«¡A¦ôp®É¶¡¬ù¸¨¦b112¦~10¤ë1¤é¥H«á¡C |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/20 ¤U¤È 08:11:41²Ä 2317 ½g¦^À³
|
Âd¶R¤¤¤ßÁ`¸g²z§õ·R¬Âªí¥Ü¡A±N»PÃÒ¥æ©Ò¦P¨B¹ê¬I¡A±ø¥ó©M¥æ©ö©Ò¤@P¡F¤]´N¬O»¡¡A°£¤F¥xÆW¦s°U¾ÌÃÒ¡]TDR¡^¥~¡A¥]¬A¤W¥«Âd¤Î²Ä¤@¤W¥«Âd¤@¥¹Ä²¤Î¨â¤j°h³õ¾÷¨î¤§¤@¡A±Nµ¹¤© 3 ¦~ªº§ïµ½´Á¡A´Á©¡º¡«á¡A¤´¥¼§ïµ½ªÌ±N¥ý°±¤î¶R½æ¡A6 Ó¤ë«á¤´¥¼¯à«ì´_¶R½æªÌ³£±N²×¤î¤W¥«Âd¡C ®Ú¾Ú¥Ø«e³W©w¡A¤W¥«Âd¤½¥q°£¤F°]³ø¥¼¥æ¡B²bÈt¼Æ¤Î«Å¥¬«¾ãµ¥±ø¥ó¡A¨ÃµL¾A·íªº°h³õ¾÷¨î¡A¤£¹L¦³Y²Å¦X¸g¸³¨Æ·|¨Mij¡B³]¸m¯S§O©eû·|¡B©e½Ð¿W¥ß±M®aµû¦ô¤ÎªÑªF·|¨Mijµ¥¡u¤Tn¡v±ø¥ó¡A¤W¥«Âd¤½¥q¥i¦ÛÄ@¤U¥«Âd¡C ¨ÌÃÒ¨é¥æ©öªk³W©w¡A·í³Ìªñ´Á°]°È³ø§i¡A·|p®v¥X¨ãÄ~Äò¸gÀç¯à¤O¦s¦b«¤j¤£½T©w©Êªº¬d®Ö©ÎªÌ¨CªÑ²bȧC©ó 5 ¤¸³£·|¦C¤JÅܧó¥æ©ö¬°¹w¦¬´Ú¨é¡A¤@¯ëºÙ¥þÃB¥æ³Î¡C¦pªG²bȶi¤@¨B§C©ó¤T¤À¤§¤@¡]§C©ó 3 ¤¸¡^¡A´N·|µ¹¤©¹w¦¬´Ú¨é¥[¤W¤À½L¥æ©ö³B¸m¡C ¥t¥~¡A¨S¥æ°]³ø±N³B¥HªÑ²¼°±¤î¥æ©ö¡A6 Ӥ뤺¨S§ïµ½±N²×¤îªÑ²¼¶R½æ¡A¤]´N¬O¤U¥«¤UÂd¡C¦b¬J¦³³W©w¤¤¡A¥un°]³øÅã¥Ü²bÈt¼ÆªÌ¡A§Yª½±µ³B¥H¤U¥«¤UÂd¡A°ß³W©w¥²¶·¦b¹ê¬I¤é 40 ¤é«e¤½§i¡A¦]¦¹Âd¶R¤¤¤ß¤½§i¤U¥«Âd«áÁÙ¦³ 40 ¤Ñ¥æ©ö´Á¡C ÃÒ¥æ©Ò°ÆÁ`¸g²z³¯ÄRëªí¥Ü¡A¦Ò¶q³¡¤À¤W¥«¤½¥q¦]°]°È¤£¨Î¡A¦³Ã±ÃÒ·|p®v¥X¨ãÄ~Äò¸gÀç¯à¤O¦s¦b«¤j¤£½T©w©Ê¬d®Ö³ø§i¡A©Î²bȤw§C©ó°]°È³ø§i©Ò¦CªÑ¥»¤Q¤À¤§¤T¡]§Y¨CªÑ²bȧC©ó 3 ¤¸¡^µ¥±¡¨Æ¡A´N²Å¦XªÑ²¼¤U¥«°h³õ¾÷¨î¡C ³¯ÄRë«ü¥X¡A²Å¦X¤Wz¨âÓ±ø¥ó¤§¤@ªº¤W¥«¤½¥q¡A¸gÃÒ¥æ©Ò¹ï¤W¥«¦³»ùÃÒ¨é¦C¬°Åܧó¥æ©ö¤èªk©Î±Ä¦æ¤À½L¶°¦XÄv»ù¥æ©ö¤èªk¡A±©ªø´Á¥¼¯à§ïµ½¡A¹ï¾ãÅé¤W¥«¤½¥q«~½è¤Î§ë¸ê¤HÅv¯q«O»Ù¦³t±¼vÅT¡A¨M©w×¥¿ÃÒ¥æ©ÒÀç·~²Ó«h²Ä 50 ±ø¤Î²Ä 50 ±ø¤§ 3¡C |
|
|
·|û¡G§_¨ì©³°Õ10148994 µoªí®É¶¡:2020/3/20 ¤U¤È 07:18:21²Ä 2316 ½g¦^À³
|
·s¨îÁÙ¨S¹ê¬I¡A¦pªG4/1½T©w¹ê¬I¦A»¡ |
|
|
·|û¡G¦Ñ¯V10146717 µoªí®É¶¡:2020/3/20 ¤U¤È 05:49:14²Ä 2315 ½g¦^À³
|
¬Ý¨£¤µ¤Ñ¦U¦ìµ×^t³d¥ô¡B.¨Dª¾¡B¤£Âèpªººë¯«¡A¯u¥O¤H·P°Ê¡A·PÁ¦U¦ìªº¥I¥X¡A¦³§A̯u¦n |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/20 ¤U¤È 05:20:09²Ä 2314 ½g¦^À³
|
To T¤j, èè§Ú¥´¥h»OÆWÃÒ¨é¥æ©ö©ÒªÑ¥÷¦³¤½¥q°Ý¤F¡A¹q¸Ü¬O³o¤ä §ë¸ê¤HªA°È¤¤¤ß±M½u¡J(02)2792-8188 ±z¶Kªº¤½§i¬O¾A¥Î¤W¥«¤½¥q¡A¦ý¬O¨È·à±d¬O¤WÂd¤½¥q©Ò¥H¤£¾A¥Î¡C ©Ò¥H§Ú¤S¥´¥hÂd¶R¤¤¤ß¸ß°Ý±j¨î¤UÂdªº±ø¥ó¡A¹q¸Ü¬O³o¤ä §ë¸ê¤HªA°È±M½u:(02)2366-6100 ¥Ļiª¾±j¨î¤UÂdªº±ø¥ó´N¬O²bȬ°t¼Æ¡A¦]¬°¨È·à±d¨Ó¥xÆW¤WÂd¬O¥Î¬ì§Þ·s³Ð¨Æ·~¤WÂdªº¡A©Ò¥H·|¦³¤T¦~ªº½w½Ä´Á¡A¬G¨È·à±d¬O¦b2017/06/01¤WÂd¡A©Ò¥H´N¥²»Ý¦b2020/06/02³o¤Ñ«e¡A·Q¿ìªknÅý¤½¥qªº²bÈÅܬ°¥¿¼Æ¡A¤~¤£·|³Qn¨D±j¨î¤UÂd¡A©Ò¥H¥Ø«eÁÙ¬O¦³ºMÂdªº¦M¾÷¡A¥H¤W¬O§Ú¥»¤H¥´³o¨â¤ä¹q¸Ü¸ß°Ýªº¡C ¥t¥~¤§«eªk»¡·|³Å°õ¦æªø»¡ªº¡A¸U¤@ºMÂd·|Åý¥xÆWªº³oÃäªÑ²¼ÂনADR¡A¦]¬°·Qn½T»{¤½¥q¬O¾Ìþ¤@¶µªk³W¡A©Î¬O¥L̤§«eADRªº¥Ó½Ð¤å¥ó¤W±¦³´£¨ì¡A¥i¥H¦³³o¼ËÂà´«¡AÅܦ¨ì¥»³Q«H°UªºªÑ²¼®ø¥¢¤F¡A¦ÓADRÁÙ¥i¥HÄ~Äò¦s¦b¡A³oÂI§Ú쥻·Qn¦V¤½¥q°Q»¡ªk¬ÝþÃä¤å¥ó¦³´£¨ì¡A¦ý¬O¦¤W¸ò¤U¤È¥´¤F´X³q¹q¸Ü³£¨S¤H±µ¡A§Ú¥u¦nµ¥¤U§«ô¤@¦A¦V¤½¥q¨DÃÒ¤F¡A¥H¤W´XÂI»¡©ú¡C Thanks! |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/20 ¤U¤È 04:35:41²Ä 2313 ½g¦^À³
|
TO ¸¤H¤j §A°Ñ¦Ò³oÃä ÁÙ¦³ªþ¥óÀÉ®× !! www.twse.com.tw/zh/announcement/announcement_detail/2376A703512A11E9A1D8005056BE380E |
|
|
·|û¡Gmogwai10144017 µoªí®É¶¡:2020/3/20 ¤U¤È 04:35:09²Ä 2312 ½g¦^À³
|
ª¦¤F¤@¨Ç·s»D¡A¸¤H¤jÁ¿ªº¬Oì³W©w¡Atim¤jªº¬O·s¼Wªº¡C¨S¬Ý¨ì·s³W©w¨ú¥Nì³W©wªº·s»D¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/20 ¤U¤È 04:26:46²Ä 2311 ½g¦^À³
|
To timchan516¤j ½Ð°Ý§A»¡³o¨Ç¸ê°T¡A¦³±ø¤åªººô¯¸¥i¥H°Ñ¦Ò¶Ü? ¦]¬°§Ú¤§«e¬O¥´µ¹Âd¶R¤¤¤ßªººÊ²z³¡¡A¥L¬O³o¼Ë¦^§Úªº! Thanks, |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/20 ¤U¤È 03:28:46²Ä 2310 ½g¦^À³
|
¤£¹ïªü ¤w¤µ¦~3¤ë©³¤W¥«¤WÂd¤½¥qÀË°e¥h¦~ªº¦~³ø®É¡A¥un²Å¦X²bȹL§C(§C©ó¤T¶ô§tt¼Æ)©Î°]°È´c¤Æ ****** ´N¾A¥Î±j¨î°h³õ¾÷¨î : 1¦~·s³W½w½Ä + 3¦~°]°È§ïµ½ + 6Ӥ백¤î¶R½æ´Á§ïµ½ + 40¤Ñ¥æ©ö½w½Ä ****** ´N¤W±¸ÑÄÀ ¹ï©ó¨È·à±d ²bÈtÈ ¤£´N¬O¤W±ªº©w¸q !! |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/3/20 ¤U¤È 02:52:47²Ä 2309 ½g¦^À³
|
¨Ó¦Û¸gÀÙ¤é³øÃö©ó¤U¥«¨î«×¤Î¹ê¬Iªº³ø¾É,¤j®a°Ñ¦Ò¤@¤U~~ money.udn.com/money/story/5607/4187453 ¦ý³Ì®tªºª¬ªp´N¬O¤½¥q¨è·NÅý¥¦¤U¥«,§Æ±æ¤£·|³o¼Ë...¤£µM·s»D½Z¨è·N±j½Õ¥H¤U¬q¸Ü,Åý¤Hı±o¦Ñ·à¦b¥xÆW¥u·Q¼µ¨ì2020/6/1... (µM¨ÌÂd¶R¤¤¤ßÃÒ¨é°ÓÀç·~³B©Ò¶R½æ¦³»ùÃÒ¨é·~°È³W«h²Ä3±ø¤§1²Ä¤@¤WÂd¤½¥q·Ç¥Î¥»°ê¤WÂd¤½¥q ³W©w¡A¤Î²Ä12±ø¤§2²Ä1¶µ²Ä4´Ú¦ý®Ñ³W©w¡A´£¥Ü¥»¤½¥q©ó¤WÂdº¡¤T¦~¥H¤º¡A±o¤£¨ü ¸Ó´Ú©Ò³W©w³Ìªñ´Á°]°È³ø§iÅã¥Ü²bȬ°t¼ÆÀ³²×¤î¨ä¦³»ùÃÒ¨éÂdÂi¶R½æ¤§¨î¡C) |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/20 ¤U¤È 01:50:42²Ä 2308 ½g¦^À³
|
To timchan516¤j, §A»¡ªº¤è¼e¤U¥«¼Ð·Ç¨S¿ù¡A¤£¹L¨È·à±d²{¦bªº²bȤw¸g¤£¬O¤W©uªº2¶ô¦h¡A¦b¦~³ø¥X¨Ó«á¡A¦]¬°»{¦CµL§Î¸ê²£´î·l¡A©Ò¥H±b±¤W쥻¬OµL§Î¸ê²£ªº001»ùȬù7»õ¦h¥x¹ô¡A¦ý¬O¦]¬°¨â¦¸¸Ñª¼¥¢±Ñ¡A©Ò¥H³Q·|p®v»{¬°¤w¸g¨S¦³ì¥ýªº»ùÈ¡A©Ò¥H³o¦¸pºâ°]³ø±N¥¦¦©°£¡A¬G¨Ï±o¨È·à±d¤½¥qªº²bÈÂରt¼Æ¡A¤j¬ù¬Otªº¤@¤d¦h¸U¡A©Ò¥H´N²bÈ´N·|Åܦ¨-0.0X--0.1X¥ª¥k¡A´NÅܦ¨°]³ø¤½§iµ¹40¤Ñ¡AµM«á±j¨î¤U¥«¡A¦ý¬O¦]¬°¨È·à±d¤WÂd®É¶¡¥¼º¡¤T¦~¡An¨ì6/1¤~º¡¤T¦~¡A©Ò¥Hµ¥6/2®É¡AY¬O¨º®É¤½¥qªº²bÈÁÙµø¬°t¡A´N·|³Q±j¨î¤U¥«¤F¡C©Ò¥H¤~»¡¤½¥qn¦bµu®É¶¡»°§Ö¬Ý¥Î¨p¶Òªº¤è¦¡¶Ò¤@¨Ç¿ú¨ÓÅý¤½¥q¸ú¹L³o¦¸¦M¾÷¡A¤U¥b¦~¼Æ¾Ú¥X¨Ó¡A¦A¥h¥«³õ¶Ò¸ê´£¤É²bÈ¡A³o¼Ë¤~¤ñ¸û¦³¾÷·|²æÂ÷¥þÃB¥æ³Î¡C °Ñ¬ÝÃÒ¥æ©ÒÀç·~²Ó«h²Ä50¤§1±ø²Ä1¶µ²Ä9´Ú ¤E¡B¨ÌÃÒ¨é¥æ©öªk²Ä¤T¤Q¤»±ø³W©w¤½§i¨Ã¥Ó³ø¤§³Ìªñ´Á°]°È³ø§iÅã¥Ü¨ä²b Ȭ°t¼ÆªÌ¡C¸É¦æ¤½§i¨Ã¥Ó³ø¤§°]°È³ø§iÅã¥Ü¨ä²bȬ°t¼ÆªÌ¥ç¦P¡C ¤U±¬O¨ä¥¦ªº±ø¤å ²Ä 50-1 ±ø ¤W¥«¤½¥q¦³¤U¦C±¡¨Æ¤§¤@ªÌ¡A¥»¤½¥q¹ï¨ä¤W¥«¤§¦³»ùÃÒ¨é¡AÀ³¨ÌÃÒ¨é¥æ©ö ªk²Ä¤@¦Ê¥|¤Q¥|±ø³W©w²×¤î¨ä¤W¥«¡A¨Ã³ø½Ð¥DºÞ¾÷Ãö³Æ¬d¡G ¤@¡B¦³¤½¥qªk²Ä¤T¦Ê¤Q¤±ø²Ä¤@¶µ²Ä¤@´Ú¦Ü²Ä¥|´Ú³W©w±¡¨Æ¨Ã¿ì²z¸Ñ´²µn °O§¹¦¨ªÌ¡A©Î¦³¤½¥qªk²Ä¤E±ø¡B²Ä¤Q±ø¡B²Ä¤Q¤@±ø¡B²Ä¤Q¤C±ø²Ä¤G¶µ ¡B²Ä¤T¦Ê¤Q¤±ø²Ä¤@¶µ²Ä¤K´Ú¡B²Ä¤T¦Ê¤E¤Q¤C±ø¤Îª÷¿Ä±±ªÑ¤½¥qªk²Ä ¤G¤Q¤@±ø¡B¤¤Q¥|±ø³W©w±¡¨Æ¡A¸g¦³Ãö¥DºÞ¾÷ÃöºM¾P©Î¼o¤î¤½¥qµn°O ¡B©R¥O¸Ñ´²¡B¼o¤î³\¥i©Î¸gªk°|µô©w¸Ñ´²ªÌ¡C ¤G¡B¦³¤½¥qªk²Ä¤G¦Ê¤¤Q¤@±ø©Î²Ä¤G¦Ê¤C¤Q¤@±ø³W©w±¡¨Æ¡A©Î¨ä¥Lì¦]¸g ¦³Ãö¥DºÞ¾÷ÃöºM¾P¨ä®ÖãªÌ¡C ¤T¡B¸gªk°|µô©w«Å§i¯}²£¤w½T©wªÌ¡C ¥|¡B¸gªk°|µô©w㤩«¾ã½T©w©Î¨Ì¤½¥qªk²Ä¤G¦Ê¤K¤Q¤±ø¤§¤@²Ä¤T¶µ²Ä¤G ´Ú³W©w»é¦^«¾ã¤§Án½Ð½T©wªÌ¡C ¤¡B¡]¥»´Ú§R°£¡^ ¤»¡B¨ä¤W¥«¯S§OªÑµo¦æÁ`ÃB§C©ó·s¥x¹ô¤G»õ¤¸ªÌ¡C ¤C¡B¨ä¦³»ùÃҨ馳¤U¦C¦U¥Ø±¡¨Æ¤§¤@ªÌ¡G ¡]¤@¡^¸g¨Ì«e±ø³W©w¤©¥H°±¤î¶R½æ¡A³sÄòº¡¤»Ó¤ë«á¤´¥¼«ì´_¨ä¦³»ùÃÒ¨é ¤§¶R½æªÌ¡C¦ý¨Ì«e±ø²Ä¤@¶µ²Ä¤Q¥|´Ú³W©w°±¤î¶R½æªÌ¡A¤£¾A¥Î¤§¡C ¡]¤G¡^¸g¨Ì«e±ø²Ä¤@¶µ²Ä¤G´Ú³W©w¤©¥H°±¤î¶R½æ¥¼º¡¤»Ó¤ë¦Ó«ì´_¨ä¦³»ù ÃҨ餧¶R½æ¡A¨Ã©ó«ì´_¶R½æ«á¤»Ó¤ë¤º¤S¸g¨Ì«e±ø²Ä¤@¶µ²Ä¤G´Ú³W ©w¤©¥H°±¤î¶R½æ¡A¥B¨ä°±¤î¶R½æ¤§´Á¶¡¦X¨Öpºâ¶W¹L¤»Ó¤ëªÌ¡C ¤K¡B¦³ª÷¿Ä¾÷ºc©Úµ´©¹¨Ó¤§¬ö¿ý¡F©Î¦³«e±ø²Ä¤@¶µ²Ä¤Q´Ú±¡¨Æ¡A¥B¦Û°±¤î ¶R½æ¤§¦¸¤@Àç·~¤é°_¡A¤»Ó¤ë¤ºµLªk¹F¦¨²Ä¥|¤Q¤E±ø²Ä¤G¶µ²Ä¤E´Ú©Ò ¦C¤§¸É¥¿µ{§Ç¨ÃÀ˪þ¬ÛÃö®Ñ¥óÃÒ©úªÌ¡C¦ý¦Û°±¤î¶R½æ¤§¦¸¤@Àç·~¤é°_ ¡A¤TӤ뤺¥H©M¸Ñ¤è¦¡¨ú¦^²¼¾Ú¡A¨Ã¸gÀ˨ã©M¸Ñ®Ñ¡B²¼¾Ú¼v¥»¤Î¨ä¥L ¸ê®Æ¡A¦V¥»¤½¥q¥Ó½ÐªÌ¡A«e¶}°±¤î¶R½æ¤§´Á¶¡±o¦Û¥»¤½¥q®Ö㤧¤é°_ «¦æ°_ºâ¡A¨Ã¥H®i©µ¤@¦¸¬°¡C ¤E¡B¨ÌÃÒ¨é¥æ©öªk²Ä¤T¤Q¤»±ø³W©w¤½§i¨Ã¥Ó³ø¤§³Ìªñ´Á°]°È³ø§iÅã¥Ü¨ä²b Ȭ°t¼ÆªÌ¡C¸É¦æ¤½§i¨Ã¥Ó³ø¤§°]°È³ø§iÅã¥Ü¨ä²bȬ°t¼ÆªÌ¥ç¦P¡C Thanks! |
|
|
·|û¡G¿ûÅK¨k¤l10144826 µoªí®É¶¡:2020/3/20 ¤U¤È 12:29:06²Ä 2307 ½g¦^À³
|
·PÁÂtimchan516¤jªº¤À¨É |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/20 ¤U¤È 12:27:28²Ä 2306 ½g¦^À³
|
·PÁÂt¤j ªøª¾ÃѤF §Æ±æéw·à®¶§@ÂI |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/20 ¤W¤È 11:18:56²Ä 2305 ½g¦^À³
|
To ¸¤H¥d¯S ±z¤§«e¦³PO ¤µ¤Ñ§Ú¦³¥´¥hÂd¶R¤¤¤ß°Ý¡A°ò¥»¤W´N¬O¤½¥qn¦b2020/06/02±N¤½¥qªº²bÈ·Q¿ìªk¬Ý¬O¥Î¨p¶ÒÁÙ¬O²{¼W©Î¬O¥ô¦ó¤è¦¡±N¥LÂର¥¿ªº¡A³o¼Ë¤½¥q¤~¯àÄ~Äò¦b¥xÆW³oÃä¸gÀç¤U¥h¡A¦pªG¨S¦³Âd¶R¤¤¤ß´N·|µo¨çn¨D¤½¥qºMÂd¤F¡C ¦pªG¤WÂd¤Hû³o¼Ë¦^µª§A´N¥x¤£±M·~¤F !! ¦]¬°·s¨î«×¦p¤U ! ¡´ 쥻ªº¤U¥«¾÷¨î ¤W¥«Âd¤½¥q¸g°]°È¤½§i¡A¨CªÑ²bÈÂରtÈ«h±j¨î¤U¥«¡C ¡i¨CªÑ²bÈ = ¸ê²£´î¥ht¶Å¡A¦A°£¥H¤½¥qµo¦æÁ`ªÑ¼Æ¡j Y¨CªÑ²bÈÂରt¼Æ¡A¥Nªí¤½¥qªº¸ê²£¤w¸g¤p©ót¶Å¡A³o®a¤½¥qn±q¤ë¥ú±ÚÁÚ¦V¤J¤£¼Å¥X¡A²zÀ³¤U¥«¡I ¤£¹L¡AªÑ²¼¤U¥«¤UÂd¡]«UºÙÅܾÀ¯È¡^¹ï¤pªÑ¥Áªº¥´À»ÁÙ¬O¤Ó¤j¤F¡A©Ò¥H±q°]³ø¤½§i²bȬ°t¡AIJµo¤U¥«±ø¥ó¡A¨ì¹ê»Ú¤U¥«¡A¶¡¹jÁÙ¦³ 40 ¤Ñ½w½Ä´Á¡C ¨Ò¦p¡G¤j¦P¶°¹Î¸Ì±µ³sÃz¥X°]°È¦M¾÷ªººñ¯à¡A½T©w 5/2 ±j¨î¤U¥«¡FµØ¬M«h¬O³Ì±ß5/12±j¨î¤U¥«¡C ¡´ ©ñ¼e«á¤U¥«¾÷¨îªº¼Ð·Ç ©ñ¼e¼Ð·Ç¡G±q²bÈÂàt ¡÷ ²bȧC©ó 3 ¤¸ IJµo±ø¥ó¡G ¨CªÑ²bȧC©ó 3 ¤¸¥H¤U¡C ¸g·|p®v¥X¨ã¬d®Ö³ø§i¡GÄ~Äò¸gÀç¯à¤O¦s¦b«¤j¤£½T©w¦]¯À¡C ¤Wz¨â¶µ±ø¥ó¥X²{¨ä¤@¡A«h¡G Åܧó¥æ©ö¤è¦¡¬°¡i¥þÃB¥æ³Î¡j¡A»Ý¥ý¹w¦¬´Ú¨é¡A¤~¯à¥æ©ö¡C ¤À½L¥æ©ö ¡÷ ¶°¦XÄv»ù¡A5 ¤À¡B10 ¤À¡B15 ¤À¡B30 ¤À¡B45 ¤À¼¼¦X¤@½L¡C ´Á©ó 3 ¦~¤º§ïµ½°]°Èª¬ªp¡C ¤T¦~´Á¨ì¤F¤´¥¼§ïµ½¡A«ç»ò¿ì? Y 3 ¦~¨ì´Á¤´¥¼§ïµ½¡A¸ÓªÑ²¼°±¤î¥æ©ö¶R½æ¡C ¦Û°±¤î¥æ©ö¶R½æ°_¡AY 6 Ӥ를¤´«ì´_¶R½æ¡A²×¤î¤W¥«¤WÂd¡I ¦P¼Ë±q²×¤î¤W¥«¤WÂd¡A¨ì¹ê»Ú¤U¥«¤UÂd®É¶¡¤´¦³ 40 ¤Ñªº½w½Ä´Á¡C ©Ò¥H§Ų́Ӻâºâ¡AªÑ²¼ÅܾÀ¯Ènªá¦h¤[®É¶¡? ·sªk³W¤W¸ôÁÙ 1 ¦~ªº¾AÀ³½w½Ä´Á¡A¤]´N¬O±N±q 2020 ¦~ 4 ¤ë 1 ¤é¶}©l¹ê¬I¡C ©ú¦~ 3 ¤ë©³¤W¥«¤WÂd¤½¥qÀË°e¤µ¦~ªº¦~³ø®É¡A¥un²Å¦X²bȹL§C©Î°]°È´c¤Æ¡A´N¾A¥Î±j¨î°h³õ¾÷¨î¡C¦A¥[¤W¥»¤å«e¬q©Ò´£¨ìªº¬yµ{¡G 1 ¦~·s³W½w½Ä + 3 ¦~°]°È§ïµ½ + 6 Ӥ백¤î¶R½æ´Á§ïµ½ + 40 ¤Ñ¥æ©ö½w½Ä ¥Ø«eªÑ²¼¨ì¾À¯ÈªºÅܨ´Á¶¡¡AÁ`pn 4 ¦~¤S 7 Ó¤ë¤S 10 ¤Ñ¡C³o 4 ¦~ 7 Ó¤ë¤S 10 ¤Ñ®É¶¡¡A´Nn¿N»¬èë°]°È¯u¯à§ïµ½¡A¤£µM¥i¯à´N±o´î¸ê©Ô¤É²bȤF¡C |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/20 ¤W¤È 10:09:20²Ä 2304 ½g¦^À³
|
¦A¸É¤@Ӥ峹 !! n¶R¦a¹pªÑ¤]n°µ¤å³¹ªü !! ¬°´£¤É¤W¥«Âd¤½¥q«~½è¡BÁקK§ë¸ê¤H½ò¨ì¡u¦a¹pªÑ¡v¡AÃÒ¥æ©Ò¡u°h³õ¾÷¨î¡v±N±q109¦~4¤ë1¤é¹ê¬I¡A¦ý©Ò¿×ªº¹ê¬I¡AÃÒ¥æ©Ò«ü¥X¡A¬O«ü¨Ì108¦~«×°]³ø¤½§i²Å¦X¤U¥«¦W³æ¡A±µ¤U¨Ó·|¥ýµ¹¤©3¦~Æ[¹î´Á¡A¤§«á¦A¸g¹L¥b¦~¼È°±¥æ©ö¤´¥¼§ïµ½¤~·|¥¿¦¡¤U¥«¡A¦]¦¹¡A³Ì§Ön112¦~10¤ë1¤é¤~·|¦³¤½¥q¤U¥«Âd¡C ÃÒ¥æ©ÒÀÀqªº°h³õ¾÷¨î¡A¬O¥H¡u²Å¦XñÃÒ·|p®v¥X¨ãÄ~Äò¸gÀç¯à¤O¦s¦b«¤j¤£½T©w©Êªº¬d®Ö³ø§i¡A©Î¨CªÑ²bȧC©ó3¤¸ªº¥þÃB¥æ³ÎªÑ¡v±N¤U¥«¡A¨ÌÃÒ¥æ©Òºô¯¸¤½§i¡A¥H¤µ¦~¦Ü²Ä¤T©u¬°¤î¡A¦@¦³12®a¤W¥«¤½¥q²Å¦X¡A¦Ó¤WÂd¨ÌÂd¶R¤¤¤ßºô¯¸¤½§i¡A«h¦³12®a²Å¦X¡CÂd¶R«ü¥X¡A¥Ø«e²Ä¤T©u°]³ø²Å¦XíL«ÍªÑ¡A¶È¦³4®a¤WÂd¤½¥q¡C ÃÒ¥æ©Ò±j½Õ¡A©ú¦~3¤ë©³«e·|¥H108¦~«×¤½§i°]³ø¬°·Ç¡A¨Ã¥¿¦¡¹ï¥~¤½§i¦W³æ¡A¦ý·|¦Aµ¹¤©¤W¥«¤½¥q3¦~ªº½Õ¾ã¡AY©¡®É¥¼½Õ¾ã¡A±N¥¿¦¡¼È°±¥æ©ö¥b¦~¡AY³o¥b¦~¤º¥i§ïµ½¡A¤´¦³¾÷·|§K©ó¤U¥«¡AY³o¥b¦~¤º¥¼§ïµ½¡A´N½T©wn¤U¥«¡A¦ôp®É¶¡¬ù¸¨¦b112¦~10¤ë1¤é¥H«á¡C |
|
|
·|û¡Gtimchan51610148760 µoªí®É¶¡:2020/3/20 ¤W¤È 10:00:20²Ä 2303 ½g¦^À³
|
«ô°U¤£nÀ~¦Û¤v¦n¶Ü? ¤U¥«Âd±ø¥ó´N¨âÓ ²bȧC©ó¤T¶ô¿ú + ·|p®v»{¬°¦³¤£½T©w«¤j¦]¯À ¨âªÌ³£¤¤¤~·|¤UÂd ! ¬°¸Ñ¨M¥xªÑÂû³J¤ô»åªÑ¡]²bÈ·s¥x¹ô 3 ¤¸¥H¤U¡^°ÝÃD¡AÃÒ¥æ©Ò¤ÎÂd¶R¤¤¤ß¤w¬ãÀÀ¤U¥«Âd¾÷¨î! ¹L¥h¤½¥q²bȬ°t¼Æ¡A¤~·|n¨D²×¤î¤W¥«Âd¡A ¥¼¨Ó¹wp±N·s¼W¤U¥«Âd±ø¥ó¡A·|p®v»{¬°¦³¤£½T©w«¤j¦]¯À¡A¥H¤Î²bȧC©ó 3 ¤¸ªÌ¡A·|n¨D§ïµ½¡AY 3 ¦~¤º¤´µLªk§ïµ½¡A«h·|n¨D¦b¥b¦~«á¤U¥«Âd¡C Âd¶R¤¤¤ßÁ`¸g²z§õ·R¬Âªí¥Ü¡A±N»PÃÒ¥æ©Ò¦P¨B¹ê¬I¡A±ø¥ó©M¥æ©ö©Ò¤@P¡F¤]´N¬O»¡¡A°£¤F¥xÆW¦s°U¾ÌÃÒ¡]TDR¡^¥~¡A¥]¬A¤W¥«Âd¤Î²Ä¤@¤W¥«Âd¤@¥¹Ä²¤Î¨â¤j°h³õ¾÷¨î¤§¤@¡A±Nµ¹¤© 3 ¦~ªº§ïµ½´Á¡A´Á©¡º¡«á¡A¤´¥¼§ïµ½ªÌ±N¥ý°±¤î¶R½æ¡A6 Ó¤ë«á¤´¥¼¯à«ì´_¶R½æªÌ³£±N²×¤î¤W¥«Âd¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/3/20 ¤W¤È 08:47:30²Ä 2302 ½g¦^À³
|
www.marketwatch.com/investing/stock/asln |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/3/19 ¤U¤È 11:39:41²Ä 2301 ½g¦^À³
|
ÁÂÁ¦U¦ìªº¦^ÂÐ~ §Ú¤â¤W«ù¦³5X±iªº¨È·à±d §Æ±æ¤£nÅܾÀ¯È!!! |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/19 ¤U¤È 09:41:21²Ä 2300 ½g¦^À³
|
·à¤lªºÄw¸ê¯à¤O¤£ºâ¤Ó®t§a µLªk¦b¸ê¥»¥«³õ¤W¶Ò¨ì¿ú¡A°®¯Ü¶¶¶Õ³Q¢¤U¥« ¨º¤§«e·F¹ÀÁÙ²{¼W¡Aªá2.5¬ü¤¸¶Rªº¹ï¨R°òª÷¹³¼ï¥J ¤Ï¥¿¤]³Ñ¨S¦h¤[¤F ¨Ó¬Ý¬Ý·à¤l¬O°_¦º¦^¥Í¡AÁÙ¬O¤@©R¶ã©I |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/19 ¤U¤È 09:24:44²Ä 2299 ½g¦^À³
|
¬ü°ê¨é°Ó¤µ¤Ñªº¨È·à¥Ø¼Ð»ù5¬ü¤¸/ªÑ Pharmaceuticals (ASLN) Christine Brown- March 19, 2020, 8:06 AM EDT SHARE ON: In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals (ASLN), with a price target of $5.00. The company¡¦s shares closed last Monday at $0.94, close to its 52-week low of $0.35. According to TipRanks.com, Chen is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -19.0% and a 31.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, EyePoint Pharmaceuticals, and Stealth Biotherapeutics. Currently, the analyst consensus on Aslan Pharmaceuticals is a Moderate Buy with an average price target of $5.00. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/19 ¤U¤È 09:19:25²Ä 2298 ½g¦^À³
|
¥þ¥@¬É¨º¤@®a¤½¥q¯à¦b3Ó¤ë内¡A¦b¥«³õ¤W¶Ò资¡C ¨º´N¬O¶W¯Å¼F®`¡C©Î¶W¯Å²Â³J¤½¥q¡C¦b¥«³õ¤j±Y¼ìªº®ÉÔ¶Ò资¡C |
|
|
·|û¡Gjones10146258 µoªí®É¶¡:2020/3/19 ¤U¤È 08:36:01²Ä 2297 ½g¦^À³
|
¦pªGºMÂdÀ³¸Ó¬O¤£¯àª½±µÂà´«³á¡AADR¥s®ü¥~¦s°U¾ÌÃÒ¡A¤±iÂd¶R¤¤¤ß±¾µPªº¥xªÑªí¹ü¤@±i¬üªÑ¡A¦pªGºMÂd¡A´N¨S¦³±¾µPªº¥xªÑ¡A¦ÛµM¤]´N¤£·|¦³¬üªÑ¤F¡A©Ò¥H¦pªG¤U¥«À³¬O¨âÃä¦P¨B¤U¥«¡C¤£ª¾¹D¤½¥qn«ç»ò¨ó§U¥xÆWªÑªFÂà´«¦¨¬üªÑ¡A³oÀ³¸Ó¤£¬O¤½¥q¨ó§U¤£¨ó§Uªº°ÝÃD¡A¦Ó¬Oµ{§Ç¤W®Ú¥»¤£¥i¯à¡C ¤½¥q²{¦b°ò¥»¤W¤w¸g¨S¤°»ò»ùȤF¡A»{¤F2300¸Uª÷ªº·l¥¢¡A¥Nªí001¤wµL»ùÈ; 002¦´N¤w¸g¨S®ø¨S®§; 003¶i«×·s»D½Z¤]¨S´£¤F¡A¦ôp¤]¬O¨S¤F; ³Ñ¤@Ó004ÁÙ¨º»òearly¡A¦Ó¥B«á±n¥Iªº¨½µ{ª÷Åv§Qª÷¨º»ò¦h...±b¤W²ÖÁ«55»õ(Á«±¼¤TӪѥ»)¡A¬Ý¼Ë¤l¬Oª±§¹¤F...®ü¤ô°h¤F´Nª¾¹D½Ö¨S¬ï¿Ç¤l¡A²{¦b¤w¸g¬Ý¨ìªÑ·¾¤F¡AÀ³¸Ó¨SÔ£Äa©À¤F.... ¦pªG¤wµLªk¦b¸ê¥»¥«³õ¤W¶Ò¨ì¿ú¡A°®¯Ü¶¶¶Õ³Q¢¤U¥«¡A¤jªÑªFn±Ï¦A¨Ó±Ï´N¦n~~¦å¥»µLÂkªº¤pªÑªF¡A·Ç³Æ¦¨¥ß¦Û±Ï·|§a... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/19 ¤U¤È 08:19:52²Ä 2296 ½g¦^À³
|
³o°ÝÃD¥h¦~¦³ªÑªF°Ý¹L¤½¥q¡A¤½¥qµo¨¥¤H¦p¦¹¦^µª¡C ¸Ô²Ó½Ð¥´¹q¸Üµ¹¤½¥q°Ý¤@¤U¡A®Ú¾Ú¨º¤@±øADRªk«ß? |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/19 ¤U¤È 08:00:03²Ä 2295 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j ¬°¦ó¥xªÑ¤UÂd¡AADR¤]·|¤U¥«? ¨âÃä¹ï©ó²bȪº³W©w¨Ã¤£¬Û¦P§r ³ÌªñÁöµM¶^«Ü¤j ¦ý¬O½L¤¤¤£¥F±µ¤âªº¶q §Ú¥»¨ÓÁÙ¥H¬°¬O¹w´Á¥xªÑ¤UÂd¥i¥HÂàADRªº¶R½L |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/19 ¤U¤È 07:52:15²Ä 2294 ½g¦^À³
|
¬Ý3Ó aslan004 ªºÁ{§É¸ê®Æ ©M ¬Ý18ÓÁ{§É¸ê®Æ®t¦h¤Ö¡H §ÚÓ¤H»{¬°¤@¼Ë! ¦³®Ä 3Ó¤H´N¦³®Ä¤F¡C 200¤Hªº2bÁ{§É¡A¥i¬Ý§ó¦h¡A Ävª§¤O:Y¨C¤ë¤@°w¦¨¥\¡A´N»ùÈ«D¤Z¤F¡C 3Ó¤H¸ê®Æ¤w¯à¦b¥h¦~12¤ëADR ¡Aq»ù2.5 ¬ü¤¸/ªÑ¡C ªñ´ÁY¦A¨p¶Ò¡A¤½¥q¤º³¡¤w¦³§ó±jªº¸ê®Æ¡A¨â¤j¸³¨Æ ¡]·s¥[©Y°]¬F³¡&Àq§JÃļt)²zÀ³¥X§ó°ª»ù®æ¡A°Ñ»P¨p¶Ò¡C §_«h¤µ¦~Q3 ¡A¥t¼W¥[¨ì18¨Òªº´Á¤¤³ø§i¡An¶ÒADR¦h¤Ö³æ»ù¡H ¥xÆW¤U¥«¡A¬ü°êADR·|¦P®É¤U¥«¡I |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/3/19 ¤U¤È 07:37:59²Ä 2293 ½g¦^À³
|
ÁÂÁ¸¤H¤jªº°T®§,·à¤Į́¯W¤F....¥u¯à¨«¤@¨Bºâ¤@¨B¤F,¨S·Q¨ì³s¬Ý´Á¤¤¼Æ¾Úµ²ªG³£¤£¤Ó¦³¾÷·|¦b¥xÆWµo¥Í,¤w¦³ÅܾÀ¯Èªº³ÌÃa¥´ºâ..... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/19 ¤U¤È 07:37:00²Ä 2292 ½g¦^À³
|
Áp¨È¦¨¥\¶}µoªZº~ªÍª¢ÀË´ú¸Õ¾¯ ¬ü°ê¦P·N¨Ï¥Î ³Ì·s§ó·s¡G2020/03/19 14:55 ¡]¤¤¥¡ªÀ°OªÌ±i«Ø¤¤·s¦Ë19¤é¹q¡^ªZº~ªÍª¢¡]2019«aª¬¯f¬r¯e¯f¡ACOVID-19¡^¬Ì±¡ÄY®m¡AÁp¨È¥Í§Þ¶°¹Î¸g¹L2Ó¤ë§V¤O«á¡A¦¨¥\¶}µo¥X§ÜÅé¦å²GÀË´ú¸Õ¾¯¡A¤wÀò±o¬ü°ê¬ÛÃö³æ¦ì¦P·N¥iºò«æ¨Ï¥Î¡C Áp¨È¥Í§Þ¶°¹Î(UBI)¦¨¥ß©ó1985¦~¡A¥DnP¤O³z¹L¥D°Ê§K¬Ì©Î³Q°Ê§K¬Ì¾÷¨î¨Óµo²{¡B¶}µo©M°Ó·~¤Æ¥iÀ³¥Î©ó«¤jºC©Ê©M¶Ç¬V¯e¯fªº§K¬ÌªvÀø©M¬Ì]²£«~¡C1998¦~Àò¬F©²ÁܽСA¦X¸ê¦¨¥ßÁp¨È¥Í§Þ¶}µo¡AP¤O³æ®è§ÜÅé¡B³J¥ÕÃÄ«~¤Î¯S®í¾Ç¦WÃĶ}µo¡C ·s¦Ë¬ì¾Ç¶é°ÏºÞ²z§½¤µ¤Ñ¥l¶}°OªÌ·|¡AÁܽÐÁp¨È¥Í§Þ¶°¹Î¦bÀË´ú¸Õ¾¯µ¥¤è±ªº¬ãµo¦¨ªG¡C Áp¨È¥Í§Þªí¥Ü¡A2003¦~ÄY««æ©Ê©I§l¹D¯gÔ¸s¡]SARS¡^Ãzµo®É¡A´¿¹B¥Î¶°¹Îªº¦X¦¨肽¯f¬r§ÜÅéÀË´ú¸Õ¾¯§Þ³N¥¥x¡A¦b4Ӥ뤺³]p¥X¥i¥H¶EÂ_SARS¯f¬r·P¬Vªº§ÜÅéÀË´ú¸Õ¾¯¡C °w¹ï³o¦¸ªZº~ªÍª¢¡AÁp¨È¥Í§Þ«ü¥X¡A¸g¹L2Ӥ몺§V¤O¡A¤w³]p¥X¯f¬r§ÜÅé¦å²GÀË´ú¸Õ¾¯¡A¨Ã»P°ê»Ú¦X§@¹Ù¦ñ¶i¦æ¤j³W¼Ò´ú¸Õ¡A©ó16¤é¦V¬ü°êFDA¡]¬ü°ê¹«~º[ÃĪ«ºÞ²z§½¡^´£¥æºò«æ¨Ï¥Î«e±ÂÅv¥Ó½Ð®×¡C Áp¨È¥Í§Þªí¥Ü¡A¥Ø«e¤wÀò¬ü°ê¦P·N¥iºò«æ¨Ï¥Î¡A±N´£¨Ñ¤©¦è¶®¹Ï»Pª÷¤s½Ã¥Í³æ¦ì¶i¦æÀË´ú¡C Áp¨È¥Í§Þ¦P®É°w¹ïªZº~ªÍª¢¶}µo°ªºë·Ç³]p«¬¬Ì]¡B¦¸³æ¦ì¬Ì]»P³J¥Õ½èÃÄ¡A´Á¯à´£¨Ñ¥þ¤è¦ì¸Ñ¨M¤è®×¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/19 ¤U¤È 02:24:12²Ä 2291 ½g¦^À³
|
ÁÂÁ¸¤H¤j¤@ª½À°¤j®a°lÂÜ ¥un½T©w¥xªÑ³oÃäY¤UÂd¯àÂà¨ìADR¡Aµ´¹ï¬O¾¯±j¤ß°w ¦]¬°¤j®a³Ì©ÈªºÁÙ¬O¤UÂd¦å¥»µLÂk §Æ±æ¤½¥q¯à»¡©ú³o³¡¤À |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/19 ¤U¤È 12:34:57²Ä 2290 ½g¦^À³
|
To ¦U¦ì·à¤Í, ¤µ¤Ñ§Ú¦³¥´¥hÂd¶R¤¤¤ß°Ý¡A°ò¥»¤W´N¬O¤½¥qn¦b2020/06/02±N¤½¥qªº²bÈ·Q¿ìªk¬Ý¬O¥Î¨p¶ÒÁÙ¬O²{¼W©Î¬O¥ô¦ó¤è¦¡±N¥LÂର¥¿ªº¡A³o¼Ë¤½¥q¤~¯àÄ~Äò¦b¥xÆW³oÃä¸gÀç¤U¥h¡A¦pªG¨S¦³Âd¶R¤¤¤ß´N·|µo¨çn¨D¤½¥qºMÂd¤F¡C µM«á§Ú¤µ¤Ñ¦³¥´¥h¤½¥q¡A¸ß°Ý¤T¥ó¨Æ±¡¡C 1. 001¦]¬°¨â¦¸¸Ñª¼¥¢±Ñ©Ò¥H³Q¦C¬°µL§Î¸ê²£´î·l¡A¦Ó¤½¥qªº¸ê²£´N¦©°£2300¸U¬üª÷³y¦¨¤½¥qªº²bÈÅܦ¨t¼Æ¡A¦ý¬O¦]¬°2020¦~¤½¥q¨Ã¥¼¥´ºâ¹ï001¦³¥ô¦ó¨ä¥Lªº¶}µo°Ê§@¡A©Ò¥H¨Ì³y·|p·Ç«h¥²¶·´£¦C¬°¸ê²£´î·l¡AY¬O¤§«á001¦³¨ä¥Lªº«áÄò¶}µo¹³¤§«e»¡ªº¤p³¡¤À¯S®í±Ú¸sªº¤G½uÁx¹DÀù³o¶ô¡A´N·|¹ï001«·s¶i¦æµû¦ô»ùȪº°Ê§@¡A¦ý¬O¦]¬°¤µ¦~³£¨S¦³³oÓ¥´ºâ©Ò¥H¥u¯à´£¦C´î·l¡C 2. ¥i§_½Ð¤½¥q´£¤@Ó¶Ò¸êpµe¤Î®É¶¡ªí¡A¦]¬°¥²¶·¦b¤µ¦~6/1¦~±N¤½¥qÂॿ¡A©Ò¥H¸ß°Ý¤½¥q¥Ø«e¥i¯à·|¶i¦æªº¶Ò¸êpµe¦³þ¨Ç? ®É¦¨¬°¦ó? ½Ð¤½¥q»¡©ú! 3. ´N¬O°²³]¤£©¯¤½¥q¦b¥xÆW³oÃäºMÂd¤F¡A¨Ì·Ó¥h¦~ªk»¡·|¤W³Å«i°õ¦æªø©Ò»¡ªº¡A·|¨ó§U¥xÆW³oÃ䪺§ë¸ê¤H±N¥xªÑÂà´«¬°ADR¡AY¬O¤£·QÂà´«ªº·|¥Î²{»ù¶R¦^¡A³oÓ»¡ªk¬O§_¦³¤å¥ó©Î¬O¤w¸g¦³«ß®v¤ÎADR¦s°U»È¦æªºI®ÑÃÒ©ú¬O¥i¦æªº¡A¦Ó¤£¬OªÅ¤f»¡¥Õ¸Ü¡A½Ð¤½¥q´£¨Ñ¤å¥óµ¹§ë¸ê¤H°Ñ¦Ò¡C ¥H¤W¬O§Ú¤µ¤Ñ¥´¥hÂd¶R¸ò¤½¥q©Ò´£¤Îªº¸ê°T¡A½Ð¤j®a°Ñ¦Ò¡C §Ú¥u¯à»¡¤@¶¡¤½¥q·d¨ì²bÈÅܦ¨tªº¡A¯uªº«Ü¤£À³¸Ó¡A¦Ó¥B³oÓµL§Î¸ê²£´î·l¡A¬O¥h¦~11¤ë¸Ñª¼¥¢±Ñ¡A´N¦³¥i¯àµo¥Í¡A¥u¬O¤½¥q¨º®ÉԨ弧iª¾§ë¸ê¤H¥i¯à·|³o¥ó¨Æ±¡µo¥Í¡Aµ²ªG§¹¦¨²Ä¤G¦¸µo¦æADR«á¡A¤Ï¦Ó²bȨS´£¤ÉÁÙ´î¤Ö¡A¯uªº¬O¦³ÂI¸Ø±i¡A¥H¤W¤@¨Ç·N¨£¤Î¬Ýªk¡A½Ð¤j®a°Ñ¦Ò¤F¡A¦V¤½¥q¸ß°Ýªº¤TÂI§Ú·|«ùÄò°lÂÜ¡A¦³·sªº®ø®§·|¦A¸ò¤j®a³ø§i¡C Thanks! |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/3/19 ¤W¤È 11:23:32²Ä 2289 ½g¦^À³
|
¦]¬°¤]¤£¬O¨CÓ¤H³£·|¥h¶}¬üªÑ¥æ©ö±b¤á §Ú¬Oı±oÂàADRªº¥i¯à©Ê«Ü§C ¦]¬°ÁÙ¬O±o¯u¹ï¤£·|Âಾªº¤H¥h¦Ò¼{!!Ãø«×¦³ÂI°ª ½Ð°Ý¥xªÑ³o»ò¦h¦~¨Ó¦³³oӮרҶÜ? |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/19 ¤W¤È 11:15:30²Ä 2288 ½g¦^À³
|
¯àÂàADRªº¸Ü¡A¶}¬üªÑ¥æ©ö±b¤á´N¦n¤F |
|
|
·|û¡G¦V¤Ñ10149121 µoªí®É¶¡:2020/3/19 ¤W¤È 11:08:02²Ä 2287 ½g¦^À³
|
½Ð°Ý¦U¦ì¤j¤j: ¨È·à±d¦pªG5¤ë©³¨S¿ìªkÅý²bÈÂॿ ¤UÂdÅܾÀ¯Èªº¾÷·|¤j¶Ü? Âà¬üªÑADR¥i¯à©Ê¤j¶Ü? ½Ð°ÝY¦¨¥\Âà¬üªÑADR¤§«án¦p¦ó¥æ©ö? ÁÂÁ¦^µª!! |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2020/3/19 ¤W¤È 08:41:28²Ä 2286 ½g¦^À³
|
¨S¦³³ÌºG ¥u¦³§óºG ªÅ¦³²z·Q °Â¸Ì¤]ªÅ ·PÁ¤]°µ¤F2¦~ªº¤j¹Ú ·PÁ¨ȷà±dªº¤@¤Á |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/18 ¤U¤È 08:17:50²Ä 2285 ½g¦^À³
|
¨Ì¥xÆW¤½¥qªk 2020¦~5¤ë31¤é«e¡A¥²¶·¼W¸ê¨Ï²bȤj©ó¹s¡AÁקK¾D²×¤î¤WÂd¡C 2¤ë26¤é¤w¶}§¹ªÑªF·|³q¹L¼W¸ê®×¡A3¤ë26¤é²zÀ³¨ú±oÃÒ´Á·|®Öã. ¥Ñ©ó¬ü°ê¬Ì±¡ADR¥«³õ¤£¨Î¡A´Á¤¤³ø§i¤½¥q«Å¥¬aslan004²Ä¤T¾¯600mg/°w¡A°µ§¹¡A¦b¤µ¦~²Ä¤T©u¤½¥¬´Á¤¤³ø§i¡A ¥Ø«e¦b5¤ë©³¥H«e¯à°µªº¡A¨Ì¾ÚªÑªF·|¨Mij: ´N¬O§ä¨â¦ì¸³¨Æ¶i¦æ¨p¶Ò¤F¡C ¥t¥~¦b¤µ¦~²Ä¤T©u«á¡A¦Aµo¦æADR¡A¨Ó°µASLAN004 ªº2bÁ{§É¤F¡C(¦ôp200~250¤H) ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¥t¥~²Ä¤G¾¯400mg/²Ä¤T¾¯600mg ,¬Ý¦ü«Ü°ª¡A¦ý¨Ì¤½¥qp¹º¤@Ӥ르¤@°w¡A´N¦X²z¤F¡C ²Ä¤G´ÁÁ{§É¶}©l´Nª¾¡C¤½¥qªºp¹º¤F¡C ¨S¿ìªk¹J¨ìCOVID-19 ¥þ²y¤j¬y¦æ¡C ¥H¤W¬OÓ¤HªºÆ[¹î ¡X¡X¡X¡X¡X¡X 1.ªÑªFÁ{®É·|¤é´Á:109/02/26 2.«n¨Mij¨Æ¶µ: °Q½×¨Æ¶µ ¡@ (1)³q¹L¥»¤½¥q¿ì²z²{ª÷¼W¸êµo¦æ´¶³qªÑ°Ñ»Pµo¦æ®ü¥~¦s°U¾ÌÃҩοì²z°ê¤º²{ª÷¼W¸ê µo¦æ´¶³qªÑ®×¡C (2)³q¹L¥»¤½¥q¿ì²z¨p¶Ò´¶³qªÑ©Î®ü¥~¦s°U¾ÌÃҮסC 3.¨ä¥LÀ³±Ô©ú¨Æ¶µ: ¥»¤½¥q¦^ÂЧë«O¤¤¤ß¤ÎÂd¶R¤¤¤ß¨Ó¨ç¡A¦³Ãö¨p¶Ò´¶³qªÑ©Î®ü¥~¦s°U¾ÌÃҮפ§»¡©ú¡A ½Ð¸Ôij¨Æ¿ý©Î¤½¶}¸ê°TÆ[´ú¯¸¤§¨p¶Ò±M°Ï¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/18 ¤U¤È 08:12:57²Ä 2284 ½g¦^À³
|
²bÈÅÜtªº pµe²Ä¤T¾¯¶q±Ú¸s¸ÕÅçµ²§ô«á¤½¥¬¥þ³¡¤TÓ¾¯¶q±Ú¸sªº¸Ñª¼¼Æ¾Ú¡A¦Ó¤£¬O¦b²Ä¤G¾¯¶q±Ú¸s¸ÕÅçµ²§ô«á¤½¥¬ éw·à§Æ±æ¬O§QªÅ¥XºÉ... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/18 ¤U¤È 07:32:48²Ä 2283 ½g¦^À³
|
¡X¡X¡X¡X¡X¡X¡X¡X¡X ¸ê®Æ¥Ñ¡@(¤WÂd¤½¥q) ¨È·à±d-KY ¡@¤½¥q´£¨Ñ §Ç¸¹ 4 µo¨¥¤é´Á 109/03/18 µo¨¥®É¶¡ 15:32:09 µo¨¥¤H ³Å«i µo¨¥¤H¾ºÙ °õ¦æªø µo¨¥¤H¹q¸Ü +65 6222 4235 ¥D¦® ¥»¤½¥q¥N·s¥[©Y¤l¤½¥qASLAN Pharmaceuticals Pte. Ltd. ¤½§i¨Ì°ê»Ú·|p·Ç«h²Ä36¸¹»{¦CµL§Î¸ê²£´î·l ²Å¦X±ø´Ú ¡@²Ä 53 ´Ú ¨Æ¹êµo¥Í¤é 109/03/18 »¡©ú 1.¨Æ¹êµo¥Í¤é:109/03/18 2.¤½¥q¦WºÙ: ASLAN Pharmaceuticals Pte. Ltd. 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¤l¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:100% 5.µo¥Í½t¥Ñ: (1)¥»¤½¥q®Ú¾Ú°ê»Ú·|p·Ç«h²Ä36 ¸¹¤½³ø³W©w¡A©ó¸ê²£t¶Åªí¤é°õ¦æ¸ê²£´î·lµû¦ô ´ú¸Õ¨Ã¸g·|p®v¬d®Ö§¹µ¤¡C©ó108¦~²Ä¥|©u°w¹ïVarlitinib§Þ³N±ÂÅv»{¦CµL§Î ¸ê²£´î·l·l¥¢ª÷ÃB¦@p¬üª÷23,000 ¥a¤¸¡]·s¥x¹ô709,499¥a¤¸¡^¡A¬ÛÃö¼Æ¦r±N ¤Ï¬M©ó108¦~«×°]°È³øªí¡C (2)¥»¤½¥q©ó108¦~11¤ë11¤é«Å¥¬Varlitinib°w¹ïÁx¹DÀù¤§¥þ²y©Ê¼Ï¯Ã¸ÕÅçTreeTopp ªºÁ{§É¸ÕÅçµ²ªG¡A¸Ó¬ã¨s¨Ã¥¼¹F¨ì¦@¦P¥Dnµû¦ô«ü¼Ð¡C°ò©ó¸Ó¹êÅ礧µ²ªG¤Î ¸ê·½°t¸m¡A¥»¤½¥q¨M©w¼È°±¹ïVarlitinib¶i¤@¨B¶}µo»P§ë¸ê¡A¨Ã¹w´ÁVarlitinib ©Ò²£¥Í¤§¥¼¨Ó²{ª÷¬y¶qª÷ÃB±N·|´î¤Ö¡C¬G©ó¸ê²£t¶Åªí¤é°w¹ïVarlitinib¶i¦æ¡@ ¥i¦^¦¬ª÷ÃB¤§µû¦ô¡A¥i¦^¦¬ª÷ÃB¬°¤½¤¹»ùÈ´î¥X°â¦¨¥»»P¨ä¨Ï¥Î»ùȤ§¸û°ªªÌ¡A ¨Ï¥Î»ùÈ«h¬O®Ú¾Ú¥¼¨Ó²{ª÷¬y¶q§é²{¦Ó±o¡C¸g¥Ñ¤WzµL§Î¸ê²£´î·l´ú¸Õ¡A½T©w ¨ä±b±»ùȤw¶W¹L¥i¦^¦¬ª÷ÃB¡A¬G¤©¥H¥þ¼Æ»{¦C´î·l·l¥¢p¬üª÷23,000¥a¤¸ ¡]·s¥x¹ô709,499¥a¤¸¡^¡C Áö¥»¤½¥q¥i¯à¦b±N¨Ó¨M©w¹ïVarlitinib¶i¦æ±´¯Á©Ê¬ã¨s¡A¦ýºI¦Ü¥Ø«e¨Ã¤£¹wp¹ï Varlitinib«ùÄò§ë¤J¸êª÷¡A¨ÃµLªk«OÃÒ¥¼¨Ó¦³¨ä¸ê·½©µÄò¶}µo¡A¬G¨Ì¾Ú¬ÛÃö·|p ·Ç«h³W©w¤©¥H»{¦C«ez´î·l·l¥¢¡C (3)¥»¤½¥q¸³¨Æ·|·~¤w³q¹L¤Wzµû¦ô¨Ã¨Mij³q¹L©ó108¦~«×»{¦C¸Ó¶µ«¤jµL§Î¸ê²£´î·l ·l¥¢¡C 6.¦]À³±¹¬I:µL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¥»¦¸¶È´N±b¦CµL§Î¸ê²£¨Ì¾Ú·|pì«h»{¦C«D²{ª÷´îÈ·l¥¢¡A¸Ó¶µ·l¥¢»{¦C¤£¼vÅT ²{ª÷¬y¶q¡A¥B¹ï¥»¤½¥q¥DnÀç¹B¶µ¥Ø¨ÃµL«¤j¼vÅT¡C ºI¦Ü108¦~12¤ë31¤é¡A¥»¤½¥q±b¤W²{ª÷¤Î¬ù·í²{ª÷¾lÃB¬°¬üª÷22,000 ¥a¤¸ ¡]·s¥x¹ô665,050¥a¤¸¡^¡C (2)¥»¤½¥q°_ªì«Y¨Ì°]¹Îªk¤H¤¤µØ¥Á°êÃÒ¨éÂdÂi¶R½æ¤¤¤ß¡]¥H¤U²ºÙÂd¶R¤¤¤ß¡^ ¥~°ê¦³»ùÃÒ¨éÂdÂi¶R½æ¼f¬d·Ç«h²Ä4±ø²Ä4¶µ¥Ó½ÐªÑ²¼¬°ÂdÂi¶R½æ¤§²Ä¤@¤WÂd¤½¥q¡A ¨Ã©ó106¦~6¤ë1¤é±¾µP¤WÂd¡C¨Ì¾Ú¥»¤½¥q108¦~«×°]°È³ø§iÅã¥Ü¡A ºI¦Ü108¦~12¤ë31¤é¥»¤½¥q²bÈÁö¬°t¼Æ·s¥x¹ô18,070¥a¤¸¡AµM¨ÌÂd¶R¤¤¤ß ÃÒ¨é°ÓÀç·~³B©Ò¶R½æ¦³»ùÃÒ¨é·~°È³W«h²Ä3±ø¤§1²Ä¤@¤WÂd¤½¥q·Ç¥Î¥»°ê¤WÂd¤½¥q ³W©w¡A¤Î²Ä12±ø¤§2²Ä1¶µ²Ä4´Ú¦ý®Ñ³W©w¡A´£¥Ü¥»¤½¥q©ó¤WÂdº¡¤T¦~¥H¤º¡A±o¤£¨ü ¸Ó´Ú©Ò³W©w³Ìªñ´Á°]°È³ø§iÅã¥Ü²bȬ°t¼ÆÀ³²×¤î¨ä¦³»ùÃÒ¨éÂdÂi¶R½æ¤§¨î¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/18 ¤U¤È 05:43:55²Ä 2282 ½g¦^À³
|
·s»D½Z ¨È·à±d-KY ¤½¥¬ 2019 ¦~²Ä¥|©u©M¥þ¦~«×°]°È·~ÁZ¤Î§ó·s¤½¥qªñªp 2020 ¦~ 3 ¤ë 18 ¤é¡A·s¥[©Y ¡V »EµJ©óÁ{§É¶¥¬q¸~½F¤Î§K¬Ì¾Ç¤§Á{§É¶¥¬q¥Íª«»sÃĤ½¥q¨È·à±d-KY (NASDAQ:ASLN, TPEx:6497)¤µ¤é¤½§GºI¦Ü 2019 ¦~ 12 ¤ë 31 ¤é¤§©u«×©M¥þ¦~«×°]°È³ø§i¡A¥H¤Î³Ì·sÁ{§É¬ãµo¶i«×¡C ¨È·à±d-KY °õ¦æªø³Å«i³Õ¤hªí¥Ü:¡u2019 ¦~¹ï¨È·à±d¨Ó»¡¬O·¥¨ãÅܲªº¤@¦~¡A§Ú̱N¬ãµo¤u§@»EµJ©ó·¥¨ã¼ç¤O ªº ASLAN004¡A¦¹¶µÃĪ«µ²¦X IL-13 ¨üÅé £\1 ¦¸³æ¦ì(¥çºÙ¬° IL-13R£\1)¤§¥þ¤H·½³æ®è§ÜÅé¥i¥H¥Î¨ÓªvÀø²§¦ì©Ê¥Ö ½§ª¢¤Î®ð³Ý¡C¥h¦~ 12 ¤ë¤½¥¬°w¹ï²§¦ì©Ê¥Ö½§ª¢¦h¾¯¶q»¼¼WÃĪ«´ú¸Õªº¼Æ¾Ú«D±`¥O¤H®¶¾Ä¡Aªì´Á¸ñ¶HÅã¥Ü¨ã¦³ Àø®Ä¥B°Æ§@¥Î§C¡A§Ú̬۫HASLAN004¨ã¦³¼ç¤O¦¨¬°ªvÀø²§¦ì©Ê¥Ö½§ª¢ªº³Ì¨ÎÃĪ«¡C¥Ø«e²Ä¤G¾¯¶q±Ú¸sªº¨ü¸Õ ªÌ©Û¶Òª¬ªp¨}¦n¡A§ÚÌp¹ºµ¥¨ì²Ä¤T¾¯¶q±Ú¸s¸ÕÅçµ²§ô«á¤½¥¬§¹¾ãªº¸Ñª¼¼Æ¾Ú¡A¦Ó«D¦b²Ä¤G¾¯¶q±Ú¸s¸ÕÅçµ² §ô«á¤½¥¬ª¼¼Æ¾Ú¡C¤½¥qªñ´Á¨j§¹¦¨ªº²{ª÷¼W¸ê¹ï§Ú̧¹¦¨¤Wz¬ãµo¶iµ{³þ©w¤F¨}¦n°ò¦¡A¦P®É§Ú̷dzƦb 2021 ¦~ªì±Ò°Ê²Ä 2b ´Á¬ã¨s¡A§@¬° ASLAN004 ¬ãµopµeªº¤U¤@¨B¡C¡v 2019 ¦~²Ä¥|©u©Mªñ´Á·~°È«GÂI Á{§É¬ã¨sµo®i ASLAN004 • ¦b¦¨¥\§¹¦¨°·±d§ÓÄ@¨ü¸ÕªÌªº³æ¤@¾¯¶q»¼¼WÁ{§É¸ÕÅç«á¡A¤w©ó 10 ¤ë¶}©lÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯¹ï·Óªº ¦h¾¯¶q»¼¼WÃĪ«¸ÕÅç¡Aµû¦ô 3 ºØ¤£¦P¾¯¶qªºASLAN004¡]200mg ¨ì600mg¡^ªvÀø¤¤«×¦Ü««×²§¦ì©Ê¥Ö½§ ª¢¯f±w¤§®ÄªG¡C • 12 ¤ë«Å¥¬²Ä¤@§å¯f±w±µ¨ü ASLAN004 ªvÀøªºªì¨Bµ²ªG¡A¦b§C¾¯¶q±Ú¸s¤¤Åã¥Üªì¨BÀø®Ä¡C¦bÀ˵ø©|¥¼¾ã ²zªºª¼¼Æ¾Ú®Éµo²{¡A3 ¦W¤w±µ¨ü¦Ü¤Ö¤@Ӥ뵹ÃĪº¯f±w¡A¨äÀã¯l±¿n©MÄY«µ{«×«ü¼Æ(EASI)µû¤À¤À§O¤U ° 85%¡B70%©M 59%¡A¦P®É EASI µû¤À¦b²Ä 4 ¶g«ùÄò¤U°¡A¹w´Á¦b 6 ¨ì 8 ¶g¥i¹F¨ì³Ì¤jÀø®Ä¡C • ¦b 12 ¤ë¤U¦¯»PÁ{§É¸ÕÅç¼Æ¾ÚºÊ¬d©eû·|·|ij«á¡A²Ä¤G¾¯¶q±Ú¸s¤w¶}©l©ó·s¥[©Y©Û¶Ò¨ü¸Õ¯f±w¡C¥Ø«e ¬Ý¨Ó©Û¶Ò±¡ªp¨Ã¥¼¨ü COVID-19 ¤j¬y¦æ¼vÅT¡A¸ÕÅ礴¥i±æ¦b 2020 ¦~¤U¥b¦~§¹¦¨¡C¨È·à±d-KY pµeµ¥¨ì ²Ä¤T¾¯¶q±Ú¸s¸ÕÅçµ²§ô«á¤½¥¬¥þ³¡¤TÓ¾¯¶q±Ú¸sªº¸Ñª¼¼Æ¾Ú¡A¦Ó¤£¬O¦b²Ä¤G¾¯¶q±Ú¸s¸ÕÅçµ²§ô«á¤½¥¬ ª¼¼Æ¾Ú¡C¨È·à±d-KY ¹wp¦b 2020 ¦~²Ä¤T©u¤½¥¬´Á¤¤¸Ñª¼¼Æ¾Ú¡A¨Ã¿ï¾Ü³Ì¦³®Äªº¾¯¶q¶i¦æÀø®ÄÂX¼W±Ú¸s ¸ÕÅç¡C ASLAN003 • ©ó¡mHaematologica Journal¡n´Á¥ZµoªíªºÁ{§É«e¼Æ¾ÚÅã¥Ü ASLAN003 ¦³¼ç¤O¦¨¬°±j®Äªº¤G²B¨Å²M»Ä²æ²B 酶(DHODH)§í¨î¾¯¡A¥H¤Î§C¬r©Ê¤À¤ÆÀøªkªº·s¼Ð¹v¡C AhR «ú§Ü¾¯ • ¨È·à±d-KY ©ó 9 ¤ë±N AhR «ú§Ü¾¯¬ÛÃö¸ê²£¤§¥þ²y©Ò¦³Åv§QÂàÅýµ¹¨È·à±d-KY ©M Bukwang Pharmaceutical ¦@¦P¦X¸ê¦¨¥ßªº¤½¥q JAGUAHR Therapeutics¡A¸Ó¶µ aryl hydrocarbon receptor AhR «ú§Ü¾¯³Ìªì«Y¥Ñ¨È·à ±d-KY »P¨ä¦X§@ªÌ¦@¦Pµo²{¤Î¶}µo¡C • JAGUAHR ¤½¥q±NP¤O©ó¿ëÃѤζ}µo¼ç¦b¥ý¾É¤Æ¦Xª«¥H¶}µo°w¹ï AhR ¶Ç»¼¸ô®|ªº¥þ·s¸~½F§K¬ÌÀøªk¨Ã´£ ¥æ·sÃÄÁ{§É¸ÕÅç¥Ó½Ð(IND)¡CBukwang ¤½¥q±N¤À¨â±è¦¸¦V JAGUAHR ¤½¥q§ë¸êÁ`ÃB¦@ 5¦Ê¸U¬ü¤¸§@¬°¬ÛÃö ¸ê²£¬ãµo¸êª÷¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/18 ¤W¤È 10:00:13²Ä 2281 ½g¦^À³
|
ºî¦X´CÅé³ø¾É¡A¤¤°ê¬ì§Þ³¡¥Íª«¤¤¤ß¥D¥ô±i·s¥Áªí¥Ü¡Aªkºû©Ô³¤w¦b²`¦`¥«²Ä¤T¤H¥ÁÂå°|¤ÎªZº~¤j¾Ç¤¤«nÂå°|¦@¦³200¨ÒªºÁ{§ÉªvÀø¹ï·ÓÆ[¹î¡A¦b¯f¬r®Ö»ÄÂà³±¤è±¡AÂà³±®É¶¡¤¤¦ìÈ©úÅãÁYµu¡A¤À§O¬°4¤Ñ©M11¤Ñ¡A¨ã¦³ÅãµÛ®t²§¡C¦b¯Ý³¡¼v¹³¾Ç§ïµ½¤è±¡A»P¹ï·Ó²Õ¬Û¤ñ¡A§ïµ½²v¤À§O¬°91.43%©M62.22%¡C 2020-03-18 07:57:03 ¡e§Y®É·s»D¡þºî¦X³ø¾É¡f·s«aª¬¯f¬r¡]COVID-19¯f¬r¡AªZº~ªÍª¢¡^¬Ì±¡½¯©µ¥þ²y¡A¥þ²y¬ì¾Ç®aÄvÁɧä´MªvÀø¤èªk¡A¤¤°ê¬ì§Þ³¡¬Q¤Ñ¦b°ê°È°|ªº°OªÌ·|¤W«Å¥¬¡A¤w¸g§ä¨ì¨ã¦³Àø®ÄªºÃĪ«ªkºû©Ô³¡]Favipiravir¡^¡A¦]¬°Á{§É¹êÅç¨}¦n¡A¤w®i¶}¶q²£¡A«Øij±N¨ä¯Ç¤J¤¤°êªvÀøªZº~ªÍª¢ªº¶EÀø¤è®×¤¤¡C ºî¦X´CÅé³ø¾É¡A¤¤°ê¬ì§Þ³¡¥Íª«¤¤¤ß¥D¥ô±i·s¥Áªí¥Ü¡Aªkºû©Ô³¤w¦b²`¦`¥«²Ä¤T¤H¥ÁÂå°|¤ÎªZº~¤j¾Ç¤¤«nÂå°|¦@¦³200¨ÒªºÁ{§ÉªvÀø¹ï·ÓÆ[¹î¡A¦b¯f¬r®Ö»ÄÂà³±¤è±¡AÂà³±®É¶¡¤¤¦ìÈ©úÅãÁYµu¡A¤À§O¬°4¤Ñ©M11¤Ñ¡A¨ã¦³ÅãµÛ®t²§¡C¦b¯Ý³¡¼v¹³¾Ç§ïµ½¤è±¡A»P¹ï·Ó²Õ¬Û¤ñ¡A§ïµ½²v¤À§O¬°91.43%©M62.22%¡C ¤¤°ê°ê®aÃĺʧ½¤w¦b2¤ë15¤é§åã®ý¦¿®ü¥¿ÃÄ·~ªÑ¥÷¦³¤½¥q¥Í²£§å¸¹¡A¦Ó´äªÑ¤W¥«¤½¥q¥|ÀôÂåÃĤ]¦b3¤ëªì«Å¥¬¡A±Ò°Êªkºû©Ô³¥Î©ó·s«¬«aª¬¯f¬r¬Ì¯fªºÁ{§É¬ã¨s¡C ¤£¹L¡A¥xÆW°]¹Îªk¤H¥Íª«§Þ³N¶}µo¤¤¤ß¦¦b3¤ë2¤é«Å¥¬¡A§¹¦¨¡uªkºû©Ô³¡v¡]Favilavir¡^ªº¹êÅç«Ç¦X¦¨¡A±N»P°ê¤ºcGMPµ¥¯Åì®ÆÃļt»P»s¾¯¼tÄâ¤â¶i¦æ¥Í²£¡A¥HªvÀøªZº~ªÍª¢±wªÌ¡C ªkºû©Ô³¬O¤é¥»´I¤s¤Æ¤u»sÃĬãµo¡A©ó1999¦~¥Ó½Ð±M§Q¡A2014¦~3¤ë¦b¤é¥»¤W¥«¡A¥Dn¥Î©óªvÀø¹ï§J¬y·P¤Î·ç樂¨FµL®Äªº¬y·P±wªÌ¡A³o´ÚÃĪ«±M§Q´Á20¦~¡A¤w©ó¥h¦~¡]2019¦~¡^8¤ë¨ì´Á¡C news.ltn.com.tw/news/world/breakingnews/3103387 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/18 ¤W¤È 09:14:46²Ä 2280 ½g¦^À³
|
ÁÉ¿Õµá©MRegeneron Pharmaceuticals¤w±Ò°ÊÃþ·ÀãÃö¸`ª¢ÃĪ«Kevzara¡]sarilumab¡^ªºÁ{§Ép¹º¡A¥HªvÀøÄY«Covid-19«aª¬¯f¬r·P¬Vªº¦í°|±wªÌ¡C Kevzara¬O¤@ºØ¥þ¤HÃþ³æ§J¶©§ÜÅé¡A¥i§í¨î¥Õ¤¶¯À6¡]IL-6¡^³~®|¡C¸ÓÃĪ«¥ÑÁÉ¿Õµá©M¦A¥Í¤¸¦@¦P¶}µo¡C 2017¦~5¤ëFDA ®Ö·Ç¤W¥«, ¨C¤G¾¯(¤ë?)3600¬ü¤¸ ¹s°â»ù. ----------------------------------------------------------- IL-6»P«¯g©Î«¯gCovid-19±wªÌªºªÍ³¡ª¢¯g¤ÏÀ³¹L«×¦³Ãö¡C ¾Ú¨â®a¤½¥qºÙ¡A¸Ó¸ÕÅç±Nº¥ý¦b¬ü°ê¯Ã¬ùªºÂåÀø¤¤¤ß¶i¦æ¡C ³o¶µ¦h¤¤¤ß¡AÂùª¼¡AII / III´Á¸ÕÅç±N¤ñ¸ûKevzara»P±`³W¤ä«ùªvÀø¡A¦w¼¢¾¯©M¤ä«ùªvÀøªº¦w¥þ©Ê©M¦³®Ä©Ê¡C ³q¹L¦Û¾AÀ³³]p¡A¸Ó¸ÕÅç¤À¬°¨âÓ³¡¤À¡A³Ì¦h¥i©Û¶Ò400¦W±wªÌ¡C ²Ä¤@³¡¤À±N¦b¬ü°êªñ16Ó¦aÂI©Û¶ÒÄY«ªºCovid-19±wªÌ¡C¥¦±N½Õ¬d¸ÓÃĪ«¹ïµo¿Nªº¼vÅT¥H¤Î¹ï¸É¥R®ñ®ðªº»Ý¨D¡C ¦P®É¡A²Ä¤GÓ¸û¤jªº³¡¤À±NºÊµø¸ûªø´Áªºµ²ªG¡A¨Ò¦p¨¾¤î¦º¤`©M´î»´¹ï¾÷±ñ³q®ð¡A¸É¥R®ñ®ð©Î¦í°|ªº»Ý¨D¡C Regeneron PharmaceuticalsÁp¦X³Ð©l¤H¡AÁ`µôݺ®u¬ì¾Ç©xGeorge Yancopoulos»¡¡G¡§¨Ó¦Û¤¤°êªº¼Æ¾Úªí©ú¡AIL-6³~®|¥i¯à¦bCovid-19±wªÌªÍ³¡¹L«×¬¡ÅDªºª¢¯g¤ÏÀ³¤¤µo´§«n§@¥Î¡C ¡§¾¨ºÞ¨ú±o¤F¥O¤H¹ª»Rªºµo²{¡A¦ý¥²¶·¶i¦æ¾A·í³]pªºÀH¾÷¸ÕÅç¥H¤F¸Ñ¯u¥¿ªº¼vÅT¡C§Ú̪º¸ÕÅç¬O¬ü°ê²Ä¤@¶µ«e¤©Êµû¦ôCovid-19±wªÌIL-6§í»s§@¥Îªº¹ï·Ó¸ÕÅç¡C¡¨ ¤W¶g¡AÁÉ¿Õµá¡]Sanofi¡^©M¦A¥Í¤¸¡]Regeneron¡^³zÅS¤Fp¹º±Ò°Ê³Í¤ÒÂÄ©ÔªvÀøCovid-19¯gª¬ªº¸ÕÅçp¹º¡C ¬°¤F¨³³t±Ò°Ê¸Ó¸ÕÅç¡A¨â®a¤½¥q»P¬ü°ê¹«~©MÃĪ«ºÞ²z§½¡]FDA¡^©M¥Íª«Âå¾Ç°ª¯Å¬ã¨s»P¶}µoºÞ²z§½¡]BARDA¡^¦X§@¡C ÁÉ¿Õµá¬ã¨s»Pµo®i¥þ²yt³d¤H¬ù¿«¡P¨½¼w¡]John Reed¡^ªí¥Ü¡G¡§¬ì¾ÇÃÒ¾Úªí©ú³Í¤Ò¤ã©Ô¡]Kevzara¡^¥i¯à¬O«¯gCOVID-19±wªÌªº¼ç¦b«nªvÀø¿ï¾Ü¡A¸Ó¸ÕÅç±N´£¨Ñ§ÚÌ»Ýnªº¥i±±¡AÄY®æªº¬ì¾Ç¼Æ¾Ú½T©wKevzara¹ïIL-6¨üÅ骺§í»s§@¥Î¬O§_¤ñ¥Ø«eªº¤ä«ùªvÀø¦n¡C¡¨ ¨½¼wÁÙ«ü¥X¡Ap¹º¦b¥¼¨Ó´X¶g¤º¦b¬ü°ê¥H¥~ªº¦a°Ï¶i¦æ¸ÕÅç¡A¥]¬A¨ü¨a³ÌÄY«ªº¦a°Ï¡A¨Ò¦p·N¤j§Q Sanofi and Regeneron Pharmaceuticals have initiated a clinical programme of rheumatoid arthritis drug Kevzara (sarilumab) to treat hospitalised patients with severe Covid-19 coronavirus infection. Kevzara is a fully-human monoclonal antibody, which inhibits the interleukin-6 (IL-6) pathway. The drug is being co-developed by Sanofi and Regeneron. IL-6 is associated with the overactive inflammatory response in the lungs of severely or critically ill Covid-19 patients. According to the companies, the trial will be initially performed at medical centres in New York, US. The multi-centre, double-blind, Phase II / III trial will compare the safety and efficacy of Kevzara in combination with usual supportive care, to placebo and supportive care combination. With an adaptive design, the trial has two parts, enrolling up to 400 patients. The first part will enrol severe Covid-19 patients in nearly 16 US sites. It will investigate the drug¡¦s impact on fever and need for supplemental oxygen. Meanwhile, the second, larger part will monitor longer-term outcomes, such as preventing death and mitigating the need for mechanical ventilation, supplemental oxygen or hospitalisation. Regeneron Pharmaceuticals co-founder, president and chief scientific officer George Yancopoulos said: ¡§Data from China suggest that the IL-6 pathway may play an important role in the overactive inflammatory response in the lungs of patients with Covid-19. ¡§Despite this encouraging finding, it¡¦s imperative to conduct a properly designed, randomised trial to understand the true impact. Our trial is the first controlled trial in the US to evaluate the effect of IL-6 inhibition prospectively in Covid-19 patients.¡¨ Last week, Sanofi and Regeneron revealed plans to initiate trials of Kevzara for the treatment of Covid-19 symptoms. To launch the trial quickly, the companies worked with the US Food and Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA). Sanofi Research and Development global head John Reed said: ¡§Scientific evidence has emerged to suggest that Kevzara may be a potentially important treatment option for critically-ill COVID-19 patients, and this trial will provide the well-controlled, rigorous scientific data we need to determine if IL-6 receptor inhibition with Kevzara is better than current supportive care alone.¡¨ Reed also notes plans to launch trials outside the US, including most affected regions such as Italy, in the coming weeks. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/17 ¤U¤È 10:30:07²Ä 2279 ½g¦^À³
|
WHAT IS KEVZARA? KEVZARA® (sarilumab) is an injectable prescription medicine called an interleukin-6 (IL-6) receptor blocker. KEVZARA is used to treat adult patients with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a disease-modifying antirheumatic drug (DMARD) has been used and did not work well or could not be tolerated. www.kevzara.com/starting-kevzara/kevzaraconnect-program¡C ¤°»ò¬OKEVZARA KEVZARA®¡]sarilumab¡^¬O¤@ºØºÙ¬°¥Õ¤¶¯À6¡]IL-6¡^¨üÅéªýº¢¾¯ªº¥iª`®g³B¤èÃÄ¡C KEVZARA¥Î©óªvÀø¤¤«×¦Ü««×¬¡°Ê©ÊÃþ·ÀãÃö¸`ª¢¡]RA¡^ªº¦¨¦~±wªÌ¡A¦Ü¤Ö¤w¨Ï¥Î¤F¥t¤@ºØÃĪ«¡A§Y§Ü¯f§Ü·ÀãÃÄ¡]DMARD¡^¡A¦ý®ÄªG¤£¨Î©ÎµLªk@¨ü¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/17 ¤U¤È 10:20:46²Ä 2278 ½g¦^À³
|
news.ltn.com.tw/news/world/breakingnews/310253 2020-03-17 14:34:52 ªZº~ªÍª¢¡n¥þ²y¬Ì]²Ä¤@°wÃn¥ú¡Iº¦W¸ÕÅçªÌ¡G·Pı«Ü´Î§Y®É·s»D¡þºî¦X³ø¾É¡fªZº~ªÍª¢¬Ì±¡¥þ²y¸vh¡A¦U°ê¥[ºò¬ãµo¬Ì]³t«×¡A¬ü°ê°ê®a½Ã¥Í¬ã¨s°|¡]NIH¡^»P²ö¼w¯Ç¡]Moderna¡^¥Í§Þ¤½¥q¦@¦P¶}µoªº¸ÕÅ綥¬q¬Ì]¡A¬ü¦è®É¶¡16¤é¦bµØ²±¹y¦{¦è¶®¹Ï¹ï¤HÅ饴¤U²Ä¤@¾¯¸ÕÅç¬Ì]mRNA-1273¡A¬°¥þ²yºÓ¤HÅéÁ{§É¸ÕÅç¡C ¡m¬üÁpªÀ¡n³ø¾É¡A²Ä¤@ÓªZº~ªÍª¢¬Ì]¤HÅéÁ{§É¸ÕÅç¬O¦b¦è¶®¹Ïªº³Í¼»ÂåÀø¶°¹ÎµØ²±¹y¬ã¨s¤¤¤ß¡]Kaiser Permanente Washington Research Institute¡^¶i¦æ¡A16¤é¸Ó¤¤¤ßº¥ý¬°43·³¤k©Ê«¢°Ç¡]Jennifer Haller¡^¶i¦æ¬Ì]ª`®g¡A·í¤ÑÁ`¦@¬°4¦W§ÓÄ@ªÌª`®g¬Ì]¡C¸Ó¤¤¤ß¹wp¦b¥¼¨Ó2Ӥ묰45¦W18¦Ü55·³ªº§ÓÄ@ªÌ±µºØ¬Ì]¡AÆ[¹î¬O§_¦³¹ï§Ü¯f¬rªº§K¬Ì¤ÏÀ³¡A¥H¤Î¦³µL°Æ§@¥Î¡A¾ãÓ¬yµ{»Ýªá¶O12¦Ü18Ӥ몺®É¶¡¡A¤~¯àÅçÃÒ¬Ì]¬O§_¦³®Ä¡C ºÓ±µ¨ü¤HÅé¸ÕÅ窺§ÓÄ@ªÌ«¢°Ç¡A¬°µØ²±¹y¦{¦è¶®¹Ï·í¦a¤H¡AµØ²±¹y¦{¦b¥þ¬ü¬Ì±¡³Ì¬°ÄY«¡C«¢°Ç»¡¡A¡u§ÚÌ©Ò¦³¤H³£·P¨ìµL§U¡A¹ï§Ú¨Ó»¡³o¬O¤@¦¸µ´¨Îªº¾÷·|¡A«Ü°ª¿³¯à°÷¬°¤j®a°µ¤@ÂI¨Æ¡C¡vª`®g¬Ì]«á¡A¦o±aµÛÀéÄ꯺®eÂ÷¶}©Ð¶¡»¡¡A¡u·Pı«Ü´Î¡C¡v¨|¦³2¦W¤l¤kªº«¢°Ç¡A«Ä¤l̤]¤ä«ù¦o°Ñ¥[¬Ì]¸ÕÅç¡A«Ä¤lÌı±o¶ý¶ý¡uº¡»Åªº¡v¡C ¥t¤@¦W±µºØ¸ÕÅç¬Ì]ªº46·³·L³n¡]Microsoft¡^¨t²Î¤uµ{®v¥¬®Ô¹ç¡]Neal Browning¡^¡A¥L¨Ó¦ÛµØ²±¹y¦{³Õ¶ëº¸¥«¡A¤k¨à¤]¦]¬°¥L°Ñ¥[¸ÕÅç·P¨ì¥úºa¡C¥L§i¶D¤p«Ä¤£n¦]¦¹¹ïªB¤Í§j¤û¡A¡u¨CÓ¤÷¥À³£§Æ±æ«Ä¤lÌ´L«¥LÌ¡A¦ýÁÙ¦³¨ä¥L¤H¡C¤£¥u¬Oª¨ª¨¦b¨º¸Ì¡C¡v ³o¦¸¸ÕÅ窺¬Ì]¥N¸¹¬°mRNA-1273¡A¥Ñ¬ü°ê°ê®a½Ã¥Í¬ã¨s°|¡]NIH¡^»P±M§ð«H¨Ï®ÖÁޮֻġ]messenger RNA, mRNA¡^Àøªk»P¬Ì]ªº¬ü°ê²ö¼w¯Ç¡]Moderna¡^¥Í§Þ¤½¥q¦@¦P¶}µo¡C¸Ó¬Ì]¤£¨Ï¥Î·À¬¡¯f¬r¡]dead virus¡^¡A¦Ó¬O¦b¹êÅç«Ç¤¤°ö¾imRNAµ¥¿ò¶Çª«½è¡A¥Ñ©óª`®gªº¬Ì]¤¤¤£§tªZº~ªÍª¢¯f¬r¥»¨¡A¦]¦¹°Ñ»P¸ÕÅ窺¤H¨S¦³¾÷·|³Q·P¬V¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/17 ¤U¤È 10:03:52²Ä 2277 ½g¦^À³
|
Monday said it has initiated a phase 2/3 trial to evaluate Kevzara in patients with severe COVID-19. The companies said it will begin enrolling patients in the trial immediately, with Regeneron leading U.S. trials and Sanofi leading upcoming overseas trials. The U.S.-based double-blind trials will begin in New York. Kevzara is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway. The companies said IL-6 could play a role in causing an overactive inflammatory response in the lungs of patients ill with COVID-19 infection. We believe that there is scientific evidence to suggest that Kevzara may be a potentially important treatment option for some patients, and this trial will provide the well-controlled, rigorous scientific data we need to determine if IL-6 inhibition with Kevzara is better than current supportive care alone, said John Reed, Sanofi¡¦s global head of research and development. Monday said it has initiated a phase 2/3 trial to evaluate Kevzara in patients with severe COVID-19. The companies said it will begin enrolling patients in the trial immediately, with Regeneron leading U.S. trials and Sanofi leading upcoming overseas trials. The U.S.-based double-blind trials will begin in New York. Kevzara is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway. The companies said IL-6 could play a role in causing an overactive inflammatory response in the lungs of patients ill with COVID-19 infection. We believe that there is scientific evidence to suggest that Kevzara may be a potentially important treatment option for some patients, and this trial will provide the well-controlled, rigorous scientific data we need to determine if IL-6 inhibition with Kevzara is better than current supportive care alone, said John Reed, Sanofi¡¦s global head of research and development. Shares of Sanofi fell 11% in premarket trading and Regeneron shed 8.3%, amid a broad-market selloff. Sanofi¡¦s U.S.-listed shares have lost 12.4% ¬P´Á¤@»¡¡A¥¦¤w¸g¶}©l¤F¤@¶µ2/3´ÁÁ{§É¸ÕÅç¡A¥Hµû¦ô«¯gCOVID-19±wªÌªº³Í¤ÒÂÄ©Ô¡C¨â®a¤½¥qªí¥Ü¡A±N¥ß§Y¶}©l©Û¶Ò±wªÌ°Ñ¥[¸ÕÅç¡A¨ä¤¤Regeneron»â¥ý©ó¬ü°ê¸ÕÅç¡A¦ÓSanofi»â¥ý©ó§Y±N¶i¦æªº®ü¥~¸ÕÅç¡C¬ü°êªºÂùª¼¸ÕÅç±N±q¯Ã¬ù¶}©l¡C Kevzara¬O¤@ºØ§¹¥þ¤HÃþ³æ§J¶©§ÜÅé¡A¥i§í¨î¥Õ¤¶¯À6¡]IL-6¡^³~®|¡C¨â®a¤½¥qªí¥Ü¡AIL-6¥i¯à¦b¾ÉPCOVID-19·P¬V±wªÌªºªÍ³¡¹L«×¬¡ÅDªºª¢¯g¤ÏÀ³¤¤µo´§§@¥Î¡C ¡§§ÚÌ»{¬°¡A¦³¬ì¾ÇÃÒ¾Úªí©ú³Í¤ÒÂÄ©Ô¹ï¬Y¨Ç±wªÌ¥i¯à¬O¼ç¦bªº«nªvÀø¿ï¾Ü¡A¸Ó¸ÕÅç±N´£¨Ñ§ÚÌ»Ýn½T©wªº¨}¦n±±¨îªºÄY®æ¬ì¾Ç¼Æ¾Ú¡A¥H½T©w³Í¤ÒÂÄ©Ô¹ïIL-6ªº§í»s§@¥Î¬O§_Àu©ó¶È´N¥Ø«eªº¤ä«ùªvÀø¦Ó¨¥¡A¡¨ÁÉ¿Õµá¥þ²y¬ãµo¥DºÞJohn Reed»¡ www.marketwatch.com/story/regeneron-sanofi-to-iniate-human-trials-of-treatment-for-patients-with-severe-covid-19-2020-03-16?mod=mw_quote_news |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/17 ¤W¤È 09:20:16²Ä 2276 ½g¦^À³
|
·PÁ´X¦ì¤j¤j¤@ª½À°¤j®a¸ò¤½¥q°lÂÜÁpô ²{¶¥¬q¯uªº¤]¥u¯àµ¥¤F ³Ìªñ³oªi¤U¶^¬Ý±o¤ßÅåÅå ¤]¤âÄo§C±µ¤F50±i¡A§â¦¨¥»¾ãÓ°§C¨ì20´X¤¸(100±i) §Ú¤w¦³Ãz±¼ªº¤ß²z·Ç³Æ¡A«oÁÙÅu¥ ©Î³\³o´N¬O½ä®{¤Ñ©Ê ¤£¹L·ÀI©Ó¾á´N¥u¨ì³o ¤£·|¦A¥[½X ³Ñ¾l¶¢¿ú´N¦sµÛµ¥§C±µ©w¦sªÑ¤F ·à¤l¥[ªo¡A¤j®a¥[ªo |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/16 ¤W¤È 09:05:06²Ä 2275 ½g¦^À³
|
¤w¸g¤S§Ö¨ì«e¦¸§CÂI¤F¡A³o¦¸¨S§QªÅ«o³o¼Ë¶^¡AÀ³¸Ó¬O¨ü¨ì¬Ì±¡¼vÅT§ë¸ê¤Hªº«H¤ß§a¡A¥[¤W¼Æ¾Ú¤Sn©µ«á¤~·|µo¥¬¡A©Ò¥H¤£¤Ö§ë¸ê¤H´N»{½ß±þ¥X¤F¡A²{¦b«ù¦³¨È·à±dn¤ßŦ«Ü±j¤~¦³¿ìªk¤F¡Anµ¥¤@¬q®É¶¡¤~·|¦³¼Æ¾Ú¥i¥H¤ä¼µªÑ»ù¤F! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/15 ¤U¤È 08:59:57²Ä 2274 ½g¦^À³
|
ªï¾Ô¥i¯àªº¬Ì±¡Ãzµo¡@¥xÆW¨M±Ä«¢¦òÅA¬°´Xªñ§¹¬üªº¡u·s¥[©Y¼Ò¦¡¡v 2020/03/13 ¡P §@ªÌ / Á¨Χg¾ã²z ¡P ¥X³B / Web only www.commonhealth.com.tw/article/article.action?nid=81147 ¥xÆWÁÙ¥¼¶i¤JCOVID-19¡]²ºÙªZº~ªÍª¢¡^ªÀ°Ï¶Ç¬V¶¥¬q¡A¤£¹L¡A¤¤¥¡¬y¦æ¬Ì±¡«ü´§¤¤¤ß¬Q¤Ñ¡]12¤é¡^«Å§G¡A¼s³]±ÄÀË©Ò©M««×¦¬ªvÂå°|¡A¥B¤£±Æ°£µø»Ýn¯Ç¤J°ò¼h¶E©Òt¾á±ÄÀˤu§@¡C¯eºÞ§½©xû¨p¤Uªí¥Ü¡A¥¼¨Ó½T¶E»´¯gªÌ¡A¤£±Æ°£¤£¤J°|ªvÀø¡C³o¶µ«Å§G¡AÅã¥Ü¥xÆW¬°«O¥þÂåÀøÅé¨t¤£±Y¶ò¡A¦b¤¤°ê¤j³°¼Ò¦¡©M·s¥[©Y¼Ò¦¡¤§¶¡¡A¿ï¾Ü¤F·s¥[©Y¼Ò¦¡¡C «ü´§¤¤¤ß«Å§G¡A·s¼W167®aªÀ°Ï±ÄÀË°|©Ò¡A¥H¤Î50®a««×¦¬ªvÂå°|¡A¥Øªº¬O±N¿zÀˤU©ñ¨ìªÀ°Ï¡A¦Ó¤£¬O¥þ³¡¶°¤¤¨ì¤j«¬Âå°|¡A¥¼¨ÓY¯f¨Ò¤j¼W¡AÂåÀø¨t²Î¤£P©óÅõºÈ¡C ¡u§Ṳ́£·|¤Ñ¯uªº¥H¬°¡A¥xÆW·|¸úÁ×¹LªÀ°Ï·P¬V¡A¡v«ü´§¤¤¤ß«ü´§©x³¯®É¤¤´¿»¡¡A§Ú°ê¦u¦í²Ä¤@ªi§ðÀ»¡A¥xÆW½T¶E¯f¨Ò¤£¦h¡A¦ý¥þ²y¬Ì±¡ÄY®m¡AªÀ°Ï·P¬V¦±ß·|¨Ó¡A¬°¦]À³ªÀ°Ï¨¾¬Ì¡A½ÃºÖ³¡¨M©w±Ä¨ú¦bªÀ°Ï´N¤À¬y´NÂå»PÂà¶E¡C ½ÃºÖ³¡Âå¨Æ¥qªø¥Û±R¨}±µ¨ü´CÅé³X°Ýªí¥Ü¡A¥Á²³¥X²{µo¿N©Î«y¹Âµ¥©I§l¹D¯gª¬¡A¦¬ªv¶E©Ò©Î¬OÂå°|»{¬°±wªÌºÃ¦ü¬OªZº~ªÍª¢«o¤S¨S¿ìªk±ÄÀˮɡA¶E©Ò©ÎÂå°|¥i¨ó§UÂà¶E¦Ü167®a«ü©wªÀ°Ï±ÄÀË°|©Ò¡C °ò¼h¶E©Ò°Êû¡@·s¥[©YPHPC¦³®Ä¤À¬y±wªÌ¡BéwÂåÀøÅé¨t ªZº~ªÍª¢µo®i¦Ü¤µ¡A¦U°ê¨¾±±¼Ò¦¡¤jP¤À¦¨¨â¬£¡G¤¤°ê¤j³°¼Ò¦¡©M·s¥[©Y¼Ò¦¡¡C¦Ó·s¥[©Yªº¨¾±±³Q¬ü°ê«¢¦ò¤j¾Ç¤½¦@½Ã¥Í¾Ç°|µo¥¬¬ã¨s³ø§i¤jÆg¡u±µªñ§¹¬ü¡v¡C ¤¤°ê¬O¤£½×¬O§_½T¶E¡A¥un¦³¯gª¬¡AµL½×¯gª¬»´«¡A¤@«ß¥þ³¡¦¬ªv¡A¶°¤¤¹jÂ÷¨ìÂå°|©Î¤è¿µÂå°|¡]Á{®ÉÂå°|¡^¡C ¦Ó·s¥[©Y¬O±Ä¨ú»´¯g©~®aªvÀø¡A«¯g¤~¦¬ªv¤J°|¡A¥HÁקKÂåÀø¨t²Ît²ü¹L«¡C ¦b±ÄÀ˱¹¬I¤W¡A¤j³°©M·s¥[©Y°µªk¤]§¹¥þ¤£¦P¡C ¤¤°ê±¿n¬O·s¥[©Yªº13,000¦h¿¡A¤H¤f¬O·s¥[©Yªº247¿¡A¦ý¤¤°ê¥þ°ê¶È500Ó¿zÀ˯¸¡A¥þ³¡¶°¤¤¦bÂå°|¡A¦Ó·s¥[©Y¬O°Êû°ò¼h¶E©Ò¡A¦b¶E©Ò´N¶i¦æµo¿N¿zÀË©M¯f¤H¡u¤À¿µ¡v¡C¡]±ÀÂ˾\Ū¡G¥þ²y¤j¬y¦æ®£ÃøÁקK¡@¬ü±M®a¡G¾÷³õÅé·Å¿zÀË°µ¥Õ¤u¡^ ·s¥[©Y¬O2003¦~¸g¾úSARSºGµh¸gÅ礧«á¡A¤~±N¶Ç¬V¯f¨¾ªvºô¤j´TÂX¤j¡A¯Ç¤J°ò¼h¶E©Ò¡A¥®É´N¦b§G¸p¡Bºt½m¶Ç¬V¯fµo¥Í®Éªº¿zÀË¡B¤À°Ï¡B¤À¬y¡BÂà¶E¡A¹J¨ìºò«æ¤½¦@½Ã¥Íª¬ªp®É¡A¬F©²¤@Án¥O¤U¡A¥þÅé°Êû¡C ¦b½Ã¥Í³¡ªù«ü¾É¤U¡A³o¨Ç¶E©Ò¨³³t¦³®Ä¦aÀ³¹ï¬ðµoª¬ªp¡A¨B½Õ¤@P¡A«ö·Ó²Î¤@ªº¼Ð·Ç¶EÂ_¡BªvÀø¡B¤W³ø¡BÂà¶E¡B¹jÂ÷¡A´î¤Ö¦³½T¶E±wªÌ¦¨¤Fº|ºô¤§³½¡A°§Cµo¥Í°|¤º·P¬V¡A¤]ÁקK¥Á²³¤@ºÛ¸Á©¹¤jÂå°|À½¡A¨ÏÂåÀø¨t²Î±Y¶ò¡C t¾á³o¨Ç¤u§@ªº°ò¼h¶E©Ò¡A¦b·s¥[©Y¥s°µ¤½¦@½Ã¥Í¨¾½d¶E©Ò¡]Public Health Preparedness Clinic, PHPC¡^¡A¤p¤pªº·s¥[©Y¡A´N¦³900¦h®a¡C ¬ü°ê«¢¦ò¤j¾Ç¤½¦@½Ã¥Í¾Ç°|´¿µo¥¬¤@¶µ¬ã¨s³ø§iºÙ¡A·s¥[©YºI¦Ü2¤ë4¤é´N¯àÀËÅç¥X18Ó¯f¨Ò¡A»¡©ú¥¦¨ã³Æ¤F¡u±µªñ§¹¬üªº¶Àª÷¤ô¥¡vÀË´ú¯à¤O¡C ´£¨Ñ»¤¦]¡@¼W¥[¶E©Ò¥[¤J·NÄ@¡B¥Á²³¤]Ä@·N«e©¹ PHPC¶E©Ò¦³¤@©wªº±ø¥ó¨î¡A·í¶Ç¬V¯fµo¥Í®É¡APHPC¶E©Ò¥i¥HÀò±o¬F©²§K¶Oµo©ñ3Ӥ몺ӤH¨¾Å@ª«½è¡B6¶g¹w¨¾¯f¬rÃĪ«¡BÀu¥ý±q°ê®aÀx³ÆÀò±oÃÄ«~¡B¬Ì]¡A¶Eªv¦³«æ©Ê¤W©I§l¹D¯gª¬ªº±wªÌ¡AµL½×³Ì«á¬O§_½T¶E¡A¤]³£¦³¶EÀø¶O©MÃĶOªº¸É¶K¡C ·s¥[©Y¬F©²¤]²Î¤@¶EÂ_«ü«n¡AºÃ¦ü±wªÌÂश¦Ü«ü©wÂå°|¡A¦p¥¼¹F¨ìºÃ¦ü¼Ð·Ç«hµ¹5¤Ñ¯f°²¡A¹ªÀyºÉ¶q¦b®a¹jÂ÷¡A¦pªG5¤Ñ¤º¨S¦³¦nÂà¡AÀ³ºÉ¥i¯à¦A§ä¦P¤@¦ìÂå¥Í¨D¶E¡C¥Á²³¥i¥H¤Wºô¶i¤J¨t²Î¡A¿é¤Jµó¹D¦WºÙ¡Aµe±´N·|¥X²{Â÷¦Û¤v2¤½¨½¥H¤ºªº©Ò¦³PHPC¶E©Ò¡A«e©¹³o¨Ç¶E©Ò¦b¶EÀø¶O©MÃĶO¤]¦³Àu´f±¹¬I¡C ¥®É°V½m¦³¯Àªº¤½½ÃÅé¨t¡AÅý¬Ì±¡¤@¶i¤J·s¥[©Y«á±o¥H¤@©]¤§¶¡¦P®É¤W½u¡A³o®MÅé¨t¹L¥h¤]¦b¬y·P¤j¬y¦æ¡B¬´¯j¼ö¡B¬Æ¦ÜÄY«Ãúŵ®É¬£¤W¥Î³õ¡C¥[¤W¬F©²¨³³t¤ÏÀ³¡B¦]¦a¨î©yªº¬ì¾Ç¨¾¬Ì¡B°T®§³z©ú¸ÔºÉ¡B¥H¤Î§¹³ÆªºÅé¨î¡A³£Åý³\¦h±M®a±À±R·s¥[©Yªº¨¾¬ÌºÞ±±¡A¨ä±M·~â¾r¬Fªv©M·NÃѧκAªº¨¾¬Ì«ä¸ô¡Aȱo¦U°êÉÃè¡C ¤¤¥¡¬y¦æ¬Ì±¡«ü´§¤¤¤ß¬Q¤Ñ¡]12¤é¡^«Å§G¡A¼s³]±ÄÀË©Ò©M««×¦¬ªvÂå°|¡A¥H¤U¬°COVID-19¡]ªZº~ªÍª¢¡^¥þ°ê«ü©wªÀ°Ï±ÄÀË°|©Ò¤Î««×¦¬ªvÂå°|¦Cªí |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/3/14 ¤W¤È 10:41:31²Ä 2273 ½g¦^À³
|
To:«Ó°¶¤j/ªÅÄ_¤j ²{¦b¤£¬O«H¤ßªº°ÝÃD,¬O¶]¤F¤]¨S¥Î.....¥u¯à¬Ý¦Ñ·à¯à§_±Ã¤ã¥X¾÷·|? ©Ò¥H¬O¦³´Á«Ý,¦ý¦³³ÌÃaªº¥´ºâ.... |
|
|
·|û¡GªÅÄ_10148533 µoªí®É¶¡:2020/3/13 ¤U¤È 04:16:46²Ä 2272 ½g¦^À³
|
À³¸Ó·|¯}©³ µL¨¥ªº±¹ï ¦æÅn¤w®¹¸j Àô®q¬Ý·´º ¦^¨Ó³Ñ¤G¶ô ¨ÌµM§ÚÁÙ¦b |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/3/13 ¤W¤È 11:15:51²Ä 2271 ½g¦^À³
|
¦A¤@®Ú´N´X¥G¦^¨ì¸Ñª¼¥¢±Ñ®Éªº§C»ù ¤j®a¤´¹ï·à¤l¦³«H¤ß¶Ü? §Ú¬OÁÙ¦b¡A¸}³Â¤F¶]¤£±¼¤F... |
|
|
·|û¡Gjoeman10145905 µoªí®É¶¡:2020/3/12 ¤U¤È 09:44:39²Ä 2270 ½g¦^À³
|
¬Ý°_¨ÓADR¤]¸òµÛ¤j½L¤@°_«n¤U¤F §ë¸êªº¿ú¦n¹³§ë¨ì¤ô¸Ì¥h ÁÙ¦^±o¨Ó¶Ü¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/12 ¤U¤È 03:05:29²Ä 2269 ½g¦^À³
|
¶Ò¸ê¥«³õ¦b¬ü°ê¡A¤G´ÁÁ{§É200¤H~250¤H¦b¬ü°ê. ¬ü°êÁÙ¦³¬Ì±¡®É¬Ò¦³·ÀI¡A¶Ò¸ê¡BÁ{§É¸ÕÅç©Û¶Ò¬Ò¤£©ö¡C ´Nµ¥¬ü°ê¬Ì±¡¹L¥h¡C ADRªÑ»ùµLº¦¶^´T¨î¡AªÑ»ù¤£¬O°ÝÃD¡C¤W¦¸¶Ò¸ê³Ì¤jªÑªF¬O¹ï¨R°òª÷¡C Sio Capital Management, LLC , 1017¤dªÑ finance.yahoo.com/quote/ASLN/holders?p=ASLN ªÑ»ù8-10¬ü¤¸¡A2~5¤Ñ´N¥i©Ô¨ì¡C ¥xÁÞ¤j»¡ªº¹ïÁ{§É¡§¼Æ¾Únº}«G¡¨«n¡C |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/12 ¤U¤È 01:36:28²Ä 2268 ½g¦^À³
|
To ¤Ñ©R¤j, §Úı±o¤½¥q¦pªG¤£»°§Ö·Q¿ìªkºû«ù¤@¤UªÑ»ù¡A§Ú·Q¥¼¨Ó¼W¸êªº®ÉÔ¡A¼W¸êªº»ù®æ´N¤£·|¤Óº}«G¡A¬Æ¦Ü¦³¥i¯àq»ù¤ñ¥h¦~ªº2.5ÁÙn§C¡A¦]¬°¤½¥q¹ïªÑ»ù³£¬O±Ä¨ú©ñ¥ôª¬ºAªº¡A¹³¤µ¤ÑÁöµM¤j½L¶^3-4%¡A¦ý¬O¨È·à±d¦¦´N¥´¤J¶^°±ªO¡A¦b¨S¦³¥ô¦óªº§QªÅ®ø®§¤§¤U¡AªÑ»ù´N¦¦´N±þ¥X¶^°±¡A¤Ó¥æ©ö¤é¤w¸g§Ö¶^30%¡A«Ü§Ö´Nnµo«°T»¡©ú¤F§a¡A§Æ±æ¤½¥q»°§Ö¯à¥X¤@¨Ç¤èªkÅýªÑ»ù¤î¶^¡A§_«hµ¥©ó¥h¦~004ªº§Q¦h¨ì²{¦b³£¬O°µ¥Õ¤u¤F¡A¯f±w©Û¦¬±¡ªp¯à«ö®É§ó·s¬O³Ì¦n¡An¤£µM§ë¸ê¤H·|¥H¬°004«ç¼Ë¤F¡A´N¬Ý¤½¥q°ª¼h«ç»ò·Q¤F? Thanks, |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/11 ¤U¤È 07:26:21²Ä 2267 ½g¦^À³
|
¨È·à¥¼¨Ó²bȼÒÀÀ: ¤@¡B¤U¦¸¼W¸êADRª÷ÃB¤Î¼W¸ê«á¨CªÑ²bȪº¼ÒÀÀ 2019¦~12¤ëªk»¡·|, ³ÅÁ`´¿»¡¡An¾a¤U¦¸¼W¸ê²æÂ÷²bȤp©ó5¤¸¤§¥i¯à¡A ¼ÒÀÀ¦p¤U 1.³æ»ù °²³] (1): 5¬ü¤¸/ªÑ (2) 8¬ü¤¸/ªÑ¡X¡X¾÷·|¤j (¬ü°ê¤ÀªR®v¥Ø¼Ð»ù®æ) ¡X¡X-2019¦~12¤ë¼W¸ê»ù2.5¬ü¤¸/ªÑ.(3Ó¤HªºÁ{§É¸ê®Æ) 2.ªÑ¼Æ °²³]: ¼W¸ê 12,000¤dªÑADR(60,000¤dªÑ¥xªÑ), ¡X¬ü°êADR¼W¥[¤@¿¬°°ò¦¡C¤W¦¸¼W¸êªÑ¼Æ¬ù²Ä¤@¦¸ªº¤@¿¡C ¼W¸ê«á25»õªÑ¥» 3.ª÷ÃB¦ôp (1) 5x12,000=60,000 ¤d ¬ü¤¸(18»õ¥x¹ô) (2)8x12,000=96,000 ¤d¬ü¤¸(28.8»õ¥x¹ô) 4.¼W¸ê«á¦ôp¨CªÑ²bÈ: ¼ÒÀÀ¦p¤U (1)18»õ¡Ï6»õ=24»õ¥x¹ô 24/25x10=9.6¤¸/ªÑ (2)28.8»õ¡Ï6»õ=34.8»õ 34.8/25x10=13.9¤¸/ªÑ¡X¡X¡X¡X-¾÷·|¤j ¥H¤W¬°Ó¤H¦ôp ¤G¡B.¦ó®É¥i¼W¸ê ? ©Û¶Òº¡6¤Hªº²Ä¤G¾¯ASLAN004 Á{§É «á2.~3Ó¤ë¡C |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/3/11 ¤W¤È 10:27:20²Ä 2266 ½g¦^À³
|
ASLAN004¦¬®×±ø¥ó¬Û·íÄY®æ,¬°¤F¨D§Ö¶Ã¦¬®×¤Ï¦Ó¤£¦n, ¤½¥q¨Ã¨S¦³»¡3¤ën¤½§i²Ä¤G¾¯Á{§Éµ²ªG, ÄY®æ¿z¿ï¯f±w¤~¯à¦³¦nªºµ²ªG, ¦³®t¤@Ó¤ë¶Ü ? «nªº¬O¼Æ¾Ú¤£¬O®É¶¡ |
|
|
·|û¡G³¯Ë¢¦w10144680 µoªí®É¶¡:2020/3/11 ¤W¤È 10:12:12²Ä 2265 ½g¦^À³
|
¯uªº¨SÃıϪºéw·à¡A´N³o¼Ë¤@¤Ñ¤@¤Ñªº¬ÝµÛ¥L¶^°±¡AµM«á¤U¥«¡A±ýúµL²\ |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/3/10 ¤U¤È 01:15:12²Ä 2264 ½g¦^À³
|
¸¤H¤j,ÁÂÁ§A~~~¨S·Q¨ì³o¬Ì±¡ÁÙ¬O¦³¼vÅT¨ì¦¬®×(ì¥H¬°³o¨Ç¯f±w¤£Ãø¦¬),¥u¯àµ¥¤F.... |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/3/10 ¤W¤È 11:24:55²Ä 2263 ½g¦^À³
|
To ©t¨àÃĤj, ±q¤W¦¸ªºÂ²³øÀɲÄ15¶¦³´£¨ì¤@¥y¡ACurrently recruiting 2nd dose cohort¡A¥Nªí2¤ë¥÷¨º®ÉÔÁÙ¦b©Û¶Ò²Ä¤G¾¯¶qªº¯f±w¡A©Ò¥Hn¦b³oÓ¤ë¥i¥H¬Ý¨ì´Á¤¤³ø§iÀ³¸Ó¬O¤£¤j¥i¯à¡A¤ñ¸û¥i¯à¬O·|¸¨¦b¥|¤ë©³©Î¤¤ëªì¨ºÃä§a¡A¤@¤ÁnºÝ¬Ý¯f±w¬OÔ£®É©Û¶Ò§¹²¦ªº¡A©Û¶Ò¯f±wªº¶i«×§Ú¦³¥´¥h¤½¥q¸ß°Ý¡A¤½¥q¨ºÃä¦^ÂЬO¨ü¨ì·s«¬«aª¬¯f¬rªº¼vÅT¡A©Ò¥H©Û¶Ò¨Ã´«¨Óªº¤ñ¹w´Áªº¤[¡A©Ò¥H´Á¤¤¼Æ¾Ú¥XÄlªº®É¶¡¤~·|©µ¿ð¡A§Ú¬O¦³n¨D¤½¥q¥i¥H´N004ªºª¬ªp¹ï§ë¸ê¤H§@¤@Ó³ø§i¡A¥u¬O¤£ª¾¤½¥q·|¤£·|§@³oÓ¶i«×§ó·s´N¤£²M·¡¤F¡C¦pªG·QnÁA¸Ñ§ó¸Ô²Ó¡A¥i¥H¥´¥h¤½¥q¸ß°Ý¬Ý¬Ý¡C Thanks, |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/3/9 ¤U¤È 07:29:20²Ä 2262 ½g¦^À³
|
¤½¥q©Ò»¡ªº¦~ªìªº´Á¤¤³ø§in¤½§G,¦³·à¤Íª¾¹D¬ÛÃö°T®§¤F¶Ü?11¤ë©³3¤H¸ÕÅç²Ä¥|¶g¥§¡EASI¬°71%....§Æ±æ12¤H(¨â¾¯¶q)¯àÀu©ó¦¹¼Æ¾Ú... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/8 ¤U¤È 01:09:17²Ä 2261 ½g¦^À³
|
udn.com/news/story/120940/4398176?from=udn_ch2cate6638sub120940_pulldownmenu_v2 ¯}¬ö¿ý¡I¤¤¬ã°|19¤Ñ»s³y·s«a¯f¬r15¤ÀÄÁ§Ö¿z¸Õ¾¯ 2020-03-08 12:33 Áp¦X³ø / °OªÌ³¯©{Ó}/§Y®É³ø¾É ¤¤¥¡¬ã¨s°|¤µ(8)¤é¦¨¥\¦X¦¨¯à¿ëÃÑ·s«a¯f¬r(SARS-CoV-2)³J¥Õ½èªº³æ®è§ÜÅé¸s¡A±N¥i§@¬°ÀË´ú§Ö¿z¸Ë¸mªºÃöÁä¸Õ¾¯¡C¹Ï¡þ¤¤¬ã°|´£¨Ñ¤¤¥¡¬ã¨s°|¤µ(8)¤é¦¨¥\¦X¦¨¯à¿ëÃÑ·s«a¯f¬r(SARS-CoV-2)³J¥Õ½èªº³æ®è§ÜÅé¸s¡A±N¥i§@¬°ÀË´ú§Ö¿z¸Ë¸mªºÃöÁä¸Õ¾¯¡C¹Ï¡þ¤¤¬ã°|´£¨Ñ ¤¤¥¡¬ã¨s°|¤µ(8)¤é¦¨¥\¦X¦¨¯à¿ëÃÑ·s«a¯f¬r(SARS-CoV-2)³J¥Õ½èªº³æ®è§ÜÅé¸s¡A±N¥i§@¬°ÀË´ú§Ö¿z¸Ë¸mªºÃöÁä¸Õ¾¯¡C¹Ï¡þ¤¤¬ã°|´£¨Ñ —B Y —I „H —H ¥Ø«eÀË´ú·s«aªÍª¢¯f¬r¡A¬O¥H®Ö»ÄÀËÅç¤è¦¡¶i¦æ¡A¥§¡¬ù4¤p®É¥B»Ý¯S®í»ö¾¹¡C¤¤¥¡¬ã¨s°|¤µ¤é«Å¥¬¦¨¥\¦X¦¨¯à¿ëÃÑ·s«a¯f¬r¡]SARS-CoV-2¡^³J¥Õ½èªº³æ®è§ÜÅé¸s¡A±N¥i§@¬°ÀË´ú§Ö¿z¸Ë¸mªºÃöÁä¸Õ¾¯¡C¥¼¨ÓY¦¨¥\¶q²£¡A¿zÀË·s«aªÍª¢¦³¾÷·|¹³¬y·P¤@¼Ë¡A15¦Ü20¤ÀÄÁ´N¯à¨³³t±oª¾µ²ªG¡A¦³®Ä´£¤É±ÄÀ˶q¯à¡C ¤¤¬ã°|°ò¦]Åé¬ã¨s¤¤¤ß·¨¦w¸k¬ã¨sûªí¥Ü¡A§Ö¿zªºÃöÁä¦b©ó¨ä§ÜÅé¸Õ¾¯»Ý¯à·Ç½T¿ëÃÑ·s«a¯f¬r¡C¥L²v»â¬ã¨s¹Î¶¤¦bµuµu19¤Ñ¤º¡A°w¹ï7ºØ¤HÃþ«aª¬¯f¬r®Ö³J¥Õ¡]Nucleocapsid protein¡^§Üì¡A»s³y¥X²Ä¤@§å46®è²@§Jµ¥¯Å²£¶qªº³æ®è§ÜÅé¡]IgG¡^¡A¨ä¤¤¦³1®è§ÜÅ馳·¥¨Îªº³æ¤@¿ëÃÑ©Ê¡A¥u¹ï·s«a¯f¬r¦³¤ÏÀ³¡A¨Ã¤£·|»PSARS¡BMERS¯f¬r©Î¨ä¥L¾ÉP¤@¯ë·P«_ªº«aª¬¯f¬r¦³¥æ¤e¤ÏÀ³¡A¥i©ó§Ö¿z®É¦³®Ä§P§O¬O§_·P¬V·s«a¯f¬r¡C ·¨¦w¸k¹êÅç«Ç¶}µo§¹¦¨¦X¦¨§ÜÅé®w§Þ³N¥¥x¡A¨äÀu¶Õ®Ö¤ß§Þ³N¦b©ó¨ä¤wÀò±M§Qªº¦X¦¨§ÜÅé®w¸s¡C§ÜÅé®wªº¨Ï¥Î¤Î«O¦s§¡¥H¤j¸z±ìµß¨t²Î¾Þ§@¡A¤£¶·°Êª«³]¬I¡A¦]¦¹®É¶¡¡B¯Ó§÷¡B¤ÎÀô¹Ò¦¨¥»·¥§C¡A¦A¥[¤W¥H¤H¤u´¼¯àpºâ¾÷³]p¡A¥i§Ö³t´£¨Ñ¤j¶q·s¿o¥B¨ã¦³¿W¯S©Ê°w¹ï§Ü쪺¹ïÀ³¿ëÃѧÜÅé¡A³o¨Ç§ÜÅé¬O´£¨Ñ¨¾¬Ì¤è®×ªº³Ð·s°ò¦¡C ¤¤¬ã°|¹ù«T´¼°|ªøªí¥Ü¡A¦¹¦¸ªº¦¨ªG¬O¥Ñ©ó¥»°|¦U¹Î¶¤¤w©ó2¤ëªì«K¶}©l³q¤O¦X§@¡A§Ö³t¦X¦¨·s«a¯f¬r®Ö³J¥Õ§Üì¡A·¨¦w¸k¹Î¶¤¹B¥Î¼Æ¤Q¦~¨Ó²Ö¿nªº§Þ³N¡A¤é¥HÄ~©]¶i¦æ§ÜÅé¦X¦¨¤Î¿z¿ï¡A¤~¦³¦¹¶µ«n¦¨´N¡C ¤¤¬ã°|ªí¥Ü¡A¬ã¨s¹Î¶¤¦b¸gÀÙ³¡¦w±Æ¤U¡A±N»P¼Æ®a¼t°Ó°Ó½Í¥Í²£§Ö¿zÀË´úªºì«¬²£«~¡CY¤@¤Á¶¶§Q¡A§Æ±æ¼t°Ó¯à¦b3¨ì4Ӥ뤺³q¹L½ÃºÖ³¡ÅçÃҨöq²£¡C¹ù«T´¼ªí¥Ü¡A¤U¤@¨B¾Ç¬ã³æ¦ì¡B¼t°Ó¤Î½ÃºÖ³¡¤´»Ýºò±K·¾³qÁpô¡A¥H¥[§Ö¯f¤HÀËÅ骺ÅçÃÒ¡A¥H«K¤j³W¼ÒÁ{§ÉÀ³¥Î¡C ©¡®É·s«aªÍª¢ÀË´ú¤è¦¡±N¥i¤ñ·Ó¬y·P§Ö¿z¡A15¦Ü20¤ÀÄÁ¤º¡A´N¯à¿zÀË¥X¶§©Ê»P§_¡C¬Û¸û©ó¥Ø«e®Ö»ÄÀË´ú¦Ü¤Öªá¤W4¤p®É¡A±N¦³®Ä´£¤É±ÄÀ˶q¯à¡A¥[§Ö¿zÀˮɶ¡¡A¬°¬Ì±¡Åܤưµ·Ç³Æ¡C |
|
|
·|û¡G°l·10148822 µoªí®É¶¡:2020/3/4 ¤U¤È 09:31:32²Ä 2260 ½g¦^À³
|
¥Lªº¤Û¿O¤ù®ÄªG¥i¯à¦³§a¡I ¼Æ¾Ú¨S¥X¨Ó¡A»¡¦b¦h³£¨S¦³¥Î... ®Ú¥»¨S¤H¶R³æ... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/4 ¤U¤È 04:21:18²Ä 2259 ½g¦^À³
|
ASLAN Pharmaceuticals (ASLN) Presents At SVB Leerink Global Healthcare Conference - Slideshow Mar. 3, 2020 8:12 AM ET | About: ASLAN Pharmaceuticals Limited (ASLN) The following slide deck was published by ASLAN Pharmaceuticals Limited in conjunction with this event. seekingalpha.com/article/4329080-aslan-pharmaceuticals-asln-presents-svb-leerink-global-healthcare-conference-slideshow?mod=mw_quote_news ^¤å²³ø,¦p¤Wºô§} |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/3/1 ¤U¤È 07:05:17²Ä 2258 ½g¦^À³
|
¨È·à±d§ó¬O¥xÆW¤¤¤Ö¼Æ¨ã¦³°ê»Ú¤j¼t»P¥ý¶i°ê®a¬F©²¤ä«ùªº·sÃĶ}µo¤½¥q¡AªÑªF&¸³¨Æ¥]¬AMerck¡B·s¥[©Y²H°¨¿ü°òª÷¡C www.marketwatch.com/investing/stock/mrk Merck & Co. Inc.(Àq§JÃļt) Market Cap(ªÑ²¼¥«È) $194.18B (1941 »õ¬ü¤¸) ·s¥[©Y²H°¨¿ü°òª÷2018 §ë¸ê²bÈ2000»õ¬ü¤¸ ¨È·à±d³Ì¤£¥Î¾á¤ßªº´N¬O$$$$$$$$ . |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/2/29 ¤U¤È 02:39:58²Ä 2257 ½g¦^À³
|
To Jones¤j ¦ý¬O¡A©h¥B¤£»¡²Ä¤G´Á¡A004¡A¡u¥un±Ò°Ê²Ä¤T´Á¡A´Nn¥ý¥I3000¸U¬üª÷¡v¡A¥H¥Ø«e±b¤W²{ª÷®Ú¥»¬O¤£°÷ªº¡A¥u¯à¦A§äìªÑªF±Ç¿ú¡A§ä¤jÃļt¦X§@ªº¾÷·|¤£¤j¡]©Ò¥HªÑªF·|¤~n¹L¨p¶Ò®×¡^¡C¦p²Ä¤T´Á¬ãµo¦¨¥\¨Ã¤W¥«¡A«á±ÁÙ¦³¹dÃBÅv§Qª÷¡AÀò§Q·|¤j¤j¨ü¨ì¼vÅT¡]¤£n§Ñ¤F±b¤WÁÙ¦³40-50»õªº²ÖÁ«¡^¡A¤£¬O«Ü¬Ý¦n¯à½½L... 1. Ãö©ó004ªº×q¦X¬ù¡A®Ú¾Úì¦X¬ù¤º®e¡A¨È·à±d-KYÀ³ºÉ¬ãµoASLAN004¦Ü·§©À©ÊÅçÃÒ(proof-of-concept)§¹¦¨¤§¸q°È¨Ã´M§ä°õ¦æ¤T´ÁÁ{§É¸ÕÅç¤Î°Ó«~¤Æ¤§¦X§@¹Ù¦ñ¡CCSL±N¥i¦¬¨ú¥]¬AÂà¥X±ÂÅv¦X¬ù¦b¤º©Ò¦³ ASLAN004 ¦¬¤J¤§ 40%¦Ü50%¡C©Ò¥Hn¤ä¥Iµ¹CSL 3000¸U¬üª÷¤§«e¡A¨È·à±d´N¥²¶·¥ý§ä¨ì°õ¦æ¤T´Á¸ÕÅç¤Î¥¼¨Ó°Ó«~¤Æªº¹Ù¦ñ¡A©Ò¥H³o3000¸U¬üª÷¬O¤£»Ýn¾á¤ßªº¡A¦pªGÁÙ¨S¦³°õ¦æ¤T´Á¬O¤£»Ýn¤ä¥I³o3000¸U¬üª÷ªº! 2. ¦Ü©ó³o¦¸¨p¶Ò®×¡A§Ú·Q¤½¥q¤]·|µ¥¨ì004´Á¤¤¼Æ¾Ú¥XÄl«á¡A¤~·|¥h°õ¦æ¡A¦Ü©ó·|±Ä¥Î«ä¼}ÁÙ¬O²{¼WþºØ¤è¦¡©O? ³oÂI§Ú·Qnµ¥¤§«á¸³¨Æ·|¤~·|ª¾¹D¤F¡AÓ¤H¤ñ¸û§Æ±æ¬O¨p¶Ò®×¡A¦]¬°¦³¤T¦~ªº³¬Âê´Á¡AÅý¤½¥q§Q¥Î³o¤T¦~ªº®É¶¡¦n¦n½Ä¨ë! 3. ¦b001 ¤@½uÁx¹DÀù¤Î¤G½uGÀù³£¸Ñª¼¥¢±Ñ«á¡A§Ú쥻¤]¥H¬°¤½¥qn¤UÂd¤F¡A¨S·Q¨ì¦b¤½¥q¤½§i004ªº¤@´Áªì¨B¼Æ¾Ú¡A¨È·à±dªºADR ASLN¡AªÑ»ù¤Ï¦Ó±q001¸Ñª¼¥¢±Ñ«áªº0.35¤@¸ôötº¦¨ì8¶ô¦h¡Aº¦±o¤ñ¸Ñª¼«eÁÙ°ª¡An¤£¬O¤½¥q¤½§iADR¼W¸ê»ù¬O2.5¤¸¡A§Ú·QADRªÑ»ù·d¤£¦nÁÙ¦³ªºº¦©O? ³oÂI§Ú¨ì²{¦b³£ÁÙ¤£¬O«Üª¾¹Dì¦]¡A©Î³\¬O¦]¬°§ù¥²ª¢¾P°â¦¨ÁZ«Ü¦n¡A¦Ó004¥Ø«eªº¦U¤è±¼Æ¾Ú³£¤ñ¦A¥Í¤¸Ãļtªº§ù¥²ª¢¨Óªº¦³®Ä³\¦h¡A©Ò¥H°ê¥~§ë¸ê¤H¤~·|¨º»ò¶R³æ¡A¨Ï±oASLNªÑ»ù°_¦º¦^¥Í¡A·íµM004¥Ø«e¤~¦b¶i¦æ²Ä¤@´Áªº¸ÕÅç¦Ó¤w¡A¥¼¨Ó¬O§_¯à³q¹L¤G´Á³£ÁÙ¥¼ª¾¡A¤£¹L§Ú·Q¥i¯àÁÙ¬Oµ¥004´Á¤¤¼Æ¾Ú¥X¨Ó«e¡A¦A¨Ó°µ§PÂ_¤F¡C Thanks! |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/2/29 ¤U¤È 01:53:51²Ä 2256 ½g¦^À³
|
«¢,³£³Ñ6¶ô¦h¤F,½¤£Â½½L¬Ý¤U¥h´N¹ï¤F....³oºØ¤p·sÃĤ½¥q,¹ï©ó004µ´¤£·|¦Û¤v°µ§¹¤G´Á´Á¤¤¥H«áªº¶¥¬q,¦Ü©ó«á±n¥IªºÅv§Qª÷¨º¬O«Ü«á±ªº¨Æ,²{¶¥¬q«nªº¬O¥ý«e©Ò»¡3¤ëªº¤@´Á´Á¤¤¼Æ¾Ú... |
|
|
·|û¡G°l·10148822 µoªí®É¶¡:2020/2/29 ¤U¤È 01:49:38²Ä 2255 ½g¦^À³
|
·Ó³o»ò»¡¡A¨È·à±d²{¦b¨ì©³¸Ó¾a¤°»ò½¨©O¡H |
|
|
·|û¡Gjones10146258 µoªí®É¶¡:2020/2/29 ¤W¤È 09:35:43²Ä 2254 ½g¦^À³
|
¦ý¬O¡A©h¥B¤£»¡²Ä¤G´Á¡A004¡A¡u¥un±Ò°Ê²Ä¤T´Á¡A´Nn¥ý¥I3000¸U¬üª÷¡v¡A¥H¥Ø«e±b¤W²{ª÷®Ú¥»¬O¤£°÷ªº¡A¥u¯à¦A§äìªÑªF±Ç¿ú¡A§ä¤jÃļt¦X§@ªº¾÷·|¤£¤j¡]©Ò¥HªÑªF·|¤~n¹L¨p¶Ò®×¡^¡C¦p²Ä¤T´Á¬ãµo¦¨¥\¨Ã¤W¥«¡A«á±ÁÙ¦³¹dÃBÅv§Qª÷¡AÀò§Q·|¤j¤j¨ü¨ì¼vÅT¡]¤£n§Ñ¤F±b¤WÁÙ¦³40-50»õªº²ÖÁ«¡^¡A¤£¬O«Ü¬Ý¦n¯à½½L... |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/2/29 ¤W¤È 12:36:40²Ä 2253 ½g¦^À³
|
§ó¥¿ 2017¦~7¤ë¬Ý©l¤G´ÁÁ{§É |
|
|
·|û¡G¥xÁÞ10138776 µoªí®É¶¡:2020/2/29 ¤W¤È 12:29:45²Ä 2252 ½g¦^À³
|
°l·¤j ³oÁûÃÄÀ³¸Ó¦b2017¦~11¤ë¬Ý©l¦b¥xÆW°µ12¤Hªº¤G´ÁÁ{§É¡A2019¦~¥|¤ëÀ³¸Ó§¹¦¨¤G´ÁÁ{§É¡A«ç»ò³£¨S¦³¬Ý¨ì¼Æ¾Ú¡H¥i¥H¤À¨É¤@¤U An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis |
|
|
·|û¡G°l·10148822 µoªí®É¶¡:2020/2/28 ¤U¤È 10:27:12²Ä 2251 ½g¦^À³
|
¦X¤@ªº²§¨ý©Ê¥Ö½§ª¢¬ã¨s¤w¸g¤G´Á¤F ¨È·à±d«oÁÙ¦b¤@´Á....¦Ó¥B¨ºÓª©¤j»¡¦X¤@¤½¥¬ªº¼Æ¾Ú¤GÓ¤ë¤G°w¬Û·í©ó¨ºÓ¤W¥«ÃĤE°w😱😱 §Æ±æ¨È·à±dªº´Á¤¤¼Æ¾Ú¯à¤ñ¦X¤@ªº§ó°ª¯Å¡I |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/2/27 ¤W¤È 09:15:59²Ä 2250 ½g¦^À³
|
4743)¦X¤@¤½§i¥»¤½¥q¦¬¨ì°ê»ÚÃļt¤ä¥I·sÃĬãµo¦X§@ij¬ùª÷¬üª÷400¸U¤¸ ¦b[Dr.Allen ªºªÑ¥«©_¹J°O]¤µ¤Ñ¦³¶K½gFB825®ð³Ý¹L±Ó¤ÀªR¥i°Ñ¦Ò¤@¤U! |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/2/24 ¤U¤È 05:31:20²Ä 2249 ½g¦^À³
|
¨È·à±d -KY ±N©ó²Ä¤E©¡ SVB LEERINK ¥þ²yÂåÀø«O°·¦~·|µoªí²³ø 2020 ¦~ 2 ¤ë 24 ¤é¡A·s¥[©Y ¡V »EµJ©óÁ{§É¶¥¬q¸~½F¤Î§K¬Ì¾Ç¤§Á{§É¶¥¬q¥Íª«»sÃĤ½¥q¨È·à±d -KY (NASDAQ:ASLN, TPEx:6497) ¤µ¤é«Å¥¬±N¦b²Ä¤E©¡ SVB Leerink ¥þ²yÂåÀø«O°·¦~·| (9th Annual SVB Leerink Global Healthcare Conference) ¤Wµoªí²³ø¡C¨È·à±d -KY °õ¦æªø³Å«i (Dr Carl Firth) »P°Ó°Èªø Stephen Doyle ±N¦b¬üªF®É¶¡ 2020 ¦~ 2 ¤ë 26 ¤é¡]¶g¤T¡^¤W¤È 9 ÂI°w¹ï¤½¥qÀç¹B·§ªpµoªí¤½¥q·§ªp¡C SVB Leerink ¥þ²yÂåÀø«O °·¦~·|±N¦b 2020 ¦~ 2 ¤ë 25 ¦Ü 27 ¤é´Á¶¡©ó¯Ã¬ùµn³õ¡C µoªí¤º®e¥i©ó¬¡°Êµ²§ô«á¦Ü¨È·à±d -KY ©xºô (www.aslanpharma.com) ªº§ë¸êªÌÃö«Y¶±¬d¬Ý¡C ¤½¥qÁ`ºâ¦³·sªº·s»D½Z¤F¡A¤£ª¾¹D³o¦¸·|¦³«ç¼Ëªº§ó·s©O? |
|
|
·|û¡G§_¨ì©³°Õ10148994 µoªí®É¶¡:2020/2/24 ¤U¤È 12:29:17²Ä 2248 ½g¦^À³
|
¨S¿ìªk¡A¦Ñ·à¥Ø«e³Q¬Ý°I¦¨³o¼Ë¤l¡A²{¶¥¬q·|³o¼Ë·Q¤]¬O±¡¦³¥iì |
|
|
·|û¡G³¯Ë¢¦w10144680 µoªí®É¶¡:2020/2/21 ¤U¤È 10:59:08²Ä 2247 ½g¦^À³
|
¦³¤H¦b¯º§Ú̳o¨Ç¨ì²{¦bÁÙ¹ï¦Ñ·à¤£Â÷¤£±óªº¶Ì¤l |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/2/21 ¤U¤È 12:25:19²Ä 2246 ½g¦^À³
|
§Æ±æ¤UÓ¤ëªì´N¯àÅ¥¨£¦Ñ·àASLN-004ªº12¤H(§C+¤¤¾¯¶q)´Á¤¤¼Æ¾Ú»·Àu©ó¹w´Á.... ¥[ªo!!!·à¤ÍÌ |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/21 ¤W¤È 11:11:27²Ä 2245 ½g¦^À³
|
1.¤¤°ê 140000¸U¤H/2000¸U¤ù=70, ¥§¡70¤Ñ¤~¨ÑÀ³µ¹¤H¥Á¤@¤ù¤f¸n¯à¤O. 2.«nÁú 5100¸U¤H/400¸U¤ù=12.75, ¥§¡12.75¤Ñ¤~¨ÑÀ³µ¹¤H¥Á¤@¤ù¤f¸n¯à¤O. 3.¤é¥» 12600¸U¤H/2000¸U¤ù=6.3, ¥§¡6.3¤Ñ¤~¨ÑÀ³µ¹¤H¥Á¤@¤ù¤f¸n¯à¤O. 4.¥xÆW 2300¸U¤H/1000¸U¤ù=2.3 , ¥§¡2.3¤Ñ¤~¨ÑÀ³µ¹¤H¥Á¤@¤ù¤f¸n¯à¤O¡C ec.ltn.com.tw/article/breakingnews/3074824 2020-02-20 22:25 ¡e½sĶ¿c¥Ã¤s¡þºî¦X³ø¾É¡fªZº~ªÍª¢¬Ì±¡«ùÄò©µ¿N¡A¬°¤FÁקK¬Ì±¡«³Ð¸gÀÙ¡A¤¤°ê¬F©²¤w¤U¥O¥þ±´_¤u¡A¦ý¦U¦a¤è¬F©²«o¼~¤ß¬Ì±¡ÀHµÛ¥þ±´_¤u¦ÓÂX¤j¡A¦]¦¹n¨D¼t°Ó³Æ§´¤f¸nµ¥¨¾¬Ìª«¸ê¡C¦ý®Ú¾Ú½Õ¬d¡AY¤¤°ê¥þ±´_¤u¡A¨C¤éªº¤f¸n»Ý¨D°ª¹F5.33»õÓ¡A¦Ó¤f¸n¼t°Ó´Nºâ²£¯àº¡¸ü¡A¤]¥u¯àº¡¨¬3.8%¡A¤f¸n¤@¸nÃø¨Dªº±¡ªpÁÙn«ùÄò«Ü¤[¡A¥ø·~¥þ±´_¤u¤§¸ô»»»»µL´Á¡C ®Ú¾Ú¤W®ü¬É±·s»D¥ý«e¦ôºâ¡A¦b²Ä¤G²£·~¡BÂåÀø¡B¥æ³q¹B¿é·~µ¥¦æ·~´_¤uªº±¡ªp¤U¡A¤¤°ê¨C¤Ñ±N¦³2.38»õ¤H»ÝnÀ¹¤f¸n¡FY¬O¥þ±´_¤u¡A«ö·Ó²Ä¢³¦¸¥þ°ê¸gÀÙ´¶¬d¼Æ¾Ú¡A°ê¤ºªk¤H³æ¦ì©MÓÅé¸gÀç¤á¦Xp´N·~¤H¤f¬°5.33»õ¤H¡A«ö¨C¤H¨C¤Ñ¢°Ó¤f¸npºâ¡A¨C¤Ñ¦Ü¤Ö»Ýn5.33»õÓ¤f¸n¡C ¤¤°ê¤u«H³¡ªº¼Æ¾ÚÅã¥Ü¡A¥Ø«e¤¤°ê°ê¤º¤f¸nªº³Ì¤j¤é²£¯à¬°2000¸UÓ¡A¥u¯àº¡¨¬3.8%ªº»Ý¨D¡C¦¹¥~¡AÂå¥Î¤f¸n¥Í²£«á¡AÁÙn¾ú¸g7¦Ü10¤Ñªº·Àµß¸ÑªR´Á¤~¯à¤W¥«¡A³o¤]¼vÅT¤F·s¼W¤f¸n²£¶q¤W¥«ªº³t«×¡C ¤¤°ê¥X²{¤f¸n¯î¡A³s»s³y¤f¸nªº³]³Æ¤]Åܱoºò¯Ê¡A¬Æ¦Ü¥X²{¤jº¦»ù¡C ·Å¦{1¤f¸n¾÷»s³y°Ó¾P°â¤Hû±i¾åÁ¨ªí¥Ü¡A¦b¦³¨Ç¥ø·~©|¥¼´_¤uªº±¡况¤U¡A¸Ó¤½¥qªº¥Í²£pµe¤w±Æ±o¤Q¤À±K¶°¡A¥æ³f®É¶¡¦b80¤Ñ¥H¤W¡AN95¤f¸n¾÷§ó¬°¼ö¾P¡A¥æ³f®É¶¡n150¤Ñ¡C ¬É±·s»D³ø¾É¡A¼sªF¬Ù©Ý´µ¹Fªø¨F«¤uªº¤f¸n¾÷쥻¨C¥x39.8¸U¤H¥Á¹ô¡A¦b»Ý¨D±j«lªº©Ô©ï¤U¡A²{¦b¨C¥x°â»ù48¸U¤¸¡A»ù®æ¤w¤Wº¦¤F2¦¨¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/21 ¤W¤È 10:56:22²Ä 2244 ½g¦^À³
|
¤é¥» 12600¸U¤H/2000¸U¤ù=6.3, ¥§¡6.3¤Ñ¤~¨ÑÀ³µ¹¤H¥Á¤@¤ù¤f¸n¯à¤O. «nÁú 5100¸U¤H/400¸U¤ù=12.75, ¥§¡12.75¤Ñ¤~¨ÑÀ³µ¹¤H¥Á¤@¤ù¤f¸n¯à¤O. ¥xÆW 2300¸U¤H/1000¸U¤ù=2.3 0, ¥§¡2.3¤Ñ¤~¨ÑÀ³µ¹¤H¥Á¤@¤ù¤f¸n¯à¤O¡C ------------------------------- ¥xÆW¤f¸n¨ÑÀ³¤H¥Á¯à¤O Àu©ó¤é¥»6.3/2.3=274% ¥xÆW¤f¸n¨ÑÀ³¤H¥Á¯à¤O Àu©ó«nÁú12.75/2.3=550% ¥xÆW¥i¨Ì°·«O¥d¤½¥¤À°t¸n¡AÀu©ó¤é¡BÁú¡C 2019¥xÆW¥@¬ÉÂåÀø«O°·«ü¼Æ²Ä¤@¦W¡A86.71¤À. «nÁú81.97¤À²Ä¤G¡A¤é¥»81.14¤À²Ä¤T¡C news.ltn.com.tw/news/world/breakingnews/3075042 ªZº~ªÍª¢¡n¤é¤º»Õ©x©Ðªø©x¡G¨C¶g«OÃҨѵ¹1»õ¤f¸n 2020-02-21 10:39:20 ¡e§Y®É·s»D¡þºî¦X³ø¾É¡f¤é¥»¤º»Õ©x©Ðªø©xµÕ¸q°¶¤µ¡]21¤é¡^ªí¥Ü¡AÃö©ó²{¤µ¤f¸n¤£¨¬ªº²{¶H¡A¬F©²¤w±q¶i¤f©M¥»¦a¤u¼t¥Í²£¨â³BµÛ¤â¡A«OÃÒ±q³o¬P´Á¶}©l¨C¶g³£¯à¨Ñµ¹1»õÓ¤f¸n¡C ¾Ú¡mNHK¡n³ø¾É¡AµÕ¸q°¶©ó¤º»Õ·|ijµ²§ô«áªº°OªÌ·|¤W«ü¥X¡A¥Ø«e¤é¥»¹Ò¤º¥Dnªº¤f¸n¤u¼t¤w24¤p®É¤£Â_¥Í²£¡A²£¯à¹F¨ì¨Ò¦~ªº2¿¥H¤W¡A¨Ã³v¨B¶}©ñ±q¤¤°ê¶i¤f¡A©Ò¥H¥i¥H«OÃÒ¨C¶g¨Ñµ¹¶q¹F¨ì1»õ¡C µÕ¸q°¶ÁÙ»¡¡A±q¤UÓ¤ë¶}©l¡A¤é¥»¬F©²·|§V¤O±N²£¯à´£°ª¨ì¨C¤ë¶W¹L6»õÓ¤f¸n¡A¨Ã¥B«ùÄòºÊ±±¥Í²£©M¤À°tª¬ªp¡A¥H¸Ñ¨M¤f¸nµu¯Êªº±¡§Î¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/21 ¤W¤È 09:17:02²Ä 2243 ½g¦^À³
|
«nÁú¤H¤f5128¸U¡A¤f¸n²£¯à600¸U¤ù/¤é(8¤p®É/126±ø²£½u/5¸U¤ù¡X¨C±ø),¥Ø«e²£¯à¶È2/3 ,¬ù400¸U¤ù¡A¦]¬°¨Ó¦Û¤¤°ê(¤f¸n¹LÂo¼h)ì®Æ¦û50%,µLªk¶i¤f¡A¾ÉP1/3²£½uµLªk¶}¤u¡C «nÁú 5100¸U¤H/400¸U¤ù=12.75, ¥§¡12.75¤Ñ¤~¨ÑÀ³µ¹¤H¥Á¤@¤ù¤f¸n¯à¤O. ¥xÆW 2300¸U¤H/1000¸U¤ù=2.3 0, ¥§¡2.3¤Ñ¤~¨ÑÀ³µ¹¤H¥Á¤@¤ù¤f¸n¯à¤O¡C ¥xÆW¤f¸n¨ÑÀ³¤H¥Á¯à¤O Àu©ó«nÁú12.75/2.3=550% ¥xÆW¥i¨Ì°·«O¥d¤½¥¤À°t¡AÀu©ó«nÁú¡C 2019¥xÆW¥@¬ÉÂåÀø«O°·«ü¼Æ²Ä¤@¦W¡A86.71¤À. «nÁú81.97¤À²Ä¤G¡A¤é¥»81.14¤À²Ä¤T¡C ªZº~ªÍª¢¡n¤å¦b±G»¨®½¤¤°ê200¸U°Æ¤f¸n «nÁú1/3¤f¸n¼t«o°±²£ 2020-02-21 00:50:40 º¦¸¤W½Z 00:50 §ó·s®É¶¡ 06:03 news.ltn.com.tw/news/world/breakingnews/3074872 ¡e§Y®É·s»D¡þºî¦X³ø¾É¡f¤¤°êªZº~ªÍª¢¦Û1¤ëÃzµo¨´¤µ¡A¬Ì±¡¤w½¯©µ¥þ²y¦h°ê¡A«nÁúÁ`²Î¤å¦b±G¥ý«e¨M©w®½µ¹¤¤°ê200¸U°Æ¤f¸n¡A¤f¸n¼t«oÃz®Æ¤¤¤è©Úµ´¨ÑÀ³¤f¸nì®Æ¡A¤å¦b±G¦]¦¹³Q«nÁúºô¤Í½|Ãz¡A¦ÓÁú´C¸g´¦ÅS¡AÁú°ê3¤À¤§1ªº¤f¸n¼t¤w¸g°±²£¡C ®Ú¾Ú«nÁú¡mMBN¡n³ø¾É¡A«nÁú¬F©²¦Û¥h¦~12¤ë¥H¨Ó¡A¤@ª½¦b½Õ¬dÁú°ê123®a¤f¸n¤u¼tªº¥Í²£±¡ªp¡A¦pªG¤u¼tÀç¹B¨C¤Ñ¯à°÷¹B¦æ8¤p®É¡A¨º»ò¨C¶¡¤u¼t¨C¤Ñ¦Ü¤Ö¯à°÷»s§@5¸UÓ¤f¸n¡A¦ý¥Ø«e¤w¦³¤f¸n·~ªÌ¤Ï¬M¡u®Ú¥»µLªk¸gÀç¡v¡AÁöµM¤é¥HÄ~©]»°¤u¡A«oWµLì®Æ¡C ³ø¾É«ü¥X¡A«nÁú¤f¸n»s³y¼t¯Ê¥Fªº¬OÂå¥Î¤f¸n¤ºªº¹LÂo¼h¡AÁú°ê¦V¨Ó±q¤¤°ê¶i¤f¤j¶q¤f¸n¹LÂo¼h¡A¦Ó·í¤¤°ê¦Û¨¯Ê¥F¦¹ì®Æ®É¡A´N°±¤î¸Óì®Æ¥X¤f¨ì¨ä¥L°ê®a¡A¥Ø«e«nÁú°ê¤º¤½¥q©Ò¥Í²£ªº¤f¸n¹LÂo¼h¡A¶È¨¬°÷¨ÑÀ³50¢H«nÁú¤f¸n»s³y¼tªº»Ý¨D¶q¡C ¾¨ºÞ¤å¦b±G¬F©²¤w¸g³]¥ß¤f¸n¨C¤é¥Í²£¶q1000¸U°Æªº¥Ø¼Ð¡A¦ý¤f¸nì®Æªº¨ÑÀ³³t«×«o»·¤£¤Î»s³y³t«×¡A«nÁú¥Ø«e¦³3¤À¤§1ªº¤f¸n»s³y¼t¤¤Â_¥Í²£¡A¥BÁ_¦b¤f¸n¤Wªº¦Õ±a¤]§Y±N±Á{¯Ê³f°ÝÃD¡A«nÁú¬F©²¢¤Á»Ýn±Ä¨úÀ³¹ï±¹¬I¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/19 ¤W¤È 10:23:29²Ä 2242 ½g¦^À³
|
¤@¡A«e¥|Ó¤ëªvÀøAD Lerikizumab 250mg/2¶g¤@°w(2019/10¤ë, ¤T´ÁÁ{§É¶}©l)¡A Duilpumab 300mg/2¶g¤@°w(2017¦~3¤ë¤W¥«,,²Ä¤@Ӽйv¤W¥«) ¤G¡B²Ä¤¨ì²Ä¤Q¤GÓ¤ëªvÀøAD Lerikizumab 250mg/4¶g¤@°w(2019/10¤ë, ¤T´ÁÁ{§É¶}©l)¡A Duilpumab 300mg/2¶g¤@°w(2017¦~3¤ë¤W¥«,,²Ä¤@Ӽйv¤W¥«) ¤T¡AASLAN004 ¸¹ºÙ¦P¯Å³ÌÀu¡A¦Ü¤ÖnÀu©ó¤Wz¤GÃÄ¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/19 ¤W¤È 10:09:09²Ä 2241 ½g¦^À³
|
¥¼¨Ó²Ä¤G´ÁADÁ{§É¦ô200¤H~250¤Hµ²ªG¡AY¥|¶g¤@°wªº¥Dn«ü¼Ð ®ÄªG¶W¶V²{¦³¤G¶g¤@°w, ¤T´ÁÁ{§É¨M©w¥|¶g¤@°w¬°¥D¡A«h¦¨¥»°50% , ¦bADªº¥«³õ¤¤±N¬ONO1. |
|
|
·|û¡G©t¨àÃÄ10140658 µoªí®É¶¡:2020/2/19 ¤W¤È 08:15:19²Ä 2240 ½g¦^À³
|
To:¤Ñ©R¤j ½Ð°Ý¤Ñ©R¤j¤j,ASLN004ªº¥¼¨Ó©Ê»PDupixent,¬Û¤ñ¦p¦ó ? |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/17 ¤U¤È 07:13:51²Ä 2239 ½g¦^À³
|
Á{§É½T©w¬Ý¨ìÀø®Ä¡I¡@³°±M®aÂË¡uÁC»Ä´â喹¡v¯Ç·sª©¶EÀø¤è®× °OªÌÃQ¦³¼w¡þºî¦X³ø¾É ¤j³°¤T´Ú§ÜªÍª¢ÃĪ«·ç¼w¦è³¡BÁC»Ä´â喹¡Bªk¤Ç©Ô³¬Ò¶i¤JÁ{§É¹êÅ綥¬q¡A¨ä¤¤¡AÁC»Ä´â喹¬OÁ{§É¨Ï¥Îªñ70¦~ªº§ÜºÄÃÄ¡C±M®aªí¥Ü¡A«ö¬J©¹ªº¬ã¨sÅã¥Ü¡AÁC»Ä´â喹¤£¶È¦³§ÜºÄªº§@¥Î¡AÁ٨㦳¼sÃЪº§Ü¯f¬r§@¥Î¤Î«D±`¦nªº§K¬Ì½Õ¸`§@¥Î¡C ¡mÀô²yºô¡n³ø¾É¡A¤j³°°ê°È°|¤µ¡]17¤é¡^Á|¦æ¡uÀ³¹ï·s«¬«aª¬¯f¬r·P¬VªÍª¢¬Ì±¡Áp¨¾Áp±±¾÷¨î°OªÌ·|¡v¡A¬ì§Þ³¡¥Íª«¤¤¤ß°Æ¥D¥ô®]¿Pºa©ó°OªÌ·|¤W´£¨ì¡A°ò©ó·í«eÁ{§ÉªvÀøªº¢¤Á»Ý¨D¡A±M®a¤@P±ÀÂËÀ³¸Ó§Ö³t±NÁC»Ä´â喹¯Ç¤J·s¤@ª©ªº¶EÀø¤è®×¡AÂX¤jÁ{§É½d³ò¡C ³ø¾ÉºÙ¡A®]¿Pºaªí¥Ü¡A¸g¥_¨Ê¡B¼s¦{¡B´ò«nµ¥¦a¤Q´X®aÂå°|µû»ù¡AÁC»Ä´â喹©ó¡uÁ{§É¤W«D±`½T©wªº¬Ý¨ì¤FÀø®Ä¡v¡AµL½×±q«¯g¤Æ²v¡B°h¼ö²{¶HÁÙ¬OªÍ³¡¼v¹³¦nÂ઺®É¶¡¡A¯f¬r®Ö»ÄªºÂà³±®É¶¡©MÂà³±²v¡AÁYµu¯fµ{³o¤@¨t¦C«ü¼Ð¡A¸g¨t²Î¡Bºî¦Xªº¬ã§P¡A¡u¥i¥H©ú½Tªº©M¤j®aÁ¿¡A¥ÎÃIJÕÀu©ó¹ï·Ó²Õ¡C¡v ®]¿Pºa¥H¥_¨Ê¤@¦ì54·³½T¶E¯f¤H¬°¨Ò¡A¸Ó¯f¤HªAÃĤ@©P«á¡A®Ö»ÄÀËÅçÂà³±¡A©Ò¦³«ü¼Ð¥þ³¡¦V¦n¡A¹F¨ì¸Ñ°£¹jÂ÷©M¥X°|ªº¼Ð·Ç¡C¦¹¥~¡A¦bÃĪ«ªº¦w¥þ©Ê¤W¡A¤@¦Ê¾l¨Ò¥ÎÃıwªÌ¤¤¡A¦Ü¤µ¥¼µo²{©MÃĪ«¬ÛÃöªº©ú½TÄY«¤£¨}¤ÏÀ³¡C ¾Ú¤F¸Ñ¡A¬ì§Þ³¡¡BÃĺʧ½µ¥³æ¦ì16¤é¥l¶}¥ÑÁé«n¤s¾á¥ô²Õªøªº±M®aµø°T·|ij¡A¦@¦P¬ã§PÁC»Ä´â喹¹ï©ó·s«aªÍª¢ªºÀø®Ä¡C·|ij¤¤¡A±M®a¤@P»{¬°¸ÓÃĬO¤@Ó¤W¥«¦h¦~ªº¦ÑÃÄ¡A¥Î©ó¼sªx¤H¸sªvÀøªº¦w¥þ©Ê¬O¥i±±ªº¡A°ò©ó«e´ÁÁ{§É®i¶}ªº¬ã¨sµ²ªG¥i¥H½T©wÁC»Ä´â喹¹ïªvÀø·s«aªÍª¢¨ã¦³Àø®Ä¡C ì¤åºô§}: Á{§É½T©w¬Ý¨ìÀø®Ä¡I¡@³°±M®aÂË¡uÁC»Ä´â喹¡v¯Ç·sª©¶EÀø¤è®× | ETtoday¤j³° | ETtoday·s»D¶³ www.ettoday.net/news/20200217/1647661.htm#ixzz6ED0ZqEQI Follow us: @ETtodaynet on Twitter | ETtoday on Facebook |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/17 ¤W¤È 11:32:19²Ä 2238 ½g¦^À³
|
company.stcn.com/2020/0217/15643171.shtml ®ü¥¿药业¬ã¨îªºªk维©Ô韦获§å¤W¥« 2020-02-17 07:49来·½¡G¤¤国证¨é报§@ªÌ¡GÀ¹¤pªe ³Å苏颖 临§É试验ªì¨B显¥Üªv疗·s«aªÍª¢疗®Ä较©ú显 ¤¤国证¨é报记ªÌ获±x¡A®ü¥¿药业¬ã¨îªº¡§ªk维©Ô韦¡¨¡]ì¦W¡§ªk¤Ç©Ô韦¡¨¡^2¤ë15¤é¥¿¦¡获±o国®a药监§½§åã¤W¥«¡C这¬O¬Ì±¡´Á间¥þ国²Ä¤@个获§å¤W¥«ªºªv疗·s«aªÍª¢ªº药ª«¡A预计将对¬Ì±¡¨¾ªv发挥«n§@¥Î¡C ¬ì§Þ³¡¥Íª«¤¤¤ß¥D¥ô张·s¥Á2¤ë15¤é¦b国务°|联¨¾联±±Éó¨î·s闻发¥¬会¤W¤¶绍¡Aªk¤Ç©Ô韦ªº临§É试验ªì¨B显¥Ü¤F较©ú显ªº疗®Ä©M较§Cªº¤£¨}¤Ï应¡C º个获§å¥Í产药ª« ¤¤国证¨é报记ªÌ获±x¡A国®a药监§½¤U发给®ü¥¿药业ªº药«~ª`册§å¥ó显¥Ü¡A为应对·s«¬«a状¯f¬rªÍª¢¬Ì±¡¡A®ÚÕu¡m药«~ºÞ²zªk¡n¡m药«~ª`册ºÞ²z办ªk¡nµ¥¡A经审¬d¡A¥»«~°ò¥»²Å¦X药«~审§åªº¦³关规©w¡Aªþ条¥ó§åã¥Í产¥»«~¡A¦P时发给药«~§åã¤å号¡B¥»«~¥Í产¤u艺¡B质¶q标ãµ¥¡C药«~³q¥Î¦Wªk维©Ô韦¤ù¡A¤S称ªk¤Ç©Ô韦¤ù¡A属¤Æ学药«~3类¡C ¡§ªk维©Ô韦¡¨¬O¤@Ïú·s«¬广谱§ÜRNA¯f¬r药ª«¡A¦Ó·s«a¯f¬r属¤_RNA单链¯f¬r¡Cªk维©Ô韦³Ì¦¥Ñ¤é¥»´I¤s¤Æ学¤u业®è¦¡会ªÀ¬ã发¡A¦}¤_1999¦~8¤ë18¤é进¦æ¤F³Ì¦ªº¤Æ¦Xª«专§Q¥Ó请¡C该药ª«¤_2014¦~3¤ë¦b¤é¥»§åã¤W¥«¡A¥Î¤_¥Ò«¬¡B¤A«¬¬y·Pªº§Ü¯f¬rªv疗¡C ¥Ñ¤_¨ä¯S©wªº§@¥ÎÉó¨î¡A¯à¦³®Ä§í¨î®J³Õ©Ô¯f¬r¡B黄热¯f¡]yellow fever¡^¯f¬r¡B°ò¤ÕªÖ¶®¯f¬r¡]chikungunya¡^¡B诺¦p¯f¬r¡]norovirus¡^¡C³Ì·sªº¤@项¬ã¨sªí©ú¡A¦bÊ^¥~细M¨t实验¤¤¡A¨ä对·s«a¯f¬rªºEC50达¨ì61.88£gM¡C 2016¦~6¤ë¡A®ü¥¿药业ÉO¤é¥»´I¤s¤Æ学¤u业®è¦¡会ªÀ签订¤F¤Æ¦Xª«专§Q独®a±Â权协议¡C®ü¥¿负责¦b¤¤国ªº¬ã发¡B¨î³y¡B销°â§tªk¤Ç©Ô韦ªº§Ü¬y·P¯f¬r药ª«¡C ®ÚÕu军¨Æ医学¬ã¨s°|¦¹«eªºÊ^¥~¬¡©Ê试验数Õu¡Aªk维©Ô韦¯à够¦³®Ä°§C·s«¬«a状¯f¬r·P¬Vªº细M¯f¬r®Ö»Ä载¶q¡A¯à够¦³®Ä§í¨î¯f¬r°ò¦]组ªºÎ`¨î¡C¦b©Ò¦³¨ü试浓«×¤U¡Aªk维©Ô韦§¡¥¼§ï变细M¬¡¤O¡A§Y对细M§¡无¬r©Ê§@¥Î¡C ªì¨B显¥Ü较©ú显疗®Ä©M较§C¤£¨}¤Ï应 2¤ë15¤é¡A¦b国务°|联¨¾联±±Éó¨î·s闻发¥¬会¤W¡A¬ì§Þ³¡¥Íª«¤¤¤ß¥D¥ô张·s¥Á称¡A¬ì¬ã¤½关组¦b¦h轮筛选ªº°ò础¤W¡A»EµJ¨ìÁC»Ä´â喹¡B伦¦a¦è韦¡]·ç¼w¦è韦¡^¡Bªk¤Ç©Ô韦µ¥¤Ö数药ª«¡A¥ý¦Z开®i¤F临§É试验¡C¥Ø«e³¡¤À药ª«¤wªì¨B显¥Ü¥X¨}¦nªº临§É疗®Ä¡C¨ä¤¤¡Aªk¤Ç©Ô韦ªº临§É试验¤J组±wªÌ达¨ì70¨Ò¡]§t对·Ó组¡^¡Aªì¨B显¥Ü¤F较©ú显ªº疗®Ä©M较§Cªº¤£¨}¤Ï应¡C¦bªv疗¦Z²Ä3¨ì4¤Ñ¡A¥Î药组ªº¯f¬r®Ö»Ä转阴²v显µÛ°ª¤_对·Ó组¡C ¦P时¡A¦b²`¦`开®iªº临§É试验ªí©ú¡A经±µ¨ü¡§ªk维©Ô韦¡¨ªv疗ªº·s«aªÍª¢±wªÌ¤wªì¨B显¥Ü¤F较©ú显ªº疗®Ä©M较§Cªº¤£¨}¤Ï应¡C²`¦`¥«²Ä¤T医°|2¤ë14¤é对¥~«Å¥¬¡A¥Ñ国®a·P¬V©Ê¯e¯f临§É医学¬ã¨s¤¤¤ß¡B²`¦`¥«²Ä¤T医°|¡]«n¤è¬ì§Þ¤j学²Ä¤Gªþ属医°|¡^发°_ªº¡§ªk维©Ô韦¡¨ªv疗·s«¬«a状¯f¬rªÍª¢ªº临§É试验¨ú±o¥i³ß¦¨®Ä¡C从¥Ø«e¤w¤J组±¡况¬Ý¡Aªk维©Ô韦¦w¥þ¦³®Ä¡A«Ø议扩¤j规¼Ò¦b临§É应¥Î¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/15 ¤W¤È 09:01:20²Ä 2237 ½g¦^À³
|
news.ltn.com.tw/news/life/breakingnews/3068598 2020-02-14 22:10:32 ¿W®a¡n·sÃÄ¡u·ç¼w¦è³¡v¹ï§ÜªZº~ªÍª¢ ¥x¤j·Ç³Æ¦n¤F ¡e°OªÌ²´f¯ø¡þ¥x¥_³ø¾É¡f¬ü°êÃļt¦N§Q¼w¬ì¾Ç¤½¥q©Ò¶}µoªº·sÃÄ·ç¼w¦è³¥i±æ¦¨¬°§ÜªZº~ªÍª¢ªº·sÃÄ¡A¥x¤j°Æ®Õªø±i¤W²Eªí¥Ü¡A¥x¤jÂå°|¬ÛÃö¥Ó½Ðµ{§Ç³£¤w§¹³Æ¡A¦N§Q¼w¤]¤wì«h¤W¦P·N¥H®¦·O¤è¦¡§K¶O´£¨Ñ¡A¥un¦³¯f¤H»Ýn¡A¥x¤j´N¥i¥H¦V¼t°Ó¥Ó½Ð¡A¼t°Ó·|¦Aµû¦ô¬O§_¾A¦X¨Ï¥Î¡C ¦N§Q¼w¬ì¾Ç¤½¥q¡]Gilead Science¡^¦´Á°w¹ï¥ìªi©Ô¯f¬r¡A¬ãµo¹êÅç·sÃÄ¡u·ç¼w¦è³¡v¡A¥h¦~ÃzµoªZº~ªÍª¢¬Ì±¡«á¡A¬ü°ê³Â¬ÙÂå¾Ç¨ó·|©Ò¥Xª©ªº¡m·s^®æÄõÂå¾ÇÂø»x¡n¤W¤ë©³¥Z¸ü¡A¦³¬ü°ê·P¬VªÌ¸gª`®g¸ÓÃÄ«á¡A¤@¤Ñ¤º¯gª¬¦nÂà¡AµL©úÅã°Æ§@¥Î¡A¨Ï¸ÓÃÄ¥i±æ¦¨¬°§Ü¬Ì·sÃÄ¡C ¥x¤j°Æ®Õªø±i¤W²E¤W©Pªí¥Ü¡A¦³°T®§Âàz¤À¨É·ç¼w¦è³¦bÁú°êÃzµoMERS®É¡Aµo´§«Ü¦nªvÀø®ÄªG¡A¦p¤µ¤S¦³¥i§Ü·s«¬«aª¬¯f¬rªº®×¨Ò¡A¥x¤jÂå°|¦b¬K¸`«e¤w»P¦N§Q¼w¤½¥q¨ú±oÁpô¡A¸Ó¤½¥q¦P·N±Ä®¦·O¤è¦¡§K¶O´£¨Ñ·ç¼w¦è³¡C½ÃºÖ³¡³q¹Lªº¡u®¦·O±ø´Ú¡v¬O«ü·í±wªÌµLÃÄ¥iÂå©Î¯f¦M®É¡AÂå®v¥i¦V½ÃºÖ³¡¥Ó½Ð¨Ï¥Î¸g¬ì¾Ç¬ã¨s¡A¦ý©|¥¼®Öã¤W¥«ªº¸ÕÅç¥ÎÃĩΪvÀø¤è¦¡¡C ¸g¹L§@·~®É¶¡¡A±i¤W²E¬Q¤ÑÃÒ¹ê¥x¤jÂå°|¥Ø«e©Ò¦³¦æ¬Fµ{§Ç³£¤w§¹³Æ¡A¥Lªí¥Ü¡A¦N§Q¼w¬ì¾Ç¤½¥q¤w¸gì«h¤W¦P·N¡A¦pªG¦³¾A·í¯f¤H¡AÄ@·N§K¶O´£¨Ñ§@®¦·OÀøªk¡A¥x¤j¦b¦æ¬Fµ{§Ç³£·Ç³Æ§¹¦¨¡A²{¦b´Nµ¥¦pªG¦³¯f¤H»Ýn¡A¥x¤jÂå°|·|¦V¼t°Ó¥Ó½Ð¡A¼t°Ó·|µû¦ô¬O§_¾A¦X¨Ï¥Î¡C ¹ï©ó¥Ø«e¾A¦XªºªvÀø«Øij¡A±i¤W²E«ü¥X¡A»´¯g¥Ø«e¬Ý°_¨Ó±Ä¥Î¤ä«ù©ÊÀøªk´N·|¦n°_¨Ó¡A¤ñ¸û¤¤««×ªºª¬ªp¡A´N¬O«Øij¨Ï¥Î§Ü·R´þÃĪ«¥[¤W¤zÂZ©ÊªvÀø¡A³o¤]³£¬O¥xÆW¥»¨Ó´N¦³ªºÃĪ«¡A«¯g´N·|»Ýn¥Ó½Ð·ç¼w¦è³¨Ó¨Ï¥Î¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/13 ¤W¤È 09:18:06²Ä 2236 ½g¦^À³
|
ªiº¸®æ´µ¹ï¦A¥Í¤¸ªºªÑ²¼µû¯Å¬°¡§·s¥Ø¼Ð»ù¡¨¡A±q465¬ü¤¸¤W½Õ¦Ü600¬ü¤¸¡C¶g¤T(2/15)¡A¦A¥Í¤¸ªÑ»ù¦¬©ó406¬ü¤¸¡C¡A www.marketwatch.com/investing/stock/regn ------- ¤ÀªR®vºÙÃĪ«Ãþ(Dupixent)¯uªº·|¦¨¬°«½S¬µ¼u---¸ÓÃĪº®pȾP°â¨C¦~¥i¯à¶W¹L100»õ¼Ú¤¸¡]109»õ¬ü¤¸¡^¡C ³ì¤°¡P¤º´Ë¡P¥d»ô´µ 2020¦~2¤ë11¤é¡A¬ü°êªF³¡®É¶¡¤W¤È9:34 VB Leerinkªº¤ÀªR®v¤w¸g§Ë²M·¡¤F³oӼƦr¡A¥LÌ»¡ªk°ê»sÃÄ¥¨ÀYÁÉ¿Õµá¡]Sanofi¡^ªº·s¥ôº®u°õ¦æ©x«Où¡P«¢¼w´Ë¡]Paul Hudson¡^¹ï¤½¥q³æ§J¶©§ÜÅéDupixentªº¹w´ú¬O¥¿½Tªº¡C «¢¼w´Ë¤@ª½«D±`¬Ý¦nDupixent¡A¸Ó¤½¥q¥iªvÀø¯SÀ³©Ê¥Öª¢©Mý³Ýµ¥¯e¯f¡A¨Ã»P¬ü°ê»sÃĤ½¥qRegeneron¤@°_¥X°â¡C¥L¦b12¤ë¥÷ªºµû½×¤¤»¡¡A---- ¤ÀªR®vªN¥±¸Ì¡Pªi¦N´µ¡]Geoffrey Porges¡^¦b©P¤Gµo¥¬ªº¤@¥÷³ø§i¤¤¼g¹D¡G¡§¸t¤û¡I¡¨ ¡§±Ä¥Î¦X²zªº·s¾AÀ³¯g¹w´ú¡A¥i¥H¹ê²{Dupixent 100»õ¼Ú¤¸ªº¦¬¯q¡C¡¨ PorgesªºµùÄÀ¥]¬A¹ïDupixent¥i¯à³Q§åã¥Î©óªvÀøªº¨ä¥L¯e¯fªº²`¤J¬ã¨s¡A±o¥Xªºµ²½×¬O¡A¸ÓÃĪ«ªº§Ö³t¤W¥«©M§ó¦h§å㪺¥i¯à©Ê·N¨ýµÛHudsonªº¦¬¤J¥Ø¼Ð¬O¥i¥H¹ê²{ªº¡C asset.barrons.com/dj-mg/dice/barrons-staffpicks-2d590600-c862-4394-b9d3-66b48c376d60/inset.json Porges¼g¹D¡G¡§¾¨ºÞÄvª§¿E¯P¡A¦ýDupixent¦bªñ´Á¤º±N¥H§ó§Öªºý³Ýµo§@³t«×©M¯SÀ³©Ê¥Öª¢ªº°ªªvÀø«ù¤[©ÊÀ»±Ñ¦@ÃÑ¡C¡¨ ¡§±qªø´Á¨Ó¬Ý¡A§Ú̪º×q«áªº¹w´ú²{¦b¤ñ¥«³õ´¶¹M¹w´Á°ª¥X10-15¢H¡A¨ä¤¤¥]¬A°w¹ï¦hºØ2«¬ª¢¯gªº·ÀI½Õ¾ã«áªº¾P°âÃB¡C¡¨ ªiº¸®æ´µ¹ï¦A¥Í¤¸ªºªÑ²¼µû¯Å¬°¡§·s¥Ø¼Ð»ù¡¨¡A±q465¬ü¤¸¤W½Õ¦Ü600¬ü¤¸¡C¶g¤@¡A¦A¥Í¤¸ªÑ»ù¦¬©ó385.21¬ü¤¸¡C¶g¤@¡APorges¶}©l¦bMarket Perform³ø¾ÉSanofi¡]SNY¡^ªº»ù®æ¡A¨Ã±N¸Ó¤½¥qªº¬ü°ê¦s°U¾ÌÃÒªº»ù®æ¥Ø¼Ð³]©w¬°58¬ü¤¸¡C --------------------------------------------------- I«áªº¬G¨Æ¡C RegeneronªºªÑ»ù¤µ¦~¤Wº¦¤F2.9¢H¡A¦ý¦b¹L¥hªº12Ӥ뤤¤U¶^¤F7.2¢H¡CÁɿյᤵ¦~ªº¬ü°ê¦s°U¾ÌÃÒ¼Wªø¤F2¢H¡A¹L¥h12Ӥ뤤¼Wªø¤F19.9¢H¡CÁɿյ᥻¤ëªì³ø§i¤F±j«lªº¦¬¯q¡C ¤°»ò¬O·sªº¡C Porges¦b©P¤@ªºµ§°O¤¤¼g¹D¡ADupixent¦ü¥G¦b¯SÀ³©Ê¥Öª¢¤¤¥e¥D¾É¦a¦ì¡C ¡§ [¯SÀ³©Ê¥Öª¢]·s¶i¤JªÌªºº¦¸§åã¥i¯à·|¦b¤µ¦~±ß¨Ç®ÉÔÀò±o§åã¡A¹wp¨ì2021¦~±N¦³¦hӥͪ«©M¤fªAÄvª§ªÌ¶i¤J¥«³õ¡A¦ýŲ©ó¨ä±j¤jªº¥\®Ä¡A¹ï¨ä¥L¯gª¬ªº¦¸n¯q³B¥H¤Î¤w³QÃÒ©úªº¨Æ¹ê¡A´À´«§ù¤Ç´Ë¯S¦ü¥G§ó¨ã¬D¾Ô©Ê¦w¥þ¡¨¡APorges¼g¹D¡C ¦Ü©ó¸ÓÃĪº·s¥Î³~¡APorges¼g¹D¡Aý³Ý±N¬O¤@Ó¥Dn¾AÀ³¯g¡A¨Ã¥B¡§¦b2-3¦~¤º¥i¥H¹ê²{¦hºØ¼ÐÅÒÂX®i¾÷·|¡¨¡C ¦b©P¤@¥t¤@¥÷¶}©l³ø¾ÉÁɿյ᪺³ø¾É¤¤¡APorges¼g¹D¡A¥L¹ïDupixentªº¾P°â¹w´ú¤ñµØº¸µóªº¦@ÃÑ°ª9-10¢H¡A¦ý¥L¹ïÁÉ¿Õµá¬Ì]³¡ªùªº¦ôp§C©ó¦@ÃÑ¡C ®i±æ¥¼¨Ó¡C Porges¼g¹D¡ADupixent¦b¯SÀ³©Ê¥Öª¢¤è±ªº¦¨¥\¬O¸ÓÃľP°âªº¿n·¥«H¸¹¡C Porges¼g¹D¡G¡§ Dupixentªº¨³³t±À¥Xy¸ñ¨Ï¤ÀªR®v¹ï³o¨Ç¦@Ãѹw´ú¥H¤Î»PºÞ²z¼hªº±R°ª¥Ø¼Ð©M´Á±æ¬Û²Åªº¦¬¤J¼ç¤O¦³¤F§ó¦h«H¤ß¡C¡¨ ¡§ Dupixentªºµo¥¬³t«×¤ñHumira¡ACosentyx¡AStelara¡AOtezla©MXeljanzªº¬ÛÃö§K¬Ì¾Ç±Ò°ÊÃþ¦üª«n§Ö¡A¨Ã¥B¦bµo¥¬ªº²Ä5¦~¤¤¡A³\¦h¦¹Ãþ²£«~ªº¨B¥ï±N¼W¥[¤@¿¥H¤W¡C¡¨ Áɿյ᪺¬ü°êªÑ²¼¦b©P¤G¶}½L«á¤£¤[¤U¶^0.4¢H¦Ü50.99¬ü¤¸¡C¦A¥Í¤¸¤Wº¦0.9¢H¡A¦Ü389.66¬ü¤¸¡C¹Dã´µ¤u·~¥§¡«ü¼Æ¤Wº¦¤F0.4¢H¡C Drug Could Be a Blockbuster, Analyst Says Josh Nathan-Kazis Published Feb 11, 2020 9:34AM EST S VB Leerink analysts have crunched the numbers, and they say that Paul Hudson, the new CEO of the French drug giant Sanofi, is right in his predictions for the company¡¦s monoclonal antibody Dupixent. SVB Leerink analysts have crunched the numbers, and they say that Paul Hudson, the new CEO of the French drug giant Sanofi, is right in his predictions for the company¡¦s monoclonal antibody Dupixent. SVB Leerink analysts have crunched the numbers, and they say that Paul Hudson, the new CEO of the French drug giant Sanofi, is right in his predictions for the company¡¦s monoclonal antibody Dupixent. Hudson has been extraordinarily bullish on Dupixent, which treats atopic dermatitis and asthma, among other conditions, and which the company sells with U.S. pharmaceutical company Regeneron. In comments in December, he said the drug¡¦s peak sales could surpass £á10 billion ($10.9 billion) a year. ¡§Holy Cow!¡¨ wrote analyst Geoffrey Porges in a note out Tuesday. ¡§£á10bn in Dupixent IS Achievable w/ Reasonable New Indication Forecast.¡¨ ¡§Holy Cow!¡¨ wrote analyst Geoffrey Porges in a note out Tuesday. ¡§£á10bn in Dupixent IS Achievable w/ Reasonable New Indication Forecast.¡¨ Porges¡¦s note, which includes a deep dive on other diseases that Dupixent could be approved to treat, concludes that the drug¡¦s quick debut and the likelihood of more approvals means that Hudson¡¦s revenue goal is reachable. asset.barrons.com/dj-mg/dice/barrons-staffpicks-2d590600-c862-4394-b9d3-66b48c376d60/inset.json ¡§We see Dupixent beating consensus in the near term with a faster asthma ramp and high treatment persistence in atopic dermatitis despite forthcoming competition,¡¨ Porges wrote. ¡§Long term our revised forecast is now 10-15% above consensus with inclusion of risk-adjusted sales for multiple type 2 inflammatory conditions.¡¨ Porges, who rates Regeneron (ticker: REGN) Outperform, set a new price target for its shares of $600, up from $465. Shares of Regeneron closed at $385.21 on Monday. Porges initiated coverage of Sanofi (SNY) on Monday at Market Perform, setting a price target of $58 on the company¡¦s American depositary receipts. The back story. Shares of Regeneron are up 2.9% this year, but down 7.2% over the past 12 months. Sanofi¡¦s American depositary receipts are up 2% this year, and up 19.9% over the past 12 months. Sanofi reported strong earnings earlier this month. What¡¦s new. In his note on Monday, Porges wrote that Dupixent appears to be dominant in atopic dermatitis. ¡§First approvals for the new entrants [in atopic dermatitis] could occur later this year, with multiple biologic and oral competitors expected on the market by 2021, but displacing Dupixent seems increasingly challenging given the robust efficacy, secondary benefits on other symptoms, and proven safety,¡¨ Porges wrote. As for newer uses for the drug, Porges wrote that asthma would be a major indication, and that there are ¡§multiple label expansion opportunities achievable within 2-3 years.¡¨ In a separate note on Monday initiating coverage of Sanofi, Porges wrote that his Dupixent sales forecast was 9-10% above the Wall Street consensus, but his estimates for Sanofi¡¦s vaccines division were below consensus. Looking ahead. Porges wrote that Dupixent¡¦s success in atopic dermatitis is a positive sign for the drug¡¦s sales. ¡§Dupixent¡¦s rapid launch trajectory has given analysts more confidence in these consensus forecasts and in the potential of revenue to match management¡¦s lofty targets and expectations,¡¨ Porges wrote. ¡§Dupixent has launched faster than relevant immunology launch analogues of Humira, Cosentyx, Stelara, Otezla, and Xeljanz, and is on pace to more than double many of these products in year 5 of launch.¡¨ Sanofi¡¦s U.S. shares were down 0.4% to $50.99 shortly after the open on Tuesday. Regeneron was up 0.9% to $389.66. The Dow Jones Industrial Average was up 0.4%. |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/12 ¤W¤È 10:21:13²Ä 2235 ½g¦^À³
|
udn.com/news/story/120936/4338380 ¤¤°ê³t«×¡v¡I³°¥ø¦¨¥\¥é»s·ç¼w¦è³ÃÄ ¤w§å¶q¥Í²£ 2020-02-12 09:58 Áp¦X³ø / °OªÌ½²±Ó«º/§Y®É³ø¾É ¬ü°ê¹êÅç©Ê§Ü¯f¬rÃĪ«¡u·ç¼w¦è³¡v³Q»{¬°¥i¯à¬OªvÀø·s«¬«aª¬¯f¬rªºÃĪ«¡C¤j³°¬ì³ÐªO¤W¥«¤½¥q³Õ·çÂåÃĬQ±ß¤½§i¡A¤½¥q¦¨¥\¶}µo·ç¼w¦è³ì®ÆÃĦX¦¨¤uÃÀ§Þ³N©M»s¾¯§Þ³N¡A¨Ã¤w¸g§å¶q¥Í²£¥X·ç¼w¦è³ì®ÆÃÄ¡C ÃÒ¨é®É³ø³ø¾É¡A³Õ·çÂåÃĤµ¡]12¡^¤é¶}½Lº¦°±¡C¤½¥q11¤é±ß¶¡¤½§i¡Aªñ¤é¦¨¥\¥é»s¶}µo·ç¼w¦è³ì®ÆÃĦX¦¨¤uÃÀ§Þ³N©M¨î¾¯§Þ³N¡A·ç¼w¦è³»s¾¯§å¶q¤Æ¥Í²£¥¿¦b¶i¦æ¤¤¡C ³Õ·çÂåÃĪí¥Ü¡A¤½¥q§¹¦¨·ç¼w¦è³ì®ÆÃĪº¥é»s©M»s¾¯¥Í²£«á¡A»Ý¸g¹LÃĪ«Á{§É¸ÕÅç¡BÃÄ«~¼f§åµ¥¦hÓÀô¸`¡CY·ç¼w¦è³³Ì²×Âà¤Æ¬°²£«~§ë¤J¥«³õ¡A»ÝnÀò±oGilead¤½¥q§@¬°±M§QÅv¤Hªº±ÂÅv¡F³o¤@¹Lµ{±N¦s¦b«¤j¤£½T©w©Ê¡C ºI¦Ü¥Ø«e¡A¤½¥q¦b·ç¼w¦è³ªºì®ÆÃÄ©M¨î¾¯¶}µo©M¥Í²£¤¤¤wµo¥Íªº¦¨¥»¹wp¬ù¬°¤H¥Á¹ô500¸U¤¸¡A«áÄò¶i¤@¨B©ñ¤j¥Í²£¡A¹wpÁÙ»Ýn§ë¤J¬ù¤H¥Á¹ô1,000¸U¤¸¡C ³Õ·çÂåÃıj½Õ¡A¸Ó¶µ¬ãµo»P²{¦³¨ä¥L·~°È¬Û¤¬¿W¥ß¡A¤½¥q¨ä¥L·~°È¹BÀ祿±`¡C¤½¥q¶}µo·ç¼w¦è³¬O¬°¤FÅTÀ³¤j³°°ê®a¸¹¥l¡A¾¨¦Àò±o§ÜÀ»·s«¬«aª¬¯f¬r¡]2019-nCoV¡^¬Ì±¡ªvÀøÃĪ«¡CY¸Ó²£«~¯à°÷Àò§å¤W¥«¡A¬Ì±¡´Á¶¡¥Dn³q¹L®½Ãص¥¤è¦¡¨ÑÀ³µ¹¬ÛÃö¯f¤H¡A¹wp¤£·|¹ï¤½¥q2020¦~«×¸gÀç·~ÁZ²£¥Í«¤j¼vÅT¡C |
|
|
·|û¡G«Ó°¶10144972 µoªí®É¶¡:2020/2/12 ¤W¤È 12:14:40²Ä 2234 ½g¦^À³
|
¤w§ë²¼+1 ÂsÄý¾¹n¥ÎIE¤~¦³¿ìªk |
|
|
·|û¡G°l·10148822 µoªí®É¶¡:2020/2/11 ¤U¤È 10:11:12²Ä 2233 ½g¦^À³
|
¦pªGºô§}µLªk¥Î¡A¥i¥H¤U¸üApp:¶°«Oe¦sºP µn¤J«á¤U±¿ï¶µªÑªFÅv¯q¨ºÃäÂIÀ»¡A¶i¥h«á·|¬Ý¨ì¨È·à±dªºªÑªF·|¡I ¦bÂI¶i¥h¸Ì±¦³¤@Ó½u¤W§ë²¼ªº¿ï¶µ¡I ´N¥i¥H¶i¦æ§ë²¼¤F¡I ³o¦¸§ë²¼¦³Ãö¥¼¨Ó¦U¦ìªºÅv¯q¡A§ÚÓ¤H¤Gӧ벼¿ï¶µ³£¬O¡§™ÃÙ¦¨¡¨ ³Â·Ð¦U¦ì·à¤Í¦³ªÅ´N¤U¸ü¡A¶i¦æ§ë²¼ ·P®¦ |
|
|
·|û¡G¥ß§»10147985 µoªí®É¶¡:2020/2/11 ¤U¤È 09:26:20²Ä 2232 ½g¦^À³
|
¸¤H¤j¡A³oÓºô§}µLªkµn¤J |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/2/11 ¤U¤È 03:15:38²Ä 2231 ½g¦^À³
|
«e±n¥[³oÓhttps¤~¦æ! www.stockvote.com.tw/evote/index.html ¦pªG¬O¥ÎAPP¤U³æªº·à¤Í¡A¥i¥Hª½±µ¦b¹q¤l§ë²¼±M°Ï¨ºÃä§ë²¼¡A´N¤£»ÝnÅçÃÒÀô¹Òµ¥¤âÄò¤F! ¤£¦n·N«ä³sµo¤T½g! |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/2/11 ¤U¤È 02:56:44²Ä 2230 ½g¦^À³
|
±µÄò«e½g¡Aºô§}¬O³oÓ¤~¹ï! www.stockvote.com.tw/evote/index.html |
|
|
·|û¡G¸¤H¥d¯S10145479 µoªí®É¶¡:2020/2/11 ¤U¤È 02:50:18²Ä 2229 ½g¦^À³
|
Hello ¦U¦ì·à¤Í¦n! ÁöµM³Ìªñ¨È·à±dªÑ»ùªí²{¤£«ç»ò¦n¡A¦ý¬O¦Û¨ªºÅv¯q¤£n§Ñ°OÅo! ¦³«ù¦³¨È·à±dªºªB¤ÍÌ¡A¦pªG¤£¯à¿Ë¦Û°Ñ¥[Á{®ÉªÑªF·|¡A½Ð°O±o¨ìTDCCªººô¯¸¥h§ë²¼¼Ú¡A¥²¶·n¦³¶W¹L2/3ªºªÑªF§ë²¼¡A³o¦¸ªº¼W¸ê®×¤~·|³q¹L¡A³o¼Ë¥¼¨Ó¤~¦³¥i¯à·|¥HªѴ«·sªÑªº¤è¦¡Åý¤j®a«ù¦³¥xªÑÂà´«¦¨ADR¡A©Ò¥H½Ð¤j®a¥i¥H¨ì¤U±³o¦Uºô§}¥h§ë²¼¡C www.stockvote.com.tw/evote/index.html ÁÂÁÂ! |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/9 ¤W¤È 11:36:27²Ä 2228 ½g¦^À³
|
2020¦~ ¥xÆW¥þ²y²Ä¤@ÂåÀø«O°·«ü¼Æ: 86.71 www.numbeo.com/health-care/rankings_by_country.jsp Numbeo¨Ï±z¥i¥H¬d¬Ý¡A¦@¨É©M¤ñ¸û¦³Ãö¥þ²yÂåÀø«O°·¨t²Îªº«H®§¡C ¥¦½Õ¬d¤F¥H¤U¦³ÃöÂåÀø«O°·ªº¤º®e¡G Âå°È¤Hûªº§Þ¯à©M¯à¤O ¥[§Ö§¹¦¨Àˬd©M³ø§iªº³t«× ²{¥N¶EÂ_©MªvÀø³]³Æ ¶ñ¼g³ø§iªº·Ç½T©Ê©M§¹¾ã©Ê ¤u§@¤Hûªº¤Íµ½©M§»ª ÂåÀø¾÷ºcªºÅTÀ³¡]µ¥«Ý¡^ ¤è«K±zªº¦ì¸m ®Ú¾Ú¥þ²y¸ê®Æ®wºô¯¸Numbeo¸ê°T¡A2020ÂåÀø«O°·«ü¼Æ(Health Care Index)±Æ¦æº]¡A¥xÆW¥H86.71¤À±Æ¦W²Ä¤@¡A«nÁú81.97¤À²Ä¤G¡A¤é¥»81.14¤À²Ä¤T¡C Numbeo¥h¦~ªº¼Æ¾Ú¥xÆW¤]±Æ²Ä¤@¡A¤À¼Æ86.22¡C ¤µ¦~±Æ¦W¥|¡B¤ªº«h¬O¼Ú¬w°ê®a¡A¤À§O¬°¤¦³Á©Mªk°ê¡C¨ä¾l«e10¦W¨Ì§Ç¬O¦è¯Z¤ú¡B¶ø¦a§Q¡B®õ°ê¡B¿D¬w©MªâÄõ¡C ¦Ü©ó¤¤°ê±Æ47¡A¤À¼Æ64.48¡C ¥þ²y¹Ô©³ªº¬O©e¤º·ç©Ô¡A¥H39.66¤À±Æ²Ä93¡A¤ñ¥ì©Ô§Jªº41.36¤ÀÁÙnÁV¿|¡C Y¥H°Ï°ì¨Ó¤À¡A¨È¬w«e3¦W¨Ì¬O¥xÆW¡B«nÁú©M¤é¥»¡A»´ä14¡A¤¤°ê16¡C ¨È¬w°Ï˼Æ3¦W¬°¥ì©Ô§J¡B©s¥[©Ô©M¨È¶ë«ôµM¡C ¬ü¬w°ê®a¤è±¡A¥[®³¤j¥H71.58³ÌÀu¡A±µµÛ¨Ì§Ç¬°¤Ì¥Ê¦h©M¾¥¦èô¡A¬ü°ê¶È±Æ²Ä¥|¡C ¼Ú¬w°ê®a«e5¦W¨Ì§Ç¬°¤¦³Á¡Bªk°ê¡B¦è¯Z¤ú¡B¶ø¦a§Q©MªâÄõ¡C³Ì«á¤@¦W¬O¦I¤ú§Q¡C www.rti.org.tw/news/view/id/2050921 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/7 ¤W¤È 08:20:52²Ä 2227 ½g¦^À³
|
Dupilumab 2019/Q4 ¾P°â¹êÁZ ¬ü°ê6.05»õ¬ü¤¸ +¨ä¥L°Ï1.46 »õ¬ü¤¸=7.51»õ¬ü¤¸ 2019¦~¥þ¦~¾P°â23.15»õ¬ü¤¸ ,¨ä¤¤¬ü°ê¾P°â18.71»õ¬ü¤¸(¦û¥þ²y¾P°â80%) ¾P°â¹êÁZ Dupixent /Dupilumab ³æ¦ì:¦Ê¸U¬ü¤¸ USA ROW ¤pp 2019 Q1 303.0 70.7 373.7 Q2 454.7 102.6 557.3 Q3 508.3 124.8 633.1 Q4 605.2 146.3 751.5 ¤pp 1,871.2 444.4 2,315.6 2018 Q1 117.2 14.2 131.4 Q2 180.9 28.3 209.2 Q3 219.6 43.0 262.6 Q4 258.6 60.2 318.8 ¤pp 776.3 145.7 922.0 2017 Q1 Q2 Q3 88.5 0.5 89.0 Q4 136.9 2.0 138.9 ¤pp 225.4 2.5 227.9 2017/03/28 FDA®Öã¤W¥« www.marketwatch.com/press-release/regeneron-reports-fourth-quarter-and-full-year-2019-financial-and-operating-results-2020-02-06?mod=mw_quote_news |
|
|
·|û¡G°l·10148822 µoªí®É¶¡:2020/2/6 ¤U¤È 10:17:14²Ä 2226 ½g¦^À³
|
¤¤°ê«H°U¤]¶}©l¤p¤p¶R ¤GÓ½æ«Ü¤jªº²{¦b¶R¶W¡A§Ú¹ê¦b¤£À´¬°¦óC¡H |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/6 ¤U¤È 05:16:07²Ä 2225 ½g¦^À³
|
³sÄò½æ2¦~¥b¡A½æ¶W7600¦h±iªº¡§³Í°ò¡¨ ¨é°Ó¡]¥~¸ê), ²Ä¤G¦¸¶R¶W¤F¡C 2020/02/06 12 0 12 12 2020/02/04 16 0 16 16 2019/08/27 0 23 23 -23 2019/08/15 0 20 20 -20 2019/08/12 0 30 30 -30 2019/08/06 0 10 10 -10 2019/08/05 0 18 18 -18 2019/08/02 0 15 15 -15 2019/08/01 0 7 7 -7 2019/07/31 0 5 5 -5 2019/07/30 0 13 13 -13 2019/07/29 0 2 2 -2 2019/07/25 0 10 10 -10 2019/07/24 0 10 10 -10 2019/07/23 0 10 10 -10 2019/07/22 0 30 30 -30 2019/07/19 0 26 26 -26 2019/07/18 0 25 25 -25 2019/07/17 0 29 29 -29 2019/07/16 0 55 55 -55 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/6 ¤U¤È 04:37:12²Ä 2224 ½g¦^À³
|
³Í°ò¨é°Ó ¤@¸ô¤j½æ¶W¡C2017¦~8¤ë¡ã2019¦~8 ¤ë¦@¤j½æ7600±i. histock.tw/stock/brokertrace.aspx?bno=9200&no=6497 2020¦~2¤ë4¤é¶}©l¶R¶W16±i¡C 2018¦~10¤ë25¤é¨ì2019¦~8¤ë¦@½æ¶W¬ù1800±i 2018¦~10¤ë11¤é«e½æ¶W¬ù5800±i ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¦Xp¡C 7600±i 2018/10/11 0 0.00 11 36.50 35.50 -11 426 -2.58 % 2018/09/17 0 0.00 21 41.90 42.00 -21 225 -9.33 % 2018/08/31 0 0.00 20 44.98 43.75 -20 803 -2.49 % 2018/08/27 0 0.00 15 46.38 46.05 -15 243 -6.17 % 2018/08/21 0 0.00 100 49.11 49.00 -100 2,867 -3.49 % 2018/08/14 0 0.00 114 43.21 44.65 -114 1,224 -9.31 % ¤j½æ/¹dÃB¥æ©ö 2018/08/13 0 0.00 11 43.28 40.60 -11 471 -2.33 % 2018/08/06 0 0.00 25 42.03 42.20 -25 196 -12.76 % 2018/07/23 0 0.00 10.2 41.98 41.25 -10 313 -3.26 % 2018/07/19 0 0.00 30 40.13 42.90 -30 619 -4.84 % 2018/06/29 0 0.00 1 40.80 40.65 -1 203 -0.49 % 2018/06/28 0 0.00 0.2 40.00 40.30 0 317 -0.07 % 2018/06/26 0 0.00 20 41.86 41.80 -20 230 -8.69 % 2018/06/14 0 0.00 0.3 47.80 47.90 0 182 -0.14 % 2018/06/13 0 0.00 216.6 47.61 47.80 -216 488 -44.33 % ¤j½æ/¹dÃB¥æ©ö 2018/06/11 0 0.00 34.2 49.50 49.40 -34 512 -6.67 % 2018/06/08 0 0.00 100 49.33 49.85 -100 1,016 -9.84 % 2018/06/05 0 0.00 201 49.82 48.80 -201 2,057 -9.77 % ¤j½æ/¹dÃB¥æ©ö 2018/06/01 0 0.00 200 49.48 49.25 -200 3,175 -6.30 % ¤j½æ/¹dÃB¥æ©ö 2018/05/15 0 0.00 157 38.15 38.05 -157 762 -20.59 % ¤j½æ/¹dÃB¥æ©ö 2018/05/09 0 0.00 42 40.01 39.80 -42 1,040 -4.04 % 2018/05/08 0 0.00 30 40.28 40.95 -30 1,923 -1.56 % 2018/05/02 0 0.00 11 49.24 50.00 -11 671 -1.64 % 2018/04/27 1 48.70 0 0.00 49.50 1 2,017 0.05 % 2018/04/26 0 0.00 76 55.49 50.00 -76 3,497 -2.17 % 2018/04/24 1 56.00 50 55.53 55.20 -49 4,086 -1.20 % 2018/04/23 0 0.00 250 51.05 53.00 -250 1,911 -13.08 % ¤j½æ/¹dÃB¥æ©ö 2018/04/20 1 50.70 0 0.00 50.70 1 1,710 0.06 % 2018/04/19 0 0.00 10 51.48 51.10 -10 2,182 -0.46 % 2018/04/13 0 0.00 100 47.80 47.30 -100 3,639 -2.75 % 2018/04/12 0 0.00 100 55.61 52.40 -100 1,473 -6.79 % 2018/04/11 0 0.00 100 56.14 57.40 -100 1,501 -6.66 % 2018/04/09 0 0.00 345 59.45 62.50 -345 4,638 -7.44 % ¤j½æ/¹dÃB¥æ©ö 2018/04/03 2 59.80 1,089 60.28 60.40 -1,087 6,699 -16.23 % ¤j½æ/¹dÃB¥æ©ö 2018/04/02 0 0.00 309 55.00 55.00 -309 3,010 -10.27 % ¤j½æ/¹dÃB¥æ©ö 2018/03/31 0 0.00 28 50.94 50.00 -28 1,386 -2.02 % 2018/03/30 0 0.00 60 49.82 49.10 -60 1,317 -4.56 % 2018/03/29 0 0.00 165 49.18 51.50 -165 1,790 -9.22 % ¤j½æ/¹dÃB¥æ©ö 2018/03/28 0 0.00 100 48.95 49.00 -100 1,608 -6.22 % 2018/03/27 0 0.00 400 46.85 47.50 -400 1,614 -24.78 % ¤j½æ/¹dÃB¥æ©ö 2018/03/26 0 0.00 265 43.37 43.20 -265 611 -43.37 % ¤j½æ/¹dÃB¥æ©ö 2018/03/23 0 0.00 214 43.51 43.15 -214 616 -34.74 % ¤j½æ/¹dÃB¥æ©ö 2018/03/22 0 0.00 23 42.36 42.10 -23 247 -9.31 % 2018/03/21 0 0.00 290 42.78 42.60 -290 462 -62.77 % ¤j½æ/¹dÃB¥æ©ö 2018/03/20 0 0.00 102 42.29 42.05 -102 385 -26.49 % ¤j½æ/¹dÃB¥æ©ö 2018/03/19 0 0.00 142 42.92 42.65 -142 311 -45.66 % ¤j½æ/¹dÃB¥æ©ö 2018/03/16 0 0.00 190 42.83 42.35 -190 440 -43.18 % ¤j½æ/¹dÃB¥æ©ö 2018/01/22 0 0.00 1 40.55 40.55 -1 480 -0.21 % 2017/08/25 0 0.00 38 34.54 35.50 -38 246 -15.45 % 2017/08/24 0 0.00 17 33.41 33.50 -17 68 -25.00 % 2017/08/23 0 0.00 28 33.56 33.45 -28 71 -39.44 % 2017/08/22 0 0.00 23 33.81 33.60 -23 95 -24.21 % 2017/08/21 0 0.00 19 34.04 33.80 -19 133 -14.29 % 2017/08/18 0 0.00 25 34.23 34.50 -25 72 -34.72 % 2017/08/17 0 0.00 24 34.96 34.80 -24 75 -32.00 % 2017/08/16 0 0.00 17 34.70 34.60 -17 73 -23.29 % 2017/08/15 0 0.00 2 35.50 35.20 -2 75 -2.67 % 2017/08/14 0 0.00 10 35.00 34.70 -10 229 -4.37 % 2017/08/11 0 0.00 2 37.20 37.05 -2 85 -2.35 % 2017/08/10 0 0.00 3 37.50 37.40 -3 263 -1.14 % 2017/08/09 0 0.00 4 39.45 39.00 -4 125 -3.20 % 2017/08/08 0 0.00 10 39.22 39.35 -10 48 -20.83 % 2017/07/14 25 42.92 0 0.00 43.00 25 234 10.68 % 2017/07/11 17 39.44 0 0.00 39.40 17 123 13.82 % |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/6 ¤U¤È 04:03:25²Ä 2223 ½g¦^À³
|
¥~¸ê¤µ¤Ñ¶R¶W6497 ¨È·à±d12±i .¦ûÁ`¦¨¥æ¶q 26±i ,12/26=21%. www.tpex.org.tw/web/stock/3insti/daily_trade/3itrade_hedge.php?l=zh-tw |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/5 ¤W¤È 08:30:26²Ä 2222 ½g¦^À³
|
news.sina.com.tw/article/20200204/34135860.html?fbclid=IwAR1UiUuyihz6cCVCMPvGgvQBoGqj-Ty0NnVtYXWMYkzxN6XV10SK4XfQt8s ¥_¨Ê·s®öºô (2020-02-04 19:41) ·s¨Ê³ø°T¡]°OªÌ ±i¨qÄõ ¤ý¥d©Ô ±i¥ü¼z¡^2¤ë4¤é¤U¤È¡A°w¹ï·s«aªÍª¢¶Ç¨Ó¦n®ø®§¡A¤¤°ê¤uµ{°|°|¤h¡B°ê®a½Ã°·©e°ª¯Å§O±M®a²Õ¦¨û§õÄõ®S¹Î¶¤¤½§GªvÀø·s«¬«aª¬¯f¬r·P¬VªºªÍª¢ªº³Ì·s¬ã¨s¦¨ªG¡Aªü¤ñ¦·º¸¡]°ê®aßӺʺ޲z§½¼f§å¦WºÙ¬°ªü¤ñ¦hº¸¡A¥H¤UºÙªü¤ñ¦hº¸¡^¡B¹FĪ¨º³¨âºØÃĪ«¥i¦³®Ä§í¨î¯f¬r¡C ¡@¡@¨âºØÃĪ«±q²³¦h§Ü¯f¬rÃĪ«¤¤¡u¿z¿ï¡v¦Ó¨Ó ¡@¡@®Ú¾Úªì¨B´ú¸Õ¡A¦bÅé¥~²ÓM¹êÅ礤Åã¥Ü¡G¡]1¡^ªü¤ñ¦hº¸¦b10¡ã30·L¼¯º¸¿@«×¤U¡A»PÃĪ«¥¼³B²zªº¹ï·Ó²Õ¤ñ¸û¡A¯à¦³®Ä§í¨î«aª¬¯f¬r¹F¨ì60¿¡A¨Ã¥BÅãµÛ§í¨î¯f¬r¹ï²ÓMªº¯fÅÜ®ÄÀ³¡C¡]2¡^¹FĪ¨º³¦b300·L¼¯º¸¿@«×¤U¡A¯àÅãµÛ§í¨î¯f¬r½Æ»s¡A»P¥¼¥ÎÃĪ«³B²z²Õ¤ñ¸û¡A§í¨î®Ä²v¹F280¿¡C ¡@¡@§õÄõ®S°|¤h«Øij±N¥H¤W¨âºØÃĪ«¦C¤J°ê®a½Ã°·©e¡m·s«¬«aª¬¯f¬r·P¬VªºªÍª¢¶EÀø¤è®×¡]¸Õ¦æ²Ä¤»ª©¡^¡n¡A§õÄõ®S°|¤h¹Î¶¤¦¨û¡B®ý¤j¤@°|°Æ°|ªø³¯§@§L´£¿ô¡G¡u³o¨âºØßÓ¬°³B¤èßÓ¡A±wªÌ¤@©wn¦bÂå¥Íªº«ü¾É¤UªA¥Î¡C¡v ¡@¡@°ê®a½Ã°·©e¥þ°ê¦X²z¥ÎÃĺʴú¨t²Î±M®a®]©¾¹ê¦b±µ¨ü·s¨Ê³ø°OªÌ±Ä³X®Éªí¥Ü¡A³o¨âºØÃĪ«§¡¬°¼sÃЧܯf¬rÃĪ«¡A¯à±q²³¦hÃĪ«¤¤¿z¿ï¥X¦³®ÄÃĪ«¡A¬O¤@ӳ߰T¡I ¡@¡@®]©¾¹ê¤¶²Ð¡A³o¨â´ÚÃĪ«¥»¨³£¬O¤§«e¤w¸g¦b¨Ï¥Îªº§Ü¯f¬rÃĪ«¡A¡u©Ò¿×¼sÃЧܯf¬rÃĪ«¡A¥i¥H³o»ò²z¸Ñ¡A¤£¤À¯f¬rªº¨ãÅéºØÃþ¡A³oÃþÃĪ«³£¥i¥H°_¨ì§Ü¯f¬rªºÀø®Ä¡C¡v ¡@¡@ÁöµM²{¦³ªº§Ü¯f¬rÃĪ«ºØÃþÁc¦h¡A¦ý¯f¬rªºÅܲ§³t«×¤]«Ü§Ö¡A©Ò¥H«Ü¦h§Ü¯f¬rÃĪ«°w¹ï¦¹¦¸¬Ì±¡ªºªí²{¨Ã¤£¬O«Ü¦n¡C®]©¾¹êªí¥Ü¡A¡u«Ü¦hÃĪ«¦b«e´Á¹ï¤£¤W¸¹¡A³o¬O³¡¤ÀÃĪ«Àø®Ä¤£¦nªº«nì¦]¡A¤]¬O·í¦~¹ïSARS¦³®ÄªºÃĪ«¡A¤µ¤Ñ®³¨Ó´N¥¼¥²¦³®Äªºì¦]¡C¡v ¡@¡@¦b®]©¾¹ê¬Ý¨Ó¡A³o¨â´ÚÃĪ«³Ì²×¥X²{¤F¨}¦nªº®ÄªG¡Aµo²{¹Lµ{´N¬O±q²³¦h§Ü¯f¬rÃĪ«¤¤ªº¡u¿z¿ï¡v¹Lµ{¡A¡u³o¤]¬O§ÚÌ´Á«Ý¤¤ªº¦³°w¹ï©Êªº§Ü¯f¬rÃĪ«¡C¡v ¡@¡@§õÄõ®S°|¤h¦P®Éªí¥Ü¡A§Ü·R´þ¯fÃĪ«§J¤OªÛ¹ïªvÀø·s«¬«aª¬¯f¬r·P¬VªºªÍª¢®ÄªG¤£¨Î¡A¥B¦³¬r°Æ§@¥Î¡C ¡@¡@Ãö©ó³o¨â´ÚßÓ¡A¦hª¾¹D¤@ÂI¨à ¡@¡@ªü¤ñ¦hº¸¬O¤@ºØ§Ü¯f¬rÃĪ«¡A¥Ñ«eĬÁpÃĪ«¤Æ¾Ç¬ã¨s¤¤¤ß¬ã»s¶}µo¡A¥Dn¾AÀ³¯g¬OAÃþ¡BBÃþ¬y·P¯f¬r¤Þ°_ªº¬y¦æ©Ê·P«_¡A¦P®É¹ï¨ä¥L¤@¨Ç©I§l¹D¯f¬r·P¬V¥i¯à¤]¦³§Ü¯f¬r¬¡©Ê¡CÆQ»Äªü¤ñ¦hº¸¥i¥H³q¹L§í¨î¯f¬rªº¯×½¤»P±J¥D²ÓMªº¿Ä¦X¡A±q¦Ó¯à°÷ªýÂ_¯f¬rªº½Æ»s¡C·s«¬«aª¬¯f¬r¬O¤@ºØ±a¦³¥~½¤ªº¯f¬r¡A¦]¦¹±À´úªü¤ñ¦hº¸¦bÃIJz¤W¹ï·s«¬«aª¬¯f¬r¦³§í»s§@¥Î¡C2003¦~©M2016¦~¡AÁé«n¤s°|¤h©Ò¦bªº¼s¦{Âå¬ì¤j¾ÇªþÄݲĤ@Âå°|µ¥¨â®a°ê¤º³æ¦ì´N¤À§O¥Ó½Ð¤Fªü¤ñ¦hº¸»s³Æ¹w¨¾©MªvÀøSARS¯f¬rÃĪ«¤¤ªº¥Î³~¡A¥H¤Îªü¤ñ¦hº¸¦b¹w¨¾©M§ÜÀ»¤¤ªF©I§l¨t²Îºî¦X©º«aª¬¯f¬rÃĪ«¤¤ªºÀ³¥Î°ê®aµo©ú±M§Q¡C ¡@¡@·s¨Ê³ø°OªÌ¬d¸ß°ê®aßӺʧ½¸ê®Æ®w¡A¥Ø«e¦@¦³6®a¥ø·~¥Í²£ÆQ»Äªü¤ñ¦hº¸¡C¨ä¤¤¡A¥ÛßÓ¶°¹Î¼Ú·NßÓ·~©M¦¿Ä¬§d¤¤ÂåÃĶ°¹Î¥Í²£ªº¬Oªü¤ñ¦hº¸¤ù¡A¦¿Ä¬º§¤ô»sÃĥͲ£ªº¬Oªü¤ñ¦hº¸Áû²É¡A¥Û®a²ø¥|ßÓªº¬Oªü¤ñ¦hº¸½¦Ån¡A¥ýÁnßÓ·~ªº¬°ªü¤ñ¦hº¸¤À´²¤ù¡C ¡@¡@2¤ë4¤é±ß¶¡¡A·s¨Ê³ø°OªÌ±q¥ÛßÓ¶°¹ÎÀò±x¡A¤½¥q¤@ª½¦b¥[ºò¥Í²£ÆQ»Äªü¤ñ¦hº¸¤ù¡A¬Ì±¡¶}©l¦Z¡A¥]¬AªZº~¡B¤W®ü¡B«¼yµ¥¦b¤º¡A«Ü¦h¬Ù¥«½Ã°·©e¤w±NÆQ»Äªü¤ñ¦hº¸¤ù¦C¬°¡u·s«¬«aª¬¯f¬r·P¬VªºªÍª¢¨¾±±º§åÃÄ«~Àx³Æ²M³æ¡v¡A¦bÁ{§É¤W¤j¶q¨Ï¥Î¡C¦]¦¹¤½¥qªº¥Í²£½u¤@ª½¥¼°±¡A¬K¸`´Á¶¡³£¦b¥[¯Z¥[ÂI¥Í²£¡C¥Ñ©ó¤W´å¤Æ¤uì®ÆßÓ¨ü¬K¸`¶}¤u¦³µ¥¦]¯À¼vÅT¡A¸Ó²£«~³B©ó²æ¾Pª¬ºA¡C ¡@¡@¦¿Ä¬§d¤¤ÂåÃĶ°¹Î¦P®É¾Ö¦³ÆQ»Äªü¤ñ¦hº¸ªºì®ÆßÓ©MÆQ»Äªü¤ñ¦hº¸¤ù¡C¨ü¦¹¼vÅT¡A¦¿Ä¬§d¤¤ªÑ»ùªñ¤é¤w¸g³sÄò4Óº¦°±¡C2¤ë3¤é¡A¦¿Ä¬§d¤¤µo§Gªº¤½§i¤¤Áٺ١A¥Ø«eªü¤ñ¦hº¸¶È³Q¹Á¸Õ©Ê¥Î©óªvÀø¡u·s«¬«aª¬¯f¬r¡v¡A©|µL¥R¨¬ªºÁ{§É¬ã¨sÃÒ¾Úªí©ú¸Ó²£«~¹ï¡u·s«¬«aª¬¯f¬r¡v¦³Àø®Ä¡C2¤ë4¤é¡A¦¿Ä¬§d¤¤ªÑ»ù¦^¸¨¡A¦ý´N¦b¦P¤@¤é±ß¶¡¡A§õÄõ®S°|¤h¹Î¶¤µo§Gªº«¤j¬ã¨s¦¨ªG¤w¸gµ¹¥X¤F¡uªü¤ñ¦hº¸¯à¦³®Ä§í¨î·s«¬«aª¬¯f¬r¡vªºµ²½×¡C ¡@¡@2019¦~1-9¤ë¡A¦¿Ä¬§d¤¤¤l¤½¥q§d¤¤ÂåÃÄÆQ»Äªü¤ñ¦hº¸¤ù¾P°â¦¬¤J¬°1602.8¸U¤¸¡A¥e¤W¥«¤½¥qªºÀç·~¦¬¤J¶È¬°1.06%¡F2018¦~¦P´Á¾P°â¦¬¤J¬°583.9¸U¤¸¡A¥e¤W¥«¤½¥qÀç·~¦¬¤J0.42%¡C¸ÓÃÄ«~¾P°â¦¬¤J¥e¤W¥«¤½¥qÀç·~¦¬¤J¤ñ¨Ò·¥¤p¡C ¡@¡@¡u§Ú̪ºì®ÆßӨ줵¤Ñ¤]¥Î§¹¤F¡A«áÄò¦ôpnµ¥¨ì¤ë©³¡C¡v2¤ë4¤é±ß¡A®ü«n¥ýÁnßÓ·~¬ÛÃöt³d¤H§i¶D·s¨Ê³ø°OªÌ¡AÆQ»Äªü¤ñ¦hº¸¤À´²¤ù¤½¥qªº¥Dn²£«~¤§¤@¡A±q1¤ë20¤é¶}©l¡A¤½¥qªº¥Í²£³]³Æ24¤p®É³s¶bÂà¡A40¦h¦Wû¤u¡u¨â¯ZË¡v¡A¤£¶¡Â_¥[¯Z¥Í²£§Ü¬ÌÃĪ«¡CºI¦Ü2¤ë4¤é¡A¤½¥q¤w¸g¥Í²£16¸U²°¦@p200¸U¤ù¡A³q¹L¶¶Â×°e¨ì¤FªZº~©wÂIÂå°|¤Î¬ÛÃöÂåÀø¾÷ºc¡A¦P®É¤]¦V¥_¨Ê¡B¤W®ü¡B¼s¦{¡B®ý¦¿¡B¤sªFµ¥27Ó¬Ù¥«°Ï¦@p300Âå°|µo¥X¤FÆQ»Äªü¤ñ¦hº¸¤À´²¤ù¡C¸Ót³d¤H©Z¨¥¡A¦Û«ü«n±ÀÂ˦Z¡A¸Ó«~ºØ¤Îì®ÆßÓ´N¨Ñ¤£À³¨D¡AºI¦Ü2¤ë4¤é¡A¤½¥qªºì®ÆßÓ¤w¸g¨Ï¥Î§¹²¦¡A¥Û®a²ø¤@®aì®ÆÃļt»Ýn¨ì¤ë©³¤~¯à¨ÑÀ³ì®ÆßÓ¡C¡u§Ṳ́w¸g§ä¨ì¤F°ê¥~ªºì®ÆßÓ¨Ó·½¡A§Æ±æ°ê®a¥i¥H¥[§Ö³oÓ«~ºØªº¶i¤fì®ÆßÓ¼f§å¡C¡v ¡@¡@¾Ú±x¡A¹FĪ¨º³¦Ò¤ñ¥q¥L¤ù°Ó«~¦WºÙ¬°´¶¿A¤O¡A¥Ñ¦è¦w·¨´Ë»sÃĦ³¤½¥q¬ãµo¡A¥Dn¥Î©ó·R´þ¯fªºªvÀø¡A2018¦~7¤ë23¤é¦b¤¤°ê¥¿¦¡Àò§å¤W¥«¡C¦è¦w·¨´Ë¬O±j¥Í¤½¥q¦bµØ»sÃĤl¤½¥q¡A¤½¶}¸ê®ÆÅã¥Ü¡A´¶¿A¤O¥ÑHIV³J¥Õ酶§í»s¾¯¹FĪ¨º³¡]800mg¡^©MßÓ¥N°Ê¤O¾Ç¼W®Ä¾¯¦Ò¤ñ¥q¥L¡]150mg¡^©T©w¾¯¶q²Õ¦¨¡C´¶¿A¤O»P¨ä¥LªvÀøHIV-1ÃĪ«Áp¦X¥Î©óHIV·P¬VªvÀø¡A¨C¤é¶È»ÝªA¥Î¤@¤ù¡AÀHÀ\¦PªA¡CÁ{§É¼Æ¾Úªí©ú´¶¿A¤OÀø®Ä½TÃÒ¥B¨ã¦³¸û°ª@ßÓ°ò¦]«Ì»Ù¡A±N·¥¤j§ïµ½±wªÌªºÃĪ«¨Ì±q©Ê¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/4 ¤U¤È 09:14:40²Ä 2221 ½g¦^À³
|
ªZº~ªÍª¢ªvÀøÀÆ¥ú¥X²{¡H¤¤°ê§Ü¬Ì±M®a§õÄõ®S¡G2´Ú¬y·P¡B·R´þÃĪ«¦³®Ä§í¨î«aª¬¯f¬r °ê»Ú¤¤¤ß 2020-02-04 20:40 ¤¤°ê¤uµ{°|°|¤h¡B°ê®a½Ã°·©e°ª¯Å§O±M®a²Õ¦¨û§õÄõ®S¹Î¶¤¡A4¤é¦bªZº~¤½¥¬ªvÀø2019·s«¬«aª¬¯f¬r·P¬VªÍª¢ªº³Ì·s¬ã¨s¦¨ªG¡A«ü¥X§Ü·R´þ¯fÃĪ«¡u¹FĪ¨º³¡v¡B§Ü¬y·P¯f¬rÃĪ«¡uªü¤ñ¦·º¸¡v¯à¦³®Ä§í¨î«aª¬¯f¬r¡C²{¦b³o¨âºØÃĪ«¤w¸g¦b®ý¦¿¬ÙÁ{§ÉªvÀø¤¤¨Ï¥Î¡A¥Ñ©ó³o¨âºØ¬Ò¬°³B¤è¥ÎÃÄ¡A¦]¦¹±wªÌ¥²¶·¦bÂå®v«ü¾É¤U¤~¥iªA¥Î¡C §õÄõ®S«ü¥X¡A®Ú¾ÚÅé¥~²ÓM¹êÅ窺ªì¨B´ú¸Õ¡G ªü¤ñ¦·º¸¦b10¨ì30·L¼¯º¸¿@«×¤U¡A»PÃĪ«¥¼³B²zªº¹ï·Ó²Õ¤ñ¸û¡A¯à¦³®Ä§í¨î«aª¬¯f¬r¹F¨ì60¿¡A¨Ã¥BÅãµÛ§í¨î¯f¬r¹ï²ÓMªº¯fÅÜ®ÄÀ³¡C ¹FĪ¨º³¦b300·L¼¯º¸¿@«×¤U¡A¯àÅãµÛ§í¨î¯f¬r½Æ»s¡A»P¥¼¥ÎÃĪ«³B²z²Õ¤ñ¸û¡A§í¨î®Ä²v¹F280¿¡C ¤¤°êªZº~ªÍª¢¬Ì±¡½¯©µ¡A®ý¦¿¬ÙªC¦{¥«4¤é«Å§G«Ê«°¡]¬üÁpªÀ¡^ ¤¤°êªZº~ªÍª¢¬Ì±¡½¯©µ¡A®ý¦¿¬ÙªC¦{¥«4¤é«Å§G«Ê«°¡]¬üÁpªÀ¡^ ªü¤ñ¦·º¸¡]Arbidol¡^¬O¤@ºØ§Ü¯f¬rÃĪ«¡A¥Ñ«eĬÁpÃĪ«¤Æ¾Ç¬ã¨s¤¤¤ß¬ã»s¶}µo¡A¾A¥Î©ó©u¸`©Ê¬y·P¯f¬rA«¬¬y·P¡BB«¬¬y·P¡B«æ©Ê¯f¬r©Ê©I§l¹D·P¬V¡BÄY«ªº«æ©Ê©I§l¹D¯e¯fºî¦X©º¡A¥]¬A¨Öµo¤ä®ðºÞª¢©MªÍª¢ªº¹w¨¾©MªvÀø¡C¹FĪ¨º³¡]Darunavir¡^«h¬O¤@ºØ¥Î©óªvÀø©M¹w¨¾·R´þ¯fªºÃĪ«¡C §õÄõ®S°|¤h»¡¡A§Ü·R´þ¯fÃĪ«§J¤OªÛ¡þ¬¥¤Ç¨º³¡]lopinavir¡^¹ïªvÀø·s«¬«aª¬¯f¬r·P¬VªºªÍª¢®ÄªG¤£¨Î¡A¥B¦³¬r°Æ§@¥Î¡C¤£¹L¤é«e®õ°ê½Ã¥Í³¡ªù¤~«Å¥¬¡A°Ò¨¦¤@®aÂå°|¹Î¶¤±N§Ü¬y·PÃĪ«¶ø¥q¥L³¡]Oseltamivir¡^¡B·R´þÃĪ«¬¥¤Ç¨º³¤Î§Q¦«¨º³¡]Ritonavir¡^²V¦X¨Ï¥Î¡AªvÀø¤@¦WªZº~ªÍª¢«¯g¯f±w¡A¡uÂû§À°sÀøªk¡v¹ê¬I48¤p®É«á¡A¸Ó¦W71·³¤¤°êÄy¤k¯f±wªºÀËÅçµ²ªG¤w±q¶§©ÊÂର³±©Ê¡C §õÄõ®S°|¤h¹Î¶¤¦¨û¡B®ý¦¿´©¶k«¯g±Ïªv²Õ»â¶¤¡B®ý¤j¤@°|°Æ°|ªø³¯§@§L´£¿ô¡A¡u³o¨âºØÃĬ°³B¤èÃÄ¡A±wªÌ¤@©wn¦bÂå¥Íªº«ü¾É¤UªA¥Î¡v¡C¥LÁÙ¤¶²Ð¡A²{¦b³o¨âºØÃĪ«¤w¸g¦b®ý¦¿¬ÙÁ{§ÉªvÀø¤¤¨Ï¥Î¡A¥¼¨ÓÀÀ¦b¨ä¥L¬Ù¤À¡C |
|
|
·|û¡G°l·10148822 µoªí®É¶¡:2020/2/4 ¤U¤È 08:24:16²Ä 2220 ½g¦^À³
|
¬°¦ó³Í°ò¤S¶}©l¶R¡A¤U¤È¬Ý¨ì¯uªº¬Oº¡°Ý¸¹... ²{¦bªº¨È·à±d¬J¸ò¤j½L¨«¤S¸ò¬üªÑ¨«... ¯uªºÅý¤HºN¤£µÛÀYºü... |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/4 ¤U¤È 05:19:28²Ä 2219 ½g¦^À³
|
¤@¸ô½æ¶W1800±iªº¨é°Ó¡A2018¦~10¤ë¥H¨Ó¡A²Ä¤@¦¸¶R¤J¡C ³Í°ò ¹ï ¨È·à±d-KY(6497) ³æ¤@¨é°Ó¾ú¥v©ú²Ó 2/04 16±i (¶R½æ¶W) ¶i¥X©ú²Óªí ¡@¦Û³]°Ï¶¡¡G ±q¡@¦~ ¤ë ¤é ¡ã ¦~ ¤ë ¤é ¤é´Á ¶R¶i(±i) ½æ¥X(±i) ¶R½æÁ`ÃB(±i) ¶R½æ¶W(±i) 2020/02/04 16 0 16 16 2019/08/27 0 23 23 -23 2019/08/15 0 20 20 -20 2019/08/12 0 30 30 -30 2019/08/06 0 10 10 -10 2019/08/05 0 18 18 -18 2019/08/02 0 15 15 -15 2019/08/01 0 7 7 -7 2019/07/31 0 5 5 -5 2019/07/30 0 13 13 -13 2019/07/29 0 2 2 -2 2019/07/25 0 10 10 -10 2019/07/24 0 10 10 -10 2019/07/23 0 10 10 -10 2019/07/22 0 30 30 -30 2019/07/19 0 26 26 -26 2019/07/18 0 25 25 -25 2019/07/17 0 29 29 -29 2019/07/16 0 55 55 -55 2019/07/15 0 75 75 -75 2019/07/12 0 3 3 -3 2019/07/11 0 46 46 -46 2019/07/10 0 69 69 -69 2019/07/09 0 10 10 -10 2019/07/08 0 391 391 -391 2019/07/05 0 277 277 -277 2019/07/04 0 41 41 -41 2019/07/03 0 5 5 -5 2019/07/02 0 15 15 -15 2019/07/01 0 5 5 -5 2019/06/28 0 16 16 -16 2019/06/27 0 50 50 -50 2019/06/26 0 5 5 -5 2019/06/25 0 10 10 -10 2019/06/24 0 4 4 -4 2019/06/21 0 13 13 -13 2019/06/20 0 14 14 -14 2019/06/19 0 26 26 -26 2019/06/18 0 27 27 -27 2019/06/17 0 35 35 -35 2019/06/14 0 75 75 -75 2019/06/05 0 8 8 -8 2019/05/29 0 10 10 -10 2019/05/03 0 5 5 -5 2019/04/11 0 15 15 -15 2019/03/21 0 20 20 -20 2019/03/12 0 2 2 -2 2019/03/04 0 5 5 -5 2019/02/12 0 5 5 -5 2019/01/08 0 34 34 -34 2019/01/07 0 25 25 -25 2019/01/02 0 28 28 -28 2018/12/28 0 17 17 -17 2018/12/20 0 15 15 -15 2018/12/14 0 13 13 -13 2018/11/27 0 13 13 -13 2018/11/26 0 10 10 -10 2018/11/23 0 30 30 -30 2018/11/08 0 17 17 -17 2018/10/25 0 15 15 -15 ´Á¶¡²Öp¶R½æ¶W±i¼Æ¡G -1,821 fubon-ebrokerdj.fbs.com.tw/z/zc/zco/zco0/zco0.djhtm?a=6497&BHID=9200&b=9200&C=3 |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/4 ¤W¤È 09:55:54²Ä 2218 ½g¦^À³
|
ªZº~ªÍª¢¡j±M®a¤ý¼sµoªv¡¤µ¥X°| ºÙ§Ü·R´þÃĪ«¹ï¥L¦³®Ä china.hket.com/article/2552303/%E3%80%90%E6%AD%A6%E6%BC%A2%E8%82%BA%E7%82%8E%E3%80%91%E5%B0%88%E5%AE%B6%E7%8E%8B%E5%BB%A3%E7%99%BC%E6%B2%BB%E7%99%92%E4%BB%8A%E5%87%BA%E9%99%A2%20%E6%9B%BE%E7%A8%B1%E6%8A%97%E6%84%9B%E6%BB%8B%E8%97%A5%E7%89%A9%E5%B0%8D%E4%BB%96%E6%9C%89%E6%95%88 ªZº~ªÍª¢¬Ì±¡«ùÄò¡A°ê®a½Ã°·©e±M®a²Õ¦¨û¡B¥_¨Ê¤j¾Ç²Ä¤@Âå°|©I§l©M¦M«¯gÂå¾Ç¬ì¥D¥ô¤ý¼sµo¡A¦«euªZº~¦Ò¹î®É¤]¬V¯f¡A½T¶E·s«¬«aª¬¯f¬rªÍª¢¡C¤º¦a¶Ç´C³ø¹D¡A¤ý¼sµo¤wªv¡¡A¤µ¤é¦b¥_¨Ê¦a¾ÂÂå°|¥X°|¡Aºë¯«¤£¿ù¡C ¥L´¿ªí¥Ü¡A¤@ºØ¹ï§Ü·R´þ¯f¯f¬rªºÃĪ«¹ï¥L¦³®Ä¡A¥O¥L¯f±¡¦nÂà¡C¦ý¥L¤]ºÙ¡A¹ï¨ä¥L¯f±w¬O§_¦³®Ä¡A»Ýn«áÄòÆ[¹î¡C ¤ý¼sµo¬Oº¦ì½T¶E·P¬V·s«¬ªÍª¢ªº±M®a²Õ¦¨û¡A¥L¥»¤ëªì´¿ÀH°ê®a½Ã°·©e±M®a²Õ«e©¹ªZº~¡A®i¶}¬ÛÃöÀË´ú®Ö¹ê¤u§@¡A¤§«á½T¶E·P¬V¡C ´¿ºÙ¬Ì±¡¥i±±ªº¤ý¼sµo¡A¦b¹jÂ÷ªvÀø´Á¶¡¡A¥L²¨²z¦Û¤v¥i¯à·P¬Vªºì¦]¡AºÙ¦Û¤v´¿¨ì´X¶¡Âå°|ªºµo¼öªù¶E¡A¦ý¨S¦³°t³Æ¨¾Å@²´Ãè¡A¦Ó¥L¦^¨ì¥_¨Ê«á¡A¥X²{µ²½¤ª¢¯gª¬¡A¤§«á¤~¥X²{µo¿N¡A¥L°ª«×ÃhºÃ¯f¬r¥ý¶i¤Jµ²½¤¡A¦A¨ì¥þ¨¡C ¡iªZº~ªÍª¢¡j±M®a¤]·P¬V¡G¦³µ²½¤ª¢¯gª¬ ©Î¦]µLÀ¹¨¾Å@²´Ãè ¡iªZº~ªÍª¢¡j¤Q¤Ñ«e¤~»¡¬Ì±¡¥i±± °ê®a±M®a¤ý¼sµo·P¬VªZº~ªÍª¢ ¥L¤é«e±µ¨ü¶Ç´C³X°Ý®É³zÅS¡AÂå¥Í«Øij¥L¥Î¤F¤@ºØ¦W¬°¡u¬¥¤Ç¨º³§Q¦«¨º³¤ù¡vªºÃĪ«¡A³o¬O¤@ºØªvÀø·R´þ¯fªº§Ü¯f¬rÃÄ¡C³oºØÃĪ«´N¥LªºÓ¨Ò¨Ó»¡¬O¦³®Äªº¡A¦ý¥Ø«eÁÙ¤£²M·¡¹ï¨ä¥L¯f±w¬O§_¦³®Ä¡A»Ýn«áÄòÆ[¹î¡C ¥LºÙ¡A«Ü¦h¯f¤H¤@¯ë»Ýn¤@©P¦h¨ì¨â©P¡A¯f±¡¤~¯à³vº¥±±¨î©M¦nÂà¡C¦Ó¥L¥u¥Î¤F¤@¤Ñªº®É¶¡¡AÅé·Å´N°¤U¨Ó¤F¡C ¤£¹L¡A¡m·s¨Ê³ø¡n¤Þz¦b¤º¦aªø´Á±q¨Æ·R´þ¯f¬ã¨s¡B¶EÂ_©MªvÀøªº¥_¨Êª¾¦W±M®aºÙ¡A¤ý¼sµo´£¨ìªºÃĪ«¡A¬O§Ü·R´þÃĪ«¡u§J¤OªÛ¡v¡A§Y¬¥¤Ç¨º³§Q¦«¨º³¤ù¡A¡u³oÓÃĦ³¨S¦³®Ä¡A¤£¬O¥HÓÅ骺¤ÏÀ³¬°·Ç¡C¡v ¸Ó¶Ç¬V¯f±M®a¤ÏÂбj½Õ¡A¥Ø«e¸ÓÃĪ«°w¹ï·s«¬«aª¬¯f¬rªÍª¢ªºªvÀø®ÄªG©|¤£©ú½T¡A¥B¦³¤@©wªº¬r°Æ§@¥Î¡A©IÆ~¤½²³¤Å¶Ã¥ÎÀݥΡA§ó¤£¥i±N¦¹ÃĥΧ@¹w¨¾·s«¬«aª¬¯f¬r·P¬VªÍª¢ªº³~®|¡C |
|
|
·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2020/2/4 ¤W¤È 09:36:04²Ä 2217 ½g¦^À³
|
¯eºÞ¸p¨¾¬ÌÂå®v¸â¯\§g¤µ¤Ñ±µ¨ü°OªÌ³X°Ý®Éªí¥Ü¡A ·R´þ§Ü¯f¬rÃĪ«¥Î©óªvÀøªZº~ªÍª¢¡A¥Ø«eÁÙ¨S¦³§¹¾ãªº¹êÅçµ²ªG¡A ¤£¹L¡A¦]¦U°ê¤w´£¥XÃþ¦ü«Øij¡A ¦]¦¹¯eºÞ¸p¬Q¤Ñèèq©wªº¡u2019·s«¬«aª¬¯f¬r¡]2019-nCoV¡^·P¬VÁ{§É³B¸m¼È¦æ«ü¤Þ¡v¡A¤w±N·R´þ§Ü¯f¬rÃĪ«¦C¤J¶Eªv«ü¤Þ¡A¶Ç²Î¤W¥Î¨ÓªvÀøC«¬¨xª¢ªº¹p¤Ú«ÂªL¡B¤zÂZ¯Àµ¥¤]¦bÃĪ«¦W³æ¤¤¡AÂå®v¥iµø±¡ªp¨M©w¬O§_¹Á¸Õ¨Ï¥Î¡C ------ ÉÃèSARS¸gÅç 3´ÚÃļȦCªZº~ªÍª¢ªvÀø«ü¤Þ 2020-02-03 20:54¤¤¥¡ªÀ ¥x¥_3¤é¹q °ê¥~³°Äò¶Ç¥X·R´þ§Ü¯f¬rÃĪ«¥i±æªvÀøªZº~ªÍª¢¡A¯eºÞ¸pªí¥Ü¡A³Ì·s¤½¥¬ªºªZº~ªÍª¢ªvÀø«ü¤Þ¡A°£±N·R´þ§Ü¯f¬rÃĪ«¯Ç¤J¡A¤]ÉÃèSARS¸gÅç¡A±N¹p¤Ú«ÂªL¡B¤zÂZ¯À¯Ç¤J¥i¹Á¸ÕÃĪ«¦W³æ¡C ¤¤¥¡¬y¦æ¬Ì±¡«ü´§¤¤¤ß¤µ¤Ñ³Ä±ß¥l¶}°OªÌ·|«ü¥X¡A¬Q¤Ñ°ê¤º·s¼W61¨ÒÄY«¯S®í¶Ç¬V©ÊªÍª¢³q³øӮסA¥Ø«e²Öp³q³ø1066¦WӮסA§t10¦W½T¶E¡B900¦W±Æ°£¡B¾l¹jÂ÷ÀËÅ礤¡]85¦WªìÅç³±©Ê¡B¨ä¾l«ÝÀËÅç¡^¡C ¥Ø«e10¦W½T¶EӮת¬ªpéw¡A«ùÄò¦í°|¹jÂ÷¡AÂå°|¤Î¦a¤è½Ã¥Í³æ¦ì¤w¶i¦æ¬Ì±¡½Õ¬d¤Î±µÄ²ªÌ°lÂܵ¥¨¾ªv¤u§@¡C10¦W½T¶EÓ®×±µÄ²ªÌÁ`p515¤H¡A¨ä¤¤35¤H¦³¯gª¬¤w³q³ø¡]32¨Ò¤w±Æ°£¡B3¨ÒÀËÅ礤¡^¡C Ä~¤¤°ê¶Ç¥X¤@´Ú§Ü·R´þ¯fÃĪ«¦³§UªvÀø·s«¬«aª¬¯f¬r¡A®õ°ê¤]¦³Âå®v¥H¬y·Pµ²¦X·R´þ¯f¬rÃĪ«¦¨¥\ªvÀø±wªÌ¡C ¯eºÞ¸p¨¾¬ÌÂå®v¸â¯\§g¤µ¤Ñ±µ¨ü°OªÌ³X°Ý®Éªí¥Ü¡A·R´þ§Ü¯f¬rÃĪ«¥Î©óªvÀøªZº~ªÍª¢¡A¥Ø«eÁÙ¨S¦³§¹¾ãªº¹êÅçµ²ªG¡A¤£¹L¡A¦]¦U°ê¤w´£¥XÃþ¦ü«Øij¡A¦]¦¹¯eºÞ¸p¬Q¤Ñèèq©wªº¡u2019·s«¬«aª¬¯f¬r¡]2019-nCoV¡^·P¬VÁ{§É³B¸m¼È¦æ«ü¤Þ¡v¡A¤w±N·R´þ§Ü¯f¬rÃĪ«¦C¤J¶Eªv«ü¤Þ¡A¶Ç²Î¤W¥Î¨ÓªvÀøC«¬¨xª¢ªº¹p¤Ú«ÂªL¡B¤zÂZ¯Àµ¥¤]¦bÃĪ«¦W³æ¤¤¡AÂå®v¥iµø±¡ªp¨M©w¬O§_¹Á¸Õ¨Ï¥Î¡C ¸â¯\§g»¡¡A¹L¥hSARS¡BMERS´Á¶¡¡A¤]¦³Âå¬É«Øij¥H¹p¤Ú«ÂªL¡B¤zÂZ¯ÀªvÀø¡A»{¬°³o¨ÇÃĪ«¥i¥Î©óªvÀø¤j³¡¤Àªº¯f¬r¡A¦ý®Ú¾Ú¸gÅç¡A®ÄªG¨Ã¤£¬O«Ü¦n¡C ¸â¯\§g«ü¥X¡A¥xÆW½T¶Eªº10¦W±wªÌ¤j³¡¤À³£¦³ªÍª¢¯gª¬¡A¥Ø«e¦h¼Æ±wªÌÁÙ¬O¥H¤ä«ù©ÊÀøªk¬°¥D¡A9¤H³£¤w°h¿N¡A¶È1¤HÁÙ¦bµo¿N¡Fȱo¶}¤ßªº¬O¡A¥xÆW½T¶Eªº10¦W±wªÌ¨Å骬ªp³£¬Û·íéw¡A«ì´_±o¤]«Ü¦n¡C ¸â¯\§g»{¬°¡A¥i¯à¬O¥xÆW±wªÌ³£¦bµo¯f«á«Ü§Ö½T¶E¡A¦~¬ö¤]¨S¦³¨ì80©Î90·³ªº°ªÄÖ¡A¬ã§P¥i¯à¬O¦]¬°³o¼Ë¤~«ì´_±o¤ñ¸û¦n¡C ¦o«ü¥X¡A®Ú¾Ú°ê»ÚÅv«Â´Á¥Z¤½¥¬ªº¬ã¨s¡AªZº~ªÍª¢±wªÌ¥X²{¯gª¬«áªº7¨ì9¤Ñ¤º¬O´c¤ÆÃöÁä´Á¡A¦pªG¨S¦³«ùÄò´c¤Æ¡A´N¦³«Ü¤j¾÷·|¦nÂà¡F¦¹¥~¡AY±wªÌ¦~¬ö¤j¡B¦³¦@¯f¡A쥻¾¹©x¥\¯à´N¤£¦n¡A¦]¦¹¹w«á¥i¯à¤]¤ñ¸û®t¡C |
|
|
|